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Dopaminergic system and its role in brain functioning
Dopamine is a neurotransmitter that plays a role in central nervous system 
(CNS) functions such as the regulation of movement, cognitive functions, 
emotions, motivation and reward [1]. Dopaminergic neurons originate in 
the midbrain, more specifically in the substantia nigra pars compacta and 
ventral tegmental area (Figure 1), and project from there into the dorsal 
striatum (nigrostriatal pathway), ventral striatum, amygdala, hippocampus 
(mesolimbic pathway), cortex (mesocortical pathway) and pituitary (tubero-
infundibular pathway) [2]. At the ends of these projections, at interneuronal 
junctions called synapses, dopaminergic signaling takes place when dopa-
mine is released from synaptic vesicles of the pre-synaptic neurons into the 
synaptic cleft, binds to dopamine receptors situated on the membrane of 
the post-synaptic neurons and activates them temporarily, launching the 
intracellular signaling cascade. The pre-synaptic membrane also contains 
dopamine “autoreceptors”, the activation of which regulates dopamine re-
lease [3].
Figure 1. Dopaminergic pathways of the human brain.
© David Richfield; Patrick J. Lynch; Filippe Vasconcellos / Wikimedia Commons / CC-BY-SA-3.0
Dopamine receptors belong to the superfamily of heptahelical transmem-
brane receptors called G-protein coupled receptors (GPCRs) and can be clas-
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sified into 2 types: D1-like, subdivided into D1 and D5 subtypes, and D2-like, 
subdivided into D2, D3 and D4 subtypes. At the secondary messenger level, 
D1-like and D2-like receptors have opposite pharmacological effects: D1-like 
signaling stimulates cyclic adenosine monophosphate (cAMP) production 
while D2-like signaling inhibits it [4].
In mammalian central nervous system, the highest densities of dopamine 
receptors, both D1-like and D2-like, are observed in the striatum, although 
D4 and D5 subtypes have higher densities in other regions, primarily cortical 
[5–10]. For D2-like receptors, dorsal striatum tends to contain mainly the D2 
subtype while ventral striatum, pallidum and nucleus accumbens tend to 
have considerable densities of the D3 subtype [11,12].
Dysregulation of dopamine signaling is implicated in many neurological dis-
orders. Degeneration of nigrostriatal pathway is found in neurodegenerative 
diseases like Parkinson’s disease and Huntington’s disease [13,14]. Addic-
tive substances like amphetamine, nicotine, and alcohol affect dopamine 
levels in the brain, and even the actions of opioids and nicotine are partially 
caused by the influence of these substances on dopaminergic signaling [15]. 
Dopaminergic signaling is also implicated in major depression [16,17]. Fi-
nally, an influential hypothesis of the pathogenesis of schizophrenia states 
that psychotic symptoms are caused by overactive dopaminergic signaling 
in the brain, stemming from elevated dopamine synthesis and intrasynaptic 
concentrations, increased dopamine receptor density or increased suscepti-
bility of dopamine receptors to activation [18–20].
Radioactive tracers in clinical diagnostics
The studies of functional anatomy and physiology of living organisms are 
greatly facilitated by the use of radioactively labeled compounds (called ra-
diopharmaceuticals when used in the clinic) which possess affinity to cer-
tain target biomolecules. Such compounds can be used as probes to assess 
the distribution and/or functionality or their targets in vivo. The advantage 
of the radioactive label is that it does not have to be extracted from the tis-
sue for quantification, and the intensity and type of radioactive decay are in-
dependent of the environment. Some radioactive isotopes generate gamma 
photons upon their decay, which easily escape from the living tissue and can 
be detected externally, providing an opportunity to perform studies non-in-
vasively and (with the right technology) obtain 3-dimensional images of the 
probe distribution in vivo. Isotopes that not only generate gamma photons 
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but also decay quickly (have half-lives on the order of minutes or hours, 
in a few cases – days) are especially good for non-invasive imaging in the 
clinic. Their short half-lives make it possible to administer relatively large 
amounts of radioactivity, which generate a lot of signal for the imaging but 
result in a low radiation burden for the patients.
Probes labeled with short-lived isotopes typically have high molar radio-
activities (specific activities) and thus can be reliably detected at extreme-
ly low concentrations. Therefore, in non-invasive imaging experiments, 
probes are administered at very low dose levels. The idea is that the probe 
does not saturate or even significantly influence the physiological processes 
that are being imaged. Such probes are called tracers (or radiotracers), while 
the administered dose which is low enough to have no consequences on the 
functioning of the imaged organism is called a tracer dose.
Methods of non-invasive imaging with radioactive tracers
There are currently two major non-invasive imaging methods based on the 
detection of gamma-photons formed in radioactive decay: positron emis-
sion tomography (PET) and single photon emission computed tomography 
(SPECT) [21,22]. The latter relies on nuclei directly emitting gamma pho-
tons upon radioactive decay (with typical energies of 100–170 keV), while 
the former relies on isotopes that decay by emitting positrons and detects 
annihilation photons (511 keV) that are generated after positrons meet elec-
trons (Figure 2).
Positron-emitting isotopes include light nonmetal elements like 11C, 13N, 
15O, 18F as well as heavier nonmetals (76Br, 124I) and radiometals (64Cu, 68Ga, 
89Zr). Single-photon emitting isotopes are primarily radiometals (111In, 67Ga, 
99mTc) and heavy nonmetals (123I). Positron-emitting isotopes like 11C, 13N 
and 15O correspond to elements naturally occurring in the majority of bio-
molecules and thus are, at least from the viewpoint of molecular design, 
especially suitable for the labeling of small-molecule tracers, where minor 
modification of chemical structure (including replacement of a single atom) 
can lead to significant changes in physico-chemical and biological proper-
ties. Other isotopes, both positron-emitting and single-photon emitting, 
can be introduced into novel small molecules specifically designed for the 
purpose; alternatively, they can be made part of prosthetic groups for the 
labeling of biologics that have high molecular weight and thus greater toler-
ance for chemical modification.
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Figure 2. Principles of PET imaging.
A – positron-emitting isotopes decay, positrons travel from the decay site, lose their kinetic 
energy in the process and eventually annihilate upon encountering an electron, which gener-
ates two 511 keV gamma-photons emitted in opposite directions from the annihilation site. 
When gamma-photon capture is simultaneously registered at two detectors in the gamma-
detector ring, a decay event can be assumed to have happened on a line connecting the two 
detectors (line of response). Regions with higher radioactivity concentrations will have more 
such lines passing through them.
B – Numerical (large picture) and graphical (inset) reconstructions of a scan performed on a 
“phantom” (artificial object with known amounts and distribution of radioactivity) in the first 
prototype PET camera reported in 1975. © The Radiological Society of North America (RSNA®). 
Reproduced from Ter-Pogossian M M, Phelps M E, Hoffman E J, et al. A positron-emission trans-
axial tomograph for nuclear imaging (PETT). Radiology 1975;114:89–98 [23].
PET technology has a number of important advantages over SPECT technol-
ogy. First, the sensitivity of PET cameras is higher than that of SPECT cam-
eras, because the latter need a collimator to form images, and the natural 
background of high-energy gamma photons used in PET is lower than for 
low-energy photons used in SPECT. Second, the reliance on two high-ener-
gy photons per decay event makes the PET signal more quantitative than the 
SPECT signal, although proper calibration of the detectors and correction 
for absorption and scattering are necessary in both cases. Third, dynamic 
imaging techniques, which make it possible to follow changes of radioac-
tivity concentration in a region of interest on a second scale, are easier to 
implement, and therefore more developed, in PET than in SPECT. Finally, 
PET cameras used in the clinic typically have greater spatial resolution than 
clinical SPECT cameras (~5 mm vs ~10 mm). On the other hand, recent de-
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velopments in SPECT technology allow, in some specific set-ups, imaging 
with spatial and temporal resolution comparable to or even exceeding those 
of PET [24,25]. Moreover, SPECT technology allows simultaneous imaging 
of more than one radiolabel: isotopes can be distinguished by their charac-
teristic gamma photon energies, while annihilation photons used for PET 
are the same for all positron-emitting isotopes. Finally, PET technology is 
generally more expensive than SPECT technology, one of the reasons for 
this being that many isotopes PET relies on (see above) have to be produced 
in cyclotrons.
To sum up, both SPECT and PET are useful tools for both clinical and pre-
clinical imaging, but high-end clinical diagnostics and fundamental as well 
as applied biomedical research tend to be carried out with PET. Tracers for 
PET imaging of the brain include enzyme substrates, receptor and trans-
porter ligands and even simple water [26].
Outcome measures of PET and SPECT imaging experiments
When using tracers (radioligands) that reversibly bind to their targets (as 
usually happens with receptors or transporter proteins) one typically wants 
to know the target density in the tissue (Bmax) and the affinity of the tracer 
for its target (1/Kd; the lower the dissociation constant, the higher the affin-
ity). Measuring these parameters using data from a single tracer injection 
is impossible, because tracers have specific as well as non-specific binding. 
During in vitro binding assays, non-specific binding can be measured in a 
separate experiment where all specific binding is inhibited by a large excess 
of unlabeled “blocker” drug. However, the same cannot commonly be done 
in vivo, because high receptor occupancy by the “blocker” drug may result 
in unwanted, potentially toxic, pharmacological effects.
Therefore, the key outcome measure for in vivo imaging with reversibly 
binding tracers is the binding potential (BP) [27]. BP is a ratio equal to the 
product of Bavail and 1/Kd. Here, Bavail is available target density. In vitro all 
receptors are available for binding, so Bavail = Bmax, but in vivo receptors may 
be internalized or occupied by other ligands (including the endogenous neu-
rotransmitter).
Because BP values are proportional to Bavail, they can be used as a measure 
of receptor availability for ligand binding in the living brain. Changes in 
BP reflect changes in overall receptor densities or in receptor occupancy by 
endogenous ligands (or both; note that it’s impossible to say what are the 
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separate contributions of these two factors when only a single BP measure-
ment is available). Receptor occupancy by exogenous drugs or by pharma-




where BPbaseline and BPchallenge are BP values measured in the subject at base-
line and after a “challenge”, i.e. after administration of a drug that competes 
with the tracer for binding to receptors or that manipulates neurotransmit-
ter levels.
Finally, available receptor density Bavail and tracer’s in vivo affinity Kd can be 
estimated separately if the BPs are determined after at least two different 
injected tracer doses (see Chapter 2 for more details).
PET and SPECT imaging of the dopaminergic system
PET and SPECT radioligands make it possible to look at the functioning 
of the dopaminergic system from different angles. Synthesis and transport 
of L-dihydroxyphenylalanine (L-DOPA), a precursor for dopamine, can be 
imaged by PET using with 6-[18F]fluoro-L-DOPA. The regional density of the 
dopamine transporter (DAT) which is responsible for the reuptake of dopa-
mine from the synaptic cleft can be imaged with SPECT ligands like [123I]FP-
CIT (marketed as DaTSCAN®), [123I]β-CIT, [123I]PE2I and [99mTc]TRODAT-1 
and PET ligands like [18F]FP-CIT. The PET tracer [11C]DTBZ can be used to 
image regional densities of the vesicular monoamine transporter (VMAT2), 
a protein that pumps dopamine into synaptic vesicles for future release. 
PET tracers for D1-like receptors ([
11C]NNC112, [11C]SCH23390) and both 
PET and SPECT tracers for D2-like receptors ([
11C]raclopride, [18F]fallypride, 
[123I]IBZM) are available [28].
Imaging of these targets is relevant both for clinical diagnostics and for 
neuroscientific research. For instance, a profound decrease of dopamine 
biosynthesis and striatal DAT and VMAT2 availability was found in Parkin-
sonian patients by 6-[18F]fluoro-L-DOPA, [11C]DTBZ and [18F]FP-CIT (PET) 
/ [123I]FP-CIT (SPECT) imaging [29–31]. Imaging with [11C]NNC112 and 
[11C]SCH23390 revealed alterations of cortical D1 receptor availability in 
schizophrenia [32]. Finally, [123I]IBZM and [11C]raclopride, benzamide li-
gands for D2 and D3 receptors (together referred to as D2/3), were found to be 
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sensitive to fluctuations in intrasynaptic dopamine levels [33,34]. This en-
abled studies of synaptic neurotransmission in both healthy subjects [35,36] 
and in pathological conditions such as schizophrenia, addiction and major 
depression [16,37–39]. Dopamine D2-like receptors have been a very popular 
target in PET imaging for more than three decades (see Figure 3), and D2-like 
receptor imaging by PET (as well as by SPECT) has become a clinical tool.
Figure 3. Publications about D2-like receptor imaging related to the total num-
ber of publications about protein target imaging by PET.
Data for the three decades from 1984 to 2013 are presented. Based on literature search results 
reported in [26].
Affinity states of dopamine D2/3 receptors
Dopamine receptors require heterotrimeric G-proteins in order to launch 
their signaling cascades after the receptors are activated by agonist ligands.
Models of GPCR signaling, of which there are many [40–43], postulate that 
there is positive cooperativity between receptor-G-protein (RG) and ago-
nist-receptor (AR) binding, which means that agonist ligands (e.g. dopa-
mine itself when we talk about dopamine receptors) have higher affinity 
toward RG complexes than towards free receptors, and G-proteins prefer to 
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couple with agonist-bound AR receptors. Indeed, this can be demonstrated 
in vitro by plotting a saturation curve for radiolabeled agonist or a compe-
tition curve for radiolabeled antagonist displaced by unlabeled agonist in 
receptor-containing membrane homogenates (Figure 4). In both cases, the 
levels of bound radioligand will change in a biphasic manner, showing that 
in a single receptor population, agonist recognizes two subsets with differ-
ent affinities (affinity difference can be 100–1000 fold for potent agonists). 
On top of that, the difference in affinities of agonist drugs for the high and 
low affinity states of the D2 receptor has been shown to correlate with their 
intrinsic activity [44].
Figure 4. High- and low-affinity states visible on saturation (blue) and competi-
tion (red) curves.
The figure shows a numerical simulation of an in vitro experiment where an antagonist ligand, 
present at fixed concentration (2 nM), is displaced from the receptors by increasing concentra-
tions (0.3 nM to 30 µM) of an agonist ligand. Percentage of total receptors occupied by the 
agonist (blue) and antagonist (red) is plotted against agonist concentration.
The antagonist ligand has an affinity of 2 nM to all receptors, the agonist has an affinity of 
3 nM for receptors in the high-affinity state and 2100 nM for receptors in the low-affinity state, 
half of all receptors are in the high-affinity state. The graph is built in Excel using binding 
isotherm equation to model drug-receptor binding (see e.g. [45]).
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In vivo imaging of the high-affinity state
The concept of the high-affinity state is potentially highly relevant for the 
in vivo imaging of dopamine D2/3 receptors and other GPCRs. If some of the 
receptors are in the high-affinity state for the agonist while others are not, 
then agonist radioligands should be more sensitive to alterations in endoge-
nous neurotransmitter levels than antagonist tracers, because they compete 
with the neurotransmitter for the same receptor subset.
Moreover, one can argue that receptors bound to G-proteins configured in 
the high-affinity state (Rhigh) represent the functional subpopulation of re-
ceptors, ready to launch the signaling cascade as soon as an agonist binds 
to them. Relative abundance of Rhigh can then be a measure of the sys-
tem’s sensitivity to neurotransmitter impulses, with more predictive value 
than total receptor density. Indeed, elevated percentages of D2/3 receptors 
in the high-affinity state (D2/3high, measured in vitro) were reported in ani-
mal models of psychosis, thought to be associated with hypersensitivity to 
dopamine [46]. By this reasoning, D2/3-agonist tracers, which only recognize 
“functional” receptors instead of all receptors, as D2/3 antagonists do, could 
be valuable tools for diagnostic purposes and investigation of pathological 
alterations in dopaminergic signaling.
New experimental evidence, which appeared while the research described 
in this thesis was being carried out, did not confirm the existence of altera-
tions in D2/3high relative abundance in neuropathological states [47,48], 
and cast doubt on the validity of the D2/3high concept in vivo [49]. However, 
the greater vulnerability of D2/3 agonist tracers to displacement by endog-
enous dopamine, compared to the “gold standard” D2/3 antagonist tracer 
[11C]raclopride, appears to hold in both pre-clinical [50–53] and clinical set-
tings [54,55].
Tracers available for D2/3 receptor imaging
For covalent labeling of brain SPECT tracers, iodine-123 is the isotope of 
choice. It has a half-life of 13.2 h. PET tracers for receptor imaging in the 
brain are usually labeled with carbon-11 or fluorine-18. The advantage of 
carbon-11 is that biomolecules can be labeled without a change of their 
structure, thus preserving all their properties. However, the very short half-
life of carbon-11 (20.4 min) means 11C-tracers can only be used in imaging 
centers that have an on-site cyclotron to produce the isotope.
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Carbon-11 20.4 0.96 1.2 4.2
Nitrogen-13 10.0 1.19 1.8 5.5
Oxygen-15 2.1 1.73 3.0 8.4
Fluorine-18 109.8 0.63 0.6 2.4
Аdapted from [60].
a Living tissue mostly consists of water, so presented values can be extrapolated to living tis-
sue as well.
Since the half-life of fluorine-18 is 109.8 min, 18F-labeled tracers can be dis-
tributed to “satellite” imaging centers within tens of (or even a few hundred) 
kilometers from the nearest production site [56]. Fluorine-18 also provides 
greater intrinsic resolution than carbon-11 because of the lower positron 
energy, and consequently shorter positron range (Table 1). The issue with 
fluorine-18 is that few relevant receptor ligands contain a fluorine atom 
naturally. Therefore, 18F-labeled tracers are usually compounds specifically 
developed for the purpose by modification of existing fluorine-free ligands, 
an endeavor that often fails, because the highly electronegative fluorine 
atom can have dramatic influence on the properties (for instance, pKa and 
LogD) of the molecule into which it is introduced [57–59].
In SPECT, the antagonist [123I]IBZM is the gold standard tracer for D2/3 re-
ceptor imaging, but no agonist SPECT tracers for D2/3 receptors are avail-
able. PET tracers available for D2/3 receptor imaging include both agonists 
and antagonists. The high-affinity antagonist [11C]N-methylspiperone 
(NMSP) was popular in the 1980s, but was later abandoned in favor of 
[11C]raclopride, because NMSP has affinity to serotonin 5-HT2A as well as to 
dopamine D2/3 receptors and its binding is insensitive to endogenous dopa-
mine levels. [18F]Fallypride and [11C]FLB457, antagonists with very high af-
finities towards D2/3 receptors, are typically used for the imaging of extrastri-
atal regions, where the densities of D2/3 receptors are low (binding of these 
traces in the striatum can be hard to quantify due to slow washout rates). 
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[18F]des-methoxy-fallypride, a lower-affinity congener of fallypride, is suit-
able for the imaging of striatal D2/3 receptors and can be considered an 
“18F version” of [11C]raclopride.
Agonist PET tracers used for D2/3 receptor imaging in humans are 
[11C](−)NPA, [11C]MNPA and [11C](+)PHNO. [11C](−)NPA and [11C]MNPA are 
based on the apomorphine scaffold, while [11C](+)PHNO is a naphtoxazine 
(Figure 5). Apomorphines, naphtoxazines and aminotetralines are the most 
intensively investigated scaffolds in the development of D2/3-agonist radio-
ligands for PET [61].
Figure 5. D2/3 agonist PET tracers currently available for human studies.
Asterisks indicate 11C-atoms. Note that each compound contains a phenethylamine motif, con-
sisting of an aromatic ring, hydroxyl groups and a basic nitrogen two carbons away from the 
ring.
The first successful 18F-fluorine labeled D2/3 agonist [
18F]FPPAT, an aminot-
etraline, was reported as far back as 2004 [62], but was not developed further 
(until very recently – see [63]), probably due to its relatively low signal-to-
noise ratio. [18F]MCL-524, an apomorphine D2/3 agonist structurally similar 
to [11C]MNPA and [11C]NPA, showed very promising results in preliminary 
evaluation, but has been developed only recently and is not yet in wide-
spread use [64].
Aim and outline of the thesis
At the onset of the research described in this thesis, there were no known 
D2/3 agonist SPECT tracers, and all D2/3 agonist PET tracers used in humans 
were labeled with carbon-11, which limited their application for clinical 
research. Creation of 18F-labeled D2/3-agonist tracers with good signal-to-
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noise ratios could greatly expand the potential area of application for the 
PET imaging of D2/3high. Such tracers could be produced commercially and 
delivered to PET imaging centers without an on-site cyclotron. Develop-
ment of a 123I-labeled D2/3 agonist would make SPECT imaging of D2/3high 
possible.
Research described in this thesis, funded by the Dutch Technology Founda-
tion (STW; grant number 10127), aimed to develop novel 18F-labeled D2/3 
agonist tracers that would be suitable for PET imaging of the high-affinity 
state of the D2/3 receptors in humans (development of potential 
123I-labeled 
SPECT tracers is described elsewhere [65]).
For this purpose, we selected a class of high-affinity D2/3-agonists not previ-
ously used for tracer development, 2-aminomethylchroman-7-ols (AMCs) 
[66], and designed, prepared and evaluated a number of potential PET trac-
ers based on this scaffold.
Chapter 2 of this thesis discusses the theoretical and practical aspects of 
GPCR high-affinity state imaging by PET. It provides an overview of experi-
mental paradigms and available agonist tracers which may be used for this 
purpose and discusses experimental evidence for the existence of the high-
affinity state of GPCRs in vivo.
Chapter 3 describes the design, preparation and pharmacological charac-
terization of AMC derivatives as potential D2/3 agonist tracers for PET. The 
affinities of tracer candidates to the high- and low-affinity states of D2 recep-
tors and to other dopamine receptor subtypes were measured in membrane 
homogenate competition assays, and the agonistic properties of AMCs at D2 
receptors were assessed in cell-based functional assays. Compounds with 
the highest affinities for D2high, (R)-2-[(4-(4-fluorobutoxy)benzylamino)
methyl]chroman-7-ol (12a or [18F]FBu-AMC13) and (R) 1-(4-(2-[18F]fluoroe-
thoxy)phenyl)-4-(4-(7-hydroxychroman-2-yl)-3-azabutyl)-piperazine (12d 
or [18F]FEt-AMC15), were labeled with fluorine-18 and evaluated by in vitro 
autoradiography in rat brain slices.
Chapter 4 is devoted to the preparation and evaluation of (R)-2-[(4-fluo-
robenzylamino)methyl]chroman-7-ol (AMC20), an additional aminomethyl 
chromane derivative with high affinity towards D2high. This compound was 
synthesized and pharmacologically characterized later than other com-
pounds mentioned in Chapter 3, but showed an order of magnitude higher 
affinity towards D2high and therefore was given high priority in tracer devel-
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opment. Chapter 4 contains data on the radiolabeling of [18F]AMC20, confir-
mation of its preferential binding to the high-affinity state of D2/3 receptors 
in rat brain slices, characterization of its distribution in living rat brain and 
proof of the D2/3-specificity of its uptake in the striatum by pre-treatment of 
animals with non-radioactive raclopride.
Chapter 5 describes further optimization of AMC ligands that were se-
lected for radiolabeling based on the pharmacological characterization pre-
sented in Chapter 3. A method for the optimization of the lipophilicity of 
[18F]fluoroalkylated ligands by varying the length of the [18F]fluoroalkyl 
chains is presented. Furthermore, the optimized ligands [18F]FEt-AMC13 
and [18F]FEt-AMC15 were evaluated in vivo, using the same scheme as was 
employed for [18F]AMC20. Most reported data concern [18F]FEt-AMC13, as 
[18F]FEt-AMC15 was found to not penetrate the blood-brain barrier.
Chapter 6 describes the automation of the synthesis of 18F-labeled building 
blocks used to prepare AMC-based tracers, based on the use of an microflu-
idic radiosynthesis module. After this partial automation, azeotropic drying 
of [18F]fluoride was no longer necessary and the production of 18F-labeled 
tracers became much easier. It also resulted in decreased radioactivity expo-
sure for researchers at late stages of the current project.
Chapter 7 presents a summary of our work on tracer development and dis-
cusses the findings of this research.
Finally, Chapter 8 identifies steps that need to be taken for further develop-
ment of AMC-based D2/3 agonist tracers. The chapter ends with a discussion 
of the relevance of agonist tracers for neuroreceptor imaging and of possible 




1. Vallone D, Picetti R, Borrelli E. Structure and function of dopamine receptors. 
Neurosci. Biobehav. Rev. 2000;24:125–32.
2. Halász B, Fuxe K, Agnati LF, Kalia M, Goldstein M, Andersson K, et al. The 
Dopaminergic System. Berlin, Heidelberg: Springer Berlin Heidelberg; 1985.
3. Beaulieu J, Gainetdinov RR. The physiology, signaling, and pharmacology 
of dopamine receptors. Pharmacol. Rev. 2011;63:182–217.
4. Neve KA, Seamans JK, Trantham-Davidson H. Dopamine Receptor Signaling. 
J. Recept. Signal Transduct. Res. 2004;24:165–205.
5. Boyson SJ, McGonigle P, Molinoff PB, Molinoff B. Quantitative autoradio-
graphic localization of the D1 and D2 subtypes of dopamine receptors in rat 
brain. J. Neurosci. 1986;6:3177–88.
6. Cortés R, Gueye B, Pazos A, Probst A, Palacios JM. Dopamine receptors in human 
brain: autoradiographic distribution of D1 sites. Neuroscience. 1989;28:263–73.
7. Camps M, Cortés R, Gueye B, Probst A, Palacios JM. Dopamine recep-
tors in human brain: autoradiographic distribution of D2 sites. Neuroscience. 
1989;28:275–90.
8. Primus RJ, Thurkauf A, Xu J, Yevich E, McInerney S, Shaw K, et al. II. Localiza-
tion and characterization of dopamine D4 binding sites in rat and human brain 
by use of the novel, D4 receptor-selective ligand [
3H]NGD 94-1. J. Pharmacol. 
Exp. Ther. 1997;282:1020–7.
9. Lahti RA, Roberts RC, Cochrane E V, Primus RJ, Gallager DW, Conley RR, 
et al. Direct determination of dopamine D4 receptors in normal and schizo-
phrenic postmortem brain tissue: a [3H]NGD-94-1 study. Mol. Psychiatry. 
1998;3:528–33.
10. Khan ZU, Gutiérrez A, Martín R, Peñafiel A, Rivera A, de la Calle A. Dopamine 
D5 receptors of rat and human brain. Neuroscience. 2000;100:689–99.
11. Stanwood GD, Artymyshyn RP, Kung MP, Kung HF, Lucki I, McGonigle P. 
Quantitative autoradiographic mapping of rat brain dopamine D3 binding with 
[125I]7-OH-PIPAT: evidence for the presence of D3 receptors on dopaminer-
gic and nondopaminergic cell bodies and terminals. J. Pharmacol. Exp. Ther. 
2000;295:1223–31.
22 Chapter 1
12. Seeman P, Wilson A, Gmeiner P, Kapur S. Dopamine D2 and D3 receptors in 
human putamen, caudate nucleus, and globus pallidus. Synapse. 2006;60:205–
11.
13. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. 
Brain dopamine and the syndromes of Parkinson and Huntington Clinical, mor-
phological and neurochemical correlations. J. Neurol. Sci. 1973;20:415–55.
14. Schwab LC, Garas SN, Drouin-Ouellet J, Mason SL, Stott SR, Barker RA. Do-
pamine and Huntington’s disease. Expert Rev. Neurother. 2015;15:445–58.
15. Sulzer D. How Addictive Drugs Disrupt Presynaptic Dopamine Neurotrans-
mission. Neuron. Elsevier Inc.; 2011;69:628–49.
16. Meyer JH, McNeely HE, Sagrati S, Boovariwala A, Martin K, Verhoeff NPLG, 
et al. Elevated putamen D2 receptor binding potential in major depression with 
motor retardation: an [11C]raclopride positron emission tomography study. Am. 
J. Psychiatry. 2006;163:1594–602.
17. Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile 
of antidepressants and related compounds at human monoamine transporters. 
Eur. J. Pharmacol. 1997;340:249–58.
18. van Rossum JM. The significance of dopamine-receptor blockade for the 
action of neuroleptic drugs. In: Brill H, Cole J, Deniker P, Hippius H, Bradley 
PB, editors. Neuropsychopharmacol. Proc 5th Coll. Int Neuropsychopharmacol. 
Excerpta Medica Foundation; 1967. p. 321–9.
19. van Kammen DP. The dopamine hypothesis of schizophrenia revisited. Psy-
choneuroendocrinology. 1979;4:37–46.
20. Seeman P. Are dopamine D2 receptors out of control in psychosis? Prog. 
Neuropsychopharmacol. Biol. Psychiatry. Elsevier B.V.; 2013;46:146–52.
21. Rahmim A, Zaidi H. PET versus SPECT: strengths, limitations and challeng-
es. Nucl. Med. Commun. 2008;29:193–207.
22. Hicks RJ, Hofman MS. Is there still a role for SPECT-CT in oncology in the 
PET-CT era? Nat. Rev. Clin. Oncol. 2012;9:712–20.
23. Ter-Pogossian MM, Phelps ME, Hoffman EJ, Mullani N A. A positron-emission 
transaxial tomograph for nuclear imaging (PETT). Radiology. 1975;114:89–98.
24. Peterson TE, Furenlid LR. SPECT detectors: the Anger Camera and beyond. 
Phys. Med. Biol. 2011;56:R145–82.
23Introduction 1
25. Slomka PJ, Pan T, Berman DS, Germano G. Advances in SPECT and PET 
Hardware. Prog. Cardiovasc. Dis. Elsevier B.V.; 2015;57:566–78.
26. Gunn RN, Slifstein M, Searle GE, Price JC. Quantitative imaging of pro-
tein targets in the human brain with PET. Phys. Med. Biol. IOP Publishing; 
2015;60:R363-411.
27. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ. A quantitative 
model for the in vivo assessment of drug binding sites with positron emission 
tomography. Ann. Neurol. 1984;15:217–27.
28. Dierckx RAJO, Otte A, de Vries EFJ, van Waarde A, Luiten PGM, editors. PET 
and SPECT of Neurobiological Systems. Berlin, Heidelberg: Springer Berlin Hei-
delberg; 2014.
29. Booij J, Tissingh G, Winogrodzka A, van Royen EA. Imaging of the dopamin-
ergic neurotransmission system using single-photon emission tomography and 
positron emission tomography in patients with parkinsonism. Eur. J. Nucl. Med. 
Mol. Imaging. 1999;26:171–82.
30. Koeppe RA, Gilman S, Junck L, Wernette K, Frey KA. Differentiating Alzhei-
mer’s disease from dementia with Lewy bodies and Parkinson’s disease with 
(+)-[11C]dihydrotetrabenazine positron emission tomography. Alzheimers. De-
ment. 2008;4:S67-76.
31. Brooks DJ. Imaging approaches to Parkinson disease. J. Nucl. Med. 
2010;51:596–609.
32. Abi-Dargham A, Moore H. Prefrontal DA transmission at D1 receptors and 
the pathology of schizophrenia. Neuroscientist. 2003;9:404–16.
33. Laruelle M. Imaging synaptic neurotransmission with in vivo bind-
ing competition techniques: a critical review. J. Cereb. Blood Flow Metab. 
2000;20:423–51.
34. Laruelle M. Measuring Dopamine Synaptic Transmission with Molecular Im-
aging and Pharmacological Challenges: The State of the Art. Neuromethods. 
2012. p. 163–203.
35. Koepp MJ, Gunn RN, Lawrence AD, Cunningham VJ, Dagher A, Jones T, 
et al. Evidence for striatal dopamine release during a video game. Nature. 
1998;393:266–8.
36. Kim J-H, Son Y-D, Kim H-K, Lee S-Y, Cho S-E, Kim Y-B, et al. Effects of age 
24 Chapter 1
on dopamine D2 receptor availability in striatal subdivisions: a high-resolution 
positron emission tomography study. Eur. Neuropsychopharmacol. Elsevier 
B.V.; 2011;21:885–91.
37. Abi-Dargham A. Do we still believe in the dopamine hypothesis? New data 
bring new evidence. Int. J. Neuropsychopharmacol. 2004;7 Suppl 1:S1-5.
38. Abi-Dargham A, van de Giessen E, Slifstein M, Kegeles LS, Laruelle M. Base-
line and amphetamine-stimulated dopamine activity are related in drug-na-
ïve schizophrenic subjects. Biol. Psychiatry. Society of Biological Psychiatry; 
2009;65:1091–3.
39. Volkow ND, Fowler JS, Wang G-J, Swanson JM. Dopamine in drug abuse and 
addiction: results from imaging studies and treatment implications. Mol. Psy-
chiatry. 2004;9:557–69.
40. De Lean A, Stadel JM, Lefkowitz RJ. A ternary complex model explains the 
agonist-specific binding properties of the adenylate cyclase-coupled beta-adr-
energic receptor. J. Biol. Chem. 1980;255:7108–17.
41. Kenakin T. Efficacy at G-protein-coupled receptors. Nat. Rev. Drug Discov. 
2002;1:103–10.
42. Weiss J. The Cubic Ternary Complex Receptor–Occupancy Model I. Model 
Description. J. Theor. Biol. 1996;178:151–67.
43. Stein RSL, Ehlert FJ. A kinetic model of GPCRs: analysis of G protein activ-
ity, occupancy, coupling and receptor-state affinity constants. J. Recept. Signal 
Transduct. Res. 2014;0:1–15.
44. Lahti RA, Figur LM, Piercey MF, Ruppel PL, Evans DL. Intrinsic activity de-
terminations at the dopamine D2 guanine nucleotide-binding protein-coupled 
receptor: utilization of receptor state binding affinities. Mol. Pharmacol. ASPET; 
1992;42:432–8.
45. Ruffolo RR. Review important concepts of receptor theory. J. Auton. Phar-
macol. 1982;2:277–95.
46. Seeman P, Schwarz J, Chen J, Szechtman H, Perreault M, McKnight GS, 
et al. Psychosis pathways converge via D2high dopamine receptors. Synapse. 
2006;60:319–46.
47. Graff-Guerrero A, Mizrahi R, Agid O, Marcon H, Barsoum P, Rusjan P, et al. 
The dopamine D2 receptors in high-affinity state and D3 receptors in schiz-
25Introduction 1
ophrenia: a clinical [11C]-(+)-PHNO PET study. Neuropsychopharmacology. 
2009;34:1078–86.
48. Narendran R, Martinez D, Mason NS, Lopresti BJ, Himes ML, Chen C-M, et al. 
Imaging of dopamine D2/3 agonist binding in cocaine dependence: A [
11C]NPA 
positron emission tomography study. Synapse. 2011;65:1344–9.
49. Skinbjerg M, Sibley DR, Javitch JA, Abi-Dargham A. Imaging the high-affinity 
state of the dopamine D2 receptor in vivo: Fact or fiction? Biochem. Pharmacol. 
Elsevier Inc.; 2012;83:193–8.
50. Cumming P, Wong DF, Gillings N, Hilton J, Scheffel U, Gjedde A. Specific bind-
ing of [11C]raclopride and N-[3H]propyl-norapomorphine to dopamine receptors 
in living mouse striatum: occupancy by endogenous dopamine and guanosine 
triphosphate-free G protein. J. Cereb. Blood Flow Metab. 2002;22:596–604.
51. Narendran R, Hwang D-R, Slifstein M, Talbot PS, Erritzoe D, Huang Y, et 
al. In vivo vulnerability to competition by endogenous dopamine: compari-
son of the D2 receptor agonist radiotracer (−)-N-[
11C]propyl-norapomorphine 
([11C]NPA) with the D2 receptor antagonist radiotracer [
11C]-raclopride. Synapse. 
2004;52:188–208.
52. Ginovart N, Galineau L, Willeit M, Mizrahi R, Bloomfield PM, Seeman P, 
et al. Binding characteristics and sensitivity to endogenous dopamine of 
[11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state 
of D2 receptors in vivo using positron emission tomography. J. Neurochem. 
2006;97:1089–103.
53. Gallezot JD, Kloczynski T, Weinzimmer D, Labaree D, Zheng MQ, Lim K, et 
al. Imaging Nicotine- and Amphetamine-Induced Dopamine Release in Rhesus 
Monkeys with [11C]PHNO vs [11C]raclopride PET. Neuropsychopharmacology. 
2013;866–74.
54. Narendran R, Mason NS, Laymon CM, Lopresti BJ, Velasquez ND, May 
MA, et al. A comparative evaluation of the dopamine D2/3 agonist radiotracer 
[11C](−)-N-propyl-norapomorphine and antagonist [11C]raclopride to measure 
amphetamine-induced dopamine release in the human striatum. J. Pharmacol. 
Exp. Ther. 2010;333:533–9.
55. Shotbolt P, Tziortzi AC, Searle GE, Colasanti A, van der Aart J, Abanades S, 
et al. Within-subject comparison of [11C]-(+)-PHNO and [11C]raclopride sensitiv-
ity to acute amphetamine challenge in healthy humans. J. Cereb. Blood Flow 
Metab. 2012;32:127–36.
26 Chapter 1
56. Keng PY, Esterby M, Dam RM Van. Emerging Technologies for Decentral-
ized Production of PET Tracers. In: Hsieh C-H, editor. Positron Emiss. Tomogr. 
– Curr. Clin. Res. Asp. InTech; 2012. p. 153–82.
57. Krohn KA, Mankoff DA, Muzi M, Link JM, Spence AM. True tracers: comparing 
FDG with glucose and FLT with thymidine. Nucl. Med. Biol. 2005;32:663–71.
58. Vasdev N, Seeman P, Garcia A, Stableford WT, Nobrega JN, Houle S, et al. 
Syntheses and in vitro evaluation of fluorinated naphthoxazines as dopamine 
D2/D3 receptor agonists: radiosynthesis, ex vivo biodistribution and autoradiog-
raphy of [18F]F-PHNO. Nucl. Med. Biol. 2007;34:195–203.
59. Kiesewetter DO, Brücke T, Finn RD. Radiochemical synthesis of [18F]fluoror-
aclopride. Int. J. Rad. Appl. Instrum. A. 1989;40:455–60.
60. Conti M, Eriksson L. Physics of pure and non-pure positron emitters for PET: 
a review and a discussion. EJNMMI Phys. EJNMMI Physics; 2016;3:8.
61. Finnema SJ, Bang-Andersen B, Wikström H V, Halldin C. Current state of 
agonist radioligands for imaging of brain dopamine D2/D3 receptors in vivo with 
positron emission tomography. Curr. Top. Med. Chem. 2010;10:1477–98.
62. Shi B, Narayanan TK, Christian BT, Chattopadhyay S, Mukherjee J. Synthesis 
and biological evaluation of the binding of dopamine D2/D3 receptor agonist, 
(R,S)-5-hydroxy-2-(N-propyl-N-(5’-[18]F-fluoropentyl)aminotetralin ([18]F-5-OH-
FPPAT) in rodents and nonhuman primates. Nucl. Med. Biol. 2004;31:303–11.
63. Mukherjee J, Majji D, Kaur J, Constantinescu CC, Narayanan TK, Shi B, et 
al. PET radiotracer development for imaging high-affinity state of dopamine 
D2 and D3 receptors: Binding studies of fluorine-18 labeled aminotetralins in 
rodents. Synapse. 2016 Nov 19;1–15.
64. Finnema SJ, Stepanov V, Nakao R, Sromek AW, Zhang T, Neumeyer JL, et al. 
[18F]-MCL-524, an 18F-Labelled Dopamine D2 and D3 Receptor Agonist Sensitive 
to Dopamine: A Preliminary PET Study. J. Nucl. Med. 2014;55:1164–70.
65. van Wieringen J-P. Evaluation of potential agonist radioligands for imaging 
dopamine D2/3 receptors. University of Amsterdam; 2015.
66. Mewshaw RE, Kavanagh J, Stack G, Marquis KL, Shi X, Kagan MZ, et al. 
New generation dopaminergic agents. 1. Discovery of a novel scaffold which 
embraces the D2 agonist pharmacophore. Structure-activity relationships of a 




Hunting for the high-affinity state 
of G-protein coupled receptors 




Non-invasive imaging of synaptic neurotransmitter receptors with positron 
emission tomography (PET) provides insights into the number of receptors 
expressed in the brain and the functioning of brain networks. Analysis of the 
imaging data yields information about the role of particular neurotransmit-
ters in the functioning of the brain in health as well as in neuropsychiatric 
disorders, including syndromes characterized by cognitive dysfunctions.
Receptors that neurotransmitters bind to are either ligand-gated ion chan-
nels (LGICs) or G-protein coupled receptors (GPCRs). For some neurotrans-
mitters, all receptors belong to a single receptor superfamily, e.g. all known 
dopamine receptors are GPCRs. Some bind to receptors from both super-
families, e.g. there are LGIC-type and GPCR-type receptors of the neu-
rotransmitters acetylcholine and glutamate.
The signaling mechanism of LGICs is comparatively simple and quick – neu-
rotransmitter binding opens the ionic channel that the receptor itself forms. 
Quick (millisecond time scale) and usually short-lasting postsynaptic re-
sponse is thus obtained. GPCRs, on the other hand, affect their downstream 
signaling pathways through mediation of trimeric proteins called G-proteins 
(Figure 1). The GPCR signaling mechanism is slower (second time scale) and 
more energy-consuming than that of LGICs, but longer lasting and much 
more versatile. Due to this versatility, GPCRs are the most popular targets 
for drugs used in clinical practice [1,2].
In vitro studies in membrane homogenates from cultured cells or isolated 
tissues have shown that in a single population of GPCRs to which antagonist 
drugs have single affinity, agonist drugs recognize two distinct receptor sub-
populations: one for which they have high affinity and one for which they 
have low affinity. The existence of a receptor subpopulation that possesses 
high-affinity towards the agonists (dubbed “high-affinity state”, Rhigh) has 
been demonstrated for numerous neurotransmitter GPCRs including dopa-
minergic [3,4], serotonergic [5–7], muscarinic [8] and opioid receptors [9]. 
The high-affinity state is commonly thought to be composed of receptor 
molecules bound to G-proteins.
The relationship between G-protein coupling and high affinity towards the 
agonist gave rise to a hypothesis that the relative abundance of Rhigh may 
characterize the responsiveness of the synaptic signaling machinery to ago-
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nist levels. Indeed, alterations of the fraction of receptors configured in the 
high-affinity state, as measured in membrane homogenates, were found in 
pathological states associated with dysregulation of neurotransmission. For 
instance, the relative abundance of the high affinity state of µ-opioid recep-
tors was decreased in guinea pigs after chronic morphine treatment [10], 
while the high-affinity state of muscarinic M1 receptors was downregulated 
in Alzheimer’s disease [11,12]. Upregulation of the high-affinity state of do-
pamine D2 receptors has been reported in several animal models of psycho-
sis [13,14].
Figure 1. Simplified signaling mechanisms of ligand-gated ion channels (A) and 
G-protein coupled receptors (B).
Assessing the availability of Rhigh may, therefore, provide more valuable 
information about the state of neurotransmission in vivo than assessing 
the availability of total receptors. Given that agonists preferentially bind to 
Rhigh, this hypothesis spurred the development of agonist PET tracers and 
their use for neuroreceptor imaging.
In this chapter we will review and discuss the molecular basis of the high-
affinity state, inherent advantages and shortcomings of agonist PET tracers 
stemming from their preferential binding to the high-affinity state, agonist 
PET tracers currently available for receptor imaging in vivo, experimental 
methods used for the imaging of high-affinity state in vivo and evidence 
collected with these methods.
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2. Nature of the high-affinity state of GPCRs
2.1. G-protein-dependent high-affinity state
The canonical view of the nature of the high-affinity state is based on the so-
called ternary complex model of G-protein signaling which originates from 
the studies of agonist binding to β-adrenergic receptors in membrane ho-
mogenates [15,16]. This model claims that in order to launch the G-protein 
signaling cascade, a “ternary” complex must form, consisting of agonist, 
receptor and G-protein. Positive cooperativity between receptor-agonist 
and receptor-G-protein binding creates the separation of the total receptor 
population into high and low-affinity states. For the agonist, receptors com-
plexed with G-proteins form the high-affinity state, whereas free receptor 
molecules represent the low-affinity state. Indeed, the preference of agonist 
ligands for the G-protein-bound high-affinity state was found to correlate 
with their intrinsic activity [17–19].
Several newer and more sophisticated versions of the ternary complex model 
have been developed in order to account for such pharmacological phenom-
ena as constitutive activity (presence of baseline signaling in the absence 
of agonists) and inverse agonism (existence of ligands that decrease rather 
than increase the level of signaling relative to baseline). These models imply 
the existence of more than two receptor species with different affinities for 
the agonist, but the main premise remains the same: G-protein binding is 
the main factor that determines the receptor’s affinity towards the agonist 
[20,21].
An important feature of the G-protein dependent high-affinity state is its 
sensitivity to guanosine triphosphate (GTP). Indeed, the high-affinity state 
of GPCRs detected in membrane homogenates usually disappears upon GTP 
addition [3–9]. The reason for this is that the canonical G-protein signal-
ing cascade involves the so-called GTP cycle (Figure 2). G-proteins are het-
erotrimers, and one of their subunits, Gα, has a binding site for guanosine 
nucleotide (this gives G-proteins their name). In an inactive G-protein, this 
site is occupied by guanosine diphosphate (GDP). Upon G-protein activation 
by an agonist-bound receptor, GDP is replaced by GTP from the cytoplasm, 
which leads to the dissociation of Gα-subunit from the Gβ and Gγ subunits 
(together referred to as Gβγ). The G-protein splits into two halves, which 
then activate downstream effectors. If the G-protein uncouples from the re-
ceptor, the receptor quickly relaxes into its inactive “low-affinity” state [22]. 
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Eventual hydrolysis of GTP to GDP in the Gα subunit lets the G-protein reas-
semble and bind to the receptor again, which closes the cycle [23].
Therefore, the GTP cycle acts as a negative feedback loop, promoting G-pro-
tein decoupling from the receptors and their (temporary) conversion into 
the low-affinity state after agonist binding. Excess GTP shifts the equilib-
rium towards complete dissociation of G-proteins from the receptors.
Figure 2. GPCR activation (left circuit) and GTP cycle (right circuit, light orange 
arrows).
2.2. Oligomerization-dependent high-affinity state
The growing amount of evidence on GPCR oligomerization in cultured 
cells and living tissues [24] and on the pharmacological relevance of such 
oligomerization (see [25] for review) has given rise to the concept of oligo-
merization-dependent high-affinity state. When the agonist interacts with 
a receptor oligomer, occupying and activating a single receptor unit with-
in it, conformational changes in this receptor influence the conformation 
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of  other receptors within the same oligomer and decrease their affinity 
for other agonist molecules (Figure 3). In other words, separation into high- 
and low-affinity states is caused by negative cooperativity effects in the ago-
nist binding to oligomerized receptors [26].
Figure 3. Oligomerization-dependent high-affinity state.
Receptor oligomerization is arguably mainly relevant for the explanation 
of the interplay between signaling pathways of different types of receptors 
[25]: interaction between oligomer subunits is conceptually simpler than 
interference of downstream cascades. However, among data from radioli-
gand binding studies there are also some results that are better explained 
by oligomerization than by G-protein coupling, such as (i) GTP-insensitive 
high-affinity agonist binding to dopamine D3 and serotonin 5-HT2A recep-
tors [27,28], (ii) detection of high- and low-affinity states of adenosine 
A2A receptors by antagonist ligands [29] and (iii) detection of several (more 
than two) binding sites with different affinities to agonists in the muscarinic 
M2 receptor population [30].
If there is cooperativity between receptor-agonist and receptor-receptor 
interaction, agonist binding might influence the degree of receptor oligo-
merization. Some studies indeed report such phenomena [31,32], but, in 
general, experimental data on the relationship between ligand binding and 
oligomerization are contradictory both in terms of whether ligand binding 
really promotes formation or dissociation of oligomers and whether this ac-
tion is correlated with intrinsic activity (see [33,34] for review).
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22.3. Influence of agonist binding on the high-affinity stateIn both G-protein-coupling and oligomerization-dependent models of high-
affinity state, agonist binding to the receptor influences receptor interaction 
with other molecules and thus can alter the relative abundance of the high-
affinity state.
G-protein-dependent high-affinity state: Under conditions where no feedback 
loops are present, as is the case with in vitro binding studies with non-living 
material like membrane homogenates and tissue slices, the relationship be-
tween agonist concentration and percentage of receptors in the high-affin-
ity state at equilibrium is straightforward. In the absence of GTP, agonist 
binding can only increase G-protein recruitment. Therefore, increasing ago-
nist concentration will make the percentage of receptors in the “G-protein-
dependent” high-affinity state grow from some “floor” value (see section 
2.5) to the “ceiling” value, determined by receptor-G-protein stoichiometry 
in the system (100% if the number of available G-proteins is greater than 
or equal to the number of receptors). On the other hand, in the presence of 
excess GTP (or its analogs) and negligible GTP hydrolysis, all G-proteins ac-
tivated by agonist-bound receptors will be dissociated and uncoupled from 
the receptors, so at any agonist concentration there will be no discernible 
high-affinity state.
In living cells and tissues, however, the GTP cycle plays the role of a nega-
tive feedback loop, which counteracts excess high-to-low or low-to-high 
conversion of affinity states caused by the agonist. Depending on the com-
bination of concentrations and kinetic rates, either G-protein-recruiting 
or G-protein-dissociating effects of agonist can become dominant. Indeed, 
mathematical simulations of GPCR signaling have demonstrated the pos-
sibility of both agonist-induced increases and agonist-induced decreases in 
the relative abundance of the G-protein-dependent high-affinity state [21].
Oligomerization-dependent high-affinity state: Negative cooperativity in 
agonist binding to oligomerized receptors implies that increasing agonist 
concentration will bring more and more receptors into “low-affinity state”. 
The percentage of receptors in the high-affinity state, equal to 100% in the 
absence of agonist, will decrease to 100% / N (N is the average number of 
receptors per oligomer) when the agonist occupies one receptor unit in each 
oligomer, converting all the other units to low-affinity state. When agonist 
concentration raises so high that agonists start to occupy receptors in the 
low-affinity state, the relative abundance of the high-affinity state will fall 
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even lower. There are no well described and widely accepted feedback loops 
for the oligomerization-dependent model of the high-affinity state.
2.4. Agonist-induced receptor internalization
Activation of GPCRs by agonists promotes not only G-protein binding 
to them, but also their phosphorylation by G-protein coupled receptor 
kinases (GRK) and internalization mediated by β-arrestins [35]. This pro-
vides an extra pathway through which the agonist can influence the relative 
abundance of the high-affinity state. Internalized receptors are de-coupled from 
G-proteins (coupled to β-arrestins instead) and removed from the cell 
surface to intracellular compartments, where the ionic environment and 
pH value can be different from extracellular conditions. This makes inter-
nalized receptors less accessible (especially for hydrophilic ligands) and 
possibly also alters their affinity towards their ligands.
In vitro, β-arrestin recruitment can happen within minutes [36,37]. Inter-
nalization of dopamine D2/3 receptors was observed within the same time-
frame in vivo and was shown to be dose-dependent [38]. Although it is not 
yet clear whether internalization mainly happens to receptors in the low- or 
in the high-affinity state [39,40], internalized D2/3 receptors on intact cells 
and µ-opioid receptors incubated in a buffer imitating endosomal medium 
were shown to have decreased affinities towards their ligands [41,42].
Therefore, high concentrations of agonist can launch receptor internaliza-
tion and change the number and relative abundances of receptor subpopu-
lations with different affinities towards imaging radioligands. On the other 
hand, in internalization-deficient β-arrestin knockout mice, baseline bind-
ing of D2/3 agonist and antagonist tracers was the same as in wild type-con-
trols [43]. Perhaps, then, basal neurotransmitter levels in the living brain 
establish a dynamic equilibrium between receptor internalization and recy-
cling.
2.5. Relative abundance of high-affinity state in the absence 
of the agonist
The oligomerization-dependent model of the high-affinity state implies 
that this is the state in which all receptors are configured in the absence 
of the agonist.
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For the G-protein-dependent high-affinity state, its baseline relative abun-
dance, that is, the degree to which G-proteins interact with the receptors 
in the absence of agonist, is a matter of debate (see [44,45] for review). One 
extreme view, called collision coupling (Figure 4A), states that in living cells 
G-proteins are not normally bound to the receptors, but instead interact with 
them transiently when receptors become activated [46]. Another extreme 
view (Figure 4B) states that G-proteins are always bound (“pre-coupled”) 
to the receptors, and do not decouple even after activation, which happens 
through structural rearrangement of the G-protein rather than through dis-
sociation [47–49].
On the one hand, collision coupling provides a straightforward interpre-
tation of differences in intrinsic activities of the agonists: agonist efficacy 
is related to the number of different G-proteins that an agonist-bound 
receptor can bind and activate per unit of time. Decoupling of G-proteins 
from the receptors upon activation explains the disappearance of the high-
affinity state upon GTP addition in membrane homogenates. On the other 
hand, receptors and G-proteins are known to be co-isolated by immunopre-
cipitation, and bioluminescence and fluorescence resonance energy transfer 
(BRET/FRET) experiments with mutated proteins incorporating fluorescent 
or bioluminescent probe demonstrate close contact between receptors and 
G-proteins in the absence of agonists [44]. Moreover, in BRET studies with 
α2 adrenergic and δ-opioid receptors, these receptors were found to interact 
with G-proteins both before and after activation by agonist [48,49].
Middle courses between the extreme views are of course possible, where 
some G-proteins are bound to receptors at baseline but decoupled upon ac-
tivation, or where G-proteins are uncoupled at baseline but become bound 
to receptors upon activation. Moreover, BRET and FRET experiments image 
the whole population of the receptors, so constant presence of a RET sig-
nal, while showing that a fraction of receptors is engaged with G-proteins, 
does not exclude the possibility of a rapid turnover of G-proteins with which 
these receptors interact.
2.6. Summary
The existence of high- and low-affinity states of GPCRs is commonly thought 
to be due to receptor interaction with G-proteins. Being a part of the canoni-
cal GPCR signaling cascade, receptor-G-protein coupling is directly related 
to the pharmacological activity of the agonists.
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GPCR oligomerization (both homo- and hetero), with negative cooperativ-
ity in agonist binding within the oligomer, can be an alternative mechanism 
leading to the formation of receptor subpopulations with different affinities 
for the agonist. It is plausible that at least for some GPCRs oligomeriza-
tion may contribute to the splitting of receptors into high- and low-affinity 
states instead of, or in addition to, G-protein coupling.
Figure 4. Two extreme modes of receptor-G-protein interaction.
In the collision-coupling model (A), G-proteins do not stably interact with receptors, but ago-
nist action on the receptor promotes G-protein recruitment to and activation by the receptors, 
which results in the dissociation of G-proteins. In the pre-coupling model (B), G-proteins are 
stably bound to the receptors, and rearrange their structures upon activation instead of dis-
sociating.
Both models of high-affinity state imply that agonists preferentially bind 
to receptors that are most ready to launch the signaling cascade, although 
in the oligomerization model it is so just because agonist binding makes 
unoccupied receptors “less ready”. Moreover, agonist binding can influence 
the relative abundance of the high-affinity state, potentially promoting its 
formation or disintegration and launching receptor internalization in intact 
cells and living tissues. Such influence is most directly demonstrated for the 
G-protein-dependent model of the high-affinity state.
3. Expected advantages and disadvantages of agonist 
tracers relative to antagonist tracers
From the notion that agonists preferentially bind to a high-affinity func-
tional subset of receptors, one can logically infer a number of applications 
in which agonist tracers should be superior, at least in theory, to antagonist 
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tracers. Note that proposed advantages of agonist tracers mentioned below 
hold independently of whether the high-affinity state is G-protein-depen-
dent or oligomerization-dependent.
3.1. Applications where agonist tracers have comparative 
advantage over antagonist tracers
3.1.1. Measurement of synaptic neurotransmission
An endogenous neurotransmitter is an agonist by definition, so it competes 
with the agonist tracer for the same subset of receptors – receptors config-
ured in high-affinity state – while an antagonist tracer also binds to receptors 
in the low-affinity state that are “ignored” by the neurotransmitter except at 
very high concentrations. This means that a change in the concentration of 
neurotransmitter of a given magnitude will lead to a greater change in ago-
nist tracer binding compared to antagonist tracer binding (Figure 5).
For receptors such as serotonin receptors where until recently no antago-
nist ligands appeared to be clearly sensitive to alterations of endogenous 
neurotransmitter levels [50], development of agonist ligands is considered 
a promising path to achieve the goal of measuring synaptic neurotransmis-
sion [51].
3.1.2. Studies of (pathological) alterations in receptor signaling
In Section 1, a few examples were given of how alterations of the percent-
age of receptors configured in the high-affinity state can accompany dis-
ease. Such findings indicate that the relative abundance of the high-affinity 
state may be a better marker of the “normality” of the receptor population 
than total receptor density. Agonist tracers should then be a convenient tool 
for pinpointing alterations of the availability of receptors configured in the 
high-affinity state in disease.
The results of some in vitro experiments with agonist and antagonist ra-
dioligands have supported the hypothesis that agonist tracers are superi-
or to antagonists in detecting pathological changes in neuroreceptor sig-
naling. In vitro binding of the serotonin 5-HT1A agonists [
18F]F15599 and 
[18F]F13640, but not of the antagonist [18F]MPPF, in post-mortem brain 
sections of Alzheimer patients was decreased compared to control brains 
[52,53]. In unilateral 6-hydroxydopamine-induced lesions of the rat brain 
(exhibiting dopaminergic neurodegeneration similar to Parkinson’s disease 
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in humans, where upregulation of Rhigh is hypothesized), the ex vivo bind-
ing of dopamine D2/3 agonist [
3H]NPA was changed to a greater extent than 
the in vitro binding of D2/3 antagonist [
3H]raclopride [54].
Figure 5. Greater sensitivity of agonist tracers to displacement (“challenge”) by 
neurotransmitter.
Agonist tracers primarily bind to the receptors configured in the high-affinity state, as do neu-
rotransmitters. Therefore, the same change in receptor occupancy by the neurotransmitter 
displaces greater fraction of bound agonist tracer (A) than of bound antagonist tracer (B).
3.1.3. Measurement of agonist drug occupancy
Many drugs owe their effect to their agonist activity at one or more kinds 
of receptors. For instance, many antiparkinsonian drugs are D2/3 agonists 
41
Hunting for the high-affinity state of G-protein coupled receptors with agonist PET tracers: 
theoretical and practical considerations
2
[55]; muscarinic receptor agonists like milameline were tried as treatment 
for Alzheimer’s disease [56]; the mechanism of action of antipsychotics may 
include not only D2/3 antagonism but also 5-HT1A agonism [57,58]; the active 
metabolite of clozapine (also an atypical antipsychotic) acts as an agonist at 
muscarinic M1 receptors [59]; opiate agonists are widely used as analgesics 
or antitussives and for treating diarrhea and opiate abuse [60].
Increased sensitivity of agonist tracers to displacement by agonist drugs 
can help in occupancy studies: opioid receptor antagonist [11C]diprenorhin 
failed to detect receptor occupancy by clinically relevant doses of opioid 
agonists [61,62].
Agonist tracers can also complement antagonist tracers in the investigations 
of the affinity-state preference of new drugs. The sensitivities of agonist and 
antagonist tracers to the displacement by the drug can be compared: drugs 
preferring the high-affinity state will displace the agonist tracer more read-
ily, while drugs not distinguishing between affinity states will show no dif-
ference in displacement efficacy. Two studies attempting this approach have 
been published [63,64], but both reported equal displacement of agonist and 
antagonist tracers by the drug, which can be interpreted in two ways: either 
the tested drugs were ideal antagonists, or the hypothesis of greater agonist 
tracer displacement by agonist drug does not hold.
3.2. Intrinsic shortcomings of agonist tracers
Though the preference for the high-affinity state makes agonist tracers po-
tentially superior to antagonists in certain imaging applications, it also re-
sults in a number of specific difficulties associated with development and 
use of agonist tracers.
3.2.1. Lower signal-to-noise ratios
The signal-to-noise ratio of a PET tracer is proportional to the density of 
receptors the tracer can bind to in the brain (Bavail) and to the tracer’s affinity 
towards these receptors (1/Kd). The density of receptors configured in the 
high-affinity state (and thus recognized by agonist tracers) is by definition 
lower than the total receptor density.
Moreover, in the G-protein dependent model of the high-affinity state, ago-
nist binding to the receptor promotes eventual decoupling of G-protein and 
the relaxation of the receptor into the low-affinity state. Although, as men-
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tioned above, the net effect of agonist binding on the relative abundance of 
the high-affinity state can be both positive and negative, negative feedback 
in the form of the GTP cycle can decrease effective affinity of the agonist to-
wards the receptors relative to what is measured in membrane homogenates 
in the absence of GTP. Indeed, GTP depletion was shown to increase the af-
finity of agonist, but not antagonist ligands to opioid receptors in cultured 
cells [65].
Therefore, affinity and non-specific binding requirements for agonist trac-
ers are stricter than for antagonists.
3.2.2. Greater likelihood of unwanted pharmacological effects
As agonist tracers preferentially bind to the functional subpopulation of the 
receptors, a lower dose of them is needed to induce significant physiological 
responses, which can distort the experimental results and cause discomfort 
to the patients.
Indeed, staying below the pharmacological dose range is a concern in opi-
oid receptor imaging with agonist tracers [66–68]. It was also reported as 
a potential concern in serotonin 5-HT1A receptor imaging with the agonist 
[11C]CUMI-101 [69], even though first tests of the same compound in humans 
showed no adverse effects [70]. Exceeding the pharmacological threshold 
is especially easy with tracers that have complex labeling chemistry. For 
instance, the dopamine D2/3 receptor agonist [
11C](+)PHNO was originally 
labeled via a four-step route, resulting in a relatively low achievable spe-
cific radioactivity [71]. As a consequence, a high incidence of nausea (em-
esis is a typical effect of D2 agonism) was reported in patients injected with 
[11C](+)PHNO [72], and it was later found that [11C](+)PHNO human PET 
studies had frequently been performed under non-tracer conditions [73].
4. Existing PET agonist tracers for GPCR imaging 
in the central nervous system
The greatest number of agonist PET tracers has been developed for the im-
aging of dopamine D2/3 receptors (see [74] for a review). Tracer development 
efforts in the last two decades have yielded a number of agonist radioligands 
for other receptors as well. The most promising agonist tracers developed 
for PET imaging of neuroreceptors are presented in Table 1.
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24.1. Definition and properties of an agonist tracerAn agonist tracer is usually defined as “a tracer based on a compound that 
has agonist activity at the receptors it binds to”. There are many ways to 
confirm and measure the degree of agonistic activity: behavioral or ex vivo 
studies examining the physiological effect of the drug, functional in vitro 
assays measuring the levels of certain secondary messengers or the recruit-
ing of proteins involved in signaling cascades to the receptors.
Because of the known correlation between intrinsic activity and the ratio 
of agonist affinities towards high- and low-affinity receptor states, it is of-
ten assumed to be self-evident that agonists preferentially bind to the high- 
affinity state. However, due to the existence of non-canonical signaling 
pathways, agonism does not necessarily imply preferential binding to re-
ceptor-G-protein complexes. One example is cariprazine, a drug which was 
recently labeled with carbon-11 and evaluated as a dopamine D2/3 recep-
tor tracer. This compound showed partial D2/3 agonist activity in secondary 
messenger assays, but did not recruit G-proteins in vitro [75–77]. Obser-
vations of G-protein recruitment may also differ between in vitro setups. 
For instance, [11C]CUMI-101, a tracer for serotonin 5-HT1A receptors, was 
defined as an agonist based on the [35S]GTPγS assay (indirect measurement 
of G-protein recruiting to the receptors) in membrane homogenates from 
cell cultures expressing recombinant human receptors, but was later found 
to act as an antagonist when the same assay was done in primate and rat 
brain homogenates [78,79].
Therefore, the most certain proof of the agonist radioligand’s preferential 
binding to the high-affinity state is directly demonstrating that it recog-
nizes high- and low- affinity states of its receptor in natural tissue or in 
transfected cell culture. It is worth noting that for some agonist tracers, 
confirmation of preferential binding to Rhigh in vitro followed in vivo evalu-
ation (compare [80] and [27]), while for some others the capability to discern 
affinity states in vitro was not assessed at all (see e.g. [81,82]).
4.2. In vivo evaluation of PET neuroreceptor tracers
Characteristics desirable for a PET tracer for brain imaging include the abil-
ity to pass the blood-brain-barrier, a low degree of metabolism, a high con-
trast between target (specific) and non-target (non-specific) binding, and 
pharmacokinetics that can be reliably quantified from a 60–90 minute-long 
PET scan (see e.g. [83–85] for review). Measuring synaptic neurotransmis-
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sion is an important application in brain imaging, therefore neuroreceptor 
tracers are tested for the sensitivity of their binding to endogenous neu-
rotransmitters, and agonists are supposed to be superior to antagonists in 
this regard.
Neuroreceptor tracers are usually evaluated in rodents or non-human pri-
mates before being moved to human studies. In non-human primates, one 
can investigate the binding of the tracers with high spatial detail using clini-
cal PET cameras. Evaluation in rodents is cheaper and enables the use of 
more invasive methods, but differences in rodent and primate physiology 
can be a confounding factor when the results are extrapolated to humans. 
In addition, the small size of rodents forces the researchers to use dedicated 
non-clinical “micro-PET” cameras and does not permit to reliably image 
minor brain structures. In order to strike the right balance between control-
lability of the experimental conditions and image quality, tracers are some-
times evaluated in (relatively) large mammals, such as cats or pigs.
4.3. Availability of agonist PET neuroreceptor tracers
Of the available agonist PET tracers, three are actively used in clinical re-
search: [11C](+)PHNO for the imaging of dopamine D2/3 receptors, [
11C]carfen-
tanil for the imaging of µ-opioid receptors and [18F]FP-TZTP for the imaging 
of muscarinic acetylcholinic M2 receptors [71,86,87]. For all of them, how-
ever, agonism is not considered the primary advantage. [11C](+)PHNO is the 
tracer currently considered the most sensitive to endogenous dopamine lev-
els, for reasons probably related to its agonism, but it appears to be more 
prized for its preferential (though not selective) binding to D3 receptors, 
compared to existing non-subtype-selective D2/3 antagonist ligands like 
[11C]raclopride [88]. [11C]carfentanil and [18F]TZTP are the only tracers avail-
able for the corresponding receptor subtypes, so there are no antagonist 
tracers with which they could be compared head-to-head.
Other agonist tracers for neuroreceptors can be separated into three cat-
egories. The first category includes tracers that have seen no or little use 
simply because they have been developed only recently. The biggest prog-
ress is achieved for the serotonin 5-HT1A receptor tracer [
11C]CUMI-101, 
the 5-HT2A receptor tracer [
11C]CIMBI-36 and the κ-opioid receptor tracer 
[11C]GR103545, which have already been successfully evaluated in humans 
[89–93]. Other agonists are the dopamine D2/3 tracer [
18F]MCL-524, the 
D2-selective tracer [
11C]SV-III-130, the putatively D3-selective tracer 
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[18F]7-OH-FHXPAT, the serotonin 5-HT1A receptor tracers [
18F]FECUMI-101, 
[18F]F13714 and [18F]F13640, the µ/κ opioid receptor tracers [11C]PEO and 
[18F]FE-PEO, and, finally, the κ-opioid tracers [11C]FEKAP, [11C]FKAP and 
11C]DKAP [94–104]. Note that this category includes a number of 
18F-versions of previously developed 11C-tracers, because the longer half-life 
of fluorine-18 makes such tracers more suitable for wide scale clinical use.
The second category contains tracers with decent imaging properties that 
have been eclipsed by their newer more successful derivatives. Such are the 
D2/3 tracers [
11C]5-OH-DPAT, [18F]FPPAT, [11C](−)NPA and [11C]MNPA that 
are eclipsed by [11C](+)PHNO, the 5-HT1A tracer [
18F]F15599 which is consid-
ered inferior to [18F]F13640 and [18F]F13714, [11C]CIMBI- 5 which is replaced 
by [11C]CIMBI-36, and [18F]sufentanil which was created as a longer half-life 
alternative to [11C]carfentanil but was not developed further [80,105–111].
Tracers from the third category are tracers with issues that hamper their 
routine application for research. For instance, two known tracers for 
D1/5 dopamine receptors, (R)-[
11C]SKF82957 and (S)-[11C]N-methyl-NNC 01-
0259 [112,113], form lipophilic metabolites that penetrate into the brain 
and confound the interpretation of the results, though this can be rem-
edied by inhibiting catechol-O-methyl transferase activity [114]. Tests of 
(S)-[11C]N-methyl-NNC 01-0259 sensitivity to endogenous dopamine levels 
yielded a negative result [115]. This halted further development of this tracer, 
although known D1/5 antagonist tracers are also insensitive to dopamine lev-
els [116]. The D3-selective agonist tracer [
18F]LS-3-134 was shown to spe-
cifically bind to D3 receptors in monkey brain, but specific binding was only 
measurable under dopamine depletion conditions [117]. The muscarinic 
M1 receptor tracer [
11C]AF-150(S) showed both specific binding and sensitiv-
ity to endogenous acetylcholine levels in rats, but the low signal-to-noise ra-
tios of this ligand cast doubt on its suitability for further research [118,119].
In order to demonstrate the preferential binding of agonist tracers to recep-
tor high-affinity state, a head-to-head comparison with reference tracers 
binding to all receptors (i.e. antagonist tracers) is required. For D1/5, D2/3, 
5-HT1A and 5-HT2A agonist tracers, counterpart antagonist tracers are avail-
able, which possess matching pharmacological selectivities (i.e. bind with 
similar relative affinities to the same receptor subtypes within the relevant 
region of interest as their “corresponding” agonist tracers) and, in case of 
D2/3 and 5-HT2A ligands, sensitivity to endogenous neurotransmitter levels 
[50,116,120,121]. The same is true for the κ-opioid agonist [11C]GR103545, 
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which was developed along with its antagonist counterpart [11C]LY2795050 
[122], and for the µ/κ-opioid agonist [11C]PEO, which can be used in conjunc-
tion with the µ-partial agonist and κ-antagonist [11C]buprenorphine [101]. 
For the µ-opioid agonist [11C]carfentanil, the M2 agonist [
18F]FP-TZTP and 
the M1 agonist [
18F]AF-150(S) there are no suitable antagonist counterparts 
[123,124]. In theory, non-selective antagonists can be used for head-to-
head comparison with concomitant blockade of receptors to which the an-
tagonist, but not the agonist, binds, but the reliability of such experimental 
schemes in vivo is questionable because of the possible pharmacological ef-
fects of such blockade.
In conclusion, agonist tracers with favorable imaging characteristics are 
available for dopamine D2/3, serotonin 5-HT1A and 5-HT2A, µ and κ-opioid 
and muscarinic M2 receptors. Agonist tracers for dopamine D1/5 and mus-
carinic M1 receptors have issues that make their use for PET imaging prob-
lematic. Preference for the high-affinity state in vitro has only been directly 
demonstrated for D1/5 and D2/3 tracers, some 5-HT1A tracers and the M1 tracer 
[18F]AF-150(S). Agonist tracers for D2/3, 5-HT1A, 5-HT2A and κ-opioid recep-
tors can be matched with antagonist tracers binding to the same receptors 
for head-to-head comparisons.
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25. Proving the existence of the high-affinity state in vivo5.1. Outcome measures of in vivo experiments
In vivo experiments with neuroreceptor radioligands measure the availabil-
ity of the receptors and changes in this availability in response to alterations 
of endogenous neurotransmitter levels or administration of exogenous 
drugs. Binding potentials and target/nontarget ratios are “raw” measures 
representing receptor availability, which can later be recalculated to recep-
tor densities or occupancies.
5.1.1. Binding potentials
The typical outcome measure of in vivo imaging experiments is the bind-
ing potential (BP), which is derived from the time-activity curves measured 
for the tissue of interest and blood plasma or other reference tissue using 
kinetic modeling approaches [188]. Binding potential represents a product 
of available binding site density (Bmax) and radioligand affinity to the bind-
ing sites (inverse of the dissociation constant, 1/Kd) and is equal to the ratio 
of the concentrations of specifically bound and free ligand in the tissue at 
equilibrium provided that radioligand dose is low enough (see Appendix for 
more explanation). Note that in vivo not all receptors may be available for 
binding, as they can be internalized, converted into low-affinity state (for an 
agonist) or occupied by neurotransmitter, so in the in vivo context the term 
Bavail is more suitable than Bmax.
Given the difficulty of determining the true concentration of the free ligand 
in the living tissue, other concentrations proportional to free ligand concen-
tration in tissue are substituted in its place. Specifically bound concentra-
tion is related to free plasma concentration (BPF), total plasma concentration 
(BPP) or “non-displaceable” concentration (BPND), i.e. total concentration of 
free and non-specifically bound ligand in the tissue [189]. It is reasonable to 
assume that free ligand concentrations in the plasma and in the interstitial 
liquid of the brain tissue are equal at equilibrium, so BPF can be considered 
the “true” BP.
5.1.2. Target/non-target ratios
When regions of interest are small relative to the PET camera resolution 
(i.e. subsections of rodent brain) it is often hard to obtain a reliable time-
activity curve with high temporal resolution. Also, in situations when a lot 
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of experimental conditions have to be tested and compared, it is often in-
feasible to obtain time-activity curves by PET or by killing large groups of 
animals at different time points. In such situations, one can take advantage 
of the “pseudo-equilibrium” state, when the concentration ratios between 
receptor-rich and receptor-free tissues remain constant even as absolute 
concentrations are changing. For a typical neuroreceptor ligand, one can 
reasonably expect the pseudo-equilibrium state to be reached within half an 
hour after injection. Once the time range in which the pseudo-equilibrium 
exists is validated, specific binding can be quantified from tissue concentra-
tions at a single time point within this time range. Such concentrations can 
be obtained by ex vivo dissection and radioactivity counting or from a static 
PET scan. Target/non-target concentration ratios can be used as is or be 
recalculated to specific binding ratios (SBRs):
where T and NT are radioligand concentrations in receptor-rich (“target”) 
and receptor-poor (“non-target”) regions of interest. Note that in the ab-
sence of specific binding SBR = 0, while T/NT = 1.
“Raw” specific binding, i.e. the difference between radioligand concentra-
tions in receptor-poor and receptor-rich regions can also be used as an out-
come measure. However, when specific binding is not normalized to the 
non-specific binding at the same time point, its value is prone to intra-sub-
ject variations in pharmacokinetics. Therefore, the use of binding ratios is 
preferred.
5.1.3. Available receptor density
Available receptor density (Bavail) can be estimated in a saturation experi-
ment. Specific binding of a radioligand is determined by two parameters: 
the density of binding sites in the region of interest (Bavail) and the affinity 
of the radioligand towards these receptors (Kd). To independently estimate 
these two parameters, specific binding of the ligand (i.e. binding potential or 
target/non-target ratio) has to be measured at least at two different injected 
doses (for radiotracers, injected dose is usually varied by changing molar 
radioactivity). Bavail can then be quantified by regression analysis.
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5.1.4. Receptor occupancy
Displacement of a tracer from the receptors by a competing ligand can be 
represented as a decrease in binding site density available to the tracer 
(Bavail). Bavail is proportional to BP, so receptor occupancy by unlabeled ago-
nist drug can be calculated as the change in binding potential or target-non-
target ratio after drug administration, relative to baseline. The same holds 
for the occupancy of the receptors by endogenous neurotransmitter, when 
drugs stimulating neurotransmitter release or depletion are administered.
5.2. Experimental paradigms used to demonstrate the existence 
of high-affinity state in vivo
In order to demonstrate that agonist tracers preferentially bind to a certain 
“high-affinity” subset of receptors in vivo three approaches have been used 
(summarized in Table 2). One approach is to directly measure the available 
binding site densities for agonist and antagonist tracers and demonstrate 
that the binding site density available to the agonist is lower. Another is 
to infer the ratio of high-affinity binding site density to total binding site 
density from the results of experiments where tracers compete for binding 
to the receptors with unlabeled ligands. A third approach is to demonstrate 
that agonist, but not antagonist, binding can be influenced by manipula-
tions of receptor-G-protein coupling.
It is important to emphasize that, in order to compare agonist and an-
tagonist tracers with each other, their pharmacological selectivity profiles 
(i.e. relative binding affinities towards different receptor subtypes) should 
be identical within the region of interest used for comparison. Otherwise 
any detected difference in binding behavior could be attributed to the rela-
tive preference of one of the tracers towards a certain receptor subtype.
In principle, all experiments described below can be performed not only 
with PET tracers labeled with short-lived positron-emitting isotopes, but 
also with radioligands labeled with long-lived isotopes such as tritium 3H. 
On the one hand, this makes the experimental paradigm non-translatable 
to the clinical setup. On the other hand, this enables the use of elegant 
approaches like the double-tracer study, where radioligands labeled with 
short-lived (e.g. 11C) and long-lived (e.g. 3H) isotopes are compared head-to-

























































































































































































































































































































































































































































































































































































































































































































Hunting for the high-affinity state of G-protein coupled receptors with agonist PET tracers: 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Hunting for the high-affinity state of G-protein coupled receptors with agonist PET tracers: 
theoretical and practical considerations
2
5.2.1. Approach 1: Comparing binding site densities
Saturation study
As explained above, a minimum of two different radioligand doses needs 
to be tested to estimate binding site density (Bavail). More doses will add 
precision and can reveal potential cooperativity effects or the presence of 
multiple binding sites with different affinities (e.g. receptor affinity states), 
provided that radioligand binding to all these sites is distinguishable from 
non-specific binding. However, published PET studies comparing binding 
site densities of agonist and antagonist tracers were restricted to two doses 
[136,192]. Another study used single-timepoint SBRs as outcome measure 
and built “real” 9–10-point saturation curves [158].
In two-dose PET-based experiments for Bavail quantification, the low dose 
corresponds to the minimum radioligand amount that can be injected, i.e. 
the “tracer dose”, which should occupy 10% or fewer receptors. The high 
dose is chosen to occupy about two thirds of all receptors [136,192].
Extracting density values from true binding potential measurements
It should be noted that performing a saturation assay with agonist radioli-
gands can lead to unwanted and dangerous pharmacological effects, espe-
cially in the case of opioid ligands [67,68].
In a head-to-head comparison of 5-HT1A agonist and antagonist tracers [69], 
Kumar and co-workers attempted to circumvent this problem by comparing 
the “true” binding potentials (BPF) for the two tracers at low injected dose 
instead of performing a second high-dose scan to independently measure 
Bavail and Kd. Given that BPF = Bavail/Kd, Bavail can arguably be calculated from 
the BPF value using in vitro Kd value for the corresponding tracer. However, 
there are two problems with this approach. First, in order to calculate BPF, 
one needs to obtain arterial input curve and free fraction in plasma for the 
investigated radioligand, in addition to time-activity curve for the region of 
interest. Such a large amount of input data makes BPF prone to experimental 
errors and biases. Second, the in vivo Kd of the radioligand is not necessarily 
equal to the in vitro Kd, especially if the latter is measured for receptors from 
a different animal species or in transfected cells.
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Studying correlation between regional binding of agonist and antagonist
Another approach to obtain insight into the relationship between available 
binding site densities for agonist and antagonist tracers while staying below 
the “tracer” threshold is to plot the binding potentials or target/non-target 
ratios measured for an agonist tracer in various brain regions against the 
corresponding measurements for an antagonist tracer and look at the cor-
relation.
If agonist binding in a certain brain region lies above the main trend on the 
correlation graph, it suggests that the relative abundance of receptors in the 
high-affinity state in this region is higher than average, and vice versa.
This approach, however, has many limitations. If the relative abundance of 
the high-affinity state is drastically different in each region, the correlation 
graph will be meaningless: there will be no main trend to pinpoint devia-
tions from. If the relative abundance of the high-affinity state is the same 
in all regions, the correlation graph will be a straight line, revealing no dif-
ferences in agonist and antagonist binding, and thus no evidence in favor 
of the existence of the high-affinity state. Therefore, analysis of the cor-
relation between agonist and antagonist binding cannot be the sole method 
of looking for the existence of high-affinity state, but can be an extra piece 
of data analysis in experiments based on other paradigms.
Studying agonist binding in disorders presumably caused 
by high-affinity state dysregulation
In vitro experiments in membrane homogenates suggest that some neuro-
logical disorders are accompanied by alterations in the relative abundance 
of the high-affinity state in a given receptor population, while changes in 
overall receptor density relative to the healthy condition are either absent 
or much less pronounced. One example is animal models of psychosis where 
the high-affinity state of D2/3 receptors is upregulated [13,198].
Therefore, another way to demonstrate the existence of high-affinity state 
in vivo is to show that its upregulation (or downregulation) can be non-
invasively detected by agonist tracers. If the relative abundance of high-
affinity state is altered, but the overall receptor density remains (relatively) 
constant, the binding of the agonist, but not of the antagonist tracer will be 
different in the diseased state relative to the healthy healthy state. Ratios of 
61
Hunting for the high-affinity state of G-protein coupled receptors with agonist PET tracers: 
theoretical and practical considerations
2
BP or SBR values for agonist and antagonist tracers can be used as outcome 
measures to normalize for possible concomitant alterations in total receptor 
density [199].
In this paradigm, the binding of each tracer only has to be assessed at a low 
pharmacologically inactive dose. However, one has to demonstrate that the 
relative abundance of high-affinity state really differs between healthy and 
diseased states, using experimental approaches other than PET (typically, 
in vitro assays). Moreover, in the diseased state, alteration of the relative 
abundance of the high-affinity state may be accompanied by alterations in 
other parameters relevant for radioligand binding. For instance, changes in 
baseline neurotransmitter levels also differentially affect the binding of ag-
onist and antagonist tracers (agonist binding is changed to a greater extent). 
Concomitant changes in several parameters pressing agonist tracer binding 
in different directions can offset each other, leading to little or no change in 
overall apparent receptor availability to the agonist tracer compared to the 
healthy state.
5.2.2. Approach 2: Studying tracer vulnerability to displacement 
by unlabeled competitor
One important difference between tracer-drug competition experiments in 
vitro and in vivo is that in the latter case the concentration of both tracer 
and drug at the receptors is not constant. While for the radioligand a true 
equilibrium between its concentrations in blood and brain tissue can be 
achieved by using bolus-plus-infusion injection scheme, the same is virtu-
ally infeasible for the unlabeled drug (tissue concentrations of which are 
much harder to monitor). Nevertheless, one can usually safely assume that 
the pharmacokinetics of the competing drug are dose-linear within the in-
vestigated dose range, so the degree of displacement of the tracer by the 
drug, ceteris paribus, is also dose-linear.
Building in vivo displacement curves
In vitro, the high-affinity state is detected by displacing an antagonist ra-
dioligand with ever increasing concentrations of unlabeled agonist drug. 
When the remaining specific binding of the radioligand is plotted against 
unlabeled agonist concentrations, the displacement is shown to proceed in 
two phases: agonist first displaces the radioligand from high-affinity sites, 
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then from low-affinity sites. The same displacement curve can be built in 
vivo by plotting binding potentials or target/non-target ratios for an an-
tagonist tracer against administered dose of unlabeled agonist drug.
The advantage of this paradigm is that it does not require an agonist radioli-
gand. Antagonist radioligands are much more numerous than agonist radio-
ligands, so displacement curve paradigm is currently applicable to a wider 
range of receptors than other paradigms mentioned below.
The downside, however, is that the generation of a displacement curve is a 
laborious undertaking. The shape of the biphasic curve is determined by five 
parameters: maximum binding level (at no displacement), minimum bind-
ing level (full displacement), agonist affinities for high- and low-affinity 
states and the percentage of receptors in the investigated population con-
figured in the high-affinity state. This means that at least five different dose 
levels (including zero) have to be used in order to test whether the obtained 
curve is mono- or biphasic.
Therefore, studies that employed the displacement curve approach typically 
used specific binding ratios obtained ex vivo at a single time point from large 
numbers of rodents [132,190], though the use of PET scanning in primates is 
also reported [193,194]. The actual number of dose levels tested was 6–9 in 
rodent and 9 in primates.
Comparing vulnerability to displacement by unlabeled agonist
An agonist tracer should be more vulnerable than an antagonist tracer to 
displacement (or “challenge”) by other agonists, because it competes with 
them for the same subpopulation of receptors. Displacement can be elicited 
by administering an appropriate agonist drug or by stimulating endogenous 
neurotransmitter release.
The advantage of using exogenous agonist drugs for displacement is that 
these drugs can be selected to be subtype-specific and to only occupy the 
receptor population that is being imaged (or even a defined subset of this 
population if the tracer binds to more than one receptor subtype).
On the other hand, manipulating neurotransmitter levels has the advantage 
of being “natural”: one looks at the competition of the tracer with the en-
dogenous ligand, the action of which on the receptors is thought to govern 
the functioning of the brain (see [116] and [50] for reviews). One can also 
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reasonably expect that the competition will only happen at receptors that 
are really situated in the synapses. Moreover, neurotransmitter levels can 
be both increased and decreased relative to the baseline. In the latter case, 
the expected result is greater increase, rather than greater decrease, of bind-
ing for the agonist tracer. However, manipulating neurotransmitter release 
has its downsides, too. First, the effect-vs-time relationship between the 
administration of the drug that stimulates a rise or fall in endogenous neu-
rotransmitter level and synaptic receptor occupancy is more complex than 
when receptors are occupied with exogenous agonist. Second, the released 
neurotransmitter can act on other receptor subtypes beyond the one being 
imaged. Third, some drugs used to manipulate neurotransmitter levels are 
known to manipulate levels of several neurotransmitters at once (e.g., am-
phetamine stimulates both dopamine and norepinephrine release). The lack 
of selectivity regarding what neurotransmitter is manipulated and which re-
ceptors are occupied can confound the interpretation of cause-and-effect 
relationships.
If the “tracer condition” is satisfied (radioligands occupy a negligible frac-
tion of all receptors), the ratio of agonist and antagonist radioligand vulner-
abilities to displacement by a challenge is a constant value as long as less 
than 100% of the high-affinity state is occupied as a result of the challenge 
(Figure 6). Therefore, in theory, a single dose of agonist drug or neurotrans-
mitter level manipulator should provide enough information to compare 
the vulnerability of agonist and antagonist tracers. In practice, because the 
actual percentage of receptors in the high-affinity state is unknown, sev-
eral challenge magnitudes are often tested, resulting in occupancies of up to 
100% [132,136,150,190], except in the human studies where the maximum 
challenge magnitude is limited by ethical considerations [139,146].
An important limitation of the vulnerability comparison paradigm is that 
the preference for the high-affinity state is not the only factor influencing 
the vulnerability of the radioligand to displacement by unlabeled drugs. For 
instance, many preclinical in vivo tracer binding experiments are performed 
in anesthetized animals, and isoflurane and ketamine anesthesia were 
found to increase the baseline binding of agonist D2/3 tracers, exaggerating 
the vulnerability of agonist tracers relative to antagonists [152,200]. The 
mechanism of such selective influence is unclear, although there are reports 
that anesthetics interfere with receptor-G-protein (un)coupling [201,202] 
and alter endogenous neurotransmitter levels [203,204]. Furthermore, 
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D2/3-antagonist tracers are known to differ between themselves in the sensi-
tivity to changes in dopamine levels [116,205]. The underlying reasons may 
be more or less favorable receptor binding kinetics (see [50,206] for discus-
sion) or differences in affinity towards surface and internalized receptors 
[207,208]. Although a head-to-head comparison of D2/3-agonist [
11C]MNPA 
and D2/3-antagonist [
18F]fallypride in internalization-deficient mice demon-
strated that competition with the neurotransmitter is sufficient to explain 
short-term (though not long-term) changes in binding for both tracers [43], 
situation can be different for other receptor types [42].
Figure 6. Relationship between agonist and antagonist tracer displacement 
and the fraction of receptors occupied by competing agonist drug or neu-
rotransmitter.
Bmax is the total receptor density available at baseline, XH is the fraction of receptors configured 
in the high-affinity state, Bocc is the amount of receptors occupied as a result of the challenge. 
Binding potentials or target/nontarget ratios of tracer binding can be considered proportional 
to the density of receptors not occupied by competitor. If Bocc< XHBmax, i.e. not all high-affinity 
state receptors become occupied, the ratio of relative decreases of agonist and antagonist 
tracer binding is constant and equal to 1/XH.
5.2.3. Approach 3: Studying vulnerability to G-protein uncoupling in vivo
Addition of GTP or its analogs decreases specific binding of agonist but not 
antagonist ligands in vitro, so uncoupling of G-proteins induced in vivo 
should lead to the same effects.
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Seeman demonstrated that GTP addition to tissues extracted from an ani-
mal after D2/3 agonist radioligand injection accelerates radioligand dissocia-
tion from D2/3 receptors in the tissue [197] and proposed the use of pertussis 
toxin to promote G-protein decoupling from the receptors in vivo. Indeed, 
physiological effects of dopamine and opioid receptor agonists were inhib-
ited by pertussis toxin injections [209–211].
This approach probes the nature of the high-affinity state, that is, it seeks an 
answer to the question “is G-protein binding to the receptor significant for 
agonist binding to the receptor?” However, this question is not the same as 
“do agonists bind to a subset of all receptors?”, which is addressed in other 
paradigms. As discussed in Section 2, all receptors may be pre-coupled to 
G-proteins. Moreover, G-protein decoupling agents (pertussis toxin or any-
thing else) will have to be introduced locally into the region of interest rath-
er than systemically through intravenous, intraperitoneal or subcutaneous 
injections. For brain imaging, that means that intrathecal and intracerebral 
injections will have to be used. Such injections are technically challenging 
and hardly (if anyhow) translatable to the clinic. Therefore, this paradigm 
has not yet been used for head-to-head comparisons of agonist and antago-
nist radioligands.
5.3. Current evidence on the existence of high-affinity state 
in vivo
5.3.1. Dopamine receptors
The majority of studies attempting to demonstrate the existence of high- 
affinity state in vivo has concerned dopamine D2/3 receptors. Agonists 
[11C](−)NPA, [11C]MNPA and [11C](+)PHNO were compared with antago-
nists [11C]raclopride and [18F]fallypride. In some studies these compounds 
were used in their unlabeled or 3H-labeled forms. A large portion of these 
studies failed to demonstrate the existence in vivo of the subpopulation of 
D2/3 receptors configured in the high-affinity state (see [212] for review).
Binding site densities for D2/3 agonist and antagonist tracers were found 
to be equal in one study [136], while in another study the average relative 
abundance of D2/3high was found to be 79% [192], which is close to the up-
per extreme of such percentages determined in vitro [213]. Saturation of 
[11C](+)PHNO binding in monkey brain was found to be biphasic, but the two 
binding sites most probably corresponded to D2 and D3 receptor subtypes 
rather than to high- and low- affinity states [214].
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In rats with brain lesions induced by 6-hydroxydopamine, binding levels of 
D2/3 antagonist [
11C]raclopride and of D2/3 agonist [
3H]PHNO were increased 
to the same extent [191]. No difference in baseline agonist binding relative 
to the healthy condition was found in dopamine beta-hydroxylase knockout 
(Dβh-KO) mice [147], in rats withdrawn from chronic ethanol and in am-
phetamine-sensitized rats [191]. In these three animal models, an upregula-
tion of D2/3high was previously demonstrated in vitro by the group of Seeman 
[198,215–217]. However, in vitro measurements of elevated striatal D2/3high 
in Dβh-KO mice could not be replicated by the group that performed the 
in vivo imaging study [147]. Moreover, most of the data on the elevation of 
D2/3high in ethanol-withdrawn rats is based on comparison of Bmax values for 
antagonist radioligands in the presence and absence of GppNHp [198,216]. 
This is an indirect method of assessing D2/3-high abundance, shortcomings 
of which are discussed in a recent review [213].
In clinical studies of diseases where alteration of D2/3high was suspected, 
binding potentials of agonist tracers in healthy and diseased subjects were 
identical [199,218–221].
The dopamine D2/3 antagonist radioligand raclopride (
11C- or 3H-labeled) was 
displaced by D2/3 agonist drugs in a monophasic manner [132,190,193]. In 
a more recent study, up to 70% of [11C]raclopride binding was displaced by 
D2/3 agonist quinpirole without any evidence of biphasicity [38].
The majority of studies comparing agonist and antagonist tracers’ vulner-
ability to displacement by agonist drugs found no difference in vulnerabili-
ties [132,150,190], though some reports confirming greater vulnerability of 
agonist tracers do exist [195,196] and the relative timing of tracer and drug 
administration was claimed to be important [196].
Nevertheless, D2/3 agonists did prove to be more sensitive than antagonists 
to endogenous dopamine levels in anesthetized rodents [43], cats [136] and 
non-human primates [138,142,149] as well as in awake humans [139,146], 
though not in awake rodents [132,190,191,200], with a single exception 
[195]. However, lack of consistency in preclinical data on neurotransmit-
ter and agonist drug challenge raises a question whether this advantage 
of the agonists stems from their preference for the high-affinity state or 
from other factors (see 5.2.2).
For dopamine D1/5 receptors, an in vivo displacement curve was built in 
baboons using the D1 antagonist [
11C]NNC-112 and the D1 agonist drug 
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DAR-0100A [194]. Occupancies above 40% were not investigated, but the 
best-fit curve was monophasic, not supporting the existence of a high-affin-
ity receptor subpopulation.
5.3.2. Serotonin receptors
A few head-to-head agonist-antagonist comparisons done with serotonin 
receptor radioligands yielded ambiguous results.
Two studies found that about 80–90% of the specific binding of antago-
nist 5-HT1A ligand [
11C]WAY-100635 could be displaced by the 5-HT1A ag-
onist 8-OH-DPAT [222,223], but in both cases only a single dose of the 
agonist was tried, so it’s impossible to say whether 8-OH-DPAT displaces 
[11C]WAY-100635 in a monophasic or a biphasic manner. In an ex vivo satu-
ration study, the binding site density of 5-HT1A agonist [
3H]CUMI-101 was 
33% lower than that of the antagonist [3H]MPPF in rat frontal cortex, but 
82% higher in rat hippocampus [158]. BPF values for [
11C]CUMI-101 across 
the baboon brain were about 45% of BPF values for 5-HT1A antagonist 
[11C]WAY100635 [69], while in vitro Kd values for the two tracers were com-
parable, but these findings should be interpreted with caution for reasons 
described in Section 5.2.1. Yet another study found considerable differences 
between the binding patterns of 5-HT1A agonist [18F]F13174 and 5-HT1A an-
tagonist [18F]MPPF in marmosets: regional BPND values even did not corre-
late when animals were imaged without the use of anesthesia [164]. Howev-
er, the variability of data (especially for [18F]F13174) was high, so it is hard to 
draw any firm conclusions regarding the existence of separate 5-HT1A recep-
tor subpopulations recognized by [18F]F13174 and [18F]MPPF from this study.
Regional BPND values of the 5-HT2A agonist [
11C]CIMBI-36 were com-
pared with regional BPND values of the 5-HT2A antagonist [
11C]MDL100907 
in monkeys [167] and regional BPND values of another 5-HT2A antagonist 
[18F]altanserin in humans [91]. Both analyses did yield deviations from linear 
correlation in the hippocampus and choroid plexus, but these could all be 
explained by the binding of [11C]CIMBI-36 to 5-HT2C receptors.
To sum up, the majority of data, both for dopamine and serotonin recep-
tors, do not support the existence of a receptor subpopulation in vivo to 
which agonists preferentially bind. There are some indisputable differences 
in the behavior of agonist tracers and antagonist tracers, such as specific 
sensitivity of the former to anesthesia and greater sensitivity to synaptic 
neurotransmitter levels, but the reason for these differences is not clear.
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5.4. Experimental data in the light of the nature 
of the high-affinity state
Though some instances of failed attempts to detect the high-affinity state 
in vivo may have resulted from insufficient characterization of the selectiv-
ity and intrinsic activity of agonist radioligands [78,79,224], the nature and 
functioning of the high-affinity state have remained complex and elusive.
Two explanations of the failure to detect high- and low-affinity states in 
vivo have been put forward. One explanation proposes that all, or almost all, 
receptors are configured in the high-affinity state in vivo [132] and perma-
nently pre-coupled to G-proteins, so that these G-proteins, at least their Gα 
subunits, do not dissociate from the receptors after activation [212]. Another 
explanation states that, whatever the baseline degree of receptor-G-protein 
pre-coupling, receptors can and do recruit new G-proteins when occupied 
by agonists, so high agonist concentrations eventually make all receptors 
bind G-proteins and thus convert to the high-affinity state [190,194]. In-
deed, receptors have been subjected to high agonist (drug or neurotransmit-
ter) concentrations in virtually all experimental paradigms used for in vivo 
detection of the high-affinity state (Table 2). In vivo imaging experiments 
last for tens of minutes, while time constants for receptor and G-protein ac-
tivation and for receptor-ligand and receptor-G-protein binding vary from 
tens of milliseconds to a few seconds [36]. Gradual G-protein recruitment in 
response to agonist binding can thus confound experimental outcomes in 
currently used paradigms and can “inflate” the apparent relative abundance 
of the high-affinity state in vivo. Indeed, in studies comparing the vulner-
ability of dopamine D2/3 agonist and antagonist tracers to drug challenge, 
the lowest doses of D2/3 agonist drugs and the dopamine release stimulator 
amphetamine (resulting in the lowest receptor occupancies and therefore 
minimal G-protein recruitment) tended to produce the greatest relative 
difference between agonist and antagonist tracer displacement (Figure 7). 
In three such studies, the lowest doses of challenge drugs resulted in zero 
or negative displacement of the antagonist [11C]/[3H]raclopride but positive 
(though small and not statistically significant) displacement of agonist trac-
ers [11C]/[3H](+)PHNO and [11C]/[3H]MNPA [132,150,190]. Superior sensitivity 
of D2/3 agonists to amphetamine-induced dopamine release in humans com-
pared to the D2/3 antagonist [
11C]raclopride was demonstrated at receptor oc-
cupancies of 22% or lower [139,146]. Finally, the D2/3 agonist [
3H]PHNO was 
found to be more vulnerable than [3H]raclopride to displacement by the ago-
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nist (−)NPA when this agonist was co-injected with the radioligands instead 
of being injected some time before their administration, although this work 
used non-normalized “raw” specific binding as outcome measure [196].
Comparison of the in vivo imaging results with available in vitro data on 
detection of the high-affinity state raises even more questions. There are 
no systematic reviews of in vitro studies assessing the percentage of re-
ceptors configured in the high-affinity state for non-dopaminergic recep-
tors. However, recently published reviews dedicated to the affinity states of 
D2/3 receptors [213,225] demonstrate not only the lack of agreement, but also 
the absence of a trend in the assessments of the abundance of the high-
affinity state of D2/3 receptors in different set-ups (Figure 8):
(i) Experiments in membrane homogenates from transfected cells and iso-
lated tissues consistently showed that a significant portion of D2/3 receptors 
is configured in the low-affinity state. Only about 20% of dopamine D2/3 re-
ceptors receptors in the rodent brain and about 30% in the human brain are 
in the high-affinity state [213].
(ii) No high-affinity state of D2/3 receptors could be detected on intact cells. 
In bovine pituitary membranes, 55% of D2/3 receptors were in the high-af-
finity state, but intact dispersed pituitary cells had only low-affinity state 
[226]. Similar results were demonstrated with transfected HEK293T and 
T-REx-293 cells expressing D2 receptors [27,41]. One study found 16% of 
D2 receptors on cultured rat pituitary adenoma cells configured in the high-
affinity state using [3H]domperidone as a radioligand [227], but these results 
have yet to be replicated.
(iii) Autoradiographic studies comparing binding site densities for agonist 
and antagonist radioligands in tissue slices again revealed the presence of 
a high-affinity subset of D2/3 receptors, but the majority of antagonist 
radioligand vs agonist drug displacement experiments demonstrated a sin-
gle high-affinity population of D2/3 receptors in tissue slices in vitro [225]. 
This is in agreement with the data from in vivo imaging (see Section 5.3.1).
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Figure 7 (previous page). Relationship between D2/3 receptor occupancy achi-
eved by challenges in vulnerability comparison experiments and the relative 
difference in displacement of agonist and antagonist tracers in these studies.
A – summary of agonist challenge experiments except [132], B – summary of agonist 
challenge experiments in [132], C – summary of neurotransmitter (dopamine) challenge 
experiments. Agonist tracers are [11C]/[3H](−)NPA (squares), [11C]/[3H]MNPA (triangles) and 
[11C]/[3H](+)PHNO (circles). Experiments were done in rodents (R), cats (C), non-human primates 
(P) and humans (H).
Data from [132] could not be merged with the other data, because SBRs from control rats in 
that study were consistently lower than SBRs from rats injected with the lowest doses of dis-
placing drugs, resulting in “negative” displacement values. For graph B, displacement values 
reported in [132] were zero-corrected by distracting from them the lowest displacement value 
observed in the whole study.
Figure 8. Lack of agreement and contiguousness between assessments of the 
abundance of receptors configured in high-affinity state in different setups.
For D2/3 receptors, a certain percentage of receptors (considerably less than 100%) is known to 
exist in high-affinity state in membrane homogenates [213]. However, no high-affinity state 
can be detected at equilibrium in intact cells [27,41,226], while in tissues and living animals 
all receptors appear to be configured in the high-affinity state [212,225].
In order to explain the low relative abundance of the high-affinity state 
in membrane homogenates within the pre-coupling model of receptor- 
G-protein interaction, one can assume that a partial damage of pre-assem-
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bled receptor-G-protein complexes happens during membrane preparation, 
but the exact mechanism of such damage is hard to define. Alternatively, 
one can assume the existence of a large intracellular reserve of receptors 
in the high-affinity state. In transfected cells, the affinity of agonist li-
gands used as PET tracers towards internalized D2/3 receptors was shown to 
be about 2-fold lower than towards surface receptors [41] – a change that 
would hardly be noticeable in saturation or competition curves. However, 
the total densities of D2/3 receptors measured in membrane homogenates 
by radioligand binding saturation and in vivo by PET are in good agreement 
[225], which does not support the existence of extra D2/3 receptors that are 
detectable in vivo but aren’t found in membrane homogenates.
The collision coupling model of receptor-G-protein interaction can be 
reconciled with measurements of the high-affinity state in membrane ho-
mogenates if one assumes that in these homogenates only a fraction of the 
total G-protein pool of the cell is available for recruitment to the receptors. 
Indeed, the number of G-proteins in living cells is likely equal to or much 
greater than the number of their cognate receptors [44,228,229]. However, 
given that G-proteins are anchored to the lipid bilayer [230], it is not clear 
how such G-protein reserve can both be easily accessible in the living tissue 
and become inaccessible or lost in membrane homogenates. Especially the 
findings of Seeman [196] are puzzling in this regard. Seeman reported that 
the IC50 values of (−)NPA in the displacement of bound [
3H](+)PHNO and 
[3H]raclopride in striatal membrane homogenates (with 2-hour equilibration 
at room temperature before readout) differed much more (~7-fold) when 
radioligands and (−)NPA were added simultaneously to the membranes 
than when membranes were pre-incubated with (−)NPA for 30 minutes 
(~2-fold). Equal vulnerabilities of [3H]raclopride and [3H](+)PHNO in the 
case of (−)NPA pre-incubation imply that (−)NPA can and does stimulate 
G-protein recruitment to all or almost all receptors in the membranes, while 
greater vulnerability of [3H](+)PHNO in case of simultaneous addition im-
plies that in the absence of an agonist, only some receptors are G-protein-
bound and therefore accessible to [3H](+)PHNO. However, even in the case 
of simultaneous addition there is enough time during the equilibration for 
(−)NPA to elicit recruitment of “spare” G-proteins to the receptors.
The absence of the high-affinity state of D2/3 receptors in isolated intact 
cells [27,41,226] is even harder to reconcile with either of the two models 
mentioned above. Collision coupling at least provides a theoretical expla-
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nation of the disappearance of high-affinity state upon agonist addition 
due to a high level of GTP in living cells. Still it remains puzzling why an 
agonist forces D2/3 receptors in dispersed cells from a natural tissue (bovine 
pituitary) to uncouple from G-proteins (convert into the low-affinity state), 
but promotes G-protein recruitment (conversion to the high-affinity state) 
when it is acting on the same receptors in intact tissue.
Switching from the G-protein-dependent high-affinity state model to the 
oligomerization-dependent model leaves the same questions open: it is not 
clear how the degrees of receptor oligomerization can be different in mem-
branes, dispersed cells and living tissues. Moreover, observation of almost 
all receptors configured in high-affinity state in vivo is hard to reconcile 
with the oligomerization-dependent model. At full oligomerization and full 
agonist occupancy, cooperativity-induced high-affinity state can have rela-
tive abundance of no more than 50% (in the case of dimers), and higher val-
ues imply that few, if any, receptors are oligomerized.
6. Conclusion
The concept of the high-affinity state postulates that a certain subset of 
receptors in the living brain is primarily responsible for receptor signaling. 
Assessing the abundance of this subset is thus potentially very relevant for 
studies concerning the responses of neurotransmission to pharmacological 
or physical stimuli and the dysregulation of neurotransmission in neuro-
logical disorders.
A number of experimental paradigms has been developed for the estimation 
of the relative abundance of receptors configured in the high-affinity state. 
The high-affinity state is preferentially recognized by agonists in vitro, so 
development of agonist PET tracers as tools for the non-invasive imaging of 
the high-affinity state has become popular in recent decades.
The greatest number of agonist tracers has been developed for dopamine 
D2/3 receptors, but agonist tracers for dopamine D1, κ-opioid and muscarinic 
M2 receptors are also known, and in recent years, radiolabeled agonists for 
serotonin 5-HT1A and 5-HT2A, κ-opioid and muscarinic M1 receptors have ap-
peared. It should be noted, however, that for many of the non-dopaminergic 
tracers the actual preference for the high-affinity state has not been directly 
tested, because functional agonism is often assumed to be combined with 
preferential binding to the high-affinity state.
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For dopamine, serotonin and κ-opioid receptors, head-to-head compari-
sons of agonist and antagonist tracers are now possible, while matching 
antagonist tracers for muscarinic M2 and µ-opioid receptors have yet to be 
developed. Given that, beyond head-to-head agonist-antagonist compari-
sons, antagonist tracers are also suitable for experiments like displacement 
curve generation (see Section 5.2.2), development of new antagonist tracers 
for M2 muscarinic and µ-opioid receptors with a pharmacological selectivity 
matching that of existing agonist tracers will arguably be more useful for the 
assessment of the affinity states of these receptors than development of new 
agonist tracers.
Agonist tracers appear to be more sensitive to endogenous neurotransmitter 
challenge, as was originally expected. However, other expectations regard-
ing agonist tracers have not been fulfilled. Agonist imaging did not reveal 
alterations in the relative abundance of the high-affinity state in neurologi-
cal disorders. The benefits of agonist tracers for the imaging of receptor oc-
cupancies by drugs have also not been proven.
Moreover, though separation of GPCRs into subsets with high- and low-
affinity state is consistently observed in membrane homogenates in vi-
tro, data from preclinical and clinical experiments does not support the 
existence of the high- and low-affinity states in vivo. The majority of these 
data concerns dopamine D2/3 receptors, but some recent results on serotonin 
receptors paint the same picture.
The relative abundance of the high-affinity state may simply be close to (or 
equal to) 100%, making the detection of low-affinity state unfeasible. Alter-
natively, agonist drugs or tracers used for in vivo experiments may inflate 
the relative abundance of the high-affinity state.
Critical revision of experimental approaches and collection of experimental 
evidence for non-dopaminergic receptors will help clarify whether the high-
affinity state of GPCRs exists in vivo and whether agonist tracers really have 
advantages over antagonist tracers because of their preferential binding to 
the high- affinity state.
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The ratio of the concentrations of specifically bound tracer (B) and free trac-
er (F) in the tissue at equilibrium is equal to the ratio of available receptor 
density and ligand-receptor affinity (Bmax/Kd) when the tracer only occupies 
a negligible fraction of all receptors (Figure A1). Therefore, radioligand dos-
es are selected to occupy no more than 10% (preferably less than 1%) of all 
receptors.












. If F << Kd, which inevitably means 




. Note that at low concentrations (F/Kd << 1), the ligand occupies 
only a small part of total receptor population, and the B/F ratio (binding potential) 
is stable (left part of the graph).
In practice, specifically bound tracer concentration B is often calculated 
as a difference between tracer concentrations in receptor-rich region of 
interest and receptor-poor reference region. Free tracer concentration, on 
the other hand, is replaced with directly measurable concentrations that are 
linearly dependent on “true” F at equilibrium [189]. These concentrations 
can be:
– free tracer concentration in plasma (equal to F if the tracer is transferred 
from tissue to plasma by passive diffusion);
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– total, i.e. free and protein-bound, tracer concentration in plasma;
– nondisplaceable, i.e. free and non-specifically bound, tracer concentra-
tion in tissue.
To determine tracer concentration in plasma (whether free or total) one 
needs to obtain arterial plasma samples, which is an invasive procedure. 
Therefore, the last option is the most popular: tracer concentration in re-
ceptor-rich tissue is related to tracer concentration in receptor-poor tissue.
Binding potentials are defined at equilibrium. Plasma and tissue concen-
trations of a tracer can be directly equilibrated with each other by admin-
istering the tracer in an infusion, but such paradigms are hard to imple-
ment. Therefore, in most PET and SPECT studies tracer is administered 
via a simple bolus injection. In that case, in order to calculate binding 
potentials, time-activity curves for regions of interest are used as input data 
for so-called kinetic modelling. Tracer distribution is described in terms of 
its transfer between virtual compartments (like “free tracer”, “non-specifi-
cally bound tracer”, “specifically bound tracer”) in accordance with the law 
of mass action. Compartmental models are then integrated to obtain gen-
eral equations describing the time course of tracer concentration in each 
compartment, and the values of individual kinetic parameters or their com-
binations are determined by curve fitting. Fewer fitting parameters often 
mean a more robust fit, so many simplifying assumptions are often made. 
Graphical analyses, simplifying the fitting process to linear regression, are 
also widely used [231,232]. Fitted parameters are then used to obtain bind-
ing potentials, essentially by extrapolating the kinetics observed in the im-
aging experiments to the situation of equilibrium.
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L I ST OF ABBREV IAT IONS
AMC – 2-aminomethylchromane
DIPEA – diisopropylethylamine
moleq – molar equivalent
UPLC – ultra performance liquid chromatography
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ABSTRACT
Imaging of dopamine D2/3 receptors (D2/3R) can shed light on the nature 
of several neuropsychiatric disorders, since D2/3R receptors are involved 
in these disorders. Agonist D2/3 tracers for PET/SPECT imaging are consid-
ered superior to antagonists because they are more sensitive to dopamine 
concentrations and may selectively label the high-affinity receptor state. 
Carbon-11-labeled D2/3R agonists have been developed but these short-liv-
ing tracers can only be used in centers with a cyclotron. Here, we report 
on the development of a series of novel D2R agonist compounds, based 
on the 2-aminomethylchroman (AMC) scaffold, which provides ample 
opportunities for the introduction of the longer living fluorine-18 or io-
dine-123. Binding experiments showed that several AMC-compounds have 
high affinity and selectivity for D2/3R and showed agonism. Two fluorinated 
compounds were 18F-labeled to enable in vitro autoradiography studies in 
rats, and both displayed specific binding to striatal D2/3R. These findings 
encourage further in vivo evaluations.
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INTRODUCTION
A disturbed dopamine system plays a central role in several neuropsychiatric 
disorders, including Parkinson’s disease (PD) [1], dementia with Lewy bod-
ies [2], schizophrenia [3], and drug addiction [4]. The prevalence of PD and 
schizophrenia is about 1% of the total population [5, 6] while the prevalence 
of (alcohol) addiction may be even higher [7] creating a large disease burden. 
For dementia with Lewy body pathology the prevalence among people above 
the age of 65 years is about 10% [8].
Dopamine receptors belong to the superfamily of G-protein coupled recep-
tors (GPCRs) and are divided into 2 subfamilies based on their action on 
adenylyl cyclase (AC). The dopamine D1-like (D1 and D5) subfamily stimu-
lates AC to produce the second messenger cyclic adenosine monophosphate 
(cAMP), while D2-like receptors (D2, D3, D4) inhibit cAMP production by AC 
[9,10]. The D2 and D3 receptor subtypes are highly involved in the pathophys-
iology and treatment of PD and schizophrenia and, like other GPCRs, they 
typically exhibit interconvertible high- and low-affinity states for agonists 
in vitro [11–13] In the high-affinity state, the receptors are coupled to the 
G-protein, and this state is considered to be the active form of the receptor 
[14]. In the low-affinity state, receptors are uncoupled from the G-proteins 
and, as a result, inactive. There is substantial evidence that alterations in 
the density of D2/3 receptors in the high-affinity state may be more relevant 
to the pathophysiology of neuropsychiatric disorders than alterations in the 
total receptor density. This is supported mostly by data from Seeman and 
co-workers [13]. In several animal models of neuropsychiatric disorders, in-
cluding psychosis, increases in striatal D2/3 high-affinity receptors of up to 
9-fold were registered as compared to control animals, while total receptor 
numbers did not increase [15]. While agonists are selective for the high-
affinity state, antagonists bind with equal affinity to the low- and high-af-
finity states of a receptor [16]. Therefore, antagonist radioligands cannot 
distinguish a shift in the state of receptors from low- to high-affinity [17]. 
Numerous compounds have been synthesized and characterized as agonist 
tracers for the imaging of D2/3 in the high-affinity state by means of positron 
emission tomography (PET) [18]. These compounds are of different chemical 
classes, including ergolines, aporphines, 2-aminotetralins, benzoquinolines 
and naphthoxazines. The aporphines [11C]NPA (N-propylnorapomorphine), 
[11C]MNPA (2-methoxy-N-propylnorapomorphine) and the naphthoxa-
zine [11C]PHNO ( 4-propyl-9-hydroxynaphthoxazine) turned out to be the 
most successful and have also been evaluated as PET tracers in man [19,20]. 
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In humans, the agonists [11C]PHNO and [11C]NPA showed better sensitiv-
ity for the detection of endogenous dopamine release than the antagonist 
[11C]raclopride [21–24]. All three mentioned tracers also performed better 
than [11C]raclopride in dopamine release measurement in rodents, pigs, cats 
and non-human primates [25]. This corroborates the notion that agonist ra-
diotracers are more prone to detect changes in neurotransmitter concen-
trations than antagonist tracers. On the other hand, all D2/3 agonist PET li-
gands successfully evaluated in humans are 11C-labeled [19,20]. Because of 
the short half-life (20.4 minutes) of carbon-11, these radioligands can only 
be used when a cyclotron is present on-site. This expensive device is how-
ever available in only the minority of hospitals. To increase the worldwide 
availability of such agonist tracers, we are developing fluorine-18-labeled 
PET tracers (half-life 109.8 min) or iodine-123-labeled (half-life 13.2 h) ago-
nist dopamine D2/3 receptor tracers for single photon emission computed 
tomography (SPECT) imaging. Accordingly, we have prepared and evalu-
ated a new series of agonist compounds based on the 2-aminomethylchro-
man-7-ol (AMC) scaffold. Structure-activity relationships for this class of 
compounds and classes related to it [27–31] including the preference for 
the high-affinity vs low-affinity state of D2 receptor and selectivity for the 
D2 receptor over other potential monoamine receptors such as the serotonin 
1A (5-HT1A) and α1 adrenergic receptor, have already been examined in detail 
by Mewshaw and co-workers [26]. Importantly, the D2-affinity and agonism 
of AMCs shows considerable tolerance to structural modifications in the 
moiety attached to the nitrogen atom of AMC core, which provides ample 
opportunities for the introduction of the 18F or 123I-label into the structure 
without compromising the necessary pharmacological properties. We have 
used data from the Mewshaw studies to design our AMCs that either bear 
an iodide or a fluorine atom, see Chart 1. We have included the non-halo-
genated reference compounds 10a-b that were already evaluated in vitro by 
Mewshaw [26], as this enables us to put receptor binding data on the new 
iodinated (11) and fluorinated (12) series of compounds into perspective. 
Introduction of the piperazine group in some of the AMC-structures was in-
spired by studies on pramipexole [32] and 5-OH-DPAT [33], piperazines that 
have shown potent and selective D3-receptor binding, as well as by several 
Mewshaw studies [27–31].
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Chart 1: The (R) 2-aminomethylchroman-7-ols (AMCs) that are investigated in 
this study: reference compounds 10, the iodide series 11 and the fluoride series 
12. The oxalate salts of the shown amine structures have been used for all as-
says and binding studies.
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Scheme 1 outlines the synthetic routes to the prepared ‘cold’ AMCs, i.e. 
the unlabeled regular 19F and 127I compounds. Details on specific transfor-
mations can be found in the Experimental section. Even though racemates 
can be used for initial screening receptor binding studies, we have chosen 
to prepare the enantiomerically pure (R)-AMC-compounds, as it is already 
known that these enantiomers are the actively binding species [26]. Accord-
ingly, the test compounds 10a-b, 11a-e and 12a-d reported in this work are 
all (R)-enantiomers, and they all have been prepared from the same parent 
compound 1, i.e. (R)-7-hydroxychroman-2-carboxylic acid ethyl ester. The 
racemate of compound 1 has been prepared from 2,4-dihydroxyacetophe-
none in two steps, according to Walenzyk [34] and Cohen [35], and thereaf-
ter this racemic mixture has been resolved to 1 (the R-enantiomer) using the 
lipase kinetic resolution procedure as reported by Kalaritis [36]. GC-analysis 
on a chiral capillary column shows for the racemate of 1 two peaks of equal 
intensity, whereas resolved 1 only shows one peak (e.e. 99%).
Three routes to the AMC target molecule series 10, 11 and 12 have been 
employed. Route A is via the unprotected tosylate 3, by reaction of 3 with 
the appropriate amine building blocks. This conveniently short route has 
been used by Mewshaw [26] also, and we have prepared molecules 10a, 11b 
and 11d via this Route A. However, we have experienced that yields remain 
low when using tosylate 3, presumably because 3 can react with itself under 
basic conditions, as opposed to reacting with the presented amine reactants. 
Furthermore, the synthesis of 3 in pyridine suffers from side-product forma-
tion; where particularly, ditosylate side product has been observed. As an 
alternative, we have used Route B that proceeds via tosylate 6 that is MOM-
protected at the 7 OH-position of the chroman group. Route B is longer, 
as it requires extra (de)protection steps, but the syntheses have shown to 
be more reliable. Preparation of 10b, 11a, 11e, 12a, 12c and 12d has been 
achieved via Route B. The MOM protective group was selected over the me-
thoxy or the benzyloxy group that had been applied by Mewshaw, as the 
methoxy group requires more harsh deprotection conditions and the ben-
zyloxy group is or may be incompatibile with the (iodo)benzyl target struc-
tures. Route B still gave rise to side-product formation, as in the cases where 
primary amines were reacted with tosylate 6, tertiary amine side-products 
were formed next to the desired secondary amine main products. We have 
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therefore also employed Route C, which is the longest route that proceeds 
via primary amine 8. In this case, a reductive amination coupling step with 
aldehyde building blocks can be performed, so that side product formation 
is largely avoided. Molecules 11a, 11c and 12b have been prepared accord-
ing to Route C. Provided the aldehyde counterpart for preparing the desired 
AMC target molecule is easily accessible; this Route C is recommended by 
us. It may even be possible to use the unprotected amine (i.e. amine 8 with-
out the MOM-group) to prepare AMCs, but we have not tested this option. 
The synthesis of the amine or aldehyde building blocks that are required for 
coupling to tosylate 3 (Route A), tosylate 6 (Route B) or amine 8 (Route C) 
are described in the Experimental section, unless these building blocks are 
simply commercially available. All the test compounds 10, 11 and 12 have 
been converted to their oxalate salts, and these salt end products have been 
used in all assays and studies that are described in this paper.
Scheme 1. Synthesis of the unlabeled AMC compoundsa.
a reagents and solvents: (a) and (e) LiBH4, THF; (b) and (f) TsCl, pyridine; (c) and (i) amine build-
ing block, DIPEA, DMSO; (d) MOMCl, DIPEA, CH2Cl2; (g) potassium phthalimide, DMF; (h) H2NNH2 
hydrate, EtOH; (j) i. aldehyde building block, MeOH and ii. NaBH4, MeOH; (k) 4M HCl, dioxane/
isopropanol. The R-group in the series of compounds 10, 11 and 12 denotes a secondary or 
tertiary amine residue; see Chart 1 for details on the specific R-groups that have been used.
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Scheme 2 shows the synthetic route to the phenols 13a and 13b, which mole-
cules are the precursors to the radiolabeled compounds [18F]12a and [18F]12d, 
respectively. The MOM-protected amine 8 has been coupled by reductive 
amination to 4-hydroxy benzaldehyde to prepare 13a. Commercially avail-
able 1-(4-hydroxyphenyl)piperazine has been converted in five steps to the 
primary amine reactant 18 that can be coupled to tosylate 6 to provide 19. 
Subsequent debenzylation of 19 affords 13b. Both precursors 13a and 13b 
require protection at the 7-OH-chroman position, as a selective coupling of 
the respective [18F]fluoroalkyltosylates to the other phenol moiety is desired. 
Protection of the NH-groups in the precursors is not needed, as coupling 
under basic conditions with the [18F]fluoroalkyltosylates is favoured at the 
phenol position over that at the NH-position. For details on the preparation 
of [18F]12a and [18F]12d, the reader is referred to the Radiolabeling section.
Scheme 2. Synthesis of the phenol precursors to the 18F-labeled AMCsa.
a reagents and solvents: (a) i. 4-hydroxybenzaldehyde, AcOH, CH2Cl2 ii NaB(OAc)3H; (b) BOC-
anhydride, DMF; (c) BnBr, DMF, K2CO3; (d) 4M HCl, dioxane; (e) tert butyl N-(2-bromoethyl)




Affinity of the compounds to the dopamine receptors determined 
by radioligand binding
All novel AMC compounds (Chart 1) as well as the reference ligands do-
pamine, PHNO and NPA were tested for their ability to compete with 
[3H]spiperone or [3H]SCH23390 for binding to various receptors of the do-
pamine receptor family. In Table 1 the results of these binding studies 
are compiled. For almost all compounds, the binding experiments on the 
D2L (D2long) receptor produced competition curves which were significantly 
better explained by biphasic models (using GraphPrism). This finding indi-
cates agonism for these ligands [37]. See Figure 1 for a typical biphasic bind-
ing curve as recorded for dopamine.
Among the AMC compounds tested, 11c had the highest affinity for the 
D2Lhigh receptor (Ki 0.68 ± 0.83 nM; mean±SD). The compounds 10a, 10b, 
11a, 11b, 12a and 12d showed high affinities with Ki values in the low nano-
molar range. The only two tertiary amine compounds, AMCs 11d and 12c, 
did not show a meaningful affinity for the D2L receptor. For 11e and 12b 
no biphasic curves were observed and measured affinities were (well) above 
10  nM (Ki 81 ± 54  nM for 11e and 156 ± 78  nM for 12b). All compounds 
showed affinities for D2S that were comparable to those recorded for D2L, 
and all tested compounds showed affinities for the dopamine D4 receptor 
in the same range as that measured for the D2L receptor, except for ter-
tiary amines 11d and 12c which had a high affinity for D4 but no meaningful 
binding to D2L. These two compounds did also show an evident affinity for 
D3 with Ki values of 24 ± 2.5 nM for 11d and 40 ±15 nM for 12c. Finally, all 
the tested compounds lacked reasonable affinity for the dopamine D1-like 
receptors (D1 and D5) (Table 1).
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Figure 1. Representative biphasic competition binding curve, where in this case 
dopamine binding to the D2L receptor is assessed.
The shown data are from one experiment, where the bound fraction of [3H]spiperone in counts 
per minute (cpm) is plotted against the log of the concentration (mol/L) of dopamine. Accord-
ing to the points of inflection (arrows) this example shows an IC50 for the D2 high-affinity state 
at 10-6 M dopamine and an IC50 for the D2 low-affinity state at 10
-4 M (these IC50-values need to 
be transformed to Ki values using the Cheng Prusoff equation [38]). The fraction of the recep-
tors in the high-affinity state is 40 ± 7%.
Ligand-induced inhibition of forskolin-induced 
cAMP accumulation
In HEK293 cells expressing the dopamine D2L receptor, dopamine inhib-
its the forskolin-induced cAMP accumulation, where this inhibition be-
comes apparent as of a certain dopamine concentration. In the cAMP assay 
(Table 2), the AMC test compounds were compared to dopamine with re-
spect to their inhibition potency, and it was found that 11e appeared to be 
less potent than the endogenous agonist dopamine, 11a and 12a were simi-
larly potent and all the other test compounds were somewhat more potent 
than dopamine with 11b appearing to be the most potent of the tested ha-
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logenated compounds. All compounds had efficacies comparable to that of 
dopamine (Table 2).
Radiolabeling
The two fluorinated compounds 12a and 12d were selected for 18F-labeling. 
The labeling was accomplished via a three-step two-pot procedure, starting 
with the synthesis of a [18F]fluoroalkyl synthon from [18F]fluoride and the 
appropriate ditosylate precursor, followed by [18F]fluoroalkylation of phenol 
precursors 13a or 13b (see Scheme 2 for their synthesis) and in situ removal 
of the MOM-protecting group applying acidic conditions (Scheme 3). The 
18F-labeled products [18F]12a and [18F]12d were purified by reversed phase 
HPLC. A typical synthesis run lasted for 150 min and started from 5 GBq of 
[18F]fluoride, from which 20–200 MBq of formulated [18F]12a or [18F]12d were 
obtained.
Table 2. Potency and efficacy maximal response (Emax) expressed as % of do-
pamine response for various ligands at the human D2L receptor determined in 
cAMP assay. All data are expressed as mean±SEM.
Ligand pEC50 Emax 
(% of dopamine)
n
Dopamine 9.2 ± 0.4 100 4
10a 10.7 ± 0.3 78 ± 5 4
10b 10.3 ± 0.4 82 ± 6 4
11a 9.2 ± 0.4 86 ± 5 4
11b 10.5 ± 0.4 86 ± 6 4
11e 8.8 ± 0.4 86 ± 5 4
12a 9.4 ± 0.3 96 ± 5 3
12d 9.8 ± 0.2 94 ± 3 3
Lipophilicity
Data regarding lipophilicity are shown in Table 3. Compounds 10a, 10b, 
11a, 11b, 11e, 12a, 12b and 12d showed a clog D (clogP7.4) in the range be-
tween 1 and 3 [39].
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Table 3. Lipophilicity of the AMC compound series 10, 11 and 12, as assessed 
with BiologP (New ClogP) calculator program from the University of Massachu-
setts.













Scheme 3. Labelling schemes of [18F]12a and [18F]12d.
Reagents and solvents: (a) K18F-Kryptofix-K2CO3, MeCN; (b) i. 13a, NaH, DMF, ii. 0.4M HCl; (c) i. 
13b, NaH, DMF, ii. 0.4M HCl.
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Radiochemical yields, purities and molar radioactivities of [18F]12a and 
[18F]12d are listed in Table 4.
Table 4. Radiochemical yields (RCY), radiochemical purities (RCP) and molar 
radioactivities (MR) of [18F]12a and [18F]12d. Data are expressed as means±SD 
and range in brackets.








HPLCa: 25±11 (3–47) 
formulatedb: 7±8 (1–22)
94±4 (85–98) 92±96 (1.4–312)
[18F]12d 
n=6
HPLC: 14±5 (6–20) 
formulated: 5±3 (1.4–11)
92±5 (85–98) 29±12 (8–40)
a HPLC fraction containing the tracer vs 18F-fluoride taken for synthesis.
b Formulated tracer vs 18F-fluoride taken for synthesis.
In vitro autoradiography
Results of in vitro autoradiography of [18F]12a and [18F]12d are presented in 
Figure 2 and Table 5.
Figure 2. In vitro autoradiography with [18F]12a at 0.19  nM (a), [18F]12a at 
4.5 nM (b) and [18F]12d (c).
Note the specific binding in the striatum for [18F]12a (only at lower concentration) and for 
[18F]12d.
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At nanomolar concentration, [18F]12a showed rather homogeneous uptake 
in sagittal rat brain slices with only slightly higher binding in the striatum. 
Striatum-to-cerebellum and striatum-to-cortex ratios were on average 1.19 
and 1.16, respectively. In the presence of 10 μM of the dopamine D2/3 antago-
nist raclopride the striatum-to-cerebellum ratio was reduced by 14% and 
the striatum-to-cortex ratio by 11%. At sub-nanomolar concentration, how-
ever, [18F]12a did demonstrate moderate but clearly visible specific uptake 
in the striatum. At 0.19 nM striatum-to-cerebellum ratios were on average 
1.85 and were reduced by 40% in the presence of 10 μM raclopride and by 
35% in the presence of 100 μM GTP. Striatum-to-cortex ratios were on aver-
age 1.68, and co-incubation with 10 μM raclopride or 100 μM GTP resulted 
in 39% and 33% decreases, respectively.
At nanomolar concentrations [18F]12d demonstrated preferential binding in 
the striatum and hippocampus. In control animals, the mean striatum-to-
cerebellum ratio was 2.64. In the presence of 10 μM raclopride or 100 μM 
guanosine triphosphate (GTP), striatum-to-cerebellum ratios were signifi-
cantly reduced by 37%. Striatum-to-cortex ratios were on average 1.90 in 
control slices and were reduced by 37% by raclopride and by 22% by 100 μM 
GTP.
Table 5. In vitro autoradiography results. Values are means±SD from the total 
number of slides assayed in n independent experiments. The number of slides 
per condition in each experiment varied from 4 to 12.


















GTP (n=1) 1.20±0.16 1.13±0.09
[18F]12d 
5.8±1.6 nM
1.48±0.01 control (n=4) 2.64±1.04 1.90±0.47
raclopride (n=4) 1.65±0.37 1.20±0.20
GTP (n=1) 1.67±0.28 1.48±0.17
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D ISCUSS ION
Our present effort is directed at developing new agonist radiotracers that 
can be used in centers without an on-site cyclotron with the aim to enable 
visualization of dopamine D2/3 receptors in the agonist high-affinity state. 
Accordingly, we have synthesized a novel group of iodinated and fluorinated 
compounds based on the AMC-scaffold that is known for its agonistic prop-
erties on D2/3 dopamine receptors and for its good selectivity of binding for 
these receptor subtypes [26].
The primary binding site of the D2 receptor is formed by transmembrane do-
mains (TMs) 3, 5 and 6 of the receptor [40]. D2 ligands contain the aromatic 
core which engages in interactions with the hydrophobic residues in TM3 
and TM6. To this core an amino group and a hydrogen bond donating group 
are attached to form an ionic bond with the conserved aspartate residue in 
TM3 and one or more hydrogen bonds with conserved serine residues in 
TM5, respectively (Figure 3).
Figure 3. Comparison of the molecular structures of some D2-agonist ligands, 
where their aryl cores are colored purple, basic nitrogens are red and H-bond 
donating hydroxyls are blue.
Orientation of the functional groups is chosen to roughly resemble the putative receptor-
bound conformations of the ligands. Note that for conformationally constrained (+)PHNO the 
lone electron pair of the nitrogen is directed roughly normally to the aryl ring and away from 
us, towards the conserved aspartate in TM3. In the 3D representation, the TM6-TM3 axis is 
directed away from the viewer, that is, TM6 is closer to the viewer than TM5, while TM3 is 
farther.
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Optimal distances between these groups and their optimal mutual orienta-
tion have been a subject of numerous studies which produced more or less 
general pharmacophore models, from the McDermed criteria developed in 
the late 1970s [41] to the more recent models [42, 43]. Notably it was found 
that the nitrogen atom can accommodate a bulky substituent extending into 
the ancillary binding pocket of the receptor formed by TM2 and TM7. The 
passage between the primary and ancillary binding pockets is narrower in 
D1-like receptors than in D2-like receptors, so the presence of such bulky 
substituents imparts D2-over-D1 selectivity [44] The second substituent at 
the nitrogen, however, cannot be greater than n-propyl [45].
Mewshaw et al. [26] proposed AMCs as a new series of compounds that meet 
the criteria for agonists with a high D2 affinity and an appropriate D2-over-
D1 selectivity. The AMC scaffold offers convenient possibilities to accom-
modate the 123I or 18F label on the N-substituent, and the same substituent 
can also be used to adjust the lipophilicity of the compound. Based on the 
benzylated secondary amine compound 10a, that was developed by Mew-
shaw and that was found to have a high affinity (sub-nanomolar) for the 
D2
high receptor, we designed three iodobenzyl and two fluoroalkyloxyben-
zyl candidate ligands. From the conformational and comparative molecular 
field analysis carried out for the AMC derivatives by the group of Mewshaw 
[46] and the modelling data for the D2 receptor [47, 48] we concluded that 
the benzyl group of 10a is likely to interact with the extracellular loop 2 
of the receptor and not with the ancillary pocket of D2 formed by TM2 and 
TM7. To probe the spatial requirements of such alignment we synthesized 
para- (11a), meta- (11b) and ortho-iodobenzyl (11c) and para- (12a) and 
ortho-(4-fluoro)butyloxybenzyl (12b) derivatives of 10a. The butyl spacer 
in 12a and 12b was selected to bring the expected lipophilicity of the com-
pounds within the log D range of 2 to 3 (Table 3), so as to ensure passage of 
the blood-brain-barrier [49].
The arylpiperazine motif is known to act as a pharmacophoric core in a 
number of high-affinity D2-agonists [31] and apparently it can fit into the 
primary binding pocket of the D2-like receptor [48]. Interestingly, Dutta and 
co-workers synthesized and evaluated a number of “hybrid” ligands based 
on an aminotetralin or a pramipexol scaffold to which an arylpiperazine 
moiety was attached via a spacer [32, 33]. In these hybrid ligands the aryl-
piperazine moiety is most probably bound in the ancillary binding pocket 
of the receptor and not in the primary binding site [50]. Inspired by these 
results, we designed four hybrid AMC derivatives with arylpiperazine side 
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chains attached to the AMC core, either directly (11d and 12c) or through 
an ethylene spacer (11e and 12d). Note accordingly that compounds 11d 
and 12c are the only tertiary amines in the series of developed compounds, 
where all the other compounds are secondary amine AMCs.
In the Mewshaw study that evaluated agonist ligands for the dopamine 
D2/3 receptor, the affinity was measured in rat striatal membranes using 
the agonist [3H]quinpirole and it was claimed that this approach specifi-
cally assessed the binding to the D2Lhigh
 receptor, because [3H]quinpirole 
should predominantly bind to D2Lhigh. Measuring affinities for the D2Llow was 
also done in rat striatal membranes, but in the presence of GTP to convert 
D2Lhigh to D2Llow, and with the antagonist [
3H]spiperone as radioligand. In 
addition, ketanserin was administered to preclude binding of spiperone to 
serotonin receptors [26]. Finally, a selection of compounds were evaluat-
ed in binding assays using membranes from cells transfected with human 
D2S, D3 and D4 receptors. We have also used membranes from cloned hu-
man dopamine receptors expressed in cell lines, but included D1, D2L, and 
D5 as well. We also used [
3H]spiperone as radioligand resulting in biphasic 
binding curves from which the affinities of the compounds for D2Lhigh and 
D2Llow could be derived (Figure 1).
Several of the prepared compounds indeed showed high affinity and selectiv-
ity for the D2/3 receptors, and agonistic action on the D2 receptor. Dopamine 
and most of the AMC compounds showed consistently biphasic competi-
tion curves for the D2L receptor which is typical for agonists. The inflec-
tion points in these curves reflect the agonist high- (D2Lhigh) and low-affinity 
(D2Llow) state (Figure 1). In line with this finding, the cAMP experiments also 
showed agonistic properties for the tested compounds.
Nevertheless, when we compare the affinity of our reference compounds 
10a and 10b to the values of Mewshaw et al., our findings show affinities 
which are 1 log scale lower (0.2 vs. 3.0 nM for 10a and 0.7 vs. 8.2 nM for 
10b). This difference can be caused either by inter-species difference (Mew-
shaw used predominantly rat receptors, we only used human receptors) or 
by differences in techniques. The latter is more likely in our opinion, as dis-
crepancy in the techniques is a well known cause of discrepancy in affinity 
measurements. For instance, for the D2Lhigh receptor we found a dopamine 
dissociation constant of 230 nM, whereas literature reports values of 2 nM 
using [3H]raclopride [51], 4.7 nM using [3H]spiperone [52] and 56 nM using 
[125I]iodosulpiride [53].
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Reported affinities of dopamine for the D2S receptor range between 
4.5–229  nM using [3H]spiperone as radioligand [54–56], while 22  nM was 
found using [125I]iodosulpiride [57]. Although we did not find a high-affinity 
state of dopamine for the D2S receptor in our experiments, a comparison be-
tween findings for the D2Shigh and the D2Lhigh is still warranted because these 
receptors are structurally almost equal.
In our experiments PHNO showed an affinity for D2Lhigh of 0.45  nM, and 
this is in line with literature findings of 0.6  nM [58] and 1.5  nM [59] for 
D2Lhigh. NPA exhibited a Ki of 0.07 nM for D2Lhigh, which is reasonably com-
parable to literature data that report Ki’s of 0.38 nM [60] and 0.11 nM [61].
All AMC derivatives designed by us had at least 100-fold lower affinities 
towards D1-like receptors than to D2-like receptors. This is in agreement 
with the established notion that bulky substituents at the nitrogen impart 
D2-selectivity.
Comparing the affinity towards D2Lhigh of the para (11a), meta (11b) and or-
tho (11c) iodobenzyl compounds shows that 11a and 11b have about equal 
affinity (3.8  nM and 2.1  nM, respectively) with 11c displaying a ten-fold 
stronger affinity (0.68 nM). This finding is in accordance with our expecta-
tion that the large iodine atom at the para-position of 11a may be accom-
modated less easily within the binding pocket (possibly clashing somewhat 
with the receptor extracellular loop) as compared to the placement of the 
meta and ortho substituted iodines in 11b and 11c. Nevertheless, 11a still 
shows a high affinity. Compound 12a with the 4-fluorobutyloxy group at 
the para-position of the benzyl ring had a D2Lhigh affinity of 5.6 nM, com-
parable to that of 11a, while its ortho-isomer 12b, surprisingly, did not ap-
pear to recognize D2Lhigh and had about 3-fold lower affinities for D2Llow and 
D3 than 12a. Apart from steric interactions, intramolecular hydrogen bond-
ing interactions between the secondary NH and the O-atom of the fluoro-
butoxy-chain may also play a role here, where these interactions can only be 
conceived for 12b (forming an ideal 6-ring) and not for 12a. Similarly such 
interactions may exist with the I-atom in 11c, but not with those in 11b or 
11a. Note that these intramolecular hydrogen bonding interactions are also 
reflected in the increased lipophilicities of compounds 11c and 12b relative 
to those of their para- or meta-substituted counterparts (Table 3). However, 
it remains difficult to be conclusive about the binding mode of 12a and par-
ticularly 12b.
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In comparison to the benzylamino-AMCs, 10a, 11a-c and 12a-b, the hybrid 
AMCs, 11d-e and 12c-d generally showed lower affinities towards all do-
paminergic receptor subtypes, both D1-like and D2-like. This fall in affinity 
was, however, not homogeneous, and the greatest decrease was observed 
for the D2 subtype receptors, as the tertiary amine hybrids 11d and 12c did 
not show a meaningful affinity towards these receptors at all, while the eth-
ylene-spaced secondary amine hybrid 11e only recognized the low-affinity 
state of D2L and D2S. This observation is in agreement with the SAR studies 
on D3-over-D2 selectivity which suggest that the ancillary binding pocket 
of D3 is more spacious than that of D2, so compounds with bulkier groups 
attached to the nitrogen atom tend to prefer binding to D3 [62, 63]. An in-
teresting exception to this trend is the ethylene-spaced secondary amine 
hybrid 12d that has a D2Lhigh affinity comparable to that of the fluorobu-
tyloxybenzyl derivative 12a, and that has a D2Lhigh-over-D2Llow preference 
that is even higher than that of 12a. It is impossible to determine on how 
exactly the arylpiperazine moiety interacts with the receptor in these hybrid 
ligands, but at least in the case of 12d the arylpiperazine must be bound in 
the ancillary pocket, because arylpiperazines that interact with the primary 
binding pocket of the receptors have very low D2-affinities when a bulky 
group, such as a fluoroalkoxy group, is placed at the para-position of the 
aryl ring [31, 55].
We successfully labeled two of our compounds, i.e. 12a and 12d, with fluo-
rine-18. We made the selection for these two compounds based on the re-
sults of the in vitro experiments described above: 12a and 12d show a high 
affinity for dopamine D2/3 receptors, a low affinity for dopamine D1-like re-
ceptors, show agonism in the cAMP experiment and have an appropriate 
lipophilicity. Scheme 3 shows our approach to prepare [18F]12a and [18F]12d, 
where particularly we chose to use [18F]fluoroalkylation onto a phenol pre-
cursor (either 13a or 13b) to arrive at the targeted tracers. The applied 
18F-labeling approach is versatile as we can quickly adapt the procedure for 
the preparation of homologous [18F]fluoroalkyl derivatives of [18F]12a or 
[18F]12d in case adjusting of the hydrophobicity of the ligand is deemed nec-
essary. In contrast, an approach where one would label compounds by direct 
18F-fluorination of tosyloxyalkyloxy or bromoalkyloxy precursors would re-
quire the preparation of every individual precursor (though fewer reaction 
steps involving 18F-containing intermediates would be an advantage).
As can be seen from Table 4, only 25–30% of the HPLC-purified [18F]12a 
or [18F]12d ended up in the formulated tracer solution. The reason for this 
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was that only 30–50% of the radioactivity could be eluted from the Oasis 
HLB SPE cartridge using the designated portions (1–2 mL) of pure ethanol, 
with the remainder of the [18F]12a and [18F]12d amines sticking to the car-
tridge. Elution efficiency rose to 80–90% when the ethanol was acidified 
with 1 v/v% ortho-phosphoric or acetic acid, but it was decided to simply 
use ethanol as eluent. The tracers [18F]12a and [18F]12d were obtained in 
reasonable yields and satisfactory molar radioactivities. Radiochemical pu-
rities were also satisfactory; all radioactive impurities present in formulated 
[18F]12a were much more polar than the tracer itself (not detectable on QC 
radio-HPLC, producing a spot with Rf = 0 on radio-TLC), and formulated 
[18F]12d contained radioactive impurities both more and less hydrophobic 
than the tracer, but the former never amounted to more than 5% of the total 
radioactivity.
We evaluated the labeled compounds [18F]12a and [18F]12d by in vitro auto-
radiography in rat brain slices. Both ligands exhibited preferential uptake in 
the striatum region, where for [18F]12a this was only visible at sub-nanomo-
lar free ligand concentrations and for [18F]12d it was found at low nanomolar 
levels (Figure 2). Given that the two compounds had comparable D2Lhigh af-
finities, the lack of discernible D2/3-specific binding of [
18F]12a at low nano-
molar concentrations may be due to its higher lipophilicity (Table 3) which 
may have lead to the D2/3-specific signal being “buried” under the non-spe-
cific signal resulting from [18F]12a binding to membrane phospholipides.
For both compounds, binding in the striatum could be blocked with the 
dopamine D2/3 receptor antagonist raclopride, and could be decreased to 
a similar extent in the presence of GTP, which suggests that the studied 
compounds indeed bind to the D2/3-receptors in the striatum, showing 
a strong preference for the high-affinity state. This promising finding stimu-
lates to perform future in vivo PET-studies of [18F]12d in rodents, especially 
since the lipophilicity of this compound is in the requested range for the 
development of accurate PET tracers [64].
Most of our novel AMC compounds showed comparable affinities for both 
the dopamine D2 and D3 receptor. This is in line with presently available 
agonist dopamine receptor PET tracers such as [11C]NPA, [11C]MNPA. In 
contrast, [11C]PHNO, which is D3-preferring in vivo [24], is currently being 
actively used to investigate the regional distribution of D3 receptors in the 
brain [65, 66] and the latest clinical research data suggest that D3-selective 
tracers might be advantageous over tracers with mixed D2/3-affinity in some 
applications [67, 68].
124 Chapter 3
Three of our four hybrid compounds (11d-e and 12c) seem selective for the 
D3 receptor over the D2 subtype. Though their D3-affinities are too low to 
consider them as candidate tracers, they confirm that high-affinity D3-selec-
tive AMCs can be made if more studies into structure-activity relationship 
for this compound class are undertaken. In addition, several of our novel 
compounds display a non-negligible affinity for the D4R (Table 1). For in-
stance, 11a and 11b, which are attractive candidates for 123I-labeling, have 
low nanomolar Ki values on D4 receptors. However, in the human striatum, 
the D4 receptor density is 16-fold lower than that of D2/3 receptors [69, 70]. 
In addition, in the striatum of rats, the D4 receptor density is 7- and 5-fold 
lower than that of D2 and D3 receptors, respectively [71]. Consequently, we 
believe that striatal binding of our tracers will predominantly reflect binding 
to D2/3 receptors.
Finally, our novel series of compounds may also offer the opportunity to 
develop 123I-labeled SPECT tracers: compound 11a may be an attractive can-
didate to label with iodine-123, since it has appropriate affinity, selectivity, 
lipophilicity and labeling seems feasible. Future studies will focus on this 
possibility.
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CONCLUS ION
We have identified a new series of agonist radiopharmaceuticals based 
on an AMC scaffold that bind with high affinity and selectivity to dopamine 
D2/3 receptors in vitro. In cAMP assays they all show nearly full agonism. 
In addition, two of these compounds were labeled successfully with [18F], 
and evaluated by in vitro autoradiography, where both of them showed spe-
cific binding in rat striatum, one at sub-nanomolar ([18F]12a) and another at 
low nanomolar ([18F]12d) concentrations. These findings stimulate further 
in vivo evaluations, e.g. animal PET and/or SPECT studies.
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EXPER IMENTAL SECT ION
Materials (chemical synthesis)
Reagents, chemicals, materials and solvents were obtained from commer-
cial sources, and were used as received: Biosolve, Merck for solvents, Cam-
bridge Isotope Laboratories for deuterated solvents, and Aldrich, Acros, 
ABCR, Merck and Fluka for chemicals, materials and reagents. All solvents 
were of AR quality. Moisture or oxygen-sensitive reactions were performed 
under an atmosphere of dry N2 or argon.
Methods for chemical synthesis and molecular 
characterization
1H-NMR and 13C-NMR spectra were recorded on a Varian Mercury (400 MHz 
for 1H-NMR, 100 MHz for 13C-NMR) spectrometers at 298 K. Chemical shifts 
are reported in ppm downfield from tetramethylsilane (TMS) for 1H NMR, 
and applying deuterated chloroform (CDCl3) or other deuterated solvents as 
internal reference for 13C NMR. Abbreviations used for splitting patterns are 
s = singlet, t = triplet, q = quartet, m = multiplet, dd = double doublet.
Melting points were measured on a Büchi melting point B-540 apparatus.
LC-PDA/MS analyses were performed on a Shimadzu LC-10 AD VP se-
ries LC coupled to a photo diode array (PDA) detector (Finnigan Surveyor 
PDA Plus detector, Thermo Electron corporation) and an ion-trap detector 
(LCQ Fleet, Thermo Scientific). Analyses were executed at 298 K using an 
Alltech Alltima HP C18 3μ column using an injection volume of 1–4 μL, a 
flow rate of 0.2 mL min-1 and typically a MeCN in H2O gradient (from 5% to 
100% MeCN, where both MeCN and H2O contain 0.1% formic acid).
Elemental and UPLC-HRMS analyses were performed on the aminomethyl-
chroman-7-ol (AMC) test compound series 10, 11 and 12 in their isolated 
oxalate forms. Elemental analyses were done to assess the number of ox-
alate groups that were attached to the AMC-amines, and were performed 
on a PerkinElmer Series II CHNS/O Analyser 2400. UPLC-HRMS was used 
to assess the purity and the exact molecular weight of the AMCs. Purities 
were typically ca. 95%, mostly higher, and have been mentioned for every 
AMC-compound. Mass deviations from the theoretical mass were typically 
between 0 and 2 ppm. UPLC was performed on a Waters Acquity UPLC, that 
was equipped with a Sample Manager (an autosampler) and a Binary Solvent 
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Manager. An Acquity UPLC BEH C18 1.7 micrometer column was used, using 
H2O and MeCN both with 0.1% formic acid as the two eluents, and applying 
an 8 minute gradient program where the amount of MeCN was increased 
from 5% to 60% in 5 minutes time. A sample solution (10% MeCN in H2O; 
0.1% formic acid) with a concentration of ca. 0.1 mg/mL was prepared and 
an injection volume of 0.1 microliter was used. For HRMS detection, a Xevo 
G2 Qtof detector using Zspray lockspray ionisation was applied.
GC-FID measurements to establish the e.e. of compound 1 were performed 
on a Shimadzu GC-2000, applying the Varian WCOT fused silica column 
(25 m, ID 0.25 mm), that is coated with CP chirasil-dex cb df 0.25 microm-
eter particles. An isothermal program was used (200 °C), applying a carrier 
gas helium flow of 30 cm/sec.
GC-MS measurements were executed on a Shimadzu GC-17A gas chromato-
graph coupled to a Shimadzu GCMS-QP5000 detector, using a Phenomenex 
Zebron ZB-35 capillary column (30 m length, ID 0.25 mm, 0.25 micrometer 
film thickness) that was operated using helium as the carrier gas and typi-
cally applying a temperature gradient from 80 °C to 300 °C.
Matrix-assisted laser desorption ionization time-of-flight mass spectrom-
etry (MALDI-TOF MS) was performed on a PerSeptive Biosystems Voyager-
DE PRO spectrometer using an α-cyano-4-hydroxycinnamic acid matrix.
Analytical thin layer chromatography (TLC) was performed on Kiesel-
gel F-254 precoated silica plates. Normal phase column chromatography 
was carried out on flash silica gel (40–63  μm mesh) or regular silica gel 
(60–200 μm), both acquired from Screening Devices B.V., or on standard-
ized aluminium oxide 90 from Merck. Reversed phase (RP) chromatography 
was performed on the Biotage Isolera One applying a SNAP KP-C18-HS car-
tridge.
The applied centrifuge was a Thermo Electron corporation Heraeus Mega-
fuge 1.0.
The synthesis of the AMC-derivative series 10, 11 and 12
A series of 9 potential agonist compounds for the dopamine D2/3 receptor, 
incorporating iodine or fluorine atoms in their structures was synthesized. 
Iodinated compounds were termed 11a, 11b, 11c, 11d and 11e. Fluoridated 
compounds were numbered 12a, 12b, 12c and 12d. For internal standard-
ization also 2 reference compounds without iodine or fluorine atoms in their 
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structure were also synthesized (namely 10a and 10b). Structural formulas 
are shown in Chart 1. All the test compound series 10, 11 and 12 reported 
in this work are (R)-enantiomers, and they all originate from starting com-
pound 1, i.e. (R)-7-hydroxychroman-2-carboxylic acid ethyl ester.
(R) 7-Hydroxychroman-2-carboxylic acid ethyl ester (1)
The racemate of 1 [34, 35] has been resolved to 1 (the R-enantiomer), using 
the lipase kinetic resolution procedure as reported by Kalaritis [36]. Accord-
ingly, the racemate of 1 (10 g, 45.5 mmol) was dissolved in THF (34 mL), and 
thereafter demi-water (270 mL) and a 0.05M phosphate buffer (68 mL) were 
added. Finally, amano lipase from Pseudomonas fluorescens (1.82  g) was 
added. The reaction mixture was treated with a 1M NaOH solution (25 mL) 
by dropwise addition in ten hours time. After NaOH-addition, the reaction 
mixture was stirred for another 8 hours. The mixture was evaporated to re-
move the THF, and the remaining aqueous mixture was extracted with ethyl 
acetate. Washing of the collected organic layers with saturated NaHCO3, 
drying with Na2SO4 and concentration gave an oil that slowly crystallized. 
Yield: typically ca. 45%.
Note that the reaction conversion, i.e. the hydrolysis of the S-enantiomer 
to the acid and the e.e. of the remaining desired R-enantiomer ester 1, was 
monitored using a chiral GC-FID method (see Methods section). Using this 
method, the racemate of 1 gives two peaks of equal intensity, while isolated 
1 (i.e. the R-enantiomer after resolution) gives one peak with no or very 
little sign of the S-enantiomer (e.e. 99%). The S-enantiomer eluted first, the 
desired R-enantiomer second. Analytical data of isolated 1 are according to 
those from the above mentioned literature sources, particularly [α]D
rt = −20.1 
(CHCl3, c = 1).
(R) (7-Hydroxychroman-2-yl)methanol (2)
Ethyl ester 1 (3.18 g, 14.4 mmol) was dissolved in THF (200 mL) and cooled 
to 0 °C. A 2M LiBH4 in THF solution (18.2 mL, 36.4 mmol, 2.5 moleqs) was 
added. The reaction mixture was stirred at rt for 3 hours, during which 
time the mixture became a milky suspension, and then it was poured into 
1/1 water/brine (200 mL) that was brought to pH=2 using a 2N HCl solution. 
After stirring for 5 hours, the mixture was extracted with diethyl ether and 
dried with Na2SO4. The fraction of starting compound (ca. 15%) that was still 
present, was removed by silica column chromatography (1/1 hexane/ethyl 
acetate). Yield: 2.1 g (80%). Analytical data are according to those from lit-
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erature [26] 1H NMR (CDCl3): δ = 6.9 (m, 1H), 6.35 (m, 2H), 5.35 (bs, 1H), 
4.05 (m, 1H), 3.85 (m, 1H), 3.75 (m, 1H), 2.85–2.6 (multiple signals, 2H), 2.2 
(bs, 1H), 1.95–1.75 (multiple signals, 2H). LC-MS: m/z = 181.1 [M+H]+ (calcd 
180.20 for C10H12O3).
Toluene-4-sulfonic acid, (R) (7-hydroxychroman-2-yl)-methyl ester (3)
A solution of the alcohol 2 (0.5 g, 2.8 mmol) in pyridine (25 mL) was stirred 
at 0 °C. 4-Toluenesulfonyl chloride (0.56 g, 2.9 mmol, 1.05 moleqs) was add-
ed in small portions, and the reaction mixture was stirred for 6 hours at 4 °C. 
The mixture was then poured in ice water, and aqueous 2N HCl was added 
to acidify to pH<2. Extraction with CH2Cl2, drying of the collected organic 
layers with MgSO4 and evaporation of the solvents gave a yellowish oil that 
was purified with silica column chromatography (2% MeOH/CHCl3). Yield 
0.56 g (60%). Analytical data are according to those from literature [26] 1H 
NMR (CDCl3): δ = 7.8 (m, 2H), 7.35 (m, 2H), 6.82 (m, 1H), 6.35 (m, 1H), 6.20 
(m, 1H), 5.55 (bs, 1H), 4.15 (multiple signals, 3H), 2.75–2.6 (multiple sig-
nals, 2H), 2.45 (s, 3H), 1.95 (m, 1H), 1.75 (m, 1H). LC-MS: m/z = 335.1 [M+H]+ 
(calcd 334.39 for C17H18O5S).
(R) 7-(Methoxymethoxy)chroman-2-carboxylic acid ethyl ester (4)
At rt, methoxylmethyl chloride (MOMCl; 0.188 mL, 2.07 mmol, 0.92 moleqs) 
was added to a solution of ester 1 (0.50 g; 2.25 mmol) and DIPEA (1.2 mL; ca. 
3 moleqs) in CH2Cl2 (25 mL). Monitoring of the progress of the reaction using 
1H NMR and LC-MS showed that extra MOMCl was required to complete the 
reaction, so another portion of MOMCl (0.188 mL; 0.92 moleqs) was added. 
Finally, the reaction mixture was washed with water, was concentrated and 
the remaining product was purified by silica column chromatography (2% 
MeOH/CHCl3). Yield: 73%.
1H NMR (CDCl3): δ = 6.92 (m, 1H), 6.66 (s, 1H), 6.56 (m, 1H), 5.11 (m, 2H), 
4.65 (m, 1H), 4.25 (m, 2H), 3.45 (s, 3H), 2.85–2.6 (multiple signals, 2H), 
2.3–2.2 (m, 1H), 2.2–2.1 (m, 1H), 1.29 (t, 3H). 13C NMR (CDCl3): δ = 170.8, 
156.6, 154.0, 129.8, 114.7, 109.4, 104.6, 94.5, 73.7, 61.3, 55.8, 24.7, 22.7, 14.1. 
LC-MS: m/z = 267.3 [M+H]+ and 235.4 [M-CH3O]
+ (calcd 266.29 for C14H18O5).
(R) (7-(Methoxymethoxy)chroman-2-yl)methanol (5)
Ethyl ester 4 (0.551 g; 2.07 mmol) was dissolved in THF (30 mL), after which 
LiBH4 (2.39 mL of a 2M solution in THF; 4.8 mmol) was added to this solu-
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tion that was cooled using an ice bath. The reaction mixture was allowed to 
heat up to rt in about two hours time. After verification that the reaction 
was completed by monitoring with LC-MS and 1H NMR, the reaction mixture 
was poured in water and extracted multiple times with ethyl acetate. The or-
ganic layer was dried using Na2SO4 and concentrated to give a colourless oil. 
This crude product was purified using silica column chromatography (2% 
MeOH/CHCl3). Yield: 90% (oil).
1H NMR (CDCl3): δ = 6.92 (m, 1H), 6.54 (multiple signals, 2H), 5.08 (s, 2H), 
4.05 (m, 1H), 3.85–3.75 (m, 1H), 3.75–3.65 (m, 1H), 3.43 (s, 3H), 2.85–
2.6 (multiple signals, 2H), 2.4–2.3 (bs, 1H), 1.95–1.85 (m, 1H), 1.85–1.7 
(m, 1H). 13C NMR (CDCl3): δ = 156.4, 155.0, 129.9, 115.4, 109.0, 104.3, 94.4, 
76.4, 65.4, 55.8, 23.8, 23.7. LC-MS: m/z = 225.0 [M+H]+ and 193.1 [M-CH3O]
+ 
(calcd 224.26 for C12H16O4). GC-FID analysis gave a single peak when using 
the chiral capillary column (see Methods section for details, see also GC-FID 
analysis of molecule 1).
Toluene-4-sulfonic acid, (R) (7-(methoxymethoxy)chroman-2-yl)-methyl 
ester (6)
Alcohol 5 (0.56 g, 2.50 mmol) was dissolved in pyridine (7.5 mL) and the 
solution was cooled to 0 °C. p-Toluenesulfonylchloride (1.05 g, 5.5 mmol, 
2.2 moleqs) in pyridine was added slowly, and the reaction mixture was 
thereafter stirred overnight at 4 °C. A small amount of ice was added to de-
stroy the excess of p-toluenesulfonylchloride, the pH of the ice-cooled mix-
ture was brought to pH=1 using a concentrated hydrochloric acid solution, 
and the product was extracted with CH2Cl2. The organic layer was washed 
with NaHCO3, with a solution of CuSO4 to remove traces of pyridine and 
finally with NaCl (aq.). Drying with Na2SO4 and concentration gave a slightly 
pinkish colored oil. Yield: 89%.
1H NMR (CDCl3): δ = 7.83 (m, 2H), 7.38 (m, 2H), 6.95 (m, 1H), 6.55 (mul-
tiple signals, 2H), 6.41 (s, 1H), 5.08 (s, 2H), 4.20 (multiple signals, 3H), 3.45 
(s, 3H), 2.85–2.6 (multiple signals, 2H), 2.45 (s, 3H), 2.05–1.95 (m, 1H), 
1.85–1.7 (m, 1H). 13C NMR (CDCl3): δ = 156.5, 154.4, 144.9, 132.7, 129.9, 
129.6, 128.0, 114.7, 110.0, 104.4, 94.4, 72.9, 71.1, 55.9, 23.8, 23.3, 21.6. LC-
MS: m/z = 401.3 [M+Na]+, 347.4 [M-CH3O]
+, (calcd 378.44 for C19H22SO6).
(R) N-(7-(Methoxymethoxy)chroman-2-yl)-methyl phthalimide (7)
Tosylate 6 (300  mg, 0.79  mmol) and potassium phthalimide (367  mg, 
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1.98 mmol, 2.5 moleqs) were suspended in DMF (10 mL). The mixture was 
stirred for 16 hours at 80 °C, and was then allowed to cool down to rt. Diethyl 
ether was added and the mixture was washed twice with a saturated aqueous 
NH4Cl solution, twice with water and one more time with a saturated NaCl 
solution in water. The organic layer was dried with Na2SO4. After removal of 
the volatiles the obtained white solid was purified with silica column chro-
matography (2% MeOH/ CHCl3). Yield: 78%.
1H NMR (CDCl3): δ = 7.80 (m, 2H), 7.30 (m, 2H), 6.90 (d, 1H), 6.51 (m, 1H), 
6.45 (s, 1H), 5.08 (m, 2H), 4.33 (m, 1H), 4.03 (dd, 1H), 3.84 (dd, 1H), 3.45 
(s, 3H), 2.74 (m, 2H), 2.03 (m, 1H), 1.78 (m, 1H). 13C NMR (CDCl3): δ = 168.2, 
156.4, 154.8, 134.0, 132.0, 129.8, 123.4, 115.0, 109.2, 104.5, 94.4, 73.0, 55.9, 
41.9, 25.4, 23.5. LC-MS: m/z = 322.2 [M-CH3O]
+, 354.3 [M+H]+, 376.4 [M+Na]+, 
643.3 [2M-H-2CH3O]
+, (calcd 353.37 for C20H19NO5).
(R) (7-(Methoxymethoxy)chroman-2-yl)-methyl amine (8)
Phthalimide protected amine 7 (200 mg, 0.566 mmol) was stirred in EtOH 
(3 mL) together with hydrazine monohydrate (0.029 mL, 0.58 mmol). The 
mixture was heated at an oil bath temperature of 80 °C for 16 hours, during 
which time the reaction mixture changed from a suspension to a clear solu-
tion and back to a suspension. The mixture was allowed to cool to rt and was 
filtered; the filtrate was evaporated and redissolved in CHCl3. The organic 
layer was washed once with a 0.1 M NaOH(aq) solution and once with water. 
The organic layer was dried with Na2SO4 and concentrated to give a colorless 
oil. Yield: 101 mg (80%).
1H NMR (CDCl3): δ = 6.90 (m, 1H), 6.51 (multiple signals, 2H), 5.08 (s, 2H), 
3.90 (m, 1H), 3.45 (s, 3H), 2.90 (d, 2H), 2.8–2.7 (m, 1H), 2.7–2.6 (m, 1H), 1.85 
(m, 1H), 1.75 (m, 1H), 1.4 (bs, 2H). 13C NMR (CDCl3): δ = 156.4, 155.3, 129.8, 
115.4, 108.8, 104.3, 94.4, 77.6, 55.8, 46.6, 25.0, 24.0. LC-MS: m/z = 224.1 
[M+H]+, (calcd 223.27 for C12H17NO3).
Route A: Coupling of tosylate 3 to the appropriate amines
(R)-2-[(Benzylamino)methyl]chroman-7-ol (10a)
Free amine. This reference compound 10a was prepared using a simi-
lar method to that described by Mewshaw [26]. Benzylamine (0.266  g; 
2.48  mmol; 3 moleqs) was added to a solution of the tosylate 3 (0.285  g; 
0.83 mmol) in DMSO (8 mL). The reaction mixture was stirred for 16 hours at 
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100 °C at which point it was poured in water (35 mL). The obtained suspen-
sion was extracted two times with ethylacetate, the collected organic layers 
were washed with water to remove DMSO, and the ethyl acetate solution 
was dried with Na2SO4. The crude free amine product was purified with silica 
column chromatography (5% MeOH/CHCl3). Yield: 90 mg (40%).
1H NMR (CDCl3): δ = 7.45–7.15 (multiple signals, 5H), 6.8 (m, 1H), 6.35 (mul-
tiple signals, 2H), 4.05 (m, 1H), 3.95 (d, 1H), 3.85 (d, 1H), 2.85 (m, 1H), 2.75 
(m, 1H), 2.7–2.6 (multiple signals, 2H), 1.85 (m, 1H), 1.65 (m, 1H). 13C NMR 
(CDCl3): δ = 156.2, 154.5, 138.3, 130.0, 128.6, 128.6, 127.4, 112.6, 109.0, 
103.3, 74.3, 54.0, 53.6, 26.2, 23.7. LC-MS: m/z = 270.3 [M+H]+, (calcd 269.34 
for C17H19NO2). MALDI-TOF-MS, m/z = 270.18 [M+H]
+.
Oxalate salt. To a solution of the free amine 10a (90 mg, 0.334 mmol) in 
THF (2 mL) was added a solution of oxalic acid dihydrate (84 mg, 0.67 mmol, 
2 moleqs) in THF (0.5 mL). Immediately after addition a solid precipitated. 
The mixture was stirred for 3 hours, a small amount of ether was added to 
improve the precipitation, the mixture was filtrated and the white solid resi-
due was washed with diethylether. Yield: 82 mg (68%).
1H NMR (DMSO-d6): δ = 8.0–6.0 (broad signal acidic protons), 7.55 
(m, 2H), 7.4 (m, 3H), 6.8 (m, 1H), 6.28 (m, 1H), 6.23 (s, 1H), 4.27 (m, 1H), 4.23 
(s, 2H), 3.2–3.0 (multiple signals, 2H), 2.75–2.5 (multiple signals, 2H), 1.95 
(m, 1H), 1.65 (m, 1H). 13C NMR (DMSO-d6): δ = 164.4, 156.5, 153.9, 132.5, 
130.0, 129.9, 128.8, 128.6, 111.9, 108.5, 102.9, 71.5, 50.6, 49.9, 24.7, 22.7. 
M.p. = 212 °C (dec). LC-MS: m/z = 270.2 [M+H]+, (calcd 269.34 for C17H19NO2). 
UPLC-HRMS [M+H]+: Calcd 270.1494, Found 270.1491 (1.1 ppm). UPLC: 99% 
purity. Elemental analysis C,H,N: Found 63.4, 5.3, 3.7, Calcd. 63.5, 5.9, 3.9 
for C17H19NO2 + 1 C2H2O4 (FW=359.4).
(R)-2-[(3-Iodobenzylamino)methyl]chroman-7-ol (11b)
Free amine. Tosylate 3 (0.38  g; 1.1  mmol) was mixed with commercially 
available 3-iodo-benzylamine (0.78  g; 3.3  mmol; 2.9 moleqs) and DIPEA 
(0.6  mL, 3 moleqs) in DMSO (10  mL), and this solution was stirred over-
night at an oil bath temperature of 100 °C. According to LC-MS no tosylate 
starting material was present anymore and the mixture was poured in wa-
ter, followed by extraction of the water layer with ethyl acetate (two times). 
The ethyl acetate layers were collected, dried with Na2SO4 and concentrated. 
Finally, the crude product was purified with silica column chromatography 
(2% MeOH/CHCl3) giving 169 mg of an oily product (39%).
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1H NMR (CDCl3): δ = 7.7 (s, 1H), 7.6 (m, 1H), 7.35 (m, 1H), 7.05 (m, 1H), 6.8 
(m, 1H), 6.35 (multiple signals, 2H), 4.05 (m, 1H), 3.85 (d, 1H), 3.80 (d, 1H), 
2.85 (m, 1H), 2.75 (m, 1H), 2.7–2.55 (multiple signals, 2H), 1.85 (m, 1H), 1.65 
(m, 1H).
Oxalate salt. The free amine 11b (169 mg, 0.43 mmol) was dissolved in THF 
(2 mL) and oxalic acid dihydrate (118 mg, 0.94 mmol, 2.2 moleqs) was added. 
A precipitation formed, and after some stirring the suspension was filtrated 
to give a white solid product. Yield: 152 mg (73%).
1H NMR (DMSO-d6): δ = 8.0–6.0 (broad signal acidic protons), 7.9 (s, 1H), 
7.75 (m, 1H), 7.55 (m, 1H), 7.25 (m, 1H), 6.85 (m, 1H), 6.28 (m, 1H), 6.25 
(s, 1H), 4.25 (m, 1H), 4.15 (s, 2H), 3.2–3.0 (multiple signals, 2H), 2.75–2.5 
(multiple signals, 2H), 1.95 (m, 1H), 1.65 (m, 1H). 13C NMR (DMSO-d6): 
δ = 164.0, 156.5, 154.0, 138.4, 137.3, 135.5, 130.7, 129.9, 129.4, 111.9, 108.5, 
102.9, 94.9, 71.7, 50.2, 49.9, 24.7, 22.8. M.p. = 214 °C (dec). LC-MS: m/z = 
396.2 [M+H]+, (calcd 395.24 for C17H18NO2I). UPLC-HRMS [M+H]
+: Calcd 
396.0460, Found 396.0455 (1.3 ppm). UPLC: 94% purity. Elemental analysis 
C,H,N: Found 47.2, 4.3, 2.4, Calcd. 47.0, 4.2, 2.9 for C17H18NO2I + 1 C2H2O4 
(FW=485.3).
(R) 1-(4-Iodophenyl)-4-((7-hydroxychroman-2-yl)methyl)piperazine (11d)
Free amine. Tosylate 3 (289  mg, 0.865  mmol) was dissolved in DMSO 
(10 mL), and to the solution DIPEA (0.334 g, 2.59 mmol, 2.9 moleqs) and 
1-(4-iodophenyl)-piperazine (500 mg, 1.74 mmol, 2.0 moleqs) were added. 
1-(4-Iodophenyl)-piperazine had been synthesized from 1-phenyl-pipera-
zine according to Hanson et al. [72] The reaction mixture was stirred over-
night at 100  °C under an argon atmosphere. According to LC-MS all the 
tosylate reactant was converted. The reaction mixture was cooled down to 
rt and was poured into water. Extraction with ethyl acetate was followed 
by drying of the collected organic layers with Na2SO4. Evaporation of the 
solvent yielded crude product (844  mg) that was purified with silica col-
umn chromatography (2% MeOH/CHCl3). A beige solid was obtained. Yield: 
120 mg (31%).
1H NMR (CDCl3 with a drop of CD3OD): δ = 7.55 (m, 2H), 6.85 (m, 1H), 6.70 
(m, 2H), 6.35 (m, 1H), 6.30 (s, 1H), 4.2 (m, 1H), 3.2 (m, 4H), 2.85–2.6 (mul-
tiple signals, 7H), 2.55 (m, 1H), 2.0 (m, 1H), 1.75 (m, 1H). LC-MS: m/z = 451.3 
[M+H]+, (calcd 450.32 for C20H23N2O2I).
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Oxalate salt. To a solution of the free amine 11d (120 mg, 0.267 mmol) in 
THF (4 mL) was added a solution of oxalic acid dihydrate (74 mg, 0.59 mmol, 
2.2 moleqs) in THF (1  mL). Immediately a white solid precipitated. After 
3 hours of stirring the reaction mixture centrifuged. The solvent was de-
canted and the residue was washed with a mixture of THF and ether (1/1). 
After drying, a white solid residue was isolated (120 mg, 83%).
1H NMR (DMSO-d6): δ = 7.5 (m, 2H), 6.8 (multiple signals, 3H), 6.25 (m, 1H), 
6.20 (s, 1H), 4.3 (m, 1H), 3.25 (m, 4H), 3.1–2.9 (multiple signals, 6H), 2.8–
2.6 (multiple signals, 2H), 2.0 (m, 1H), 1.65 (m, 1H). 13C NMR (DMSO-d6): 
δ = 162.6, 156.5, 154.3, 150.0, 137.4, 129.9, 118.0, 112.1, 108.2, 102.9, 
81.3, 71.8, 60.4, 52.3, 46.4, 25.5, 22.9. M.p. = 177  °C (dec). LC-MS: m/z =  
451.2 [M+H]+, (calcd 450.32 for C20H23N2O2I). UPLC-HRMS [M+H]
+: Calcd 
451.0882, Found, 451.0882 (0 ppm). UPLC: 96% purity. Elemental analysis 
C,H,N: Found 48.9, 4.1, 4.8, Calcd. 48.9, 4.7, 5.2 for C20H23N2O2I + 1 C2H2O4 
(FW=540.4).
Route B: General procedure for coupling of the 
MOM-protected tosylate 6 to the appropriate amines
The tosylate 6 is added to a solution of the amine (typically in a molar excess 
relative to the tosylate) in DMSO. DIPEA is also present (in molar excess 
relative to the tosylate). The reaction mixture is heated to 80–100 °C under 
an inert atmosphere of argon, and during 1 or 2 days the progress of the re-
action is followed with LC-MS. In cases where primary amine starting com-
pounds are used, LC-MS analysis of the reaction mixture shows the excess 
of the primary amine starting compound and the secondary amine desired 
product, but also tertiary amine by-product. After reaction, the mixture is 
poured into cold water and the product is extracted using ethyl acetate. 
Evaporation yields an oily product that requires column chromatographic 
purification. The obtained secondary amine products can severely stick to 
silica, so alumina is sometimes used as the stationary phase. The applied 
eluent is a mixture of CHCl3 with a small percentage of MeOH (typically 1 to 
2 v/v%), or a gradient with gently increasing MeOH-contents starting from 
pure CHCl3.
(R) N-[7-(Methoxymethoxy)chroman-2-yl]methyl 1-hexyl amine (9a)
n-Hexylamine (0.321  g, 3.18  mmol) was dissolved in DMSO (5  mL) with 
5 moleqs of DIPEA (0.9 mL). Tosylate 6 (397 mg, 1.05 mmol) was added and 
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the reaction mixture was heated overnight at 95 °C under an argon atmo-
sphere. The mixture was cooled and poured into water followed by extrac-
tion of the aqueous layer ethyl acetate. Concentration of the organic layer 
gave a slightly colored oil (378 mg), that gave 193 mg of pure product after 
silica column chromatography (2% MeOH/CHCl3). Yield 60%.
1H NMR (CDCl3): δ = 6.92 (m, 1H), 6.53 (multiple signals, 2H), 5.10 (s, 2H), 
4.11 (m, 1H), 3.44 (s, 3H), 2.90–2.55 (multiple signals, 5H), 2.0–1.9 (m, 1H), 
1.8–1.6 (multiple signals, 3H), 1.50 (m, 2H), 1.4–1.2 (multiple signals, 6H), 
0.88 (t, 3H). 13C NMR (CDCl3): δ = 156.4, 155.2, 129.9, 115.5, 108.8, 104.3, 
94.4, 75.2, 55.8, 54.3, 50.1, 31.7, 30.0, 27.0, 25.7, 24.0, 22.6, 14.0. LC-MS: m/z 
= 308.3 [M+H]+, (calcd 307.43 for C18H29NO3).
(R) N-[7-(Methoxymethoxy)chroman-2-yl]methyl 4-iodobenzyl amine (9b)
The tosylate 6 (327 mg, 0.865 mmol) was added to a solution of commer-
cially available para-iodobenzylamine (0.4 g; 1.83 mmol) in DMSO (5 mL) 
and DIPEA (0.8 mL). The mixture was heated to 85 °C, was kept under argon 
and was stirred overnight. After cooling down to rt, the reaction mixture 
was poured into water. Extraction with ethyl acetate, and evaporation of the 
volatiles yielded a slightly colored oil. This crude material was purified with 
silica column chromatography (2% MeOH/CHCl3), yielding 283 mg product 
(75%).
1H NMR (CDCl3): δ = 7.64 (m, 2H), 7.12 (m, 2H), 6.95 (m, 1H), 6.53 (multiple 
signals, 2H), 5.11 (s, 2H), 4.15 (m, 1H), 3.80 (s, 2H), 3.45 (s, 3H), 2.9–2.6 
(multiple signals, 4H), 2.0–1.9 (multiple signals, 2H), 1.75 (m, 1H). 13C NMR 
(CDCl3): δ = 156.4, 155.1, 139.9, 137.3, 130.0, 129.8, 115.4, 108.9, 104.3, 94.4, 




Primary amine 24 (0.585 g, 1.77 mmol, 1.5 moleqs) was dissolved in DMSO 
(5 mL) with 4 moleqs of DIPEA (0.8 mL). Tosylate 6 (442 mg, 1.17 mmol) 
was added and the reaction mixture was heated to 85 °C, and was kept over-
night under a gentle flow of argon. The reaction mixture was then cooled 
and poured into water. Extraction with ethyl acetate and evaporation of the 
solvent yielded a slightly colored oil that was purified with alumina column 
chromatography (2% MeOH/CHCl3). Yield: 250 mg (40%).
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1H NMR (CDCl3): δ = 7.50 (m, 2H), 6.95 (m, 1H), 6.67 (m, 2H), 6.53 (multiple 
signals, 2H), 5.08 (s, 2H), 4.15 (m, 1H), 3.44 (s, 3H), 3.17 (m, 4H), 2.95–2.65 
(multiple signals, 6H), 2.65–2.55 (multiple signals, 6H), 2.0–1.9 (multiple 
signals, 2H), 1.75 (m, 1H). 13C NMR (CDCl3): δ = 156.4, 155.2, 150.9, 137.7, 
129.9, 117.9, 115.5, 108.9, 104.3, 94.4, 81.2, 75.0, 57.8, 55.8, 54.2, 53.0, 48.7, 
46.4, 25.7, 24.0. LC-MS: m/z = 538.3 [M+H]+, (calcd 537.44 for C24H32N3O3I).
(R) N-[7-(Methoxymethoxy)chroman-2-yl]methyl 4-(4-fluorobutoxy)benzyl 
amine (9e)
Amine 21 (0.198 g, 1.00 mmol, 1.2 moleqs) was dissolved in DMSO (5 mL) 
with 5 moleqs of DIPEA (0.75 mL). The tosylate 6 (318 mg, 0.84 mmol) was 
added, the mixture was heated to 95 °C and was left to react for 2 days while 
being kept under an argon atmosphere. The reaction was cooled down and 
poured in water. Extraction with ethyl acetate yielded a slightly colored oil 
that was purified using silica column chromatography (2% MeOH/CHCl3), 
and subsequent RP C18 chromatography using an aqueous eluent gradient. 
Yield: 124 mg (36%).
1H NMR (CDCl3): δ = 7.25 (m, 2H), 6.90 (m, 1H), 6.85 (m, 2H), 6.53 (mul-
tiple signals, 2H), 5.05 (s, 2H), 4.6 (m, 1H), 4.45 (m, 1H), 4.15 (m, 1H), 3.95 
(m, 2H), 3.8 (s, 2H), 3.4 (s, 3H), 2.9–2.65 (multiple signals, 4H), 2.0–1.7 (mul-
tiple signals, 7H). LC-MS: m/z = 404.3 [M+H]+, (calcd 403.49 for C23H30NO4F).
(R) 1-(4-(2-Fluoroethoxy)phenyl)-4-((7-(methoxymethoxy)chroman-2-yl)-
methyl)-piperazine (9g)
1-(4-(2-Fluoroethoxy)-phenyl)-piperazine was prepared from com-
mercially available 1-(4-hydroxyphenyl)-piperazine according to Ti-
etze et al. [73], thereby using the 1-fluoro-2-tosyloxy-ethane building 
block that was prepared [74] from commercially available 2-fluoroetha-
nol. 1-(4-(2-Fluoroethoxy)-phenyl)-piperazine (0.305 gram, 1.36  mmol, 
1.2 moleqs) was dissolved in DMSO (5 mL) with 3 moleqs of DIPEA (0.6 mL). 
The tosylate 6 (428 mg, 1.13 mmol) was added and the reaction mixture was 
heated to 95 °C. Overnight stirring under an inert argon atmosphere was 
followed by cooling down of the reaction mixture and pouring it in water. 
Extraction with ethyl acetate and concentration yielded a slightly colored 
crude oil that was purified using silica column chromatography (2% MeOH/
CHCl3). Yield: 320 mg (66%).
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1H NMR (CDCl3): δ = 7.0–6.8 (multiple signals, 5H), 6.56 (multiple signals, 
2H), 5.12 (s, 2H), 4.79 (m, 1H), 4.67 (m, 1H), 4.20 (m, 2H), 4.15 (m, 1H), 
3.46 (s, 3H), 3.13 (m, 4H), 2.9–2.55 (multiple signals, 8H), 2.1–2.0 (m, 1H), 
1.85–1.7 (m, 1H). LC-MS: m/z = 431.4 [M+H]+, (calcd 430.52 for C24H31N2O4F).
(R) 1-(4-(2-Fluoroethoxy)phenyl)-4-(4-(7-(methoxymethoxy)chroman-2-yl)-
3-azabutyl)-piperazine (9h)
Primary amine 26 (0.364 g, 1.36 mmol, 1.2 moleqs) was dissolved in DMSO 
(5 mL) with 3 moleqs of DIPEA (0.6 mL). The tosylate 6 (428 mg, 1.13 mmol) 
was added and the reaction mixture was heated overnight at 100 °C and was 
kept under a gentle flow of argon. The reaction mixture was cooled down and 
poured into water. Extraction with ethyl acetate, and concentration gave a 
slightly colored oil (0.36 g). Finally, purification with alumina column chro-
matography (2% MeOH/CHCl3) gave a yield of 47% of pure product (250 mg).
1H NMR (CDCl3): δ = 7.0–6.8 (multiple signals, 5H), 6.54 (multiple signals, 
2H), 5.10 (s, 2H), 4.79 (m, 1H), 4.67 (m, 1H), 4.20 (m, 1H), 4.13 (m, 2H), 
3.44 (s, 3H), 3.12 (m, 4H), 3.0–2.5 (multiple signals, 12H), 2.05–1.9 (mul-
tiple signals, 2H), 1.75 (m, 1H). LC-MS: m/z = 474.4 [M+H]+, (calcd 473.59 for 
C26H36N3O4F).
Route C: General procedure for coupling the MOM-protected 
amine 8 to the appropriate aldehydes
The MOM-protected primary amine 8 and the appropriate aldehyde (1 mol 
moleq) are mixed in MeOH and stirred overnight at rt. During this step the 
imine is formed. The conversion is followed with 1H NMR by inspecting the 
aldehyde signal (due to reversibility of the reaction in the presence of wa-
ter, monitoring by LC-MS is not possible). After completion of imine forma-
tion, 1.1 mol moleqs of NaBH4 is added and the reaction mixture is stirred 
at rt for 1 up to 3 hours. 1H NMR can be used to monitor imine conversion. 
The reaction mixture is poured in water, the aqueous solution is stirred for 
1 hour and is then extracted with CH2Cl2, or alternatively with CHCl3. Due to 
the presence of boron salts it may be necessary to first adjust the pH of the 
water layer to acidic (pH=1), then back to slightly basic (pH=8) and do the 
extraction at this higher pH. Drying of combined organic layers with Na2SO4 
is followed by removal of the solvents to yield the product.
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(R) N-[7-(Methoxymethoxy)chroman-2-yl]methyl 4-iodobenzyl amine (9b)
4-Iodobenzaldehyde was prepared from commercially available p-iodo 
benzoic acid using a two-step procedure [75] via the p-iodo benzyl alco-
hol. Amine 8 (418  mg, 1.87  mmol) and freshly prepared 4-iodobenzalde-
hyde (433 mg, 1.87 mmol) were stirred in MeOH (10 mL). NaBH4 (77.7 mg, 
2.06 mmol) was added. Extraction with CHCl3 and thereafter with CH2Cl2. An 
oily product was obtained (766 mg, 93%). The analytical data are identical to 
those reported for the same 9b product as prepared and isolated via Route 
B (vide supra).
(R) N-[7-(Methoxymethoxy)chroman-2-yl]methyl 2-iodobenzyl amine (9c)
2-Iodobenzaldehyde was prepared from its commercially available benzyl 
alcohol precursor [76]. Amine 8 (192 mg, 0.86 mmol) was stirred with 2-io-
dobenzaldehyde (200  mg, 0.86  mmol) in MeOH (5  mL). According to the 
1H NMR, still ca. 4% of aldehyde was present, but nevertheless NaBH4 (42 mg, 
1.11  mmol, 1.3 moleqs) was added. After extraction, the crude yellow oil 
(331 mg) was purified by silica column chromatography (ethyl acetate/hex-
ane 1/1) to yield 209 mg (56%) of product.
1H NMR (CDCl3): δ = 7.80 (m, 1H), 7.40 (m, 1H), 7.28 (m, 1H), 6.95 (mul-
tiple signals, 2H), 6.53 (multiple signals, 2H), 5.08 (s, 2H), 4.15 (m, 1H), 3.87 
(s, 2H), 3.45 (s, 3H), 2.9–2.6 (multiple signals, 4H), 2.05–1.85 (multiple sig-
nals, 2H), 1.85–1.75 (m, 1H). 13C NMR (CDCl3): δ = 156.4, 155.2, 142.0, 139.3, 
129.8, 129.4, 128.7, 128.2, 115.5, 108.9, 104.4, 99.5, 94.4, 75.2, 58.0, 55.8, 
53.2, 25.6, 23.9. LC-MS: m/z = 440.2 [M+H]+, (calcd 439.29 for C19H22NO3I).
(R) N-[7-(Methoxymethoxy)chroman-2-yl]methyl 2-(4-fluorobutoxy)benzyl 
amine (9f)
Amine 8 (205  mg, 0.92  mmol) was stirred with 2-(4-fluorobutoxy) benz-
aldehyde 22 (179 mg, 0.92 mmol) in MeOH (5 mL). According to 1H NMR 
some 10% of aldehyde was still present, but nevertheless NaBH4 (45  mg, 
1.19 mmol, 1.3 moleqs) was added. The crude yellowish oil (340 mg) was 
purified with silica column chromatography (ethyl acetate/hexane 1/1) to 
yield 221 mg of product (60%).
1H NMR (CDCl3): δ = 7.26 (m, 1H), 7.23 (m, 1H), 6.85 (multiple signals, 2H), 
6.80 (m, 1H), 6.53 (multiple signals, 2H), 5.10 (s, 2H), 4.56 (bs, 1H), 4.45 
(t, 1H), 4.15 (m, 1H), 4.06 (t, 2H), 3.85 (dd, 2H), 3.44 (s, 3H), 2.90–2.6 (mul-
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tiple signals, 4H), 2.05 (bs, 1H), 2.0–1.85 (multiple signals, 5H), 1.8–1.7 
(m, 1H). 13C NMR (CDCl3): δ = 156.9, 156.4, 155.3, 129.9, 129.8, 128.3, 128.1, 
120.4, 115.5, 111.0, 108.8, 104.3, 94.5, 84.5, 82.8, 75.6, 67.1, 55.8, 53.6, 49.4, 
27.4, 27.2, 25.7, 25.4, 25.3, 24.0. LC-MS: m/z = 404.3 [M+H]+, (calcd 403.49 
for C23H30NO4F).
Route B and C: General procedure for deprotection 
of the MOM-group
The appropriate MOM-protected compound 9 (100 to 300 mg) was dissolved 
in an 4M HCl solution in dioxane (2 to 5 mL; HCl in high molar excess) and 
isopropanol (2 to 5 mL). The reaction mixture was stirred for about 3 hours 
at rt, while a N2 flow was maintained over the reaction mixture. From time 
to time, N2 was bubbled through the solution in order to remove volatile 
reaction products from the mixture. The reaction mixture may turn hazy 
due to precipitation of the ammonium salt. After completion of the reaction 
(the reaction was monitored by LC-MS), the mixture was added to water and 
the pH was brought to slightly basic by addition of a NaOH-solution. The 
product was isolated from the water layer by several extractions using CHCl3 
or CH2Cl2 with some added THF, followed by drying of the collected organic 
layers with Na2SO4 and evaporation of the solvent.
General procedure for preparation of the oxalate salt. The isolated free 
amine compound was dissolved in THF and a solution of oxalic acid dihy-
drate in THF was added. The reaction mixture turned hazy due to precipi-
tation of the oxalate ammonium salt. After about 3–5 hours of stirring the 
reaction mixture was centrifuged and the solvent was pipetted or decanted 
off. The residue was stirred in a fresh 1:1 mixture of diethyl ether and THF 
and was centrifuged again. The solvent was removed and the precipitate was 
dried to yield a white, off-white or slightly brownish powder product.
(R)-2-[(Hexylamino)methyl]chroman-7-ol (10b)
Free amine. This reference compounds 10b has already been reported by 
Mewshaw [26], albeit that the racemic mixture was prepared and not the 
(R)-enantiomer. Furthermore, we have prepared 10b via its MOM-protected 
precursor, while Mewshaw had prepared the racemate via its benzyl-pro-
tected precursor. Compound 9a (121 mg, 0.39 mmol) was dissolved in a so-
lution of 4M HCl in dioxane (2 mL) and isopropanol (3 mL). Yield after work 
up: 100 mg (96%).
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1H NMR (CDCl3): δ = 6.78 (m, 1H), 6.45 (m, 1H), 6.32 (m, 1H), 4.07 (m, 1H), 
2.90 (t, 1H), 2.8–2.5 (multiple signals, 5H), 1.85 (m, 1H), 1.75–1.5 (multiple 
signals, 3H), 1.4–1.2 (multiple signals, 6H), 0.88 (t, 3H). 13C NMR (CDCl3): 
δ = 156.7, 154.5, 130.0, 112.2, 109.4, 103.0, 74.2, 54.2, 50.0, 31.6, 29.2, 
26.9, 26.3, 23.7, 22.5, 14.0. LC-MS: m/z = 264.3 [M+H]+, (calcd 263.38 for 
C16H25NO2).
Oxalate salt. The free amine 10b (120 mg, 0.456 mmol) was dissolved in 
THF (2 mL), and oxalic acid dihydrate (86 mg, 0.68 mmol, 1.5 moleqs) in 
THF (1 mL) was added. A white solid precipitate was isolated (115 mg; 71%).
1H NMR (DMSO-d6): δ = 9.0–6.0 (broad signal, acidic protons), 6.85 (m, 1H), 
6.28 (m, 1H), 6.23 (s, 1H), 4.25 (m, 1H), 3.25–3.05 (multiple signals, 2H), 2.9 
(m, 2H), 2.75–2.5 (multiple signals, 2H), 1.95 (m, 1H), 1.65 (multiple sig-
nals, 3H), 1.25 (m, 6H), 0.9 (t, 3H). 13C NMR (DMSO-d6): δ = 164.6, 156.6, 
153.9, 129.9, 111.9, 108.5, 102.9, 71.3, 50.1, 47.3, 30.7, 25.7, 25.2, 24.7, 22.7, 
21.9, 13.9. M.p. = 152 °C (dec). LC-MS: m/z = 264.3 [M+H]+, (calcd 263.38 for 
C16H25NO2). UPLC-HRMS [M+H]
+: Calcd 264.1964, Found 264.1966 (0.8 ppm). 
UPLC: 92% purity. Elemental analysis C,H,N: Found 60.6, 7.7, 3.6, Calcd. 
61.2, 7.7, 4.0 for C16H25NO2 + 1 C2H2O4 (FW=353.4).
(R)-2-[(4-Iodobenzylamino)methyl]chroman-7-ol (11a)
Free amine. Compound 9b (171  mg, 0.389  mmol) was deprotected in 
4M HCl in dioxane (3.5 mL) and isopropanol (3.5 mL). After work-up, an oil 
was obtained in 80% yield (123 mg).
1H NMR (CD3OD): δ = 7.65 (m, 2H), 7.15 (m, 2H), 6.80 (m, 1H), 6.27 (m, 1H), 
6.23 (m, 1H), 4.05 (m, 1H), 3.80 (bs, 2H), 2.9–2.5 (multiple signals, 4H), 1.93 
(m, 1H), 1.65 (m, 1H). 13C NMR (CDCl3): δ = 156.0, 154.4, 137.8, 137.7, 130.6, 
130.1, 112.7, 109.1, 103.2, 93.1, 74.2, 53.6, 53.5, 26.2, 23.6. LC-MS: m/z = 
396.2 [M+H]+, (calcd 395.24 for C17H18NO2I). MALDI-TOF-MS, m/z = 396.0 
[M+H]+.
Oxalate salt. The free amine 11a (118 mg, 0.299 mmol) was dissolved in 
THF (4 mL), and oxalic acid dihydrate (49 mg, 0.389 mmol) in THF (1 mL) 
was added. A white solid was isolated (90 mg, 62%).
1H NMR (DMSO-d6): δ = 8.0–6.0 (broad signal acidic protons), 7.75 (m, 2H), 
7.30 (m, 2H), 6.80 (m, 1H), 6.28 (m, 1H), 6.25 (s, 1H), 4.25 (m, 1H), 4.15 
(s, 2H), 3.2–3.0 (multiple signals, 2H), 2.75–2.5 (multiple signals, 2H), 1.95 
(m, 1H), 1.65 (m, 1H). 13C NMR (DMSO-d6): δ = 164.2, 156.5, 154.0, 137.4, 
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132.6, 132.2, 129.9, 111.9, 108.5, 102.9, 95.3, 71.7, 50.1, 50.0, 24.7, 22.8. M.p. 
= 211  °C (dec). LC-MS: m/z = 396.1 [M+H]+, (calcd 395.24 for C17H18NO2I). 
UPLC-HRMS [M+H]+: Calcd 396.0460, Found 396.0466 (1.5 ppm). UPLC: 95% 
purity. Elemental analysis C,H,N: Found 48.4, 4.5, 2.3, Calcd. 47.0, 4.2, 2.9 
for C17H18NO2I + 1 C2H2O4 (FW=485.3).
 (R)-2-[(2-Iodobenzylamino)methyl]chroman-7-ol (11c)
Free amine. Compound 9c (209 mg, 0.48 mmol) was dissolved in a mixture 
of 4M HCl dioxane (2.4 mL) and isopropanol (2.4 mL). After 1 hour, extra 
amounts of 4M HCl in dioxane (1 mL) and isopropanol (l mL) were added. Af-
ter work-up, a glassy product was obtained in a quantitative yield (188 mg).
1H NMR (CDCl3): δ = 7.82 (m, 1H), 7.40 (m, 1H), 7.35 (m, 1H), 6.95 (m, 1H), 
6.76 (m, 1H), 6.35 (m, 1H), 6.30 (m, 1H), 4.10 (m, 1H), 4.05 (d, 1H), 3.90 
(d, 1H), 2.9–2.75 (multiple signals, 2H), 2.75–2.5 (multiple signals, 2H), 1.8 
(m, 1H), 1.65 (m, 1H). 13C NMR (CDCl3): δ = 155.9, 154.7, 140.6, 139.7, 130.2, 
130.0, 129.3, 128.5, 112.8, 108.8, 103.4, 99.7, 74.4, 57.8, 53.0, 26.1, 23.7. LC-
MS: m/z = 396.2 [M+H]+, (calcd 395.24 for C17H18NO2I).
Oxalate salt. The free amine 11c (188 mg, 0.48 mmol) was dissolved in THF 
(2 mL) and oxalic acid dihydrate (132 mg, 1.05 mmol, 2.2 moleqs) in THF 
(1 mL) was added. A white solid residue was isolated (219 mg, 94%).
1H NMR (DMSO-d6): δ = 8.0–6.0 (broad signal acidic protons), 7.95 (m, 1H), 
7.60 (m, 1H), 7.45 (m, 1H), 7.13 (m, 1H), 6.80 (m, 1H), 6.30–6.25 (multiple 
signals, 2H), 4.3–4.1 (multiple signals, 3H), 3.1 (m, 2H), 2.7–2.6 (multiple 
signals, 2H), 2.05 (m, 1H), 1.65 (m, 1H). 13C NMR (DMSO-d6): δ = 163.6, 156.5, 
154.1, 139.4, 136.8, 130.3, 130.2, 129.9, 128.6, 112.0, 108.4, 103.0, 100.9, 
72.3, 55.5, 50.9, 24.9, 22.8. M.p. = 209 °C (dec). LC-MS: m/z = 396.2 [M+H]+, 
(calcd 395.24 for C17H18NO2I). UPLC-HRMS [M+H]
+: Calcd 396.0460, Found 
396.0466 (1.5  ppm). UPLC: 97% purity. Elemental analysis C,H,N: Found 
46.8, 4.0, 2.6, Calcd. 47.0, 4.2, 2.9 for C17H18NO2I + 1 C2H2O4 (FW=485.3).
(R) 1-(4-Iodophenyl)-4-(4-(7-hydroxychroman-2-yl)-3-azabutyl)-piperazine 
(11e)
Free amine. Compound 9d (115 mg, 0.214 mmol) was dissolved in 4M HCl 
in dioxane (3.5 mL) and isopropanol (4 mL). The reaction was not complete 
after 3 hours, so the reaction mixture was evaporated to yield an oily prod-
uct. A fresh solution of 4M HCl in dioxane was added, and after a further 
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90 minutes of stirring under N2, the reaction was complete. A quantitative 
yield of an oil was obtained after work-up.
1H NMR (CDCl3): δ = 7.50 (m, 2H), 6.77 (m, 1H), 6.64 (m, 2H), 6.49 (s, 1H), 6.28 
(m, 1H), 4.08 (m, 1H), 3.10 (m, 2H), 3.05 (m, 2H), 2.9–2.3 (multiple signals, 
14H), 1.83 (m, 1H), 1.65 (m, 1H). 13C NMR (CDCl3): δ = 156.4, 154.5, 150.9, 
137.7, 129.9, 117.7, 112.2, 109.2, 103.4, 81.0, 74.5, 56.4, 54.0, 52.6, 48.7, 
46.0, 26.3, 23.7. LC-MS: m/z = 494.2 [M+H]+, (calcd 493.39 for C22H28N3O2I). 
MALDI-TOF-MS, m/z = 494.0 [M+H]+.
Oxalate salt. The free amine 11e (105 mg, 0.214 mmol) was dissolved in 
THF (4 mL), and oxalic acid dihydrate (63 mg, 0.50 mmol, 2.3 moleqs) in THF 
(1 mL) was added. A white solid was isolated (93 mg, 57%).
1H NMR (DMSO-d6): δ = 8.0–6.0 (broad signal acidic protons), 7.5 (m, 2H), 
6.85 (m, 1H), 6.8 (m, 2H), 6.28 (m, 1H), 6.23 (s, 1H), 4.3 (m, 1H), 3.35–3.1 
(multiple signals, 8H), 2.8–2.6 (multiple signals, 8H), 2.0 (m, 1H), 1.65 
(m, 1H). 13C NMR (DMSO-d6): δ = 162.9, 156.5, 153.8, 150.4, 137.3, 130.0, 
117.8, 111.9, 108.6, 102.9, 80.7, 71.2, 52.9, 52.2, 50.2, 47.4, 43.7, 24.7, 22.7. 
M.p. = 201 °C. LC-MS: m/z = 494.2 [M+H]+, (calcd 493.39 for C22H28N3O2I). 
UPLC-HRMS [M+H]+: Calcd 494.1304, Found 494.1294 (2.0 ppm). UPLC: 99% 
purity. Elemental analysis C,H,N: Found 43.4, 4.8, 5.4, Calcd. 44.1, 4.5, 5.5 
for C22H28N3O2I + 3 C2H2O4 (FW=763.5).
(R)-2-[(4-(4-Fluorobutoxy)benzylamino )methyl]chroman-7-ol (12a)
Free amine. Compound 9e (124  mg, 0.308  mmol) was dissolved in a so-
lution of 4M HCl in dioxane (2  mL) and isopropanol (2  mL). No starting 
compound was present according to LC-MS analysis, but there were some 
impurities present. After aqueous work-up, the crude product was purified 
by silica column chromatography (eluent: heptane/THF =1/1). Yield: 45 mg 
(41%) of a solid.
1H NMR (CDCl3): δ = 7.35 (d, 2H), 6.90 (d, 2H), 6.78 (m, 1H), 6.38 (multi-
ple signals, 2H), 4.60 (m, 1H), 4.45 (m, 1H), 4.08 (m, 1H), 4.00 (t, 2H), 3.90 
(dd, 2H), 2.9–2.5 (multiple signals, 4H), 2.0–1.75 (multiple signals, 5H), 1.7 
(m, 1H). 13C NMR (CDCl3): δ = 158.3, 156.3, 154.5, 130.2, 130.1, 130.0, 114.6, 
112.4, 109.2, 103.3, 84.6, 82.9, 74.2, 67.2, 53.6, 53.5, 27.3, 27.1, 26.3, 25.2, 
23.7. LC-MS: m/z = 360.0 [M+H]+, (calcd 359.44 for C21H26NO3F). MALDI-
TOF-MS, m/z = 360.1 [M+H]+.
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Oxalate salt. The free amine 12a (87 mg, 0.242 mmol) was dissolved in THF 
(2 mL), and oxalic acid dihydrate (46 mg, 0.365 mmol, 1.5 moleqs) in THF 
(1 mL) was added. The residue was a white solid (68 mg, 68%).
1H NMR (DMSO-d6): δ = 7.5–5.0 (broad signal acidic protons), 7.45 (d, 2H), 
6.95 (d, 2H), 6.8 (m, 1H), 6.3 (m, 1H), 6.25 (s, 1H), 4.55 (m, 1H), 4.45 (m, 1H), 
4.25 (m, 1H), 4.1 (s, 2H), 4.0 (m, 2H), 3.2–3.0 (multiple signals, 2H), 2.75–2.6 
(multiple signals, 2H), 1.95 (m, 1H), 1.85–1.7 (multiple signals, 4H), 1.65 
(m, 1H). 13C NMR (DMSO-d6): δ = 164.4, 158.9, 156.5, 153.9, 131.6, 129.9, 
124.0, 114.5, 111.9, 108.5, 102.9, 84.4, 82.8, 71.5, 67.1, 50.0, 49.5, 26.7, 
26.5, 24.7, 22.7. M.p. = 177  °C. LC-MS: m/z = 360.1 [M+H]+, (calcd 359.44 
for C21H26NO3F). UPLC-HRMS [M+H]
+: Calcd 360.1975, Found 360.1970 
(1.4  ppm). UPLC: 95% purity. Elemental analysis C,H,N: Found 60.4, 6.0, 
2.8, Calcd. 61.5, 6.3, 3.1 for C21H26NO3F + C2H2O4 (FW=449.5).
(R)-2-[(2-(4-Fluorobutoxy)benzylamino)methyl]chroman-7-ol (12b)
Free amine. Compound 9f (227 mg, 0.563 mmol) was dissolved in a mixture 
of 4M HCl dioxane (2.4 mL) and isopropanol (2.4 mL). After 1 hour, an extra 
amount of 4M HCl in dioxane (1.5 mL) was added. After work-up, an oily 
product was obtained (202 mg, 100%).
1H NMR (CDCl3): δ = 7.25 (multiple signals, 2H), 6.95 (m, 1H), 6.90 (m, 1H), 
6.75 (m, 1H), 6.40 (m, 1H), 6.27 (m, 1H), 4.45 (m, 1H), 4.36 (m, 1H), 4.1–4.0 
(multiple signals, 4H), 3.80 (d, 1H), 2.85–2.5 (multiple signals, 4H), 2.0–1.75 
(multiple signals, 5H), 1.65 (m, 1H). 13C NMR (CDCl3): δ = 157.0, 156.5, 154.6, 
130.3, 129.9, 128.8, 126.5, 120.6, 112.4, 111.1, 109.1, 103.3, 84.5, 82.8, 74.4, 
67.2, 53.2, 49.1, 27.4, 27.2, 26.3, 25.4, 25.3, 23.7. LC-MS: m/z = 360.3 [M+H]+, 
(calcd 359.44 for C21H26NO3F).
Oxalate salt. The free amine 12b (202 mg, 0.563 mmol) was dissolved in 
THF (2 mL) and oxalic acid dihydrate (156 mg, 1.24 mmol, 2.2 moleqs) in 
THF (1 mL) was added. In this case, no precipitate was formed after addi-
tion, nor after 3 hours of stirring at rt, so diethylether was added to induce 
precipitation. Centrifugation, washing and drying gave a white solid residue 
(159 mg, 63%).
1H NMR (DMSO-d6): δ = 8.0–6.0 (broad signal acidic protons), 7.45 (m, 1H), 
7.4 (m, 1H), 7.05 (m, 1H), 7.0 (m, 1H), 6.85 (m, 1H), 6.28 (m, 1H), 6.23 (s, 1H), 
4.5 (m, 1H), 4.4 (m, 1H), 4.3 (m, 1H), 4.2 (q, 2H), 4.1 (m, 2H), 3.2–3.1 (mul-
tiple signals, 2H), 2.75–2.6 (multiple signals, 2H), 1.95 (m, 1H), 1.85–1.7 
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(multiple signals, 4H), 1.65 (m, 1H). 13C NMR (DMSO-d6): δ = 164.2, 156.9, 
156.5, 153.9, 131.3, 130.6, 129.9, 125.1, 120.4, 111.9, 111.8, 108.5, 102.9, 
84.4, 82.8, 71.5, 67.4, 50.2, 45.6, 26.7, 26.5, 24.7, 22.7. M.p. = 54  °C. LC-
MS: m/z = 360.3 [M+H]+, (calcd 359.44 for C21H26NO3F). UPLC-HRMS [M+H]
+: 
Calcd 360.1975, Found 360.1978 (0.8  ppm). UPLC: 99% purity. Elemental 




Free amine. Compound 9g (120 mg, 0.279 mmol) was dissolved in a solu-
tion of 4M HCl in dioxane (2.5 mL) and isopropanol (4 mL). A slightly col-
ored solid was obtained.
1H NMR (THF-d8): δ = 7.75 (bs, 1H), 6.8–6.6 (multiple signals, 5H), 6.08 
(m, 1H), 6.03 (m, 1H), 4.58 (m, 1H), 4.45 (m, 1H), 4.1–3.9 (multiple signals, 
3H), 2.95 (bs, 4H), 2.7–2.4 (multiple signals, 8H), 1.98 (m, 1H), 1.6 (m, 1H). 
13C NMR (THF-d8): δ = 157.7, 156.5, 153.4, 147.2, 130.2, 118.3, 115.7, 113.2, 
108.5, 103.8, 83.5, 81.9, 74.6, 68.5, 68.3, 63.1, 55.0, 51.1, 27.1, 24.5. LC-MS: 
m/z = 387.3 [M+H]+, (calcd 386.47 for C22H27N2O3F).
Oxalate salt. The free amine 12c (108 mg, 0.279 mmol) was dissolved in 
THF (4 mL), and oxalic acid dihydrate (155 mg, 1.23 mmol, ca. 4.5 moleqs) 
in THF (1 mL) was added. A white solid residue was obtained (119 mg, 90%).
1H NMR (DMSO-d8): δ = 8.0–6.0 (broad signal acidic protons), 6.95–6.8 
(multiple signals, 5H), 6.28 (m, 1H), 6.2 (s, 1H), 4.75 (m, 1H), 4.65 (m, 1H), 
4.35 (m, 1H), 4.15 (m, 1H), 4.1 (m, 1H), 3.25–3.0 (multiple signals, 10H), 
2.75–2.6 (multiple signals, 2H), 1.98 (m, 1H), 1.6 (m, 1H). 13C NMR (DMSO-d6): 
δ = 163.0, 156.5, 154.2, 152.1, 144.8, 129.9, 117.6, 115.1, 112.1, 108.3, 
102.9, 83.1, 81.4, 71.5, 67.4, 67.2, 60.2, 52.5, 47.8, 25.4, 22.8. M.p. = 105 °C. 
LC-MS: m/z = 387.3 [M+H]+, (calcd 386.47 for C22H27N2O3F). UPLC-HRMS 
[M+H]+: Calcd 387.2084, Found 387.2078 (1.5  ppm). UPLC: 95% purity. 
Elemental analysis C,H,N: Found 60.3, 5.7, 5.5, Calcd. 60.5, 6.1, 5.9 for 
C22H27N2O3F + C2H2O4 (FW=476.5).
(R) 1-(4-(2-Fluoroethoxy)phenyl)-4-(4-(7-hydroxychroman-2-yl)-3-azabutyl)-
piperazine (12d)
Free amine. Compound 9h (200 mg, 0.422 mmol) was dissolved in a 4M HCl 
solution in dioxane (2 mL) and isopropanol (2 mL). The reaction was not 
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complete after 3 hours, so an extra portion of 4M HCl solution in dioxane 
was added (2 mL), and the mixture was stirred overnight at rt under N2. A 
slightly colored oil was obtained after work-up. Yield: 160 mg (88%).
1H NMR (CDCl3): δ = 6.85 (m, 4H), 6.8 (m, 1H), 6.5 (m, 1H), 6.3 (m, 1H), 4.8 
(m, 1H), 4.7 (m, 1H), 4.2 (m, 1H), 4.15 (multiple signals, 2H), 3.1–2.4 (mul-
tiple signals, 16H), 1.8 (m, 1H), 1.65 (m, 1H). LC-MS: m/z = 430.3 [M+H]+, 
(calcd 429.54 for C24H32N3O3F).
Oxalate salt. The free amine 12d (160 mg, 0.373 mmol) was dissolved in 
THF (4 mL), and oxalic acid dihydrate (300 mg, 2.38 mmol, ca. 6 moleqs) in 
THF (1 mL) was added. The isolated residue was a white solid (225 mg, 86%).
1H NMR (DMSO-d6): δ = 8.0–6.0 (broad signal acidic protons), 6.9–6.8 (mul-
tiple signals, 5H), 6.28 (m, 1H), 6.24 (s, 1H), 4.75 (m, 1H), 4.64 (m, 1H), 
4.30 (m, 1H), 4.20 (m, 1H), 4.12 (m, 1H), 3.3–3.1 (multiple signals, 4H), 3.1 
(m, 4H), 2.8–2.5 (multiple signals, 8H), 1.95 (m, 1H), 1.65 (m, 1H). 
13C NMR (DMSO-d6): δ = 162.4, 156.5, 153.8, 151.8, 145.4, 130.0, 117.3, 115.1, 
111.9, 108.6, 102.9, 83.1, 81.5, 71.2, 67.5, 67.3, 52.9, 52.4, 50.3, 49.0, 43.6, 
24.7, 22.7. M.p. = 198  °C (dec). LC-MS: m/z = 430.3 [M+H]+, (calcd 429.54 
for C24H32N3O3F). UPLC-HRMS [M+H]
+: Calcd 430.2506, Found 430.2499 
(1.6  ppm). UPLC: 99% purity. Elemental analysis C,H,N: Found 52.6, 5.4, 
5.5, Calcd. 51.5, 5.5, 6.0 for C24H32N3O3F + 3 C2H2O4 (FW=699.6).
The synthesis of the precursors to [18F]12a and [18F]12d: 
phenols 13a and 13b
Precursor to [18F]12a: (R) N-[7-(Methoxymethoxy)chroman-2-yl]
methyl 4-hydroxybenzyl amine (13a).
The primary amine 8 (146  mg, 0.65  mmol), commercially available 4-hy-
droxybenzaldehyde (80 mg, 0.65 mmol) and acetic acid (43 mg, 0.72 mmol, 
1.1 moleqs) were stirred in CH2Cl2 (4 mL) for 2.5 hours and at rt. Accord-
ing to 1H NMR, the reaction was complete, so sodium triacetoxyborohydride 
(305 mg, 1.44 mmol, 2.2 moleqs) was added and the reaction mixture was left 
to stir for 18 hours at rt. Monitoring with LC-MS showed that conversion to 
the desired product was ca. 80%. The mixture was brought to a pH of 7 with 
a 0.1M NaOH aqueous solution, and was then extracted with CH2Cl2. Drying 
of the organic layer with Na2SO4, evaporation of the solvent and purifica-
tion with silica column chromatography (hexane/ethyl acetate 1/1) gave the 
product in a yield of 76% (164 mg).
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1H NMR (CDCl3): δ = 7.12 (m, 2H), 6.9 (m, 1H), 6.65 (m, 2H), 6.55 (multiple 
signals, 2H), 5.1 (s, 2H), 5.05 (bs, 2H), 4.2 (m, 1H), 3.75 (m, 2H), 3.4 (s, 3H), 
2.9–2.6 (multiple signals, 4H), 1.9 (m, 1H), 1.7 (m, 1H). 13C NMR (CDCl3): 
δ = 156.4, 156.0, 155.0, 130.0, 129.9, 129.8, 115.8, 115.5, 109.0, 104.3, 94.5, 
74.5, 55.9, 53.3, 53.2, 25.7, 23.9. LC-MS: m/z = 330.1 [M+H]+, (calcd 329.40 
for C19H23NO4).
Precursor to [18F]12d: the multistep synthesis to phenol 13b.
Compounds 15 and 16 were prepared according to a patent procedure [77].
4-(4-Benzyloxy-phenyl)-piperazine-1-carboxylic acid tert butyl ester (15)
4-(4-Hydroxyphenyl)-piperazin-1-carboxylic acid tert butyl ester (14) was 
prepared according to Tietze [73]. Compound 14 (2 g, 7.19 mmol), benzyl 
bromide (1.23  g, 7.19  mmol) and K2CO3 (0.99  g, 7.19  mmol) were mixed 
in DMF (2 mL). The reaction mixture was stirred at 50 °C under argon for 
16 hours, and was then poured in water. The suspension was filtrated and the 
residue was purified with silica column chromatography (2% MeOH/CHCl3). 
Yield: 1.94 g (73%). Analytical data were according to those reported in a 
patent [77]. 1H NMR (CDCl3): δ = 7.5–7.3 (multiple signals, 5H), 6.9 (multiple 
signals, 4H), 5.02 (s, 2H), 3.56 (t, 4H), 3.0 (t, 4H), 1.48 (s, 9H). LC-MS: m/z = 
369.2 [M+H]+, (calcd 368.48 for C22H28N2O3).
1-(4-Benzyloxyphenyl)piperazine (16)
Compound 15 (1.75 g, 4.75 mmol) was mixed with a 4N HCl dioxane solution 
(30 mL) and was stirred for 1 hour at rt. The reaction mixture was filtrated 
and washed with ethyl acetate to afford the HCl-salt, a white solid residue. 
Extraction using chloroform and a basic aqueous solution gave the amine 
product. Yield: 1.3  g (100%). Analytical data were according to those re-
ported in a patent [77]. 1H NMR (CDCl3): δ = 7.5–7.3 (multiple signals, 5H), 
6.9 (multiple signals, 4H), 5.0 (s, 2H), 3.0 (bs, 8H), 1.5 (bs, 1H). LC-MS: m/z = 
269.3 [M+H]+, (calcd 268.36 for C17H20N2O).
1-(4-Benzyloxyphenyl)-4-(2-N-(tertbutyl-carbamate)-ethyl)-piperazine (17)
tert-Butyl N-(2-bromoethyl)carbamate was prepared according to a lit-
erature procedure [78]. Secondary amine 16 (0.4 g; 1.49 mmol) was mixed 
with DMF (5  mL), DIPEA (2.6  mL; 14.9  mmol; 10 moleqs) and tert-butyl 
N-(2-bromoethyl)carbamate (0.33 g: 1.49 mmol) yielding a suspension. The 
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mixture was stirred at 40  °C for 72 hours, and turned into a clear brown 
solution. Pouring into water gave a suspension that was extracted with di-
isopropyl ether. The organic layer was dried with Na2SO4 and evaporated till 
dryness; the crude product residue was purified using silica column chroma-
tography (2/1 pentane/THF). Yield: 369 mg (60%).
1H NMR (CDCl3): δ = 7.5–7.3 (multiple signals, 5H), 6.9 (multiple signals, 
4H), 5.0 (s, 2H), 4.95 (bs, 1H), 3.25 (m, 2H), 3.05 (m, 4H), 2.6 (m, 4H), 2.5 
(t, 2H), 1.45 (s, 9H). 13C NMR (CDCl3): δ = 152.9, 145.9, 137.3, 128.5, 127.8, 
127.4, 125.5, 118.0, 115.5, 79.2, 70.5, 57.2, 53.0, 50.5, 37.1, 28.4. LC-MS: m/z 
= 412.3 [M+H]+, (calcd 411.55 for C24H33N3O3).
1-(4-Benzyloxyphenyl)-4-(2-aminoethyl)-piperazine (18)
BOC protected amine 17 (0.74 g; 1.79 mmol) was dissolved in CH2Cl2 (8 mL) 
and TFA (2 mL), and the solution was stirred for 1 hour at rt. Evaporation of 
the solvents and redissolution into (8 mL) and TFA (2 mL) was followed by 
further stirring at rt until 1H NMR and TLC analyses showed that the BOC 
group had been deprotected. Dilution with CHCl3 and washing of the organic 
layer with a 0.1 M NaOH (pH=10) to which NaCl was added to enhance the 
phase separation, was followed by drying of the organic layer with Na2SO4 
and evaporation of the volatiles to yield a beige solid (528 mg, 95%).
1H NMR (CDCl3): δ = 7.5–7.3 (multiple signals, 5H), 6.9 (multiple signals, 
4H), 5.0 (s, 2H), 3.15 (m, 4H), 2.8 (m, 2H), 2.6 (m, 4H), 2.5 (t, 2H), 1.65 
(bs, 2H). LC-MS: m/z = 312.3 [M+H]+, (calcd 311.43 for C19H28N3O).
(R) 1-(4-Benzyloxyphenyl)-4-(4-(7-(methoxymethoxy)chroman-2-yl)-
3-azabutyl)-piperazine (19)
A solution of tosylate 6 (300 mg, 0.793 mmol) in 1/1 dioxane /DMSO (1 mL) 
was added to a mixture of DIPEA (1.4 mL, 7.93 mmol, 10 moleqs) and amine 
18 (306 mg, 0.952 mmol, 1.2 moleqs) in 1/1 dioxane /DMF (1 mL). This mix-
ture was stirred overnight at 90 °C. According to LC-MS there was still some 
tosylate present so DIPEA (0.5 mL) was added and the reaction mixture was 
stirred at 90 °C for another 24 hours. The mixture was then poured into wa-
ter (pH became ca. 9–10), and the aqueous layer was extracted with CHCl3. 
The organic layer was washed with NaCl (aq), dried with Na2SO4 and concen-
trated to the crude product that was purified with alumina column chroma-
tography (1/1 ethyl acetate/pentane). Yield: 156 mg (32%).
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1H NMR (CDCl3): δ = 7.45–7.3 (multiple signals, 5H), 6.9 (multiple signals, 
5H), 6.55 (multiple signals, 2H), 5.1 (s, 2H), 5.0 (s, 2H), 4.15 (m, 1H), 3.4 
(s, 3H), 3.1 (m, 4H), 2.9–2.7 (multiple signals, 6H), 2.6 (multiple signals, 
6H), 1.95 (multiple signals, 2H), 1.75 (m, 1H). 13C NMR (CDCl3): δ = 156.5, 
155.2, 152.9, 146.0, 137.4, 129.9, 128.5, 127.8, 127.4, 118.0, 115.5, 114.9, 
108.9, 104.4, 94.5, 75.1, 70.5, 57.8, 55.9, 54.3, 53.4, 50.6, 46.5, 25.8, 24.0. 




The benzylated molecule 19 (156  mg, 0.30  mmol) was dissolved in EtOH 
and Pd/C catalyst (Degussa type) was added. The mixture was shaken under 
hydrogen at 70 psi, and the conversion was monitored by 1H NMR. Filtration 
over two paper filters and one using a syringe filter (45 µm regenerated cel-
lulose) gave a yield of 121 mg product (94%).
1H NMR (CDCl3): δ = 6.9 (m, 1H), 6.8 (m, 2H), 6.75 (m, 2H), 6.5 (multiple 
signals, 2H),5.1 (s, 2H), 4.2 (m, 1H), 3.4 (s, 3H), 3.1 (m, 4H), 2.9–2.7 (mul-
tiple signals, 6H), 2.6 (multiple signals, 6H), 1.95 (m, 1H), 1.75 (m, 1H). 
13C NMR (CDCl3): δ = 156.5, 155.1, 150.3, 145.4, 130.0, 118.5, 116.0, 115.5, 
109.0, 104.4, 94.5, 74.7, 57.4, 55.9, 54.1, 53.3, 50.8, 46.1, 25.8, 24.0. LC-MS: 
m/z = 428.4 [M+H]+ and 214.7 [M+2H]2+, (calcd 427.55 for C24H33N3O4).
The preparation of amine and aldehyde building blocks 
for coupling to tosylate 3 (Route A), tosylate 6 (Route B) 
or amine 8 (Route C)
tert-Butyl (4-(4-fluorobutoxy)-benzyl)-carbamate (20)
tert-Butyl (4-hydroxybenzyl)-carbamate, as prepared [79] from the HBr salt 
of 4-hydroxy-benzylamine (3.17  g, 14.2  mmol), was mixed with commer-
cially available 1-bromo-4-fluoro-butane (2.62 g, 17 mmol, 1.2 moleqs) and 
K2CO3 (2.36 g, 17 mmol, 1.2 moleqs) in MeCN (75 mL). The reaction mixture 
was stirred overnight at 80 °C under an inert argon atmosphere, was cooled 
down to rt and was filtered to remove salts. The filtrate was concentrat-
ed and the crude product was purified with silica column chromatography 
(2% MeOH/CHCl3). Drying under vacuum removed traces of 1-bromo-4-flu-
orobutane. Yield: 2.9 g (68%).
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1H NMR (CDCl3): δ = 7.2 (m, 2H), 6.85 (m, 2H), 4.8 (bs, 1H), 4.55 (m, 1H), 4.45 
(t, 1H), 4.2 (m, 2H), 3.95 (t, 2H), 1.95–1.8 (multiple signals, 4H), 1.45 (s, 9H). 
13C NMR (CDCl3): δ = 158.2, 155.8, 131.0, 128.8, 114.5, 84.5, 82.9, 79.1, 67.2, 
44.1, 28.3, 27.2, 27.0, 25.2, 25.1. LC-MS: m/z = 242.0 [M-C4H8]
+, (calcd 297.37 
for C16H24NO3F).
4-(4-Fluorobutoxy)-benzyl amine (21)
BOC-protected amine 20 (0.56 g, 1.87 mmol) was stirred at rt for 10 minutes 
in 4M HCl in dioxane (0.6 mL). The reaction mixture developed into a hazy 
suspension. The mixture was evaporated to dryness and the residue was dis-
solved in water that was adjusted to a basic pH using a NaOH solution. The 
product was extracted using CH2Cl2. the organic layer was dried using Na2SO4 
and was evaporated to yield the desired amine product. Yield: 261 mg (71%).
1H NMR (CDCl3): δ = 7.2 (m, 2H), 6.85 (m, 2H), 4.55 (m, 1H), 4.45 (t, 1H), 4.0 
(t, 2H), 3.8 (s, 2H), 1.9 (multiple signals, 4H), 1.4 (bs, 2H). 13C NMR (CDCl3): 
δ = 157.8, 135.6, 128.2, 114.5, 84.5, 82.9, 67.2, 45.9, 27.3, 27.1, 25.3, 25.2. 
LC-MS: m/z = 198.1 [M+H]+, 181.3 [M-NH2]
+, (calcd 197.25 for C11H16NOF).
2-(4-Fluorobutoxy)-benzaldehyde (22)
2-Hydroxybenzalhyde (1 g, 8.18 mmol) and 1-bromo-4-fluorobutane (1.52 g, 
9.8 mmol, 1.2 moleqs), both commercially available, were mixed with K2CO3 
(2.26 g, 16.3 mmol, 2 moleqs) in DMF (40 mL). The suspension was stirred 
overnight under argon at an oil bath temperature of 50  °C. The next day 
the reaction mixture was filtrated and diluted with water, so that the prod-
uct could be extracted from the water layer using diethyl ether (twice). The 
ether layer was washed twice with water and once with a saturated NaCl 
solution and was then dried with Na2SO4. Starting bromide was still present 
in the product, but it could be removed by co-evaporation with diisopro-
pylether. Yield: 1.43 g (89%).
1H NMR (CDCl3): δ = 10.5 (s, 1H), 7.8, (m, 1H), 7.55 (m, 1H), 7.0 (m, 2H), 
4.60 (m, 1H), 4.46 (m, 1H), 4.13 (t, 2H), 2.05–1.8 (multiple signals, 4H). 
13C NMR (CDCl3): δ = 189.6, 161.2, 135.9, 128.3, 124.8, 120.6, 112.4, 84.3, 
82.7, 67.8, 27.2, 27.0, 25.2, 25.1. GC-MS: m/z = 121 [M-C4H8F]




1-(4-Iodophenyl)-piperazine [72] (4.6  g, 15.1  mmol), tert-butyl N-(2-bro-
moethyl)carbamate [78] 3.7 g, 16.6 mmol, 1.1 moleqs.) and DIPEA (5.3 mL, 
30.4 mmol, 2 moleqs.) were dissolved in MeCN (30 mL). The mixture was 
stirred overnight at 50 °C and was kept under argon. The reaction mixture 
was evaporated till dryness and was redissolved in CHCl3. The solution was 
washed two times with water and once with a NaCl solution, and was then 
dried over Na2SO4. After concentration, the crude product was purified with 
silica column chromatography (1% MeOH /CHCl3). Yield 80%.
1H NMR (CDCl3): δ = 7.50 (m, 2H), 6.65 (m, 2H), 4.95 (bs, 1H), 3.25 (m, 2H), 
3.15 (m, 4H), 2.6 (m, 4H), 2.5 (t, 2H), 1.45 (s, 9H). LC-MS: m/z = 432.1 [M+H]+, 
(calcd 431.32 for C17H26N3O2I).
1-(2-Aminoethyl)-4-(4-iodophenyl)-piperazine (24)
The BOC protected amine 23 (1.58 g, 3.65 mmol) was added slowly to a con-
centrated 10M HCl solution in water (2 mL). The reaction was stirred for 15 
minutes at rt, was diluted with water (50 mL) and was adjusted to a pH of 9 
to 10 using a NaOH solution in water. The product was isolated by extraction 
of the water layer with ethyl acetate (twice), drying of the organic layer over 
Na2SO4 and evaporation of the volatiles. Yield: 0.78 g (65%).
1H NMR (CDCl3): δ = 7.45 (m, 2H), 6.75 (m, 2H), 3.1 (m, 4H), 3.0 (bs, 2H), 2.65 
(t, 2H), 2.5 (m, 4H), 2.35 (m, 2H). 13C NMR (CDCl3): δ = 150.9, 137.7, 118.0, 




1-(4-(2-Fluoroethoxy)-phenyl)-piperazine [73] (1.88  g, 8.4  mmol), tert- 
butyl N-(2-bromoethyl)carbamate [78] (2.07 g, 9.24 mmol, 1.1 moleqs) and 
DIPEA (mL) were mixed in MeCN (20 mL). The mixture was stirred overnight 
under argon at an oil bath temperature of 50 °C. The reaction mixture was 
concentrated and redissolved in CH2Cl2 to enable washing with water (twice) 
and with a saturated NaCl solution (once). The organic layer was dried with 
Na2SO4 and was concentrated to afford crude product that was purified us-
ing silica column chromatography (elution gradient starting with CHCl3 and 
finally using 3% MeOH/ CHCl3). After evaporation of the solvent a yellowish 
solid was obtained. Yield: 2.42 g (78%).
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1H NMR (CDCl3): δ = 6.85 (multiple signals, 4H), 4.95 (bs, 1H), 4.75 (m, 1H), 
4.65 (m, 1H), 4.2 (m, 1H), 4.15 (m, 1H), 3.25 (m, 2H), 3.05 (m, 4H), 2.6 (m, 
4H), 2.5 (t, 2H), 1.45 (s, 9H). 13C NMR (CDCl3): δ = 155.9, 152.5, 146.2, 118.0, 
115.5, 82.9, 81.2, 79.0, 67.8, 67.6, 57.2, 53.0, 50.4, 37.1, 28.4.
1-(2-Aminoethyl)-4-(4-(4-fluoroethoxy)phenyl)-piperazine (26)
The BOC protected amine 25 (2.42 g, 6.58 mmol) was stirred in concentrated 
10M HCl solution in water (20 mL). A thick white foam formed, and after 
20 minutes water (75 mL) was added as well as solid NaOH to adjust the pH 
to about 10. The product was extracted from the water layer using CH2Cl2 
(2 times). Drying of the collected organic layers (Na2SO4) and after evapora-
tion of the solvent gave a white solid. Yield: 1.47 g (84%).
1H NMR (CDCl3): δ = 6.85 (multiple signals, 4H), 4.75 (m, 1H), 4.65 (m, 1H), 
4.2 (m, 1H), 4.15 (m, 1H), 3.05 (m, 4H), 2.8 (t, 2H), 2.6 (m, 4H), 2.45 (t, 2H), 
1.4 (bs, 2H). 13C NMR (CDCl3): δ = 152.4, 146.2, 117.9, 115.4, 82.8, 81.1, 67.7, 
67.5, 61.1, 53.3, 50.4, 38.7. LC-MS: m/z = 268.3 [M+H]+, (calcd 267.35 for 
C14H22N3OF).
The preparation of [18F]fluoroalkylation precursors 
and reference compounds: tosylates 27–30
1,4-Butanediol ditosylate (27)
p-Toluenesulfonyl chloride (3.17 g, 16.6 mmol) was dissolved in 10 mL of 
dry CH2Cl2. To this solution 3.0 mL (2.29 g, 22.7 mmol) of dry triethylamine 
was added. The mixture was cooled to 0 °C in an ice bath and 610 μL (616 mg, 
7.6 mmol) of dry 1,4-butanediol was added. After 30 min of stirring, another 
60 μL of 1,4-butanediol was added. The mixture was left to stir overnight, 
with the reaction mixture temperature coming up to rt. On the next day, 
the mixture was diluted with an extra portion of CH2Cl2 (15 mL), cooled to 
0 °C and acidified by slowly adding 50 mL 0.8M HCl. The organic layer was 
separated and washed with 0.3M HCl (3×50 mL). The CH2Cl2 solution of the 
crude product was then concentrated in vacuo and the product was purified 
on a silica column eluted with hexane/ CH2Cl2/ethyl acetate (6/6/1) to yield 
1.93 g of final product as white crystals. Yield: 58%.
1H-NMR (300 MHz, CDCl3) δ: 7.76 (d, J = 8.4 Hz, 4H), 7.35 (d, J = 8.4 Hz, 4H), 
3.95–4.03 (m, 4H), 2.45 (s, 6H), 1.65–1.74 (m, 4H).
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1,2-Ethanediol ditosylate (28)
This compound was prepared and isolated in as similar fashion as its bu-
tane-spaced counterpart 27. Analytical data were according to expectations.
4-Fluorobutyl tosylate (29)
Tetrabutylammonium fluoride trihydrate (66 mg, 0.25 mmol) was dried by 
co-evaporation in vacuo with three 3 mL portions of acetonitrile (the tem-
perature in the flask was not allowed to rise above 30 °C to prevent decompo-
sition of the tetrabutyl ammonium fluoride). Then the dried tetrabutyl am-
monium fluoride was redissolved in a small quantity of dry acetonitrile and 
this solution was added to a solution of 1,4-butanediol ditosylate (100 mg, 
0.25 mmol). The reaction was conducted in refluxing acetonitrile for 24 h, 
and the conversion was monitored by TLC on silica plates (hexane/ethyl ac-
etate 2/1, Rf = 0.75). After the reaction ended, acetonitrile was evaporated 
in vacuo, the residue redissolved in hexane/ethyl acetate (2/1 v/v) and the 
product was purified on a silica column eluted with hexane/ethyl acetate 
(2/1 v/v) to yield 30 mg of final product as brownish crystals. Yield: 48%.
1H-NMR (300 MHz, CDCl3) δ: 7.79 (d, J = 8.1 Hz, 2H), 7.35 (d, J = 8.1 Hz, 2H), 
4.44 (dt, J1 = 47.0 Hz, J2 = 5.6 Hz, 2H), 4.08 (t, J = 4.08 Hz, 2H), 2.46 (s, 3H), 
1.67–1.84 (m, 4H).
2-Fluoroethyl tosylate (30)
2-Fluoroethyl tosylate was synthesized according to the same protocol 
as 1,4-butanediol ditosylate. Instead of 1,4-butanediol, 2-fluoroethanol 
(240  μL, 268  mg, 4.2  mmol) was reacted with p-toluenesulfonyl chloride 
(755 mg, 4.0 mmol). Yield: 760 mg of final product was obtained (86%) as a 
colorless slightly yellowish oil.
1H-NMR (200 MHz, CDCl3) δ: 7.82 (d, J = 7.6 Hz, 2H), 7.37 (d, J = 6.8 Hz, 2H), 
4.58 (dt, J1 = 47.0 Hz, J2 = 4.2 Hz, 2H), 4.27 (dt, J1 = 27.6 Hz, J2 = 4.0 Hz, 2H), 
2.48 (s, 3H).
Cell culturing and preparation of membranes
Human embryonic kidney 293 cells (HEK293) stably expressing the hu-
man dopamine receptor subtypes were cultured in RPMI 1640 medium with 
2 mM L-glutamine in the additional presence of 100 U/ml penicillin, 100 U/
ml streptomycin. To maintain selection pressure, 50 μg/ml neomycin and 
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5 µg/ml puromycin was also added to the medium of cells expressing dopa-
mine D2L, D2S, D3 and D4 receptors, and D1 and D5 receptors, respectively. 
Cells were harvested by scraping the culture dishes, washed by centrifuga-
tion at 200 g and afterwards lysed in ice-cold buffer containing 5 mM TRIS 
and 5 mM MgCl2 at pH 7.4. The suspension was homogenized with 8 up and 
down strokes in a glass/teflon homogenizer and centrifuged twice for 1 h at 
30,000 g at 4 °C. Pellets were resuspended in buffer (50 mM TRIS pH 7.4) and 
rehomogenized with 4 up and down strokes in the glass/teflon homogenizer, 
aliquots were frozen in liquid nitrogen and stored at −80 °C. Protein content 
was measured by using the method of Bradford [80]. For experiments on do-
pamine D2S and D3 receptors, membrane preparations were obtained from 
PerkinElmer (Waltham USA).
Receptor binding assays
For the radioligand experiments the samples were thawed and re-homog-
enized in Mg-containing buffer (50 mM TRIS, 5 mM KCl, 2 mM CaCl2 and 
2 mM MgCl2 pH 7.4) to allow formation of the agonist high-affinity state. 
Re-homogenization was done with a short burst (10  sec) of an ultra tur-
rax at full speed. Binding experiments were performed with 40–60 μg pro-
tein per assay, an assay volume of 1000 μl, a radioligand concentration of 
0.15  nM for the [3H]spiperone (D2L, D2S, D3 and D4 receptors) assays and 
1.5 nM for [3H]SCH23390 (D1 and D5 receptor) assay with an incubation time 
of 2 h at 25 °C and a pre-incubation of 15 minutes at 25 °C. Non-specific 
binding was defined using 1 µM (+)-butaclamol (antagonist for dopamine 
receptors). To avoid oxidation of the compounds 0.05% ascorbic acid was 
added to all solutions. All experiments were performed in duplicate in 
96 well platform, reactions were terminated by rapid vacuum filtration 
over Whatman GF/C filter plate with ice-cold buffer (50 mM TRIS). For the 
D3 receptor binding experiments plates were pre-coated with 0.1 % PEI. Fil-
ter radioactivity was measured in a PerkinElmer Topcount with Microscint-
O cocktail as scintillant. The competition experiments were analysed using 
the Prism programme (version 5.01, Graphpad Software, San Diego, Calif. 
USA) fitting sigmoidal curves to the data. Resulting IC50 values were con-
verted to Ki values based upon the Cheng-Prusoff equation [38].
cAMP accumulation
To determine concentrations of cAMP formed in the assay the LANCE™ 
cAMP 384 kit of PerkinElmer was used according to the manufacturer’s pro-
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tocol. Transfected HEK 293 cells stably expressing the dopamine D2L were 
cultured as mentioned before. They were detached from the surface of the 
culture dish with 2 ml dissociation solution and washed with HBSS and after 
that resuspended in a standard buffer (SB) containing HBSS 0.05% BSA (and 
5 mM HEPES. The stimulation solutions contained SB with 1.0 mM 3-iso-
butyl-1-methylxanthine (IBMX), 63.2 μM forskolin and the different con-
centrations of the dopamine agonists. After the stimulation solutions were 
added to the well plate the cell suspensions (diluted to 6000 cells/well) were 
added in a 1:1 ratio so the final concentrations of IBMX and forskolin in the 
assay were 0.5 mM and 31.6 μM, respectively. The plate was incubated for 
30 min at room temperature for the stimulation and subsequently different 
detection reagents and antibody solutions were added to a total volume of 
20 μl/well. Measurements were carried out on a Victor 2 plate reader (Wal-
lac, PerkinElmer, Zaventum, Belgium) 3 hours after adding the detection 
mixtures.
Lipophilicity
Lipophilicity (clogP and clogD) of the unlabeled compounds was calculated 
using the BiologP (New ClogP) calculator program from the University of 
Massachusetts, Boston:
http://intro.bio.umb.edu/111-112/OLLM/111F98/newclogp.html
LogD of the 18F-labeled compounds was determined using radioactivity re-
maining on the HLB cartridge after its elution with ethanol during the for-
mulation procedure (vide infra). The cartridge was dried for 5 min in strong N2 
flow and eluted with at least 1.5 ml n-octanol. Then 500 μl of octanol eluate 
was mixed with 500 μl 1 M phosphate buffer pH 7.4 and vigorously vortexed 
for 5 min. After that, the mixture was centrifuged at 17 000 g for 10 min and 
3×100 μl aliquots of organic and aqueous phase were loaded into a gamma-
counter for radioactivity measurement. To correct for possible presence of 
radioactive impurities in the tracer, aliquots of organic and aqueous phases 
were later analyzed by radio-TLC and the counts obtained from the gamma-
counter were corrected according to the percentage of impurities found in 
aqueous and organic phases. LogD was calculated with the formula:
where CPMorg is the mean cpm in the organic aliquots,  is the mean 
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percentage of radioactivity accounting for intact tracer in organic aliquots 
(as determined from radio-TLC) and CPMorg and  are the corresponding 
values for the aqueous phase.
For each tracer batch used for logD determination, the experiment was con-
ducted in duplicate. LogD values are means calculated from at least two in-
dependent experiments.
Materials (in vitro experiments)
The transfected dopamine receptor cell lines were a generous gift of Prof. 
Gross (Abbott). Human D2S and D3 membranes were obtained from Perkin-
Elmer (Waltham USA). [3H]spiperone (molar radioactivity 16.2 Ci/mmol) 
and [3H]SCH23390 (molar radioactivity 73.1 Ci/mmol) were obtained from 
PerkinElmer (Boston USA). (+)butaclamol, R(−)-propylnorapomorphine HCl 
and dopamine HCl were obtained from Sigma-Aldrich (Zwijndrecht, The 




18F-fluoride in enriched H2
18O water was adsorbed on an anion-exchange 
column (QMA) and later eluted into a reaction vial with 1–1.5 ml of 1.5 mg/
ml K2CO3, 5 mg/ml Kryptofix solution in 9:1 v/v mixture of acetonitrile and 
water. After the elution of QMA, acetonitrile and water were evaporated 
at 130 °C under nitrogen flow. For further water removal, 1 ml anhydrous 
acetonitrile was added into the reaction vial and evaporated. Then 5 mg of 
1,4-butanediol ditosylate (27) in 1 ml anhydrous acetonitrile was added into 
the vial, the vial was sealed, and the reaction was carried out for 4 min at 
130 °C followed by cooling for 5 min . One ml of water was added to the 
cooled reaction mixture and the resulting mixture was loaded into the HPLC 
loop. 4-[18F]fluorobutyltosylate was purified by reverse-phase HPLC using 
Alltima C18 5μ 250×10 mm column eluted with acetonitrile/10 mM H3PO4 
(65/35 v/v) at 5 ml/min (retention time 7.0 min, k’ = 3.9; as confirmed using 
the reference compound 4-fluorobutyltosylate 29). The collected radioac-
tive fraction was diluted 2–3 fold with water and 4-[18F]fluorobutyltosylate 
was adsorbed on a tC18 light Seppak cartridge. The cartridge was rinsed 
with 5  ml pure water and dried for 5  min in strong nitrogen flow. After-
wards 4-[18F]fluorobutyltosylate was eluted from the cartridge with 0.7 ml 
156 Chapter 3
dry DMF into a v-vial containing 0.6 mg the precursor 13a, 30 μl dry DMF 
and 2–3 mg NaH. The reaction vial was sealed and the alkylation reaction 
was conducted for 10 min at 120 °C, then 1 ml 0.4 M HCl was added into 
the vial with a syringe. Then the MOM-group was deprotected which lasted 
10 min at 120 °C. [18F]12a was purified by reverse-phase HPLC using Alltima 
C18 5μ 250×10 mm column eluted with acetonitrile/10 mM H3PO4 (40/60 v/v) 
at 5 ml/min (retention time 9.8 min, k’ = 5.4 (see Scheme 3).
The collected HPLC fraction was diluted with 2–3 volumes of water and 
[18F]12a was adsorbed on a Oasis HLB SPE cartridge. The cartridge was rinsed 
with 5 ml pure water and [18F]12a was then eluted with 1–2 ml absolute eth-
anol (typically 20–40% recovery). After the partial or complete evaporation 
of ethanol in nitrogen flow (with or without application of vacuum) the trac-
er was formulated in physiological saline (ethanol content in the formulated 
tracer was kept below 10%). The identity of [18F]12a was confirmed by co-
elution with the unlabeled 12a on reverse-phase HPLC and radio-TLC. From 
the same data radiochemical purity was assessed. Reverse-phase HPLC was 
carried out on Platinum EPS 5μ 250×4.6 column eluted with acetonitrile/
physiological saline/formic acid (70/30/0.1 v/v) at 2 ml/min (retention time 
6.4  min, k’ = 4.5). For quality control radio-TLC was carried out on silica 
plates eluted with dichloromethane/methanol/ammonia (100/5/1, Rf = 0.25) 
and ethyl acetate/methanol/triethylamine (100/5/1, Rf = 0.5).
Preparation of [18F]12d
The procedure described above for [18F]12a was also used for the prepara-
tion of [18F]12d, with the following modifications: Ethylene glycol ditosyl-
ate (28) and precursor 13b were used instead of 1,4-butanediol ditosylate 
(27) and precursor 13a, respectively. 2-[18F]fluoroethyl tosylate purifica-
tion conditions were: Alltima C18 5μ 250×10 mm column eluted with ace-
tonitrile/10  mM sodium acetate buffer pH  4.0 (60/40 v/v) at 5  ml/min 
(tR = 6.8 min, k’= 3.8; as confirmed using the reference tosylate 30). At the 
end of the deprotection step, the reaction mixture was diluted with 10 ml 
water, titrated with 1 M NaOH to pH of 4–7 and then put through the Oasis 
HLB SPE cartridge. Adsorbed radioactivity was then eluted from the cartridge 
with 1 ml acetonitrile/DMF mixture (1/1 v/v). The eluate was further diluted 
with water to a total volume of 1.5–2 ml and injected onto the Alltima C18 
5μ 250×10 mm HPLC column for purification of [18F]12d, (see Scheme 3).
[18F]12d purification conditions were: Alltima C18 5μ 250×10 mm column 
eluted with a gradient of acetonitrile in 10 mM sodium acetate buffer: iso-
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cratic 45% acetonitrile during the first 2  minutes, then a linear decrease 
from 45% at 2 minutes to 30% acetonitrile at 15 minutes (retention time of 
[18F]12d, 10.6 min, k’ = 5.9.
HPLC conditions for the identity confirmation and RCP assessment were: 
Platinum EPS 5μ 250×4.6 column eluted with acetonitrile/10 mM phosphate 
buffer pH 7 (65/35 v/v) at 2 ml/min (tR = 11.0 min, k’ = 7.3).
Quality control TLC conditions were: dichloromethane:methanol:ammon
ia 100:5:1 (Rf = 0.25) and ethyl acetate:methanol:ammonia:triethylamine 
100:5:5:1 (Rf = 0.3). Before putting radioactive samples onto the TLC plates, 
drops of 12d oxalate standard solution containing 2 μg of compound were 
put onto the start positions of each lane to exclude on-plate decomposition 
of no-carrier-added 18F-labeled compound.
Autoradiography
Frozen brains of young (10–12 weeks of age; 300–350  g body-weight) 
male Sprague-Dawley rats (Harlan, Netherlands) were cut into two halves 
along the sagittal symmetry plane. Each half was mounted, lateral side up, 
on a paper slide pre-treated by Tissue-Tek fixing cocktail (Sakura, 
the Netherlands) and fixed by placing it onto a Petri dish floating on liquid ni-
trogen. After fixing, brains were cut at −12 °C into sagittal slices 20 μm thick 
using a Leica microtome, and the slices were thaw-mounted on Superfrost 
(70×22 mm, Fischer) adhesive slides. Only slices containing both striatal and 
cerebellar regions (representing non-specific binding) were used. Slides were 
organized in pairs and in each pair new slices were mounted alternately on 
the first or the second slide of the pair, so that slices in corresponding posi-
tions on the two slides forming a pair would represent adjacent tissue layers. 
The slices were allowed to dry, then put into storage boxes with dessicator 
(silicagel) bags and kept at −80 °C till they were used (no longer than 1 week).
On the day of the experiment the slides with mounted slices were taken 
out of storage and allowed to come to room temperature for 5–10 min-
utes. After that, incubation buffer (50 mM Tris-HCl, 5 mM KCl, 2 mM CaCl2, 
2 mM MgCl2, 120 mM NaCl, pH 7.4 25 °C) was applied to the slides using 
an automatic pipette (1–1.2  ml/slide) and the slides were pre-incubated 
for 15  min at room temperature. The pre-incubation buffer was then re-
moved and the slides were placed into staining jars containing incubation 
buffer and radioligand ([18F]12a or [18F]12d) at the concentration of about 
5 nM (4.5±3.6 nM for [18F]12a; 5.8±1.6 nM for [18F]12d; (n=4)). Four condi-
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tions were tested: radioligand only, radioligand in NaCl-free buffer, radioli-
gand and 10 μM raclopride (non-specific binding only) and radioligand and 
100 μM GTP (low-affinity state only). The slides were incubated for 35 min 
at 37  °C, then washed once with ice-cold incubated buffer (3.5  min) and 
dipped for 30 sec into ice-cold sterile water to remove buffer salts.
After drying the slides in a stream of room-temperature air, they were 
exposed on phosphor storage screens for 6–10 hours. Afterwards the stor-
age screens were read by Cyclone Storage Phosphor System (Packard In-
struments Co). Quantification of plate readings was done with Optiquant 
software (version 3.00, Packard Instruments Co), drawing regions of interest 
manually on the striatum and cerebellum.
The animal experiments were performed by licensed investigators in com-
pliance with the Law on Animal Experiments of The Netherlands. The pro-
tocol was approved by the Committee on Animal Ethics of the University of 
Groningen. The rats were maintained at a 12-h light/12-h dark regime and 
were fed standard laboratory chow ad libitum.
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L I ST OF ABBREV IAT IONS
1TCM – one-tissue compartment model
2TCM – two-tissue compartment model
BPND – Binding Potential Non-Displaceable (equilibrium concentra-




GPCR – G-protein coupled receptor
GTP – guanosine triphospate
HPLC – high-pressure liquid chromatography
HRMS – high-resolution mass-spectrometry
MOMCl – methoxymethyl chloride
PET – positron emission tomography
ROI – region of interest
SRTM – simplified reference-tissue model
SUV – standardized uptake value (regional uptake relative to mean 
uptake across the body)
TAC – time-activity curve
THF – tetrahydrofurane
TLC – thin-layer chromatography
TsCl – p-toluenesulfonyl chloride
UPLC – ultra-productive liquid chromatography
VT – total distribution volume of a radioligand in the tissue (i.e. the 
sum of distribution volumes of free, non-specifically and specifically 
bound radioligand)
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ABSTRACT
Dopamine D2/3 receptor (D2/3R) agonist positron emission tomography (PET) 
tracers are better suited for the imaging of synaptic dopaminergic neuro-
transmission than D2/3R antagonists, and may also offer the opportunity to 
study in vivo the high-affinity state of D2/3R (D2/3RHigh). Aiming to develop 
18F-labeled D2/3R agonists suitable for widespread clinical application, we re-
port here on the synthesis, in vitro and in vivo evaluation of a D2/3R-agonist 
ligand from the aminomethyl chromane (AMC) class – (R)-2-[(4-[18F]fluoro-
benzylamino)methyl]chroman-7-ol ([18F]AMC20).
Methods: In vitro affinities of AMC20 towards dopaminergic receptor sub-
types were measured in membrane homogenates prepared from HEK293 cells 
expressing human dopamine receptors. Agonism of AMC20 was assessed in 
the arrestin recruitment assay in CHO-K1 cells expressing D2RLong recep-
tors. D2/3R-specific binding of [
18F]AMC20 was evaluated in brain slices of 
Sprague-Dawley rats by in vitro autoradiography and in living rats by in vivo 
small-animal PET imaging and ex vivo autoradiography. PET data were ana-
lyzed with one and two-tissue compartmental models (1TCM/2TCM), sim-
plified reference tissue model (SRTM) and Logan graphical analysis. Speci-
ficity of binding was tested by blocking D2/3R with raclopride (co-incubation 
with 10 µM in vitro, administration of 1.0 mg/kg in vivo).
Results: In membrane homogenates AMC20 demonstrated picomolar af-
finity at D2RHigh (mean Ki = 85 pM) and excellent selectivity against 
D2RLow (mean Ki = 84 nM, 988-fold selectivity) and D1-like receptors (mean 
Ki = 5062 nM at D1R). The efficacy of AMC20 was 90% of that of dopamine 
in the arrestine recruitment assay. Up to 70% of total binding of [18F]AMC20 
in the D2/3R-rich striatum in rat brain slices was D2/3R-specific, in living 
rats the uptake ratio between the striatum and the D2/3R-poor cerebellum 
reached 2.0–2.5, depending on the measurement method. Radiometabo-
lites of [18F]AMC20 did not enter the brain. Striatal binding potential (BPND) 
of [18F]AMC20 varied between 0.49 and 0.59 depending on the estimation 
method. Pre-treatment with 1 mg/kg raclopride reduced the apparent spe-
cific binding of [18F]AMC20 in the striatum.
Conclusion: [18F]AMC20 shows specific binding to D2/3R in the striatum 
of living rats. Further optimization of the chemical structure of [18F]AMC20 




Imaging of dopamine D2 and D3 receptors (D2/3R) by PET is a topic of particu-
lar interest, as deregulation of D2/3-signaling is implied in many neuropsy-
chiatric disorders [1–4].
Most PET tracers currently used for D2/3R imaging are antagonists [5]. 
Throughout the recent two decades, development of agonist tracers for 
G-protein-coupled neurotransmitter receptors has gained popularity, 
spurred by the consistent observations by several authors [6–8] that in vitro 
agonists bound to receptor-G-protein complexes with higher affinity than to 
free receptors, while antagonists bound to all receptors with equal affinity.
Preference for this subset of receptors (called the “high affinity state”) makes 
agonists potentially better suited than antagonists for the imaging of syn-
aptic neurotransmission, as the neurotransmitters themselves are agonists 
and exhibit the same preference. Indeed, 11C-labeled D2/3R-agonists dem-
onstrated greater sensitivity to amphetamine-induced dopamine release in 
humans compared to the antagonist [11C]raclopride [9,10].
Moreover, dysregulated relative abundance of the high-affinity state of D2/3R 
might underlie the state of dopamine supersensitivity, which is associat-
ed with psychosis, Parkinson’s disease and addiction [11]. Agonist tracers 
might provide new insights for the research into and (early) diagnosis of 
such disorders.
Of many candidate compounds of various classes tested as potential 
D2/3R agonist PET tracers [12] only three were eventually used in humans, 
namely the apomorphines (–)-N-propyl-norapomorphine ([11C](–)NPA), 
(R)-2-11CH3O-N-n-propylnorapomorphine ([
11C]MNPA) and the naphtoxa-
zine (+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxa-
zin-9-ol ([11C](+)PHNO). The scope of use of [11C]tracers is limited by the 
short half-life of carbon-11 (20.4 min), while tracers labeled with longer-
living radioisotopes like fluorine-18 (half-life of 109.8  min) have a much 
greater potential. (R)-(−)-2-[18F]fluoroethoxy-N-n-propylnorapomorphine 
([18F]MCL-524), an 18F-labeled apomorphine derivative, showed very prom-
ising results in monkeys [13], but has not yet been reported to be used in 
humans.
We aimed to develop 18F-labeled D2/3R-agonist radioligands for PET. We 
have based our research on the aminomethyl chromanes (AMCs), a class of 
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D2/3-agonists first described as such by Mewshaw and co-workers [14]. AMCs 
were not used for the PET tracer development before.
Elaborating on the molecules described by Mewshaw, in particular 
(R)-2-(benzylaminomethyl)chroman-7-ol (AMC1, denoted as 10a in Chap-
ter 3), we have recently prepared a series of fluorinated AMCs and evaluated 
them as potential PET tracers [15]. By attaching a fluoroalkoxy moiety to 
the benzyl ring of AMC1 and systematically varying the length of the fluo-
roalkoxy group we obtained FBu-AMC13 and FEt-AMC13 (Figure 1; denoted 
as, respectively, 12a and 12d in Chapter 3). [18F]FEt-AMC13 demonstrated 
specific binding to striatal D2/3R in rat brain slices as well as in living rats, 
with a strong preference towards D2/3RHigh (high-affinity state of D2/3R) [16].
The [18F]fluorine label can also be attached directly to the benzyl ring of 
AMC1. This would minimize the alteration of the AMC1 structure caused by 
the introduction of the label and provide greater potential in vivo stability 
compared to [18F]fluoroalkyl derivatives. In fact, racemic para-fluorobenzyl 
derivative of AMC1 was already reported by Mewshaw to have sub-nano-
molar affinity towards D2Rhigh receptors and very good selectivity against 
D2RLow [1]. Here we report the preparation of the R-enantiomer of this de-
rivative, AMC20 and its in vitro and in vivo evaluation.
Figure 1. Structures of AMC1, FBu-AMC13, FEt-AMC13 and AMC20.
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MATER IALS AND METHODS
Chemistry, Radiochemistry and Pharmacology
The preparation and characterization of [18F]AMC20, of its 19F-reference and 
precursors are described in the Appendix (see also Figure S1 there).
In vitro binding experiments in HEK293 cell membrane homogenates were 
performed as described earlier [15]. β-Arrestin recruitment assay was per-
formed as described in the Appendix.
In vitro autoradiography in rat brain slices is described in detail in the Ap-
pendix. Briefly, sagittal slices from male Sprague-Dawley rats containing 
both striatum and cerebellum were incubated in a Tris-based buffer (pH 7.4) 
in the presence of varying concentrations of [18F]AMC20 (~2…80 nM) with or 
without 10 μM raclopride (D2/3-antagonist) or 100 μM guanosine-5’-triphos-
phate sodium salt (GTP, stimulator of G-protein uncoupling from the re-
ceptors). Then the slices were washed, dried and exposed against phosphor 
storage screens. On the resulting images, striatal and cerebellar regions of 
interest were manually drawn and mean exposure per region was quantified.
Animals
Animal experiments were performed by licensed investigators in compli-
ance with the Law on Animal Experiments of The Netherlands. The protocol 
was approved by the Committee on Animal Ethics of the University of Gron-
ingen. Young male (10–12 weeks of age, 300–350 g body weight) Sprague-
Dawley rats (Harlan, the Netherlands) were used for all experiments. The 
rats were maintained at a 12-h light/12-h dark regime and were fed standard 
laboratory chow ad libitum.
Small-animal PET
Distribution of [18F]AMC20 was studied in rats pre-treated with physiologi-
cal saline (controls, n=4) or 1 mg/kg D2/3R-antagonist raclopride (as tartrate 
salt, n=4). Saline and raclopride (in random order) were injected intrave-
nously about 30  min before tracer injection. An extra group of rats (n=4) 
were pre-treated with saline and injected with [11C]raclopride to serve as 
positive controls for D2/3-specific brain uptake.
Before all manipulations the animals were anesthetized with a mixture 
of isoflurane/air (inhalation anesthesia, 5% ratio during induction, 2% at 
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maintenance). Cannulae were inserted into their left femoral arteries and 
veins; the operation took 45–50  min. Then they were positioned supine 
inside the camera (Focus 220 microPET, Siemens-Concorde), two rats at a 
time, one above the other with their heads in the camera’s field of view. A 
515 sec transmission scan with a Co-57 point source was carried out. Tracer 
([18F]AMC20 or [11C]raclopride, Table 1) in 1 ml saline was injected through 
the venous cannula as a 60-second long using an infusion pump. The second 
(upper) animal was injected 16 min after the first (lower).
PET data were acquired using a list-mode protocol (106-minute long for 
[18F]AMC20, 76-minute long for [11C]raclopride). Acquisition began at the 
moment of the injection of radioactivity in the first rat.
In each rat, arterial blood samples of 0.10–0.15 ml were withdrawn through 
the arterial cannula at 10, 20, 30, 40, 50, 60, 90, 120, 180, 300, 450, 600, 900, 
1800, 3600 and 5400 (for [18F]AMC20) seconds after tracer injection.
After withdrawing aliquots of intact blood, samples were centrifuged to ob-
tain plasma. Radioactivity of plasma and intact blood aliquots was measured 
with a gamma-counter. Radiometabolite content in the deproteinated plas-
ma was assessed by thin layer chromatography (radio-TLC). Detailed pro-
cedures of arterial blood and plasma workup are described in the Appendix.
After the end of the PET scans (98±8 min post-injection for [18F]AMC20) anes-
thetized animals were sacrificed by heart extirpation and dissected. Samples 
of brain and peripheral tissues were taken. All samples were weighed and 
their radioactivity was measured in a gamma-counter.









[18F]AMC20 6.3±1.7 1.58±1.00 32±16
[11C]raclopride 16.9±5.3 1.26±0.16 36±3
MicroPET Data Analysis
List-mode data from the 106-minute-long and 76-minute-long scans were 
reframed into, respectively, 90-minute-long and 60-minute-long dynamic 
sequences of 6×10, 4×30, 2×60, 1×120, 1×180, 4×300, 3×600 and (for 90-min-
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ute-long scans) 2×900  sec frames. The data were reconstructed per time 
frame using an iterative reconstruction algorithm (attenuation-weighted 
2-dimensional ordered-subset expectation maximization, provided by Sie-
mens; 4 iterations, 16 subsets; zoom factor, 2). Datasets were fully corrected 
for random coincidences, scatter, and attenuation. Data from the transmis-
sion scan were used for attenuation correction. The final datasets consisted 
of 95 slices, with a slice thickness of 0.8 mm and an in-plane image matrix 
of 128×128 pixels of size 0.47×0.47 mm.
PET data were analyzed with Inveon 3.0 software package (Siemens Medical 
Solutions, USA, Inc). Regions of interest (ROIs) were drawn manually on a 
T2 MRI template of rat brain around the striatum, brainstem, cortex, hippo-
campus, hypothalamus, thalamus, olfactory bulbs and cerebellum, around 
the whole brain and around the pituitary gland. The MRI template was 
co-registered with the PET scan by image fusion. The time-activity curves 
(TAC) per ROI were determined in Bq/cm3 and used in this form for kinetic 
analysis, but converted into standardized uptake values (SUVs) for presen-
tation purposes.
Kinetic analysis is described using the nomenclature proposed by Innis et 
al [17]. ROI TACs were analyzed with one-tissue (1TCM) and two-tissue 
(2TCM) compartmental models of reversible binding and with Logan graphi-
cal analysis, using metabolite-corrected plasma-derived arterial input func-
tion and whole blood time-activity curve. Fractional cerebral blood volume 
was defined as 3.6%. ROI TACs were also analyzed with simplified reference 
tissue model (SRTM), using cerebellum as reference region.
Distribution volumes (VT) per ROI were determined from 1TCM and 2TCM-
derived rate constants and by Logan analysis.
Binding potentials (BPND) per ROI relative to cerebellum were calculated 
from the obtained VT values as VT (target) / VT (cerebellum) – 1, or estimated 
directly with STRM.
Ex Vivo Autoradiography and Brain Radiometabolite Analysis
Anesthetized rats, pre-treated with saline (n=3) or raclopride (n=3) were 
injected (30±5  min after pre-treatment) with a short bolus of [18F]AMC20 
(3.8±1.0 MBq, 0.75±0.19 nmol/kg) into the penile vein. Rats were sacrificed 
by heart extirpation 35  min post-injection. Brains were quickly extracted 
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and separated into two halves along the sagittal symmetry plane or along 
the coronal plane spanning the thalamus.
One brain half was sliced on the microtome and the slices containing the 
striatum were exposed against the phosphor storage screens. From the other 
half, radioactivity was extracted by homogenization in acetonitrile (>90% 
efficiency) and analyzed by radio-TLC. Detailed protocols for both proce-
dures are presented in the Appendix.
Outcome Measures of D2/3R-specific Binding
D2/3R-specific binding of [
18F]AMC20 was quantified using BPND values (as 
described above) and specific binding ratios (SBR), the latter calculated as: 
target region radioactivity / cerebellar radioactivity – 1. Both were estimated 
under control conditions as well as under raclopride challenge conditions.
Statistics
All data are presented as means ± standard deviations. Where a comparison 
of means was done, 2-sided unpaired Welch t-test was used. P-values below 
0.05 were considered significant. In case of multiple comparisons, no cor-




Competition curves of [3H]spiperone displacement from the Long isoform 
of D2R by AMC20 were significantly better fitted by the two-site binding 
model (KiHigh = 85 pM, KiLow = 84 nM, 988-fold difference) than by one-
site binding model. Such bi-phasic binding is a hallmark of an agonist, and 
the difference in the agonist affinities for the two recognized binding sites 
is known to correlate with the intrinsic activity [18]. This also accounted 
for D2RShort and D3R (Table 2). No second high-affinity binding component 
was detected for D1R. The D1R affinity of AMC20 was an order of magnitude 
lower than the lowest affinity at a D2-like receptor (Table 2).
Arrestin recruitment assay showed AMC20 to be an almost full agonist 
(Emax of 90.3±5.4% compared to dopamine) with a pEC50 of 8.86±0.05.
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[18F]AMC20 was synthesized within 150  min (including purification and 
quality control) using the three-step two-pot reductive amination proce-
dure (Figure 2) in 24±7% radiochemical yield and >95% radiochemical purity 
(both values referring to the formulated product). The molar radioactivity 
was 39±23 GBq/µmol at end-of-synthesis
The logD distribution coefficient (octanol/phosphate buffer pH  7.4) of 
[18F]AMC20 was found to be 2.33±0.03.
Figure 2. The radiosynthesis of [18F]AMC20.
In Vitro Autoradiography
In rat brain slices, [18F]AMC20 showed preferential uptake in the D2/3R-rich 
striatum (Figure 3A). At the lowest radioligand concentration tried (1.7 nM), 
striatal SBR of [18F]AMC20 was 5.27±1.49 at baseline and 0.89±0.29 (by 83%) 
in the presence of 10 μM raclopride, so 70% of the [18F]AMC20 binding in 
the striatum was D2/3R-specific. In the concentration range of 1.7–7.8 nM, 
10 μM raclopride decreased striatal SBR values by 74–89% compared to con-
trol conditions, while 100 μM GTP decreased the SBR by 62–78%, imply-
ing that most of the D2/3R-specific striatal binding of [
18F]AMC20 was to the 
high-affinity subset of the receptors (Figure 3B).
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Uptake in Living Rat Brain under Control Conditions
[18F]AMC20 showed excellent blood-brain barrier (BBB) penetration (Figure 
4): 3.5 min post-injection 1.7% injected dose (ID) accumulated in the brain.
The tracer primarily accumulated in the striatum, while the cerebellum 
showed the lowest uptake (Figure 5A). PET-derived striatum-to-cerebel-
lum uptake ratio of [18F]AMC20 peaked 35 min post-injection at 1.97±0.13 
(Figure 5B). The same ratio for [11C]raclopride 35  min post-injection was 
6.43±0.89. Ex vivo autoradiography-derived striatum-to-cerebellum ratio of 
[18F]AMC20 at the same time post-injection was 2.48±0.34.
Ex vivo measurements of the [18F]AMC20 uptake in the brain and periph-
eral tissues performed after the PET scan are given in Table S1 (figures and 
tables with the letter S are found in the Appendix).
Figure 3. In vitro autoradiography assay results of [18F]AMC20.
Representative images (A) and the influence of radioligand concentration on the mean±SD stri-
atal SBR of [18F]AMC20 (B) in control slices and in slices co-incubated with raclopride (10 µM) 
or GTP (100 µM). * P < 0.05 relative to control values, 2-sided Welch test.
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Figure 4. Representative in vivo PET images of [18F]AMC20 and [11C]raclopride.
Images are summed from 5 min post-injection till the end of scan. Harderian glands (on top) 
are masked.
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Figure 5 (previous page). Uptake of [18F]AMC20 (A, B) and [11C]raclopride (C, D) 
in the rat brain.
A, C – ROI TACs of control rats. B, D – striatum-to-cerebellum ratios in saline (SAL) and raclo-
pride-pre-treated (RAC) rats.
Points represent group means, error bars show standard deviations. * P < 0.05 relative to con-
trol group, 2-tailed Welch t-test.
Tracer Metabolism
[18F]AMC20 was quickly metabolized and excreted from the plasma (Figure 
6A,B). Plasma elimination half-life was 3.9 min. Radiometabolites found in 
the plasma and in the radioactivity extracted from the brain 35 min post-
injection showed Rf values of 0 in the radio-TLC analysis, compared to 
Rf of 0.65 for [
18F]AMC20. Intact [18F]AMC20 constituted 95% of radioactivity 
from the abovementioned brain tissue extract (Figure S2), suggesting that 
radiometabolites of [18F]AMC20 were hydrophilic and did not penetrate the 
BBB.
In vivo defluorination was also low, as follows from the much lower tracer 
uptake in the parietal bone compared to the brain tissue (Table S1).
Figure 6. Metabolism and pharmacokinetics of [18F]AMC20 in the plasma of liv-
ing rats.
A – percentage of parent in plasma radioactivity; B – intact [18F]AMC20 concentration in plas-
ma.




ROI TACs of control rats were consistently better approximated by 2TCM 
and SRTM than by 1TCM (Figure S3), as assessed by Akaike information cri-
terion. However, no consistent estimates of individual rate constants could 
be obtained from 2TCM fits (Table S2).
Logan graphical analysis produced the most robust ROI VT estimates 
(Table S3). 2TCM-derived VT values correlated better with Logan VT values 
(r = 0.98) than did 1TCM VT values (r = 0.95; Figure S4). The 2TCM rate con-
stant ratios k3/k4 did not provide robust BPND estimates (data not shown), 
but VT-based 2TCM BPND were robust and correlated better with Logan BPND 
values (r = 0.99) than did 1TCM BPND values (r = 0.93).
SRTM BPND values correlated best with Logan BPND (r = 0.95), somewhat less 
well with 2TCM BPND (r=0.92) and still less well with 1TCM BPND (r=0.88; 
Figure S5).
The highest BPND values in saline-pre-treated rats, 0.49–0.59 depending on 
the estimation method, were found in the striatum (Table 3, Table S4).
Raclopride Challenge
Raclopride pre-treatment resulted in 35% decrease of peak PET-derived stri-
atal SBR of [18F]AMC20 relative to controls (0.63±0.12 vs 0.97±0.13, p<0.01). 
Blockade of D2/3R-specific signal in striatum was clearly seen on the ex vivo 
autoradiography images (Figure S6), autoradiography-based SBR fell by 41% 
(0.88±0.21 vs 1.48±0.34, p<0.01).
Depending on the model used for kinetic analysis, striatal BPND fell by 
21–29% (p<0.05 for SRTM; p<0.07 for Logan and 1TCM; p=0.09 for 2TCM; 
Table 3, Table S4).
The occupancy of D2/3R by raclopride estimated from ROI VT values with 
modified Lassen plot analysis [19] was found to be 34–37% (p<0.05 for 
1TCM, 2TCM and Logan). Comparison of the actual ROI VT values with 
the estimated non-displaceable volume of distribution (VND) implied that 
39–48% of striatal VT and 5–22% of cerebellar VT were potentially displace-
able (Figure S5).
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This study is a continuation of our work on the development of D2/3R agonist 
PET tracers based on the AMC scaffold [15,16]. Here we evaluated in vitro 
and in vivo a new candidate tracer, AMC20.
AMC20 was confirmed to be a potent D2R-agonist by arrestine recruitment 
assay and demonstrated the highest D2RHigh affinity (85 pM) and D2RHigh/
D2RLow selectivity (988-fold) of all AMCs so far evaluated by us (Table 2). 
Likewise, in rat brain slices [18F]AMC20 exhibited high striatal SBRs and was 
as highly sensitive to the D2/3RHigh-eliminating GTP as to the D2/3R-blocker 
raclopride.
In living rats, [18F]AMC20 penetrated the BBB well and preferentially accu-
mulated in the striatum. The 2TCM model approximated the time-activity 
curves of [18F]AMC20 generally better than the 1TCM model, but there was 
no consistency in the estimates of individual rate constants of 2TCM. It 
may be that the data (i.e. PET counts and input curves) were not of suffi-
ciently high quality to precisely estimate these constants. Still, the VT values 
derived from the 2TCM rate constants, as well as VT-based BPND values, were 
robust and consistent, so these outcome measures were used for the evalu-
ation of [18F]AMC20. Interestingly, both VT and BPND obtained from 2TCM 
correlated better than VT and BPND obtained from 1TCM with the corre-
sponding measures obtained by Logan analysis, which does not assume any 
particular number of kinetic compartments.
Changes of striatal BPND and SBR induced by 1 mg/kg raclopride were gen-
erally consistent with the estimates of D2/3R occupancy by raclopride, but 
disagreed with the literature data for 11C-labeled D2/3R agonists: as little as 
0.2 mg/kg displaced over 80% of apparent D2/3R-specific [
11C](+)PHNO up-
take [20], while 1–2 mg/kg raclopride displaced >90% specific striatal uptake 
of [11C]MNPA and [11C]PHNO in Sprague-Dawley rats [20–22].
Crude estimation of the D2/3R occupancy by [
18F]AMC20 in our experiments, 
assuming the equality of non-D2/3R-specific binding in striatum and cere-
bellum and using the approach described by Skinbjerg et al. [23], produced 
values ranging from 2% to 15% (7% on average). This means our injected 
tracer doses could have been high enough to cause a “mass effect” distort-
ing our measurements. However, baseline SBRs and binding potentials of 
[18F]AMC20 in control rats did not tend to decrease with the injected dose 
(Figure S6), so we do not consider the violation of tracer conditions likely.
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Imprecise estimation of the specific portion of total tracer binding, resulting 
from high non-specific binding, may have led to the underestimation of the 
degree of specific binding blockade by raclopride. Low apparent displace-
ment of D2/3R-specific striatal binding may also suggest that in the brain 
[18F]AMC20 specifically binds to sites other than D2/3R, which have compar-
atively high density in the striatum. Binding to D1 has been ruled out in 
this study, while racemic AMC20 was shown to be selective for D2R against 
5-HT1A and α1 receptors [14], but selectivity against other non-dopaminergic 
receptors has yet to be tested.
Compared to the earlier evaluated [18F]FEt-AMC13 [16], [18F]AMC20 showed 
greater decrease of striatal SBRs and BPND in response to raclopride treat-
ment in living rats (Table S5). However, [18F]AMC20 is inferior to exist-
ing 11C-labeled D2/3 agonists [13,21,22] in terms of baseline striatal BPND 
(0.49–0.59 vs >0.8) and, apparently, also in terms of sensitivity to raclopride 
treatment.
The higher non-specific binding of [18F]AMC20, resulting from its consid-
erably higher lipophilicity (LogD 2.33±0.03) relative to [18F]FEt-AMC13 
(LogD 1.67±0.07), seems to have prevented [18F]AMC20 from attaining a 
high signal-to-noise ratio despite its high D2/3Rhigh affinity.
[18F]AMC20 and [18F]FEt-AMC13, both based on the AMC1 structure, have, 
therefore, two common problems. One is the low signal-to-noise ratio, 
proportional to the association and dissociation rates of tracer binding to 
the receptors at equilibrium. Signal-to-noise ratio may be limited by the 
non-specific binding of the tracer in the tissue, which leaves less free tracer 
available for specific binding, or by the quick release of specifically bound 
agonist tracer from the receptors due to the receptor’s relaxation into the 
low-affinity state after G-protein activation by agonist – a known potential 
issue for agonist tracers of G-protein-coupled receptors [11].
Another problem is the suspected lack of pharmacological selectivity of 
[18F]AMC20 and [18F]FEt-AMC13 towards D2/3R.
Screening of the AMC20 and FEt-AMC13 against non-dopaminergic recep-
tors and more thorough studies of their binding kinetics in a more con-
trolled environment (in vitro) are necessary to find out which factors limit 
the signal-to-noise ratio of these compounds as D2/3R-imaging agents and to 
produce and evaluate new optimized AMC derivatives.
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CONCLUS ION
We have evaluated a novel aminomethyl chromane-derived D2/3R agonist 
radiopharmaceutical. The agonist, AMC20, demonstrated very high affin-
ity towards the high-affinity state of human D2/3RLong in cell membrane 
homogenates. [18F]AMC20 showed specific binding to the striatal D2/3R in 
rat brain slices in vitro as well as in living rat brain. The signal-to-noise 
ratio of [18F]AMC20 was on a par with that of the structurally related tracer 
[18F]FEt-AMC13 evaluated by us earlier. Further investigations of the struc-
ture-activity relationships of [18F]AMC20 and related compounds can lead to 
a radioligand suitable for D2/3R imaging in vivo.
Acknowledgements
J.A.J.M. (Jef) Vekemans, Eindhoven University of Technology, (TU/e), is 
thanked for his advice on synthetic design; J.L.J. (Joost) van Dongen and 
R.A.A. (Ralf) Bovee (both TU/e) are thanked for their expertise on and execu-
tion of the HRMS measurements and the elemental analyses, respectively. 
Prof. E.W. (Bert) Meijer (TU/e and ICMS Eindhoven), is thanked for enabling 
the execution of the synthetic part of the presented research.
Aren van Waarde, Antoon Willemsen, Janine Doorduin, Jurgen Sijbesma and 
Mohammed Khayum (all – department of Nuclear Medicine and Molecular 
Imaging, University Medical Center Groningen, University of Groningen) 
are thanked for their advice on the design and help with the execution of the 
microPET study.
This work was supported by a grant from the Dutch Technology Foundation 
STW (grant 10127).
189
Synthesis and Evaluation in Rats of the Dopamine D2/3 Receptor Agonist [
18F]AMC20 





Reagents, chemicals, materials and solvents were obtained from commer-
cial sources, and were used as received: Biosolve, Merck for solvents, Cam-
bridge Isotope Laboratories for deuterated solvents, and Aldrich, Acros, 
ABCR, Merck and Fluka for chemicals, materials and reagents. All solvents 
were of AR quality.
1H-NMR and 13C-NMR spectra were recorded on Varian MR (300 or 400 MHz 
for 1H-NMR, 100  MHz for 13C-NMR) spectrometers at ambient tempera-
ture. Chemical shifts are reported in ppm, applying deuterated chloroform 
(CDCl3) or other deuterated solvents as internal reference. Abbreviations 
used for splitting patterns are s = singlet, t = triplet, q = quartet, m = multi-
plet, dd = double doublet.
LC-PDA/MS analyses were performed on a Shimadzu LC-10 AD VP series 
LC coupled to a photo diode array (PDA) detector (Finnigan Surveyor PDA 
Plus detector, Thermo Electron corporation) and an ion-trap detector (LCQ 
Fleet, Thermo Scientific). Analyses were executed at 298 K using an Alltech 
Alltima HP C18 3μ column using an injection volume of 1–4 μL, a flow rate 
of 0.2 mL min-1 and typically a MeCN in H2O gradient (from 5% to 100% 
MeCN, where both MeCN and H2O contain 0.1% formic acid).
Elemental analyses and UPLC-HRMS analyses were performed on AMC20 in 
its isolated oxalate form. Elemental analyses were done to assess the num-
ber of oxalate groups attached to AMC20 and were performed on a Perkin-
Elmer Series II CHNS/O Analyser 2400. UPLC-HRMS was used to determine 
the purity and the exact molecular weight of AMC20. UPLC was performed 
on a Waters Acquity UPLC equipped with a sample manager (an autosam-
pler) and a binary solvent manager. An Acquity UPLC BEH C18 1.7 microm-
eter column was used applying H2O and MeCN, both containing 0.1% formic 
acid, as the two eluents and applying an 8 minute gradient program where 
the content of MeCN was increased from 5 to 60% in 5 minutes time. A sam-
ple solution (10% MeCN in H2O with 0.1% formic acid) with a concentration 
of ca. 0.1 mg/mL was prepared and an injection volume of 0.1 microliter was 
used. For HRMS detection, a Xevo G2 Qtof detector using Zspray lockspray 
ionisation was applied.
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Analytical thin layer chromatography (TLC) was performed on Kiesel-
gel F-254 precoated silica plates. Normal phase column chromatography 
was carried out on flash silica gel (40–63  μm mesh) or regular silica gel 
(60–200 μm), both acquired from Screening Devices B.V., or on standardized 
aluminium oxide 90 from Merck.
Synthesis of AMC20 reference and precursors
The synthetic routes to the [19F]AMC20 and the [18F]AMC20 precursor amine 
5 are outlined in Figure S1. The synthesis of all AMC derivatives shown in 
this figure has been already described in detail elsewhere [15], except the 
preparation of AMC20 itself and of its precursor 4, which is described here. 
Briefly, all compounds were prepared starting from 2,4-dihydroxyacetophe-
none (1) that was converted in two steps [24,25] and a third lipase kinetic 
resolution step [26] to the key AMC-intermediate (R)-ethyl 7-hydroxychro-
man-2-carboxylate (2). The 7-hydroxyl group of the chromane moiety of 2 
was protected by the methoxymethyl (MOM) group, the ethyl ester group 
was reduced to the primary alcohol, and this alcohol was tosylated to 
arrive at molecule 3. ‘Cold’ AMC20 was obtained by coupling of 3 with 
p-fluorobenzylamine to give molecule 4 and then removing the MOM pro-
tecting group. Secondary amineAMC20 was converted to its oxalate salt, 
and this salt was used in the assays that are described in this manuscript. 
Finally, tosylate 3 was used in a standard two-step Gabriel synthesis to pre-
pare primary amine 5.
(R) N-[7-(Methoxymethoxy)chroman-2-yl]methyl 4-fluorobenzyl amine (4)
Tosylate 3 (250  mg, 0.66  mmol), commercially available 4-fluorobenzyl-
amine (124  mg, 0.99  mmol, 1.5 moleqs) and DIPEA (341  mg, 2.64  mmol, 
4 moleqs) were dissolved in DMSO (5 mL). The reaction mixture was stirred 
for 24 hours at 85 °C, and was then poured into ice water. The aqueous layer 
was extracted with ethyl acetate to yield crude product that was purified by 
alumina column chromatography (2% MeOH/CHCl3). Yield: 124 mg (57%).
1H NMR (CDCl3): δ = 7.30 (m, 2H), 7.00 (m, 2H), 6.93 (m, 1H), 6.53 (multiple 
signals, 2H), 5.08 (s, 2H), 4.15 (m, 1H), 3.85 (s, 2H), 3.45 (s, 3H), 2.9–2.6 
(multiple signals, 4H), 1.93 (m, 1H), 1.8 (multiple signals, 2H). LC-MS: m/z = 
332.4 [M+H]+, (calcd 331.39 for C19H22NO3F).
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(R)-2-[(4-Fluorobenzylamino)methyl]chroman-7-ol (AMC20)
The MOM-protected secondary amine 4 (125 mg, 0.378 mmol) was dissolved 
in an 4M HCl solution in dioxane (2 mL) and isopropanol (2 mL). The reaction 
mixture was stirred for about 3 hours at rt, while a N2 flow was maintained 
over the reaction mixture. From time to time, N2 was bubbled through the 
solution in order to remove volatile reaction products from the mixture. The 
reaction mixture may turn hazy due to precipitation of the ammonium salt. 
After completion of the reaction (the reaction was monitored by LC-MS), 
the mixture was added to water and the pH was brought to slightly basic 
by addition of a NaOH-solution. The free amine oil product was isolated 
from the water layer by several extractions using CHCl3 or CH2Cl2 with some 
added THF, followed by drying of the collected organic layers with Na2SO4 
and evaporation of the solvent.
Yield 63 mg (58%).
1H NMR (CDCl3): δ = 7.35 (m, 2H), 7.0 (m, 2H), 6.77 (m, 1H), 6.30 (multiple 
signals, 2H), 4.05 (m, 1H), 3.90 (d, 1H), 3.85 (d, 1H), 2.85–2.75 (multiple sig-
nals, 2H), 2.7–2.5 (multiple signals, 2H), 1.8 (m, 1H), 1.7 (m, 1H). 13C NMR 
(CDCl3): δ = 163.5, 161.0, 156.1, 154.4, 133.5, 130.5, 130.4, 130.1, 115.6, 
115.4, 112.6, 109.2, 103.2, 74.1, 53.4, 53.2, 26.2, 23.6. LC-MS: m/z = 288.4 
[M+H]+, (calcd 287.33 for C17H18NO2F).
Preparation of the oxalate salt of AMC20: the free amine of AMC20 
(63 mg, 0.219 mmol) was dissolved in THF (3 mL) and oxalic acid dihydrate 
(61 mg, 0.484 mmol, 2.2 moleqs) in THF (1 mL) was added. The reaction mix-
ture turned hazy due to precipitation of the oxalate ammonium salt. After 
about 3–5 hours of stirring the reaction mixture was centrifuged and the 
solvent was pipetted or decanted off. The residue was stirred in a fresh 1:1 
mixture of diethyl ether and THF, and was centrifuged again. The solvent 
was removed and the precipitate was dried to yield a white solid residue 
(41 mg, 50%).
1H NMR (DMSO-d6): δ = 6.0–3.5 (broad signal acidic protons), 7.55 
(m, 2H), 7.25 (m, 2H), 6.8 (m, 1H), 6.3 (m, 1H), 6.25 (s, 1H), 4.25 (m, 1H), 4.2 
(m, 1H), 3.2–3.0 (m, 2H), 2.75–2.6 (multiple signals, 2H), 2.0 (m, 1H), 1.65 
(m, 1H). 13C NMR (DMSO-d6): δ = 164.0, 163.4, 161.3, 156.5, 153.9, 132.4, 
132.3, 129.9, 128.9, 115.6, 115.4, 111.9, 108.5, 102.9, 71.6, 49.9 (2Cs), 24.7, 
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22.8. LC-MS: m/z = 288.4 [M+H]+, (calcd 287.33 for C17H18NO2F). HRMS 




[18F]fluoride was produced in the Scanditronix MC-17F cyclotron (Scanditro-
nix, Uppsala, Sweden) and delivered from the target into the hotcell with 
helium overpressure. Synthetic procedures were performed manually. Ra-
diochemical conversions and purities were determined by radio-HPLC us-
ing beta-sensitive detectors and dose-calibrators (Veenstra Instruments) 
and by radio-TLC using Cyclone phosphor storage screens (multisensitive, 
Packard) and OptiQuant software.
[18F]fluoride production and drying
[18F]fluoride in enriched [18O]water was adsorbed on an anion-exchange col-
umn (QMA) (pre-activated with NaHCO3 solution) and then eluted from it 
into the drying vial with 1–1.5  ml of K2CO3-Kryptofix solution in 9:1 v/v 
mixture of acetonitrile and water, respectively. After the elution of QMA, 
acetonitrile and water were evaporated at 130 °C under nitrogen flow. For 
further water removal, 1 ml anhydrous acetonitrile was added into the reac-
tion vial and evaporated. The operation was repeated three times. In total, 
[18F]fluoride drying process took about 15 min.
Preparation of [18F]AMC20
Trimethylammonium benzaldehyde triflate (2 mg) in 1 mL anhydrous DMSO 
were added into the vial with dried [18F]fluoride (prepared as described above) 
complexed with K2CO3 (1.5–2.2  mg) and 5–7.5  mg/ml Kryptofix. The vial 
was sealed and the reaction was carried out for 2.5 min at 130 °C followed 
by cooling for 5 min. Then 1 mL of water was added to the cooled reaction 
mixture. [18F]FBA was purified by reverse-phase HPLC using Platinum C18 
EPS 5μ 250×10 mm column eluted with acetonitrile/10 mM H3PO4 (40/60 v/v) 
at 4 ml/min (retention time 9.7 min, k’ = 3.0). Collected radioactive fraction 
was diluted 2–3 fold with water and 4-[18F]fluorobenzaldehyde was adsorbed 
on Oasis HLB SPE cartridge. The cartridge was rinsed with 5 mL of pure wa-
ter and dried for 5 min in strong nitrogen flow. Afterwards 4-[18F]fluoroben-
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zaldehyde was eluted from the cartridge with 0.9 mL methanol (cartridge 
was eluted in reverse position; about one third of ethanol got absorbed by 
the resin) into a v-vial containing primary amine 5 (0.6 mg) and NaBH3CN 
(2 mg) in 100 μl methanol. 5 μl glacial acetic acid was added into the vial, the 
vial was sealed and reductive amination was conducted for 10 min at 120 °C. 
The vial was allowed to cool down for 2–3 min, then 1 mL 0.4N HCl was 
added into it to allow for deprotection of the MOM-group that lasted 10 min 
at 120 °C. [18F]AMC20 was purified by reverse-phase HPLC using Platinum 
C18 EPS 5μ 250×10  mm column eluted with acetonitrile/10  mM H3PO4 
(50/50 v/v) at 5 mL/min (retention time 10.1 min, k’ = 4.1).
The collected HPLC fraction was diluted with 10 volumes of water and 
[18F]AMC20 was adsorbed on an Oasis HLB SPE cartridge. The cartridge was 
rinsed with 5 mL pure water and [18F]AMC20 was then eluted with 1–2 mL 
absolute ethanol (typically giving a 50% recovery). After partial or com-
plete evaporation of ethanol in nitrogen flow (with or without application of 
vacuum) the tracer was formulated in physiological saline (ethanol content 
in the formulated tracer was kept below 10%). The identity of [18F]AMC20 
was confirmed and the radiochemical purity was assessed by reverse-phase 
HPLC and radio-TLC, respectively. Reverse-phase HPLC was carried out on 
Platinum EPS 5µ 250×4.6 column eluted with acetonitrile/water/formic acid 
(60/40/0.1 v/v) at 2 mL/min (retention time 14.7 min, k’ = 13.6). Radio-TLC 
was carried out on silica plates eluted with ethylacetate/methanol/triethyl-




Agonism of AMC20 at D2 receptors was determined with the PathHunt-
er™ eXpress DRD2L CHO-K1 β-Arrestin GPCR Assay (catalog number 
93-0446CP2M) from DiscoveRx (Fremont, CA), used according to the sup-
plied protocol. At first 8000 cells/well were seeded in a 96-well plate and in-
cubated 48 hours at 5% CO2 and 37 °C. Then dilutions of AMC20 were added 
and the plates were incubated for 90 minutes at 5% CO2 and 37 °C. After that 
the detection mixture was prepared and added to the assay. Subsequently 
the plates were incubated for 60 minutes at room temperature after which 
chemiluminescence was measured on a multiplate reader (Victor 2, Wallac, 
PerkinElmer).
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In vitro autoradiography assay
Frozen brains of young (10–12 weeks of age; 300–350 g body-weight) male 
Sprague-Dawley rats (Harlan, Netherlands) were cut into two halves along 
the sagittal symmetry plane. Each half was mounted, lateral side up, on a 
paper slide pre-treated by Tissue-Tek fixing cocktail (Sakura, the Nether-
lands) and fixed by placing it onto a Petri dish floating on liquid nitrogen. 
After fixing, brains were cut at −12 °C into sagittal slices 20 μm thick us-
ing a Leica microtome, and the slices were thaw-mounted on Superfrost 
(70×22 mm, Fischer) adhesive slides. Only slices containing both striatal and 
cerebellar regions (representing non-specific binding) were used. Slides were 
organized in pairs and in each pair new slices were mounted alternately 
on the first or the second slide of the pair, so that slices in corresponding 
positions on the two slides forming a pair would represent adjacent tissue lay-
ers. The slices were allowed to dry, then put into storage boxes with dessicator 
(silicagel) bags and kept at −80 °C till they were used (no longer than 1 week).
On the day of the experiment the slides with mounted slices were taken out 
of storage and allowed to come to room temperature for 5–10 minutes. Af-
ter that, incubation buffer (50 mM Tris-HCl, 5 mM KCl, 2 mM CaCl2, 2 mM 
MgCl2, 120 mM NaCl, pH 7.4 25 °C) was applied to the slides using an auto-
matic pipette (1–1.2 ml/slide) and the slides were pre-incubated for 15 min 
at room temperature. The pre-incubation buffer was then removed and the 
slides were placed into staining jars containing incubation buffer and radio-
ligand ([18F]AMC20) with or without 10 μM raclopride (D2/3-antagonist) or 
100 μM guanosine-5’-triphosphate sodium salt (GTP, stimulator of G-pro-
tein uncoupling from the receptors). The slides were incubated for 35 min at 
37 °C, then washed once with ice-cold incubated buffer (3.5 min) and dipped 
for 30 sec into ice-cold sterile water to remove buffer salts.
After drying the slides in a stream of room-temperature air, they were ex-
posed on phosphor storage screens for 6–10 hours. Afterwards the storage 
screens were read by Cyclone Storage Phosphor System (Packard Instru-
ments Co). Quantification of plate readings was done with Optiquant soft-
ware (version 3.00, Packard Instruments Co), drawing regions of interest 
manually on the striatum and cerebellum.
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Animal tissues workup
Measuring the whole blood time-activity curve and 
metabolite-corrected plasma input curve
25  μl aliquots of whole blood were withdrawn from each arterial blood 
sample taken from each rat. The rest was centrifuged at 3500 g for 5 min, 
25 μl supernatant (plasma) aliquots were withdrawn and deproteinated with 
75 μl of ice-cold acetonitrile. From the resulting 100 μl, 2–8 μl portions (i.e. 
2–8% of volume) were taken for thin layer chromatography analysis (radio-
TLC), to assess radiometabolite content. Radio-TLC was performed on silica 
plates. Samples of the formulated tracers (diluted) were run along with de-
proteinated plasma samples to confirm the identity of the parent compound 
in plasma. Eluent system was ethylacetate/methanol/triethylamine 100/5/1, 
recorded Rf of [
18F]AMC20 was 0.65.
The radioactivity of the plasma and whole blood samples was measured 
using a well-type gamma-counter (LKB-1282-Compugamma, LKB Wallac).
Ex vivo autoradiography
The selected half of the brain (rostral or randomly taken left/right) was 
quickly frozen over liquid nitrogen and prepared for cutting on the micro-
tome in the same manner as brains used for in vitro autoradiography (see 
above). 40  µm thick slices were cut, mounted on Superfrost glass slides, 
permitted to dry and then directly applied to the phosphor storage screens.
Brain radiometabolite analysis
The half of the brain not selected for ex vivo autoradiography was homog-
enized in 3 ml ice-cold acetonitrile using Heidolph IDAX600 homogenizer at 
maximum speed. Homogenate was centrifuged at 3500 g for 5 min and the 
supernatant (containing >95% total radioactivity) was analyzed by radio-
TLC in the same way as described above for the plasma.
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Figure S1. The scheme of synthesis of unlabeled AMC20 and of primary amine 
5, the precursor to [18F]AMC20.
Reagents and solvents: (a) p-fluorobenzylamine, DIPEA, DMSO; (b) 4M HCl, dioxane/isopropa-
nol.
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Figure S2. Radio-TLC analysis of brain tissue radiometabolites of [18F]AMC20.
A representative TLC lane is shown, as an actual image (top) and as a profile graph of total 
exposure (bottom). Solvent system is ethylacetate/methanol/triethylamine (100/5/1). Solvent 
front movement is left-to-right. Peak 1 represents radiometabolites of [18F]AMC20, peak 2 
represents intact [18F]AMC20.
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Figure S3. Representative striatal (A) and cerebellar (B) TACs of [18F]AMC20 (in 
a control rat) and the corresponding fits with 1TCM, 2TCM and SRTM models.
2TCM fits had lower Akaike’s information criterion (AIC) value than 1TCM fits in 57 out of 80 
(71%) cases. SRTM fits had lower AIC value than 2TCM fits in 69 out of 80 (86%) cases.
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Figure S4. Correlation of region-of-interest total distribution volumes (VT) of 
[18F]AMC20 obtained by Logan analysis with VT values obtained by analyses 
with 1TCM and 2TCM models.
Points represent fits for individual regions in individual animals (both control and raclopride-
pre-treated). Data for striatum, hippocampus, thalamus, hypothalamus, cortex, brainstem, cer-
ebellum, olfactory bulbs and pituitary are used.
Unity line (x = y) and linear regression lines for 1TCM and 2TCM data, along with their equa-
tions and r-criterion values are shown on the graphs.
200 Chapter 4
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Figure S6. Ex vivo autoradiography images of [18F]AMC20 uptake in control (A) 
and raclopride-treated (B) rats.
Representative sagittal and coronal slices are shown. Profile section through the striatum in 
coronal slices is presented at the bottom, showing absolute exposure values.
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Figure S8. Relationship of injected doses of [18F]AMC20 with SRTM-derived (A), 
Logan-derived (B) and 2TCM-derived (C) striatal binding potentials (BPND) and 
with PET-derived peak striatal specific binding ratios (D) in saline (open circles) 
and raclopride-pre-treated rats (closed circles).
Points represent measurements in individual animals. Linear trend lines are shown for each 
treatment group.
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(continued on the next page)
Table S1. Ex vivo uptake (SUV units, mean±SD) of [18F]AMC20 in brain and 






Adipose tissue 0.40±0.33 0.46±0.55
Adrenal glands 1.52±0.77 1.07±0.37
Bladder 2.37±1.90 1.04±0.61
Bone 0.09±0.03 0.12±0.02





Large Intestine 0.45±0.42 0.36±0.19






Small Intestine 0.18±0.09 3.25±3.63




Table S1 (continuation). Ex vivo uptake (SUV units, mean±SD) of [18F]AMC20 












Medulla with pons 0.25±0.11 0.18±0.03
Midbrain 0.21±0.09 0.16±0.04
Olfactory bulbs 0.20±0.08 0.15±0.02
Pituitary 0.47±0.14 0.49±0.04
Rest of brain 0.23±0.10 0.18±0.04
Striatum 0.25±0.12 0.17±0.03
Thalamus + Hypothalamus 0.21±0.09 0.16±0.05
Total Brainstem 0.23±0.10 0.18±0.03
Total Cortex 0.20±0.09 0.17±0.04
Whole brain 0.21±0.09 0.17±0.04
Bodily fluids
Whole Blood 0.21±0.06 0.14±0.06
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L I ST OF ABBREV IAT IONS
1TCM – one-tissue compartment model
2TCM – two-tissue compartment model
BPND – binding potential non-displaceable (equilibrium concentration 
ratio of specifically bound radioligand to non-displaceable radioligand 
in tissue)
DMF – N,N’-dimethylformamide
ESI-MS – electron-spray ionization mass-spectrometry
GPCR – G-protein coupled receptor
GTP – guanosinetriphospate
HPLC – high-pressure liquid chromatography
LC – liquid chromatography
MS/MS – tandem mass spectrometry
PET – positron emission tomography
ROI – region of interest
SPECT – single photon emission computed tomography
SRTM – simplified reference-tissue model
SUV – standardized uptake value (regional uptake relative to mean 
uptake across the body)
TAC – time-activity curve
TLC – thin-layer chromatography
UV-VIS – ultraviolet/visible
VT – total distribution volume of a radioligand in the tissue (i.e. the 
sum of distribution volumes of free, non-specifically and specifically 
bound radioligand)
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ABSTRACT
Background: Agonist positron emission tomography (PET) tracers for do-
pamine D2/3 receptors (D2/3Rs) offer greater sensitivity to changes in endog-
enous dopamine levels than D2/3R antagonist tracers. D2/3R agonist tracers 
currently available for clinical research are labeled with the short-lived 
isotope carbon-11, which limits their use. We aimed to develop high-affin-
ity D2R agonists amenable for labeling with the longer-living fluorine-18. 
Here we report the evaluation as potential PET tracers of two homologous 
series of [18F]fluorinated tracers based on the 2-aminomethylchroman 
(AMC) scaffold: (R)-2-((4-(2-fluoroalkoxy)benzylamino)methyl)chroman-
7-ols (AMC13 homologues) and (R)-2-((2-(4-(4-(fluoroalkoxy)phenyl)pi-
perazin-1-yl)ethylamino)methyl)chroman-7-ols (AMC15 homologues). We 
varied the length of the 18F-fluoroalkyl chain in these structures to balance 
brain penetration and non-specific binding of the radioligands by adjusting 
their lipophilicity.
Methods: The tracers were evaluated in brain slices of Sprague-Dawley 
rats by in vitro autoradiography and in living rats by microPET imaging and 
ex vivo autoradiography. PET data were analyzed with one and two-tissue 
compartmental models (1TCM/2TCM), simplified reference tissue model 
(SRTM) and Logan graphical analysis. Specificity of binding was tested by 
blocking D2/3R with raclopride.
Results: Homologues with shorter fluoroalkyl chain consistently showed 
greater D2/3R-specific-to-total binding ratios in the striatum than those with 
longer chains. The fluoroethoxy homologue of AMC13 ([18F]FEt-AMC13) 
demonstrated the highest degree of D2/3R-specific binding among the evalu-
ated tracers: mean striatum-to-cerebellum uptake ratio reached 4.4 in vitro 
and 2.1/2.8 in vivo/ex vivo (PET/autoradiography). Striatal binding potential 
(BPND) relative to cerebellum was 0.51–0.63 depending on the estimation 
method. Radiometabolites of [18F]FEt-AMC13 did not enter the brain. In vi-
tro, application of 10 μmol/L raclopride reduced D2/3R-specific binding of 
[18F]FEt-AMC13 in the striatum by 81%. In vivo, pre-treatment with 1 mg/kg 
(2.9 μmol/kg) raclopride led to 17–39% decrease in D2/3R-specific binding in 
the striatum.
Conclusions: Varying the length of the [18F]fluoroalkyl chain helped im-
prove the characteristics of the original candidate tracers. Further modifica-
tions of the current lead [18F]FEt-AMC13 can provide an agonist radiophar-
maceutical suitable for D2/3R imaging by PET.
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INTRODUCTION
Disregulation of dopamine signaling through dopamine D2 and D3 recep-
tors (D2/3Rs) is implicated in many neuropsychiatric disorders [1–4], making 
imaging of D2/3Rs by positron emission tomography (PET) highly relevant.
The majority of PET tracers developed for D2/3R imaging are antagonists [5], 
but in the last two decades, agonists have attracted attention as potential 
PET ligands for G-protein coupled neurotransmitter receptors (GPCRs). In 
in vitro competition studies, agonists consistently show higher affinity for 
receptor molecules bound to G-proteins (“high-affinity state”) than for free 
receptors (“low-affinity state”) [6–8]. Agonists are therefore expected to se-
lectively recognize the “high-affinity” subset of receptor population in the 
imaging experiments, while antagonists bind to all receptors disregarding 
“affinity states” [9].
Though the existence of a separate “high-affinity state” subpopulation of 
D2/3R in the brain is still not conclusively demonstrated in vivo [10], ra-
diolabeled D2/3R agonists indeed turned out to be more sensitive than the 
antagonist [11C]raclopride to amphetamine-induced release of dopamine 
(itself also an agonist) in rodents, cats, non-human primates and humans 
[11–17]. Alteration of the relative abundance of “high-affinity state” D2/3Rs 
(D2/3R-high), detected by in vitro methods, is implied in dopamine super-
sensitivity, a state relevant to psychosis, Parkinsonism and drug addiction 
[18]. Changes in this in vitro-based parameter are likely to be translated into 
effects observable in vivo, so agonist tracers might provide new insights for 
the research into, and (early) diagnosis of, these common neuropsychiatric 
disorders.
Numerous scaffolds have been investigated in the development of D2/3R 
agonist PET tracers [19], but representatives of only two classes, name-
ly the apomorphines [11C](–)NPA and [11C]MNPA and the naphtoxazine 
[11C](+)PHNO, have hitherto been used in human PET studies. These trac-
ers can only be used in hospitals with an on-site cyclotron due to the short 
half-life of carbon-11. Fluorine-18-labeled tracers (half-life of 109.8 min) 
have greater potential of widespread application in the clinic and are 
also more suitable for long-duration experiments in the research set-up. 
[18F]5-OH-FPPAT, an aminotetraline tracer, showed promising results in rats 
and monkeys [20], but no evaluation in humans has been published so far. 
A [18F]fluorinated analog of [11C](+)PHNO failed to demonstrate D2/3R spe-
cific binding in rats [21], while the recently described [18F]MCL-524, struc-
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turally related to [11C]MNPA, showed very promising results in non-human 
primates [22].
We aimed to increase the availability of fluorine-18-labeled D2/3R agonist 
tracers for PET. For this purpose we selected the 2-aminomethylchroman-
7-ol (AMC) scaffold. Structure-activity relationships of this class of high-
affinity D2R-agonists were previously investigated by Mewshaw and co-
workers [23].
Recently, we have described the preparation of two 18F-labeled AMCs 
(Figure 1): (R)-2-[(4-(4-[18F]fluorobutoxy)benzylamino)methyl]chroman-
7-ol ([18F]FBu-AMC13, denoted as 12a in Chapter 3) and (R) 1-(4-(2-[18F]
fluoroethoxy)phenyl)-4-(4-(7-hydroxychroman-2-yl)-3-azabutyl)-piper-
azine ([18F]FEt-AMC15, denoted as 12d in Chapter 3). Both compounds, 
when tested in their non-radioactive 19F-form, showed nearly full agonism 
at the long isoform of human D2R and low-nanomolar affinities towards 
the high-affinity state of these receptors: on average 5.6  nM and 6.7  nM 
for FBu-AMC13 and FEt-AMC15, respectively. The affinities of these two 
compounds towards human D2R and D3R were comparable to each other, 
with no detectable preference for any of the two receptor subtypes [24]. Both 
[18F]FBu-AMC13 and [18F]FEt-AMC15 also demonstrated specific binding to 
the D2/3R-high in rat striata. We wanted to further evaluate these radioli-
gands in vivo and optimize their brain penetration and non-specific binding 
by adjusting their lipophilicity. We reasoned that the latter goal could be 
achieved by varying the length of the [18F]fluoroalkyl chain in the structures 
of the tracers, because these chains are situated outside the main pharma-
cophore of the AMCs [24], so shortening or elongating them will likely have 
no influence on the affinity of the resulting ligands towards D2/3R.
This study reports on the synthesis of 18F-labeled AMC13 and AMC15 homo-
logues with varied alkyl chain lengths and on the in vitro and in vivo evalu-
ation of these compounds.
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Figure 1. Structures of the evaluated homologues of AMC13 and AMC15.
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Reagents, chemicals, materials and solvents were obtained from commercial 
sources, and were used as received: Biosolve, Merck for solvents, Cambridge 
Isotope Laboratories for deuterated solvents, and Aldrich, Acros, ABCR, 
Merck and Fluka for chemicals, materials and reagents. All solvents were of 
analytical grade quality.
1H-NMR and 13C-NMR spectra were recorded on Varian MR (300 or 400 MHz 
for 1H-NMR, 100  MHz for 13C-NMR) spectrometers at ambient tempera-
ture. Chemical shifts are reported in ppm, applying deuterated chloroform 
(CDCl3) or other deuterated solvents as internal reference. Abbreviations 
used for splitting patterns are s = singlet, t = triplet, q = quartet, m = multi-
plet, dd = double doublet.
LC/ESI-MS/MS analyses were performed on a Shimadzu LC-20AD series 
LC coupled to an API3000 mass-spectrometer (Applied Biosystems/MDS-
SCIEX, Toronto, Canada), a triple quadrupole mass spectrometer supplied 
with an atmospheric pressure ionization source, and an ion-spray interface. 
Analyses were executed at 298 K using an Alltech Alltima C18 5μ 150×2.1 mm 
column using an injection volume of 10 μL, a flow rate of 0.4 mL/min and 
a gradient of MeCN/propan-2-ol in H2O (from 5% to 95% organic compo-
nent, where both MeCN/propan-2-ol and H2O contain 0.1% formic acid). 
MS/MS analysis was performed in the Multiple Reaction Monitoring mode.
Analytical thin layer chromatography (TLC) was performed on Kieselgel 
F-254 precoated silica plates. Normal phase column chromatography was 
carried out on regular silica gel 60 (0.040–0.063, Merck).
1,2-Ethanediol ditosylate, 1,3-propanediol ditosylate, 1,4-butanediol di-
tosylate, 2-fluoroethyl tosylate, 3-fluoropropyl tosylate and 4-fluorobutyl 
tosylate were prepared according to procedures described in the literature 
[24, 25]. Analytical data (1H-NMR, 13C-NMR) were according to expectations.
The preparation and characterization of phenol precursors for 18F-fluoro-
alkylation, (R) N-[7-(methoxymethoxy)chroman-2-yl]methyl 4-hydroxy-
benzyl amine and (R) 1-(4-hydroxyphenyl)-4-(4-(7-hydroxychroman-2-yl)-
3-azabutyl)-piperazine were described earlier in van Wieringen et al. [24].
19F-references for FBu-AMC13 and FEt-AMC15 were prepared and char-
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acterized as described previously in van Wieringen et al. [24]. Of the new 
homologous ligands, 19F-reference was only prepared for FEt-AMC13, the 
homologue that showed the most promising results in vivo. Given the use of 
the very similar radiolabeling methods for all ligands, and the close struc-
tural relatedness of the new homologues to the originally developed FBu-
AMC13 and FEt-AMC15, we decided not to prepare 19F-references for other 
homologues.
(R)-2-[(4-(4-Fluoroethoxy)benzylamino)methyl]chroman-7-ol (19F-reference of 
FEt-AMC13)
A solution of (R) N-[7-(methoxymethoxy)chroman-2-yl]methyl 
4-hydroxybenzyl amine (28.4 mg, 0.11 mmol) in 1.5 ml dry DMF and 5 mg 
NaH were stirred in an oil bath at 80 °C. To this mixture 2-fluoroethyl tosyl-
ate (22.8 mg, 0.11 mmol) dissolved in 1.2 ml dry DMF was added in three por-
tions of 0.4 ml over the period of 1 hour. The mixture was stirred at 80 °C for 
24 h. After that, the reaction mixture was cooled down and N2 was bubbled 
through the solution to create inert atmosphere. Then 2 ml of 4M HCl solu-
tion in dioxane were added to the mixture, and it was stirred for 5 h at room 
temperature in the atmosphere of N2. N2 was further bubbled through the 
solution to remove volatile reaction products from the mixture. Thereafter 
the reaction mixture was diluted with 50 ml water and the pH was brought 
to 8–8.5 by addition of a Na2CO3-solution. The mixture was extracted by 
CH2Cl2 (3×10 ml), organic extract was washed with water (3×10 ml), dried 
with Na2SO4 and evaporated in vacuo. The residue was purified using silica 
column chromatography (ethyl acetate/methanol/triethylamine 100/5/1). 
Yield: 8.5 mg (24%), as a slightly yellowish solid.
1H NMR (CD3OD/CDCl3): δ = 7.37 (d, 2H), 6.98 (d, 2H), 6.87 (d, 1H), 6.39 
(dd, 1H), 6.21 (d, 1H), 4.83 (t, 1H), 4.71 (t, 1H), 4.29 (t, 1H), 4.22 (t, 1H), 4.12 
(m, 1H), 4.01 (bs 2H), 3.01 (m, 2H), 2.9–2.5 (multiple signals, 2H), 2.05–
1.65 (multiple signals, 2H). 13C NMR (CD3OD/CDCl3): δ = 162.7, 160.0, 158.2, 
134.5, 133.9, 133.0, 118.8, 116.6, 112.5, 107.0, 86.6, 84.8, 76.6, 71.3, 71.1, 
55.6, 55.2, 35.7, 33.4, 29.5, 27.3.
Radiochemistry
[18F]Fluoride was produced in the Scanditronix MC-17F cyclotron (Scan-
ditronix, Uppsala, Sweden) and delivered from the target into the hotcell 
with helium overpressure. Figure 2 gives an overview of the applied radio-
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chemistry.
Synthetic procedures were performed manually. Radiochemical conversions 
and purities were determined by radio-HPLC using beta-sensitive detec-
tors and dose-calibrators (Veenstra Instruments) and by radio-TLC using 
Cyclone phosphor storage screens (multisensitive, Packard) and OptiQuant 
software.
Figure 2. Labelling routes for the homologous series of [18F]AMC13 and 
[18F]AMC15.
Preparation of [18F]fluoroalkyl tosylates
[18F]Fluoride in enriched H2
18O water was adsorbed on an activated an-
ion-exchange column (QMA) and later eluted into the reaction vial with 
1–1.5 ml of 1.5 mg/ml K2CO3, 5 mg/ml Kryptofix solution in 9:1 v/v mixture 
of acetonitrile and water, respectively. After the elution of QMA, acetoni-
trile and water were evaporated at 130 °C under nitrogen flow. For further 
water removal, 1 ml anhydrous acetonitrile was added into the reaction vial 
and evaporated. Then 5  mg of alkyl ditosylate precursor (ethyl, propyl or 
butyl) in 1 ml anhydrous acetonitrile was added into the vial, the vial was 
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sealed and reaction was carried out for 4 min at 130 °C followed by cooling 
for 5 min. 1 ml of water was added to the cooled reaction mixture and the 
resulting mixture was loaded into the HPLC loop. [18F]fluoroalkyl tosylates 
were purified by reverse-phase HPLC using Alltima C18 5μ 250×10 mm col-
umn eluted with acetonitrile/water at 5 ml/min. Acetonitrile content in the 
mobile phase was 65% for [18F]fluorobutyl tosylate and 50% for [18F]fluoro-
propyl and [18F]fluoroethyl tosylate. Under these conditions, retention times 
of all thee [18F]fluoroalkyl tosylates were in the range of 6–8 min. Collected 
radioactive fraction was diluted 2–3 fold with water and 4-[18F]fluoroalkyl 
tosylate was adsorbed on tC18 light Seppak cartridge. The cartridge was 
rinsed with 5 ml pure water and dried for 5 min in strong nitrogen flow.
Preparation of [18F]FEt-AMC13, [18F]FPr-AMC13 and 
[18F]FBu-AMC13
(R) N-[7-(Methoxymethoxy)chroman-2-yl]methyl 4-hydroxybenzyl amine 
(1, 0.6 mg) in 30 µl dry DMF and 2–3 mg NaH were put into a V-vial. There-
after, the corresponding [18F]fluoroalkyltosylate was eluted into the vial 
from the tC18 light Seppak cartridge with 0.6–0.7 ml dry DMF. The reaction 
vial was sealed and the alkylation reaction to acquire compounds 3 were 
conducted for 10  min at 120  °C. Then 1  ml 0.4N HCl was added into the 
vial with a syringe and deprotection of the MOM-group followed that also 
lasted 10 min at 120 °C. The product was purified by reverse-phase HPLC 
using Alltima C18 5μ 250×10 mm column eluted with acetonitrile/10 mM 
H3PO4 at 5 ml/min. Acetonitrile content in the mobile phase was 30% for 
[18F]FEt-AMC13 and 35% for [18F]FPr-AMC13 and [18F]FBu-AMC13. Reten-
tion times were 10.6 min for [18F]FEt-AMC13, 9.2 min for [18F]FPr-AMC13 
and 10.8 min for [18F]FBu-AMC13. Collected HPLC fraction was diluted with 
2–3 volumes of water and the radioactivity was adsorbed on Oasis HLB SPE 
cartridge. The cartridge was rinsed with 5 ml pure water and radioactivity 
was then eluted with 1–2 ml absolute ethanol. Typical recovery was 20–40% 
for pure ethanol and 80–90% for 100/1 v/v mixture of ethanol with acetic or 
ortho-phosphoric acid; in synthesis runs for in vivo experiments only pure 
ethanol was used. After partial or complete evaporation of ethanol in nitro-
gen flow (with or without application of vacuum) the tracer was formulated 
in physiological saline (ethanol content in the formulated tracer was kept 
below 10%).
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Preparation of [18F]FEt-AMC15, [18F]FPr-AMC15 and 
[18F]FBu-AMC15
The procedure described above for [18F]AMC13 homologues was also used 
for the preparation of [18F]AMC15 homologues, with the following modifica-
tions:
Instead of (R) N-[7-(methoxymethoxy)chroman-2-yl]methyl 4-hydroxy-
benzyl amine (1), (R) 1-(4-hydroxyphenyl)-4-(4-(7-hydroxychroman-2-yl)-
3-azabutyl)-piperazine (2) was used as the precursor. MOM-protected mol-
ecules 4 were the intermediates for the [18F]AMC15 homologues (Figure 2). 
At the end of the deprotection step the reaction mixture was diluted with 
10 ml water, titrated with 1 M NaOH to pH of 4–7 and then put through 
the Oasis HLB SPE cartridge. Adsorbed radioactivity was then eluted from 
the cartridge with 1 ml acetonitrile/DMF mixture (1/1 v/v). Eluate was fur-
ther diluted with water to a total volume of 1.5–2 ml and the crude prod-
uct was purified by HPLC using Alltima C18 5μ 250×10  mm column. For 
[18F]FEt-AMC15 purification the column was eluted with a gradient of ace-
tonitrile in 10  mM acetate buffer with pH  4.0 at 5  ml/min (45% acetoni-
trile during the first 2  min, then a linear decrease from 45% at 2  min to 
30% acetonitrile at 15 min). Retention time of [18F]FEt-AMC15 was 8.4 min. 
[18F]FPr-AMC15 and [18F]FBu-AMC15 purification the column was eluted 
with 25% acetonitrile in 10  mM H3PO4at 5  ml/min. Retention times were 
9.2 min for [18F]FPr-AMC15 and 11.0 min for [18F]FBu-AMC15.
Non-carrier-added [18F]FEt-AMC15 was found to decompose on the silica 
plate, so before TLC runs with [18F]FEt-AMC15 and its longer-chain homo-
logues (including the analysis of plasma and tissue extracts), the start posi-
tions of the lanes on the TLC plate were pre-treated with AMC15 oxalate 
standard aqueous solution (2 μg in 2 µl) to hamper the on-plate decomposi-
tion.
Characterization and identity confirmation of tracers
All tracers were characterized by analytical radio-HPLC and radio-TLC. 
Conditions and results of the characterization are presented in Table S1 (for 
tables and figures with the letter S see Appendix).
The presence of the corresponding “carrier” (i.e. tracer molecules that con-
tain a 19F-atom) in the formulated tracer solutions was confirmed by high 
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performance liquid chromatography – electron spray tandem mass-spec-
trometry (LC-ESI-MS/MS) analysis with the monitoring of fragmentation re-
actions of the tracer molecules. For all radioligands, ion current peaks with 
expected M/z ratios giving expected fragmentation products were observed 
(Table S2). Identity of [18F]FEt-AMC13, [18F]FBu-AMC15 and [18F]FEt-AMC15 
was also confirmed by co-elution with reference products.
LogD measurement
LogD of the tracers was measured using the radioactivity remaining on the 
HLB SPE cartridges after their elution with ethanol during the tracer for-
mulation procedure (see above). The cartridge was dried with nitrogen for 
5 min and eluted with at least 1.5 ml n-octanol. 500 μl of octanol eluate was 
mixed with 500 μl of 1 M phosphate buffer (pH 7.4) and vigorously vortexed 
for 5  min. The mixture was then centrifuged at 17 000  g for 10  min and 
3×100 μl aliquots of organic and aqueous phase were loaded into a gamma-
counter for radioactivity measurement. To correct for possible presence of 
radioactive impurities in the tracer, aliquots of organic and aqueous phases 
were later analyzed by radio-TLC and the counts obtained from the gamma-
counter were corrected according to the percentage of impurities found in 
aqueous and organic phases. LogD was calculated with the formula:
where CPMorg is the mean radioactivity of the organic aliquots,  is the 
mean percentage of radioactivity accounting for intact tracer in organic ali-
quots (as determined from radio-TLC) and CPMorg and  are the corre-
sponding values for the aqueous phase.
For each tracer batch used for logD determination, the experiment was per-
formed in duplicate. LogD values are means calculated from at least two 
independent experiments.
In vitro autoradiography
In vitro autoradiography assay was performed as previously described [24]. 
Frozen brains of young (10–12 weeks of age; 300–350 g body-weight) male 
Sprague-Dawley rats (Harlan, Netherlands) were cut at −12  °C into sagit-
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tal slices 20 μm thick using a Leica microtome, and the slices were thaw-
mounted on Superfrost (70×22  mm, Fischer) adhesive slides. Only slices 
containing both striatal and cerebellar regions were used. The slides with 
slices mounted them were allowed to dry, then put into storage boxes with 
silicagel bags and stored at −80 °C.
On the day of the experiment (within one week from the preparation of the 
slices) the slides were taken out of storage and allowed to come to room 
temperature for 5–10 minutes. Then 1–1.2 ml of incubation buffer (50 mM 
Tris-HCl, 5 mM KCl, 2 mM CaCl2, 2 mM MgCl2, 120 mM NaCl, pH 7.4 25 °C) 
was applied per slide and the slides were pre-incubated for 15 minutes 
at room temperature. The buffer was then removed and the slides were 
placed into staining jars containing radioligand solution (concentration 
range of 0.1–10 nM) in the incubation buffer with or without 10 μM raclo-
pride (D2/3 antagonist) or 100  μM guanosine-5’-triphosphate sodium salt 
(GTP, stimulator of G-protein uncoupling from the receptors). After 35 min-
utes of incubation at 37 °C, slides were washed once with ice-cold incuba-
tion buffer (3.5 min) and dipped for 30 sec into ice-cold distilled water to 
remove buffer salts.
After drying the slides in a stream of room-temperature air, they were ex-
posed on phosphor storage screens for 6–10 hours. The storage screens 
were read by Cyclone Storage Phosphor System (Packard Instruments Co). 
Quantification of plate readings was done with Optiquant software (version 
3.00, Packard Instruments Co).
MicroPET study in rats
Three radioligands were evaluated in vivo: the originally developed 
[18F]FBu-AMC13 and [18F]FEt-AMC15, and [18F]FEt-AMC13, the homologue 
that showed the best results in the in vitro autoradiography experiments 
(see Results section).
Animal experiments were performed by licensed investigators in compli-
ance with the Law on Animal Experiments of The Netherlands. The protocol 
was approved by the Committee on Animal Ethics of the University of Gron-
ingen. Young male (10–12 weeks of age, 300–350 g body weight) Sprague-
Dawley rats (Harlan, the Netherlands) were used for all experiments. The 
rats were maintained at a 12-h light/12-h dark regime and were fed standard 
laboratory chow ad libitum.
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Distribution of the radiotracers was studied in rats pre-treated, at random, 
with physiological saline (controls) or raclopride tartrate (1  mg/kg calcu-
lated per raclopride base, equivalent to 2.9 μmol/kg). Saline and raclopride 
were administered intravenously (1 ml/kg injected volume).
An additional group of saline pre-treated rats, injected with [11C]raclopride, 
served as positive controls for D2/3R specific brain uptake.
Two rats were scanned simultaneously. Before all manipulations, animals 
were anesthetized with a mixture of isoflurane/air (inhalation anesthesia, 
5% ratio during induction, 2% at maintenance). Cannulae were placed into 
the rats’ left femoral arteries and veins; the operation took 45–50  min. 
The rats were positioned supine inside the camera (Focus 220 microPET, 
Siemens-Concorde), one above the other with their heads in the camera’s 
field of view. A 515 sec transmission scan with a Co-57 point source was 
performed. Tracer was injected through the venous cannula as a slow bolus 
(1 ml volume, 60-second long) using an infusion pump. The second (upper) 
animal was injected 16 min after the first (lower). Injected radioactivities 
and doses are given in Table 1.















[18F]FEt-AMC13 9.4±1.2 0.55±0.14 4/4 47±27
[18F]FBu-AMC13 20.8±10.6 0.45±0.26, 
10.4, 11.0a
3/3 52±19
[18F]FEt-AMC15 26.6±15.2 1.06±0.65 3/3 48±10
[11C]raclopride 16.9±5.3 1.26±0.16 4 (saline only) 36±3
a One rat in the saline-treated group and one rat in the raclopride-treated group were injected 
with respectively 10.4 and 11.0 nmol/kg tracer. As all outcome measures (time-activity curves, 
uptake ratios) obtained from these animals were very close to the results from other animals 
in the corresponding groups, these results were not omitted or separated, but combined with 
the rest of the data.
PET acquisition was started during the injection of radioactivity in the first 
rat. A 106 minute-long (76 minute-long in case of [11C]raclopride) list-mode 
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acquisition protocol was used for the scan.
Throughout the scan, arterial blood samples (15–19 samples; 0.10–0.15 mL 
each) were withdrawn from each rat through the arterial cannula. Time in-
tervals between samples gradually increased from 5–10 sec right after in-
jection to 30 min at the end of the scan.25 μl aliquots of whole blood were 
withdrawn from each sample. The rest was centrifuged at 3500 g for 5 min, 
25 μl supernatant (plasma) aliquots were withdrawn and deproteinated with 
75  μl of ice-cold acetonitrile. From the resulting 100  μl, 2–8  μl portions 
(i.e. 2–8% of volume) were taken for thin layer chromatography analysis 
(radio-TLC), to assess radiometabolite content.
The radioactivity of the plasma and whole blood samples was measured us-
ing a well-type gamma-counter (LKB-1282-Compugamma, LKB Wallac).
Radio-TLC was performed on silica plates. Samples of the formulated trac-
ers (diluted) were run along with deproteinated plasma samples to confirm 
the identity of the parent compound in plasma. Eluent systems used and 
TLC Rf-values recorded are presented in Table S1.
After the end of the PET scans (i.e. 98±8 min after tracer injection) anesthe-
tized animals were sacrificed by heart extirpation and dissected. Samples of 
brain and peripheral tissues were taken. All samples were weighed and their 
radioactivity was measured in a gamma-counter.
MicroPET image reconstruction and data analysis
List-mode data from the 106-minute-long and 76-minute-long scans were 
reframed into, respectively, 90-minute-long and 60-minute-long dynamic 
sequences of 6×10, 4×30, 2×60, 1×120, 1×180, 4×300, 3×600 and (for 90-min-
ute-long scans) 2×900  sec frames. The data were reconstructed per time 
frame using an iterative reconstruction algorithm (attenuation-weighted 
2-dimensional ordered-subset expectation maximization, provided by Sie-
mens; 4 iterations, 16 subsets; zoom factor 2). Datasets were fully corrected 
for random coincidences, scatter, and attenuation. Data from the transmis-
sion scan were used for attenuation correction. The final datasets consisted 
of 95 slices, with a slice thickness of 0.8 mm and an in-plane image matrix 
size of 128×128 and pixel size of 0.47×0.47 mm.
Reconstructed images were analyzed with Inveon 2.0 software (Siemens 
Medical Solutions, USA, Inc). Regions of interest (ROIs) were drawn manu-
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ally on a T2-weighted MRI template of rat brain around the striatum, brain-
stem, cortex, hippocampus, hypothalamus, thalamus, olfactory bulbs and 
cerebellum, around the whole brain and around the pituitary gland. The MRI 
template was co-registered with the PET scan by image fusion. The time-ac-
tivity curves (TAC) per ROI were determined in Bq/cm3 units and converted 
into standardized uptake values (SUVs).
Kinetic analysis is described using the nomenclature proposed by Innis et al 
[26]. ROI TACs of [18F]FEt-AMC13 were analyzed with one-tissue and two-
tissue compartmental models of reversible binding (1TCM and 2TCM, re-
spectively) to obtain individual rate constants. From these, the regional dis-
tribution volumes (VT) were calculated and compared to those obtained with 
Logan graphical analysis. Binding potentials (BPND) were calculated from the 
distribution ratios as VT (target) / VT (cerebellum) – 1, or estimated with the 
simplified reference tissue model (SRTM) using the cerebellum as reference 
region.
Metabolite-corrected plasma-derived arterial input function and whole 
blood time-activity curve were used for Logan, 1TCM and 2TCM analyses. 
Fractional cerebral blood volume was set to 3.6% [27]. For one rat in the 
raclopride-treated group no input curves could be obtained, therefore its 
PET data were only analyzed with SRTM.
Ex vivo autoradiography study in rats
To further assess the specific binding of [18F]FEt-AMC13 to the striatal 
D2/3R, two groups of rats were anesthetized, pre-treated with saline (n=3) or 
raclopride (n=3) and 26±3 min later injected with a bolus of [18F]FEt-AMC13 
(4.2±1.4 MBq, 0.14±0.04 nmol/kg) into the penile vein. 35 min later rats were 
sacrificed by heart extirpation. Brains were quickly extracted and separated 
into two halves along the sagittal symmetry plane or along the coronal plane 
spanning the thalamus.
One half of the brain (rostral or randomly taken left/right) was quickly fro-
zen over liquid nitrogen and prepared for cutting on the microtome in the 
same manner as brains used for in vitro autoradiography [24]. 40 µm thick 
slices were cut, mounted on Superfrost glass slides, permitted to dry and 
then directly applied to the phosphor storage screens.
Another half of the brain was homogenized in 3  ml ice-cold acetonitrile 
using Heidolph IDAX600 homogenizer at maximum speed. Homogenate 
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was centrifuged at 3500 g for 5 min and the supernatant (containing >95% 
total radioactivity) was analyzed by radio-TLC in the same way as described 
above for the plasma.
D2/3R-specific binding quantification
Degree of D2/3R-specific binding of the tracers was characterized by BPND 
(as given above) or the specific binding ratio (SBR) given as:
target region radioactivity / cerebellar radioactivity - 1.
Both were calculated under control conditions and in response to the raclo-
pride challenge.
Statistics
All data are presented as means ± standard deviations. Comparison of means 
was done using 2-sided unpaired Welch t-test. P-values below 0.05 were 




The labeling scheme used for the preparation of the tracers is given in Fig-
ure 2. Radiochemical yields and purities, molar radioactivities and logD val-
ues of the prepared tracers are listed in Table 2. Radio-HPLC and radio-TLC 
characterization data of the prepared tracers can be found in Table S1. LC-
ESI-MS/MS characterization data of the 19F-compounds (remaining carrier) 
in the decayed samples of purified tracers are described in Table S2.
For both [18F]AMC13 and [18F]AMC15 homologues, reverse-phase radio 
HPLC retention times, normal-phase TLC retention factors and logD values 
increased with the length of the [18F]fluoroalkyl chain.















[18F]FEt-AMC13 12±6 >95 102±30 1.67±0.07
[18F]FPr-AMC13 7±6 >95 29±27 1.98±0.08
[18F]FBu-AMC13 8±7 93±2 85±83 2.50±0.06
[18F]FEt-AMC15 5±3 93±2 25±15 1.48±0.002
[18F]FPr-AMC15 3±1 93±5 9±7 2.39±0.001
[18F]FBu-AMC15 6±0.3 93±6 10±3 2.71±0.07
Radiochemical yields and purities refer to isolated products. Values are means±SD of ≥3 deter-
minations from ≥2 independent experiments.
In vitro autoradiography
All [18F]fluoroethyl and [18F]fluoropropyl compounds showed preferential 
uptake in the D2/3R-rich striatum (Figure 3). [
18F]FEt-AMC13 had the high-
est striatal SBR, followed by [18F]FPr-AMC13 and [18F]FEt-AMC15 (Table 3). 
[18F]FBu-AMC13 only showed discernible specific binding at the lowest con-
centration tested.
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In the presence of 10 μM of raclopride SBR values of all AMC13 homologues 
decreased by 79–88%, and those of all AMC15 homologues by 60–64% com-
pared to control conditions. GTP decreased the SBR values to the same ex-
tent, implying that the striatal binding of all tracers was predominantly to 
the high-affinity subset of the D2/3Rs (Table 3).
In vivo and ex vivo brain uptake of the tracers under 
control conditions
[18F]FEt-AMC13 and [18F]FBu-AMC13 showed good blood-brain barrier (BBB) 
penetration (Figure 4). Brain uptake peaked at 0.7% injected dose (ID) and 
0.9% ID, respectively, 3 min after radiotracer injection.
For both tracers the brain region with the lowest uptake was the cerebel-
lum. [18F]FBu-AMC13 had the highest uptake in the brainstem, followed 
by the striatum; striatum-to-cerebellum uptake ratio peaked at 1.41±0.08 
(Figure S1). [18F]FEt-AMC13 and [11C]raclopride had the highest uptake in the 
striatum (Figure 5). Striatum-to-cerebellum uptake ratio of [18F]FEt-AMC13 
peaked 45 min post-injection at 2.08±0.25 (Figure 5b); the same ratio mea-
sured by ex vivo autoradiography was 2.81±0.29 (35 min post-injection). The 
striatum-to-cerebellum ratio of [11C]raclopride was 7.45±1.60 (45 min post-
injection; Figure 5d).
[18F]FEt-AMC15 essentially did not penetrate the BBB. Its in vivo brain up-
take peaked at 0.2% ID, 3 min post-injection and fell to 0.04% ID 60 min 
post-injection.
Ex vivo measurements of the uptake of the tracers in the brain and periph-
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Figure 3. Representative in vitro autoradiography images of rat brain slices for 
the assayed radioligands.
Left column – slides incubated with radioligand only. Middle column – radioligand and 10 μM 
raclopride. Right column – radioligand and 100 μM GTP.
Figure 4. Representative PET images for three [18F]fluoroalkyl-AMC radioli-
gands and [11C]raclopride acquired in rats.
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Figure 5. Uptake of [18F]FEt-AMC13 (a, b) and [11C]raclopride (c, d) in rat brain.
a, c – region-of-interest time-activity curves of control rats. b, d – Striatum-to-cerebellum 
ratios in rats pre-treated with saline (SAL) and 1 mg/kg (2.9 μmol/kg) raclopride (RAC). Points 
represent group means, error bars show standard deviations.
Tracer metabolism
[18F]FEt-AMC13 and [18F]FBu-AMC13 were quickly metabolized in the plas-
ma, while [18F]FEt-AMC15 was more stable (Figure 6). Tracers were elimi-
nated from the plasma with half-lives of 3 to 12 min. Radiometabolites of all 
tracers in the plasma and in the brain tissue extract were considerably more 
hydrophilic than their corresponding parent compounds, as they all had 
TLC Rf values of 0, compared to Rf of 0.16–0.56 for the tracers themselves 
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(Table S1). Intact [18F]FEt-AMC13 constituted 92% of radioactivity from 
brain tissue extract 35 min post-injection (Figure S2).
Uptake in the parietal bone was lower than in the brain tissue for all 
[18F]AMC13 homologues (Table 4), suggesting low levels of in vivo defluori-
nation.
Figure 6. Metabolism and pharmacokinetics of [18F]FEt-AMC13, [18F]FBu-AMC13 
and [18F]FEt-AMC15 in the plasma of living rats.
a – percentage of intact tracer in the total plasma radioactivity. b – concentration of intact 
tracer in the plasma (i.e. metabolite-corrected plasma input curves). Points represent group 
means, error bars show standard deviations. Horizontal axes show time after tracer injection.
Kinetic modeling for [18F]FEt-AMC13
2TCM and SRTM fits of ROI TACs were consistently better than 1TCM fits 
(Figure S3) as assessed by Akaike’s information criterion, but the estimates 
of individual rate constants of 2TCM were highly variable and often physi-
ologically implausible (Table S4).
The most robust ROI VT estimates were obtained from the Logan analysis 
(Table S5). Logan VT values correlated better with 2TCM VT (r = 0.97) than 
with 1TCM VT values (r = 0.89; Figure S4). No robust BPND estimates could 
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be obtained from the k3/k4 rate constant ratio of 2TCM (data not shown), 
but BPND estimates calculated from 1TCM, 2TCM and Logan VT data and ob-
tained by SRTM correlated well with each other for all regions except the 
pituitary and olfactory bulbs (Figure S5).
The highest BPND values in control rats were found in the striatum (1TCM: 
0.63±0.08; 2TCM: 0.56±0.05, Logan: 0.52±0.01; SRTM: 0.51±0.02).
Blocking experiments
Pre-treatment with 1 mg/kg (2.9 μmol/kg) raclopride decreased peak PET-
based striatal SBR of [18F]FEt-AMC13 by 17% (from 1.08±0.25 to 0.90±0.11), 
though the SBR change was not statistically significant (p=0.25). Striatal SBR 
based on after-scan biodistribution measurements decreased by 31% (from 
1.07±0.10 to 0.74±0.27), but was also not statistically significant (p=0.17). 
Ex vivo autoradiography-based SBR fell by 39% (from 1.81±0.29 to 1.06±0.17), 
which was statistically significant (p<0.01), and the blocking of D2/3R specific 
striatal binding was clearly visible on the autoradiography images (Figure 
S6).
Striatal BPND fell by 18–27% (p<0.05 for 2TCM, Logan and SRTM; see Table 
5 and Table S6) depending on the kinetic model used. Modified Lassen plot 
analysis [28] estimated the raclopride-induced D2/3R occupancy at 20–25% 
(p<0.05 for 1TCM and 2TCM), while 41–55% of striatal VT and 11–26% of 
cerebellar VT were estimated to be potentially displaceable, i.e. represent 
D2/3R specific binding (Figure S7).
For [18F]FBu-AMC13 pre-treatment with raclopride decreased absolute up-
take in all brain regions, and striatum-to-cerebellum uptake ratios were 
higher in raclopride-treated group than in the saline-treated group (Figure 
S1c).
For [18F]FEt-AMC15, pre-treatment with raclopride caused no detectable al-
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DISCUSS ION
We have previously described the design, synthesis and in vitro evaluation 
of a series of high-affinity D2/3 agonists based on the AMC scaffold. Two 
compounds from that series, FBu-AMC13 and FEt-AMC15, were confirmed 
to have high-affinity towards D2/3R and act as agonists at D2R [24]. They were 
18F-labeled and showed favorable results in the in vitro autoradiography ex-
periments. In this study we have evaluated these compounds in vivo and 
further optimized their characteristics by shortening or lengthening the 
[18F]fluoroalkyl chains in their structures. We did not directly measure the 
affinities and intrinsic activities of the shorter-chain homologues of FBu-
AMC13 and longer-chain homologues of FEt-AMC15 towards D2/3R, assum-
ing that changing the fluoroalkyl chain would have negligible influence on 
these parameters, because this fluoroalkyl chain is situated outside the main 
AMC pharmacophore [24].
Both raclopride and GTP decreased striatal SBRs of all tracers significantly 
and to a similar extent, which was consistent across the homologous se-
ries (Table 3). This indicates that all our tracers specifically bind to striatal 
dopamine D2/3 receptors in their G-protein-coupled “high-affinity state”. 
Tracers with a shorter alkyl chain showed higher in vitro autoradiography-
based striatal SBR values (Et>Pr>Bu). These findings are in agreement with 
our hypothesis that varying the [18F]fluoroalkyl chain length would influence 
non-specific binding, but not the D2/3R-affinity or agonism of the tracers.
In vivo, [18F]FEt-AMC15 showed very low levels of BBB penetration, which 
may be the consequence of the tracer’s low lipophilicity and/or may imply 
that it is a substrate for one of the drug efflux pump proteins such as P-
glycoprotein. Meanwhile, [18F]FEt-AMC13, which is the short-alkyl-chain 
homologue of [18F]FBu-AMC13, showed greatly improved specific-to-non-
specific binding ratios compared to the “original” radioligand, while retain-
ing good brain penetration and favorable metabolic profile.
Our approach has proven to be a useful and relatively simple tactic for the 
adjustment of the radioligands’ lipophilicity with the goal of optimizing 
their non-specific binding and brain penetration.
The time-activity curves of [18F]FEt-AMC13 were better approximated with 
the 2TCM model than with 1TCM model, and 2TCM-derived VT and BPND 
estimates correlated better than 1TCM-derived VT and BPND estimates with 
the same data obtained from Logan analysis that makes no assumptions 
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regarding the number of kinetic compartments. However, the 2TCM model 
did not always provide reliable estimates of the individual rate constants of 
[18F]FEt-AMC13 uptake in the brain. This may have been caused by the qual-
ity of input data: insufficient counts or imprecise estimates of the plasma 
input can make the optimization routine converge at a local minimum. For-
tunately, the estimates of VT and BPND were more robust and consistent, so 
these were used for the evaluation of [18F]FEt-AMC13.
Estimation of the magnitude of the D2/3R blockade induced by 1  mg/kg 
(2.9 μmol/kg) raclopride in rats’ striata in vivo performed with the use of dif-
ferent approaches produced consistent results: changes in striatal BPND and 
(PET and autoradiography-derived) SBR were similar to the modified Las-
sen plot-based estimate of D2/3R occupancy by raclopride. Depending on the 
estimate, raclopride pre-treatment blocked 17–39% of D2/3R-specific signal 
in the striatum. Though a bolus dose injected in an in vivo experiment can’t 
be directly compared with ligand concentration applied in an in vitro ex-
periment, our in vivo findings are also arguably consistent with our in vitro 
findings, where a higher concentration of raclopride (10 μmol/L) used in the 
in vitro autoradiography study induced a greater decrease (81%) in striatal 
SBR in rat brain slices compared to control conditions.
Our in vivo findings, however, do not agree with the published stud-
ies which reported >90% displacement of apparent D2/3R-specific stria-
tal uptake of [11C]MNPA and [11C]PHNO in Sprague-Dawley rats with 
1–2 mg/kg (2.9–5.8 μmol/kg) raclopride [29–31]. Even a 5-fold lower dose 
(0.2  mg/kg, 0.58  μmol/kg) displaced over 80% of apparent D2/3R-specific 
[11C](+)PHNO uptake [30]. It is not clear why the apparent displacement 
of [18F]FEt-AMC13 from the striatum by 1  mg/kg raclopride is lower than 
what is reported for other D2/3R tracers in the literature. It’s unlikely that 
we violated the so-called “tracer conditions”, because crude estimation of 
the D2/3R occupancy by [
18F]FEt-AMC13 itself using the approach described 
by Skinbjerg et al. [32] produced the values of no more than 3% in all our 
experiments. It may be that the signal-to-noise ratio in our data was insuf-
ficient, which made it difficult to precisely estimate the contribution of spe-
cific binding to total tracer binding in various ROIs. The presence of specific 
binding of [18F]FEt-AMC13 to sites other than D2/3R, which have compara-
tively high density in the striatum, may also be implied. We have previously 
demonstrated that FBu-AMC13, a longer-chain homologue of FEt-AMC13, 
has low affinity towards D1 receptors (7  μM on average) [24], while 
(R)-2-[(benzylamino)methyl]chroman-7-ol and 2-[(4-hydroxybenzylamino)-
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methyl]chroman-7-ol, compounds structurally closely related to FEt-
AMC13, were shown by Mewshaw and co-workers to be selective for 
D2/3R against serotonin-1A and adrenergic α1 receptors [23]. In the in vi-
tro autoradiography study, presence of 10  μmol/L raclopride decreased 
striatal SBR of [18F]FEt-AMC13 by 81%, which also does not support the 
hypothesis of the existence of significant non-D2/3R-specific binding of 
[18F]FEt-AMC13 in the striatum. Still, a separate study of pharmacological se-
lectivity of FEt-AMC13, including direct determination of the affinities of FEt-
AMC13 towards high- and low-affinity states of D2/3R, is necessary to clarify 
this issue.
Apart from striatum, olfactory bulbs and pituitary gland are known to con-
tain high densities of D2/3R available to agonist radioligands [33]. However, 
no blocking effect of raclopride could be observed in these regions (Table 4, 
Table 5), and the relatively high tracer uptake in the pituitary is more likely 
to be explained by the pituitary being situated outside the BBB than by the 
presence of D2/3R-specific binding of [
18F]FEt-AMC13 there.
Striatum-to-cerebellum ratio of 2.08 is on par with the value of 2 reported 
in rats for [18F]5-OH-FPPAT [20] and with the value of 1.97 obtained for our 
other separately evaluated AMC derivative [18F]AMC20 [34]. However, the 
striatal BPND values of 0.51–0.63 obtained for [
18F]FEt-AMC13 are lower than 
the values of at least 0.8–1.0 reported in rodents for existing 11C-labeled 
D2/3 agonists [19,29,31]. Non-specific binding of the tracer in the tissue can 
slow down the association rate of the tracer-receptor binding by leaving less 
free tracer in the tissue. The launch of the canonical signaling cascade in-
duced by agonist binding eventually leads to the uncoupling of the G-pro-
tein from the receptor and the relaxation of the receptor into its low-affinity 
state [18, 35], which may increase the effective dissociation rate of an ago-
nist tracer from the receptors. To find out which factors limit the signal-to-
noise ratio of [18F]FEt-AMC13, a more thorough study of its binding kinetics 
in a more controlled environment (e.g. in vitro) is necessary.
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CONCLUS IONS
We have evaluated two homologous series of agonist radiopharmaceuticals 
based on the AMC scaffold that bind with high affinity and selectivity to 
D2/3R in vitro. Varying the length of the [
18F]fluoroalkyl group allowed us 
to significantly improve the specific-to-non-specific binding ratio of one of 
our original structures. The resulting ligand, [18F]FEt-AMC13, demonstrated 
specific binding to the striatal D2/3R in vitro as well as in vivo. In vitro find-
ings also confirmed the tracer’s binding to the high-affinity state of D2/3R. 
Further investigation of the binding characteristics of FEt-AMC13 and op-
timization of its molecular structure can lead to an improved 18F-labeled 
radioligand suitable for clinical D2/3R imaging by PET.
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Figure S4. Correlation of region-of-interest total distribution volumes (VT) 
of [18F]FEt-AMC13 obtained by Logan analysis with VT values obtained by anal-
yses with 1TCM and 2TCM models.
Linear regression lines along with their equations and r and p values and the unity line (x=y) 
are shown on the graphs.
Points represent fits for individual regions in individual animals (both control and raclopride-
pre-treated). Data for striatum, hippocampus, thalamus, hypothalamus, cortex, brainstem, 
cerebellum, olfactory bulbs and pituitary are used.
252 Chapter 5
253
Synthesis and evaluation in rats of homologous series of 18F-labelled dopamine D2/3 receptor 










































































































































































































































































































































































































































































































































Figure S6. Ex vivo autoradiography images of [18F]FEt-AMC13 from control (left) 
and raclopride-treated (right) rats.
Representative sagittal and coronal slices (top) and a profile section through the coronal slices 
showing absolute exposure values (bottom).
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(continued on the next page)
Table S1. Radio-HPLC and radio-TLC characterization data for [18F]AMC13 and 
[18F]AMC15 homologues.
Compound QC1 k’ QC2 k’ TLC Rf
[18F]FEt-AMC13 12.3a 2.1c 0.40e
[18F]FPr-AMC13 12.9a 4.0c 0.46e
[18F]FBu-AMC13 12.9a 5.9c 0.56e
[18F]FEt-AMC15 9.1b 7.1d 0.16f
[18F]FPr-AMC15 9.8b 9.5d 0.22f
[18F]FBu-AMC15 12.2b 12.3d 0.50f
a Platinum C18 EPS 100A 5 μm, 250×5 mm; acetonitrile/water/formic acid 55/45/0.1; 
2 ml/min.
b Platinum C18 EPS 100A 5 μm, 250×5 mm; acetonitrile/10 mM NaH2PO4 pH7.0 70/30; 
2 ml/min.
c Gracesmart5 μm, 250×5 mm;acetonitrile/10 mM H3PO4 25/75, 2 ml/min.
d Gracesmart5 μm, 250×5 mm;acetonitrile/10 mM NaH2PO4 pH7.0 40/60, 2 ml/min.
e ethylacetate/methanol/triethylamine 100/5/1, silica plates.
f ethylacetate/methanol/ammonia/triethylamine 100/5/5/1, silica plates.
Table S2. MS/MS transitions and LC retention times of [18F]AMC13 and 
[18F]AMC15 homologues.
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Table S2 (continuation). MS/MS transitions and LC retention times of 
[18F]AMC13 and [18F]AMC15 homologues.
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Background: Microchannel microfluidic platforms are popular tools for the 
development of radiosynthetic approaches, offering rapid testing of reac-
tion conditions and dose-on-demand production. However, radioactivity 
losses during [18F]fluoride drying by azeotropic distillation have a particu-
larly adverse impact on isolated product yields in microfluidic syntheses. 
Here, we report the development of an azeotropic distillation-free method 
of .[18F]fluoride drying and its use in automated syntheses of 18F-labeled 
building blocks for candidate positron emission tomography (PET) tracers.
Methods: Azeotropic distillation-free drying of [18F]fluoride (“flushing-elu-
tion” procedure) was achieved by flushing the [18F]fluoride-loaded anion-
exchange column with dry acetonitrile or dimethyl sulfoxide (DMSO) and 
then eluting the [18F]fluoride with tetraethyl ammonium bicarbonate (TEAB) 
solutions in acetonitrile/tert-butanol or DMSO/tert-butanol mixtures. [18F]
Fluoride dried in this fashion was used to prepare w-[18F]fluoroalkyl tosyl-
ates from ditosylate precursors in acetonitrile and 4-[18F]fluorobenzaldehyde 
from trimethylammonium precursor in DMSO on the microfluidic module 
Advion Nanotek LF, in reaction optimization and batch production modes.
Results: [18F]Fluoride drying by flushing-elution took 5 min, while drying by 
azeotropic distillation took 15 min on average. At reaction temperatures of 
150 °C and higher, [18F]fluoride dried by flushing-elution could be converted 
into w-[18F]fluoroalkyl tosylates and 4-[18F]fluorobenzaldehyde with yields 
as high as observed with [18F]fluoride conventionally dried by azeotropic dis-
tillation. Batch synthesis protocols with optimized labeling conditions us-
ing azeotropically dried [18F]fluoride produced 2-[18F]fluoroethyl tosylate in 
78±16% non-isolated and 28±11% isolated yield. Protocols using the flush-
ing-elution procedure produced 2-[18F]fluoroethyl tosylate in 85±5% non-
isolated and 53±9% isolated yield. 4-[18F]fluorobenzaldehyde was obtained 
in 77±13% non-isolated and 14±6% isolated yield with azeotropic distilla-
tion and in 73±14% non-isolated and 37±7% isolated yield without.
Conclusion: [18F]Fluoride dried by flushing-elution procedure was success-
fully used to label both aliphatic and activated aromatic substrates; optimal 
18F-fluorination yields were similar to those obtained with conventionally 
dried [18F]fluoride. In automated batch syntheses of 18F-labeled building 
blocks, replacement of azeotropic distillation by flushing-elution cut total 
synthesis time and improved isolated yields by decreasing losses of [18F]fluo-
ride radioactivity during the drying step.
273
Automated preparation of 18F-synthons on a microfluidic synthesis module 
with and without the use of azeotropic distillation for [18F]fluoride drying
6
INTRODUCTION
The use of microfluidic radiochemistry for positron emission tomography 
(PET) tracer production has attracted significant interest in the recent de-
cade. Microfluidic synthesis systems provide flexibility in the choice of re-
action conditions (e.g. permit to use solvents at temperatures above their 
“normal” boiling points) and decrease time and reagent expenses connected 
with the optimization of labeling conditions [1,2]. Two major categories of 
microfluidic reactors are “microvessel” and “microchannel” types [2]. The 
former are scaled-down versions of conventional batch reactors, while in 
the latter the labeling takes place in a microscopic channel, through which 
the reaction mixture is pumped.
Microchannel synthesis systems are a popular platform for the development 
of microfluidic synthetic approaches. For example, the commercially avail-
able Advion Nanotek LF synthesis system has been used for proof-of-con-
cept radiolabeling studies [3–7] as well as for the production of PET tracers 
for pre-clinical [8] as well as clinical imaging [9,10]. Nevertheless, the value 
of the microchannel modules like Nanotek for radiopharmaceutical synthe-
sis on a clinical scale is not yet fully assessed. The use of Nanotek to op-
timize labeling conditions for automated batch syntheses on conventional 
modules is limited by the peculiarities of microchannel microfluidic labeling 
[11], although the correspondence between conventional and microfluidic 
conditions may be more straightforward for simple substrates [12]. Alter-
natively, multi-dose batch syntheses can be performed on the microfluidic 
module itself: greater reaction speed and wider applicable temperature range 
may provide greater possibilities, compared to the conventional setup, to 
enhance the yield of target product over byproducts. However, the major-
ity of published studies that involved radiolabeling on Nanotek focused on 
small-scale labeling runs, deliberately using no more than half (and often 
less than one tenth) of total 18F-radioactivity loaded into the module per 
run. Therefore, more studies are needed to investigate the net efficiency of 
reagent and [18F]fluoride use in batch microfluidic syntheses carried out on 
microchannel platforms.
Preparation of [18F]fluoride for radiolabeling is a major concern in the de-
velopment of both conventional and microfluidic procedures. Drying of 
[18F]fluoride by azeotropic distillation, the classical approach, is time-con-
suming and leads to the loss of [18F]fluoride through its adsorption on the 
walls of the drying vessel. The “stickiness” of dried [18F]fluoride is partic-
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ularly detrimental for microchannel setups, because of the high surface-
to-volume ratio of the environment and the fact that drying and labeling 
processes take place in different locations. Elimination of azeotropic distil-
lation is thus especially beneficial for microfluidic synthesis.
The main goal of the current work was to streamline [18F]fluoride prepa-
ration for microfluidic 18F-labeling by eliminating the azeotropic distilla-
tion step. To achieve this goal, we have tested the reactivity of [18F]fluoride 
in solvent mixtures containing tert-butanol [13,14] or water (as reference 
protic solvent) in microfluidic labeling. Tetraethylammonium bicarbonate 
(TEAB) was used as phase transfer agent, because it led to fewer microre-
actor cloggings than potassium-Kryptofix complex [15]. Model reactions 
chosen were the formation of [18F]fluoroalkyl tosylates through bimolecular 
nucleophilic (SN2) 
18F-fluorination and the formation of 4-[18F]fluorobenzal-
dehyde through aromatic nucleophilic (SNAr) 
18F- fluorination.
The secondary goal was to use the improved [18F]fluoride preparation meth-
ods in the development of automated microfluidic synthesis procedures for 
[18F]fluoroalkyl tosylates and [18F]fluorobenzaldehyde and to investigate the 
net efficiency of radioactivity use in these procedures. [18F]Fluoroalkyl tosyl-
ates and [18F]fluorobenzaldehyde are used by our group as building blocks to 
prepare aminomethylchromane dopamine D2/3 receptor tracers described in 
Chapters 3−5 of the current thesis as well as tracers for other targets [16]. 
We have performed automated batch syntheses of [18F]fluoroethyl tosylate 
([18F]FEtTos) and [18F]fluorobenzaldehyde using both conventional azeo-
tropic distillation and tert-butanolic solutions of TEAB to prepare [18F]fluo-
ride for labeling, and assessed the impact of [18F]fluoride preparation meth-
od on the yields of 18F-fluorination reactions and on overall isolated yields 
of the desired products.
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Reagents, chemicals, materials and solvents were obtained from commer-
cial sources, and were used as received: Biosolve, Merck for solvents, Al-
drich, Acros, ABCR, Merck and Fluka for chemicals, materials and reagents. 
All solvents were of analytical grade quality.
4-Fluorobenzaldehyde was from Fluka. Trimethylammonium benzaldehyde 
triflate (TBCHO), 1,2-ethanediol ditosylate (EDT), 1,4-butanediol ditosylate 
(BDT), 2-fluoroethyl tosylate, and 4-fluorobutyl tosylate were prepared ac-
cording to procedures described in the literature [17–19].
Analytical thin layer chromatography (TLC) was performed on Kieselgel 
F-254 precoated silica plates. Non-radioactive compounds were visualised 
on developed TLC plates by irradiating the plates with a 254 nm UV lamp.
Radiochemistry
General
Non-carrier added [18F]fluoride was produced via the 18O(p,n)18F nuclear re-
action in [18O]water in the Scanditronix MC-17F cyclotron (Scanditronix, 
Uppsala, Sweden) and delivered from the target into a 5 ml V-vial inside the 
hotcell using helium overpressure.
[18F]Fluoroalkyl tosylates were prepared from ditosylate precursors in aceto-
nitrile (MeCN), [18F]fluorobenzaldehyde was prepared from trimethylammo-
nium triflate precursor in DMSO (Figure 1). Solvents for labeling were dried 
over molecular sieves and filtered through 0.2 µm PTFE filters. Solid-phase 
extraction (SPE) cartridges (Sep-Pak Acell Plus QMA Plus Light, Sep-Pak 
tC18 Plus Short, Oasis HLB Plus Short) were supplied by Waters Corporation 
(USA), except MP-1 anion-exchange cartridges, which were from ORTG Inc. 
(USA).
Identity of 18F-labeled products was confirmed by their co-elution with 
[19F]reference compounds on high performance liquid chromatography 
(HPLC) columns and/or thin layer chromatography (TLC) plates. Charac-
terization data for [18F]fluoroalkyl tosylates and [18F]fluorobenzaldehyde are 
presented in Table 1.
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Figure 1. Labelling routes used to obtain [18F]fluoroalkyl tosylates (A) and 
[18F]fluorobenzaldehyde (B).
Radioactive compounds on TLC plates were visualized by exposing the 
plates on Cyclone phosphor storage screens (multisensitive, Packard), read-
ing the screens on the Cyclone Plus Storage Phosphor system (PerkinElmer, 
USA) and quantifying the data with OptiQuant software.
HPLC was run on a system consisting of Hitachi LaChrom L-7100 pump, Hi-
tachi Lachrom Elite L-2400 UV/Vis detector and Bicron Frisk-Tech radiation 
detector.
This work was carried out on the Advion Nanotek LF microfluidic synthesis 
system (Advion Biosystems, USA) connected to the PET Tracer Synthesizer 
(Nuclear Interface GmbH, Münster, Germany).
Advion Nanotek LF Microfluidic Synthesis System
Radiolabeling on the Nanotek system is carried out by pumping the reaction 
mixture through the heated microfluidic reactor. The reactors are coiled 
tubes made of fused silica and housed in a silicone polymer bedding inside a 
brass ring cast. Effective reaction time is equal to the time a particle of the 
reaction mixture needs to pass the reactor. In this work, reactors with inner 
diameter of 100 µm and length of 2 m were used (reactor volume 15.7 μl).
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Table 1. Characterization data for [18F]fluoroalkyl tosylates and [18F]fluoroben-
zaldehyde.
Compound HPLC dataa TLC data








precoated silica plates 
eluted with hexane/
ethyl acetate (2/1 v/v) 
Rf = 0.6







Same plates eluted 
with hexane/ethyl 
acetate (5/1 v/v) 
Rf = 0.6







Same plates eluted 
with hexane/ethyl 
acetate (5/1 v/v) 
Rf = 0.8
a Conditions are listed as: column type, eluent composition; eluent flow; wavelength for ab-
sorption monitoring.
The Nanotek system consists of a Concentrator Module (CM), a Pump Mod-
ule (PM) and a Reactor Module (RM). The CM was used for [18F]fluoride ex-
traction and drying (Figure 2), while PM and RM were used to mix dried 
[18F]fluoride with precursor solution and pump the mixture through the 
reactor (Figure 3A). During labeling optimization, boluses of the reacted 
mixture were collected into Eppendorf vials for radio-TLC analysis. During 
automated syntheses of [18F]fluoroalkyl tosylates and [18F]fluorobenzalde-
hyde, the outflow of the reactor was transferred to the Nuclear Interface 
module (Figure 3B) for purification.
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The CM includes a thermostated vial housing, into which a 3-ml or a 5-ml 
V-vial can be placed, and a low-pressure 2.5  ml syringe pump connected 
to a 6-way valve. The PM and RM together include three high-pressure 
(up to 500 psi) syringe pumps connected to 8-way bridged valves: two 0.5 ml 
syringe pumps on the PM and one 1.0 ml pump on the RM. The pumps of 
the PM are numbered P1 and P2, the pump on the RM is numbered P3. The 
valve ports are denoted by letters from A to H. Pump valves have reagent 
loops made of PEEK tubing (~400 μl volume) attached to them. In this work, 
the P1 loop was used to store labeling precursor, while the P3 loop was used 
to store dried [18F]fluoride. The RM also contains a reactor unit with four 
thermostated reactor slots. Microfluidic reactors (up to four) are mounted 
on the reactor plate and inserted into the reactor slots. The reactor plate 
contains slots for tubing lines coming from the pumps and for the reactors 
themselves. Within the reactor plate, there are channels forming three-way 
junctions, so that reagents delivered by the pumps can be mixed and direct-
ed into the reactor. Thus, labeling precursors and dried [18F]fluoride were 
first loaded into, respectively, P1 and P3 loops, and then pumped through 
the reactor (Figure 3A).
The RM also contains an 8-way distribution valve (distribution hub, DH) and 
three 3/2 way solenoid valves. These valves were used to govern the flow of 
nitrogen gas and target water in the schemes of [18F]fluoride preparation on 
the CM.
The Nanotek system also has three semiconductor-based radioactivity de-
tectors, which can be used to monitor radioactivity movement within the 
system. In this work, one detector was attached to the P3 pump loop, an-
other one – to the vial housing of the CM module, and the third one was 
used to detect the delivery of the irradiated target water to the receiving 
V-vial. Auxiliary connection boards present in the Nanotek module allow 
the coupling of extra input or output devices to the system; we have con-
nected a fourth radioactivity detector to one of the auxiliary port to monitor 
the absorption of purified 18F-products on SPE cartridges.
The Nanotek system was controlled by a standard laptop with the 1.40 re-
lease of the Nanotek software installed. For labeling optimization work, 
the built-in Automatic Discovery routine was used. For [18F]fluoride drying, 
batch synthesis and maintenance operations (such as system cleaning), cus-
tom macros were written using the coding language built-in into the soft-
ware.
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Before and after each synthesis, all PM and RM tubing and pumps involved 
in the labeling (Figure 3A) were rinsed with dry reaction solvent (MeCN of 
DMSO). CM pump and tubing were rinsed with MeCN/water 1/1 mixture. 
Tubes through which target water was supposed to flow were additionally 
dried by nitrogen flow.
Nuclear Interface PET Tracer Synthesizer
The Nuclear Interface module consists of a number of reagent vials con-
nected to the thermostated reactor with tubing lines. The reactor contains 
a movable needle, which can be used to inject the contents of the reactor 
onto the HPLC column. The movement of reagents around the module is 
achieved by helium pressure and regulated by solenoid valves installed on 
the tubing lines. The module is also coupled to an HPLC system consisting 
of Water 510 pump and Linear UVIS 200 UV/Vis detector (radioactivity de-
tection is done by the built-in detector in the module). Another radioactivity 
detector is installed near the reactor, which makes it possible to monitor the 
delivery of radioactivity to the reactor and its withdrawal from it.
In this work, the Nuclear Interface module was used for the HPLC purifica-
tion of the 18F-labeled products prepared on the Nanotek system and absorp-
tion of the purified products on the SPE cartridge. The plumbing scheme of 
the relevant elements of the Nuclear Interface module is shown in Figure 3B.
The Nuclear Interface module was controlled by a desktop PC with GINA 
Star SynChrom software installed. A macro for the purification procedure 
was created using the graphical user interface of the GINA Star software.
Before and after each synthesis, all tubing and vials of the Nuclear Interface 
module involved in the labeling (Figure 3B) were rinsed with 70% ethanol.
[18F]fluoride extraction and drying
Irradiated target water was passed through the anion-exchange column 
(MP-1 with 25 mg sorbent or QMA Light with 100 mg sorbent) to trap the 
[18F]fluoride. Two approaches were used to prepare [18F]fluoride for labeling: 
conventional approach, where [18F]fluoride was dried by “azeotropic distil-
lation” (AD), and “flushing-elution” (FE) approach devoid of the azeotropic 
distillation step. In the AD approach, [18F]fluoride was eluted from the an-
ion-exchange column with either 2 mg K2CO3 and 10 mg Kryptofix 2.2.2 in 
1 ml MeCN/water (9/1 v/v) or 5 mg TEAB in 1 ml methanol, then dried by tri-
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ple azeotropic evaporation with MeCN at 110 °C under nitrogen flow and re-
solubilized in dry reaction solvent. In the FE approach, the anion-exchange 
column was flushed with dry MeCN, [18F]fluoride was eluted with 5 mg/ml 
TEAB in 0.45 ml of reaction solvent mixed with tert-butanol (tBuOH) or wa-
ter, and the eluate was used directly for 18F-labeling.
During the optimization of labeling conditions, trapping, elution and drying 
of [18F]fluoride was performed manually, and the vial with dry [18F]fluoride 
solution was then connected to the F port of the P1 pump unit of the Nan-
otek system. For batch syntheses, both [18F]fluoride approaches were auto-
mated using the Advion Nanotek LF Microfluidic Synthesis System.
Automated AD approach (Figure 2A). Irradiated target water was transferred 
from the “fresh [18O]H2O” vial through the trap-and-release column (QMA 
Light or MP-1) into the “used [18O]H2O” vial by the CM syringe (CS). Then, 
the SV3 solenoid valve was switched to direct the flow into the 3 ml drying 
vial (heated to 110 °C), and the trap-and-release column was eluted with 
1 ml 5 mg/ml TEAB in methanol. Methanolic solution of [18F]fluoride was 
added into the drying vial in 100 μl portions, with pauses to let the previous 
portion evaporate before the next one is added. Evaporation was accelerated 
by applying nitrogen flow through the vial and was monitored visually using 
a web-camera installed inside the hotcell. After full evaporation of metha-
nol, 3×100 μl portions of MeCN were added into the drying vial to azeotropi-
cally evaporate residual methanol and possible traces of water. Finally, the 
vial was cooled, dried [18F]fluoride was resolubilized in 0.45 ml dry MeCN or 
DMSO (the solution was pumped in and out of the loop 3 times to achieve 
homogeneity and enhance resolubilization).
While this protocol works with both TEAB solutions in methanol and car-
bonate-Kryptofix solutions in water-MeCN, only the former was used for 
trap-and-release column elution in batch syntheses. In short reaction runs 
performed within the Automatic Discovery setup, the system tolerated both 
bases well, but in prolonged labeling runs, the presence of potassium car-
bonate in the reaction mixture led to frequent clogging and ruining of the 
microfluidic reactors.
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Figure 2. Plumbing schemes of the Nanotek Concentrator Module used for the 
preparation of [18F]fluoride for labeling.
A – Plumbing scheme for the azeotropic distillation (AD) approach. B – Plumbing scheme for 
the flushing-elution (FE) approach.
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Figure 3. Simplified plumbing schemes of the Nanotek system (A) and the Nu-
clear Interface module (B).
Automated FE approach (Figure 2B). As in the AD approach, the first step 
was the trapping of the [18F]fluoride on the trap-and-release column. The 
column was then rinsed with dry MeCN (directed into the waste by the DH 
valve), blown with air and eluted with 0.45 ml of 5 mg/ml TEAB in MeCN/
tBuOH or DMSO/tBuOH. The tBuOH content was 50% in both cases, which 
corresponds to 25% tBuOH in the actual reaction mixture. Elution mixtures 
with other mixing ratios and/or containing water instead of tBuOH were 
only tried in manual optimization runs. The volume of the eluting solu-
tion (0.45 ml) had to match, with some safety margin, the volume of the 
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P3 reagent loop (~400 μl). Therefore, in this approach, only MP-1 columns 
with 25 mg sorbent were used, as QMA Light columns with 100 mg sorbent 
could not be efficiently eluted with such small volumes. Eluted [18F]fluoride 
was collected at the bottom of an Eppendorf vial placed inside the (unused) 
V-vial employed in the AD scheme, so elution could again be monitored 
through the web-camera. To ensure homogeneity, the dry [18F]fluoride was 
mixed by pumping it in and out of the loop three times.
Automatic Discovery runs on the Nanotek system
The influence of temperature, reactor residence time and co-solvent on the 
yields of [18F]FBuTos and [18F]fluorobenzaldehyde labeling was investigated 
using the Automatic Discovery routine of the Nanotek software. Boluses of 
precursor solution (10 μl) and dried [18F]fluoride (10 μl) were simultaneously 
dispensed from the P1 and P3 loop by the corresponding pumps to achieve 
their mixing at 1/1 volume ratio. The speed of pumping was varied to 
achieve different reactor residence time of 5, 10, 20 or 60 sec. Reactor tem-
perature was set at 90, 120, 150 or 180 °C. Co-solvent, i.e. water or tBuOH, 
percentage in the reaction mixture was 5%, 10% or 25% v/v (the latter – only 
with tBuOH). When labeling was performed in MeCN, a backpressure regu-
lator (BPR) set to 200 psi was installed after the reactor to prevent MeCN 
from boiling (Figure 3A). Precursor concentration in the reaction mixture 
was fixed at 5 mg/ml (12.6 mM) for butanediol ditosylate ([18F]FBuTos pre-
cursor) and at 2  mg/ml (6.4  mM) for trimethylammonium benzaldehyde 
([18F]fluorobenzaldehyde precursor). P1 reagent loop was loaded with pre-
cursor solution of double concentration, so as to achieve the designated 
concentration upon 1/1 mixing with [18F]fluoride solution at the entrance 
of the microfluidic reactor. Portions of reacted mixture were collected into 
0.5  ml Eppendorf vials for further analysis. Conversion of [18F]fluoride to 
[18F]FBuTos and [18F]fluorobenzaldehyde was monitored by TLC on silica 
plates (hexane/ethyl acetate).
Automated batch synthesis of 2-[18F]fluoroethyl tosylate
[18F]fluoride (5−10 GBq at end of bombardment) was worked up using either 
AD or EF approach, as described above. The obtained solution of [18F]fluoride 
in dry MeCN (in case of the AD approach) or MeCN/tBuOH 1/1 (v/v, in case 
of the EF approach) was loaded into the P3 loop of the Nanotek system. The 
P1 loop was loaded with 10 mg/ml 1,2-ethanediol ditosylate in dry MeCN. 
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Contents of both loops were then simultaneously pumped towards the reac-
tor, which was being heated to 180 °C. The pumping speeds were adjusted 
so that both [18F]fluoride and precursor boluses reached the entrance of the 
reactor simultaneously. Backpressure regulator set to 200 psi was installed 
at the outflow of the reactor, so pressure build-up caused by pumping also 
prevented the solvent inside the reactor from boiling during the heating-up 
phase. After that, at total speed of 96 μl/min (achieving reactor residence 
time of 10 s), [18F]fluoride and precursor were pumped through the micro-
fluidic reactor and into the Nuclear Interface reactor vessel (Figure 3B) with 
1 ml water in it. The reactor was allowed to cool down as soon as all reagents 
had passed through it. Organic solution of crude [18F]FEtTos arriving in the 
Nuclear Interface reactor vessel was mixed with water present in the ves-
sel by bubbling helium through the mix with the aid of the needle. Then, 
through the same needle, crude [18F]FEtTos was injected onto the HPLC col-
umn (Ultracarb ODS 10 µm 250×10 mm). The column was eluted at 5 ml/min 
with 45% MeCN in water, and radioactivity and 225 nm UV absorption of the 
eluate were monitored. The [18F]FEtTos fraction (tR 8.3 min) was collected 
by switching the 3/2 valve V18 to direct the flow from the HPLC column into 
the SPE bottle containing 80 ml water. Purified [18F]FEtTos was mixed with 
this water by bubbling nitrogen through it and then, using the pressure of 
the same nitrogen, the diluted solution of [18F]FEtTos was forced through 
the SPE column (tC18 Sep-Pak pre-activated with 5  ml 40% ethanol). Fi-
nally, using helium pressure, the SPE column was rinsed with 5 ml water in 
the vial above the V3 valve. The SPE column with [18F]FEtTos adsorbed on it 
was then available for further use in manual synthesis.
Automated batch synthesis of 4-[18F]fluorobenzaldehyde
[18F]fluorobenzaldehyde was synthesized according to the same procedure 
as [18F]FEtTos, with the following modifications. [18F]Fluoride solution for 
labeling was obtained in DMSO when the AD approach was used, and in 
DMSO/tBuOH 1/1 (v/v) when the EF approach was used. Precursor solu-
tion loaded into P1 loop was 4 mg/ml trimethylammoinum benzaldehyde 
in DMSO. No backpressure regulator was installed on the line connecting 
the outflow of the Nanotek microfluidic reactor and the reactor vessel of 
the Nuclear Interface module. HPLC purification conditions were: Ultracarb 
ODS 10 µm 250×10 mm column, elution at 5 ml/min with 40% MeCN in wa-
ter, tR of [
18F]fluorobenzaldehyde 6.9 min. Purified [18F]fluorobenzaldehyde 
was adsorbed on Oasis HLB column (with no pre-activation).
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Analysis of efficiency of radioactivity use
In order to assess the efficiency of radioactivity transfer between differ-
ent steps of the automated synthesis procedures developed in this work 
and pinpoint “bottlenecks”, the amounts of radioactivity found in different 
wastes generated by the synthesis procedure were measured and corrected 
for decay. This refers to radioactivity remaining in extracted target water, 
eluted trap-and-release columns, used [18F]fluoride drying vials, radioactiv-
ity rinsed from the Nanotek tubing lines etc.
286 Chapter 6
RESULTS
Optimization of labeling conditions for [18F]FBuTos 
and [18F]fluorobenzaldehyde. Co-solvent influence
The influence of temperature, reaction time and the presence of water or 
tBuOH on the conversion yields of [18F]fluoride to 4-[18F]fluorobutyl tosyl-
ate ([18F]FBuTos) and 4-[18F]fluorobenzaldehyde [18F]fluorobenzaldehyde is 
illustrated in Tables 2 and 3, respectively.
Presence of water in the reaction mixture slowed down formation of both 
[18F]FBuTos and [18F]fluorobenzaldehyde. At 180  °C, the highest tempera-
ture investigated, only 27% of 18F-radioactivity corresponded to [18F]FBuTos 
after 5  sec reaction in the presence of 5% water v/v, compared to 84% in 
“dry” conditions. For [18F]fluorobenzaldehyde, the presence of 5% water v/v 
decreased the 18F-fluorination yield to 22%, compared to 70% with azeo-
tropically dried [18F]fluoride. At lower temperatures (<120 °C) 18F-fluorina-
tion yields for both [18F]FBuTos and [18F]fluorobenzaldehyde did not exceed 
15% even at 60 sec reaction time.
The presence of tBuOH decreased 18F-fluorination yields at tempera-
tures below or equal to 120 °C in a concentration-dependent manner. For 
[18F]FBuTos, 18F-fluorination yield over 60  sec at 120  °C was 80% with 
azeotropically dried [18F]fluoride, 41% with 5% v/v tBuOH, 29% with 10% 
v/v tBuOH and 16% with 25% v/v tBuOH. For [18F]fluorobenzaldehyde, re-
spective figures were 57%, 35%, 29% and 14%. However, at temperatures 
above or equal to 150 °C tBuOH had little effect on 18F-fluorination yields 
even at 25% v/v. [18F]FBuTos yield over 10 sec at 180 °C was 83% with “dry” 
[18F]fluoride and 76% with 25% tBuOH. [18F]fluorobenzaldehyde yield in the 
same conditions was 75% with “dry” [18F]fluoride and 78% in 25% tBuOH.
Optimization of “dry” [18F]fluoride elution 
from trap-and-release column
Efficiency of [18F]fluoride elution from MP-1 cartridge was compared for 
TEAB solutions in MeCN/water, MeCN/tBuOH and DMSO/tBuOH mixtures 
with varying water or tBuOH percentages. Both co-solvents increased the 
efficiency of [18F]fluoride elution as their percentage rose (Figure 4). More-
over, in MeCN-based mixtures with co-solvent percentages of 20% v/v or 
less, tBuOH was even more effective in eluting [18F]fluoride than water. For 
example, 450 μl (approximately equal to Nanotek reagent loop volume) of 
287
Automated preparation of 18F-synthons on a microfluidic synthesis module 
with and without the use of azeotropic distillation for [18F]fluoride drying
6
90/10 and 80/20 MeCN/tBuOH mixtures with 5 mg/ml TEAB eluted respec-
tively 73% and 89% trapped [18F]fluoride, compared to 47% and 63% for 
MeCN/water mixtures with same mixing ratios.
Automated batch syntheses of [18F]FEtTos 
and [18F]fluorobenzaldehyde
For [18F]fluoroalkyl tosylates as well as for 4-[18F]fluorobenzaldehyde, the 
temperature of 180 °C and the reactor residence time of 10 sec were chosen 
as optimal parameters for scaling up to batch synthesis. While [18F]fluoro-
butyl tosylate was used during optimization of SN2 
18F-fluorination condi-
tions, the scale-up focused on its shorter homolog, [18F]fluoroethyltosylate 
([18F]FEtTos), because the latter was more relevant to PET tracer develop-
ment.
Figure 4. Efficiency of [18F]fluoride elution from MP-1 cartridges with 5 mg/ml 
TEAB in MeCN/water (A), MeCN/tBuOH (B) and DMSO/tBuOH (C) mixtures.
All values are based on single determinations.
Scaled-up automated batch syntheses of [18F]fluorobenzaldehyde and 
[18F]FEtTos were carried out with [18F]fluoride prepared via both AD and FE 
(azeotropic distillation-free) protocols (see Methods). Based on the results 
of trap-and-release column elution tests, the content of tBuOH in the TEAB 
solution used for the elution of trap-and-release column in the FE protocol 
was set to 50% (resulting in 25% tBuOH in the final reaction mixtures).
The syntheses lasted 50−60  min from end-of-bombardment. [18F]Fluoride 
preparation phase lasted 15 min with the AD protocol and 5 min with the FE 
protocol. Labelling step (with nominal reactor residence time of 10 s) lasted 
8 min. Different phases of the developed automated batch synthesis proto-
col are compared by their length in Figure 5.
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Table 2. Radiochemical yields (non-isolated) of [18F]FBuTos in relation to tem-








Water as co-solvent tBuOH as co-solvent
Reactor residence time, 
sec
Reactor residence time, 
sec




90 n.i.b n.i. n.i. n.i. n.i. n.i. n.i. n.i.
120 65 76 79 81 65 76 79 81
150 81 80 80 81 81 80 80 81
180 84 83 82 80 84 83 82 80
5% 90 <1 <1 <1 1 <1 1 2 4
120 1 1 1 5 6 12 29 41
150 6 10 12 33 27 47 68 66
180 27 48 62 70 62 60 61 58
10% 90 <1 <1 <1 <1 <1 1 1 3
120 <1 <1 1 2 4 8 16 29
150 2 3 4 12 19 35 58 65
180 13 22 19 41 61 69 67 62
25% 90 n.i. <1 <1 1 3
120 3 4 11 16
150 19 33 47 65
180 66 76 71 72
All labeling was performed on the Nanotek system using Automatic Discovery routine. Co-
solvent content in the final reaction mixture (precursor + [18F]fluoride) is shown. [18F]fluoride 
was prepared via the “flushing-elution” approach and TEAB was used as phase transfer catalyst 
in all experiments except no co-solvent experiments (see below). Butanediol ditosylate con-
centration was 5 mg/ml (13.3 mM) in all experiments. Radiochemical yields were determined 
by radio-TLC and are single determinations.
a In “0% co-solvent” experiments, potassium-Kryptofix was used as phase-transfer catalyst 
and [18F]fluoride was dried by azeotropic distillation. Radiochemical yields shown in water and 
tBuOH columns for no co-solvent experiments represent the same dataset and are averages 
from 3 independent repetitions.
b Not investigated.
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Table 3. Radiochemical yields (non-isolated) of [18F]fluorobenzaldehyde in re-








Water as co-solvent tBuOH as co-solvent
Reactor residence time, 
sec
Reactor residence time, 
sec




90 n.i.b n.i. n.i. n.i. n.i. n.i. n.i. n.i.
120 18 19 34 57 18 19 34 57
150 45 45 60 66 45 45 60 66
180 70 75 82 75 70 75 82 75
5% 90 3 6 7 8 1 1 3 10
120 5 3 2 2 8 12 17 35
150 11 8 9 13 40 66 68 63
180 22 24 33 38 78 76 73 57
10% 90 n.i. 1 3 12 30
120 13 13 19 29
150 47 56 68 60
180 80 81 65 68
25% 90 n.i. <1 <1 2 8
120 3 5 8 14
150 27 38 59 60
180 76 78 71 66
All labeling performed on the Nanotek system using Automatic Discovery routine. Co-solvent 
content in the final reaction mixture (precursor + [18F]fluoride) is shown. TEAB used as phase 
transfer catalyst in all experiments. Trimethylammonium benzaldehyde concentration was 
2 mg/ml (6.4 mM) in all experiments. Radiochemical yields were determined by radio-TLC and 
are single determinations.
a In no co-solvent experiments, [18F]fluoride was dried by azeotropic distillation. Radiochemi-




Figure 5. Length of different phases of automated microfluidic batch synthesis 
protocol used to prepare [18F]FEtTos and [18F]fluorobenzaldehyde.
Losses of radioactivity in different phases of [18F]FEtTos and [18F]fluoroben-
zaldehyde synthesis are presented in Table 4. The most inefficient synthesis 
step was [18F]fluoride drying and loop loading in schemes with azeotropic 
distillation. In the case of [18F]FEtTos labeling in MeCN, 39±15% of radio-
activity eluted from trap-and-release cartridge was lost during the drying 
and loop loading step, and in the case of [18F]fluorobenzaldehyde labeling 
in DMSO, the losses were 49±13%, mainly because [18F]fluoride got stuck 
to the drying vessel wall. Without azeotropic distillation, <5% of eluted 
radioactivity was lost in both cases. Elimination of azeotropic distillation 
also decreased the losses of radioactivity inside microfluidic module: from 
27±7% to 21±5% for [18F]FEtTos labeling and from 39±20% to 24±4% for 
[18F]fluorobenzaldehyde labeling. Losses at other steps were similar for 
the two products, with and without azeotropic distillation, except in azeo-
tropic distillation-free [18F]fluorobenzaldehyde syntheses, where on average 
89±1% of starting 18F-radioactivity in target water was trapped on the trap-
and-release column.
Automated batch procedures produced [18F]FEtTos in 78±16% (n=6) non-
isolated and 28±11% (n=6) isolated yield with azeotropic distillation, and 
in 85±5% (n=3) non-isolated and 53±9% (n=2) isolated yield with flushing-
elution protocol. [18F]fluorobenzaldehyde was obtained in 77±13% (n=5) 
non-isolated and 14±6% (n=5) isolated yield with azeotropic distillation, 
and in 73±14% (n=4) non-isolated and 28±11% (n=6) isolated yield with 
flushing-elution protocol. Radiochemical purity of HPLC-purified and SPE 
concentrated products was >97%. Molar radioactivities of [18F]FEtTos and 
[18F]fluorobenzaldehyde were 30–90 GBq/µmol and 7–18 GBq/µmol, respec-
tively.
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DISCUSS ION
This work aimed to optimize [18F]fluoride preparation for microfluidic nu-
cleophilic 18F- fluorination of aliphatic and aromatic substrates by elimi-
nating the azeotropic distillation step, to implement the optimized proto-
cols in the automated microfluidic synthesis procedures for [18F]fluoroalkyl 
tosylates and [18F]fluorobenzaldehyde and to investigate the efficiency of 
18F-radioactivity use at different steps of these procedures.
The compounds chosen as model products for the current study were 
[18F]fluoroalkyl tosylates (4-[18F]fluorobutyl tosylate and 2-[18F]fluoroethyl 
tosylate in the first place) and 4-[18F]fluorobenzaldehyde. The synthesis 
of [18F]fluoroalkyl tosylates from azeotropically dried [18F]fluoride, both 
in conventional and microfluidic conditions, has been thoroughly inves-
tigated both by us and by other groups [6,12]. Moreover, [18F]fluoroalkyl 
tosylate synthesis is a good example of SN2 
18F-fluorination. 4-[18F]Fluo-
robenzaldehyde, meanwhile, is a useful building block for the creation of 
4-[18F]fluorobenzylamino moiety and a good example of SNAr 
18F-fluorina-
tion. Finally, both [18F]fluoroalkyl tosylates and [18F]fluorobenzaldehyde are 
used as building blocks for PET radioligand development both in our group 
[16] (including the research described in the current thesis) and elsewhere 
[7,20]. Therefore, automation and optimization of their synthesis provided 
both theoretical insights and practical benefits.
Precursor concentration in 4-[18F]fluorobenzaldehyde preparation protocol 
was chosen to be 2-fold lower that in the preparation protocol for [18F]fluo-
roalkyl tosylates (6.4 mM vs 13.3–13.5 mM). The reason was that the triflate 
precursor for [18F]fluorobenzaldehyde contained 19F-fluorine, which could 
take part in isotopic exchange reaction with [18F]fluoride used for radiola-
beling. Nevertheless, molar radioactivity of [18F]fluorobenzaldehyde turned 
out to be 5–10 fold lower than that of [18F]FEtTos, despite similar synthesis 
times and amounts of radioactivity with which the syntheses were started.
Elimination of azeotropic distillation from 
the radiosynthesis protocol
Drying by azeotropic distillation is known to be a time-consuming proce-
dure that leads to losses of [18F]fluoride radioactivity (through deposition on 
distillation vessel walls and incomplete resolubilization) and limits the iso-
lated yield of any radiosynthesis based on nucleophilic fluorination. There-
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fore, getting rid of this distillation step is a goal that often comes up in the 
development of radiosyntheses with fluorine-18. Lots of azeotropic distil-
lation-free approaches of [18F]fluoride preparation are known, but many of 
them require either sophisticated equipment [21] or reagents [22,23]. Good 
results were reported for organic solutions of KOH-Kryptofix [24], but potas-
sium salts led to frequent clogging of the Nanotek reactor, both in our hands 
and in reports of others [15]. There are reports of successful microfluidic 
nucleophilic 18F-labeling [5,25], where [18F]fluoride was introduced into the 
reaction in irradiated [18O]water without any preparation, but whatever the 
real versatility and reproducibility of such approach, it is not applicable for 
batch syntheses because of the high volumes that would need to be reacted.
The method used in this work combined two approaches: (1) replacing po-
tassium carbonate-Kryptofix combination with tetraethylammonium bicar-
bonate to avoid microreactor clogging [15] and (2) using a tertiary alcohol 
(tBuOH) as co-solvent to enhance [18F]fluoride ion solvation without im-
pacting its nucleophilicity as much as it happens with water [13,14]. The im-
provement of [18F]fluoride solvation with the addition of tBuOH was clear-
ly visible in MP- 1 elution studies (Figure 4), where mixtures with greater 
tBuOH content eluted [18F]fluoride more efficiently. Water also increased 
the efficiency of [18F]fluoride elution, but it greatly slowed down both 
[18F]FBuTos (SN2) 
18F-fluorination and [18F]fluorobenzaldehyde (SNAr) 
18F-fluorination reactions at all temperatures investigated, decreasing the 
yields compared to no co-solvent conditions (Tables 2 and 3). In contrast, 
while tBuOH did slow down both 18F-fluorination reactions at temperatures 
of 90 °C and 120 °C, it had little effect on the yields at temperatures of 150 °C 
and 180 °C. Scaled-up batch syntheses confirmed this finding: 18F-fluorina-
tion yields in co-solvent-free conditions and in the presence of 25% tBuOH 
were very close to each other for both [18F]FEtTos (78±16% co-solvent-free, 
85±5% with tBuOH) and [18F]fluorobenzaldehyde (77±13% co-solvent-free, 
74±14% with tBuOH). These results demonstrate that our method is suffi-
ciently versatile to achieve efficient radiofluorination of both aliphatic and 
aromatic substrates.
Two recently published reports describe the successful use of TEAB solutions 
in water-organic mixtures for [18F]fluoride elution from QMA and MP-1 col-
umns with subsequent 18F- fluorinations in conventional setup [26,27]. Both 
groups successfully performed SN2 
18F- fluorinations with TEAB as phase 
transfer catalyst and up to 5% water in the reaction mixtures, and one of the 
groups performed SNAr 
18F-fluorinations as well. These results imply that 
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azeotropic distillation-free 18F-fluorinations can be successfully carried out 
even using water as co-solvent, but our findings suggest that the product 
yields could probably be even better if tBuOH were used instead.
Radiosynthesis automation on the Nanotek microfluidic 
synthesis system
The small volume of microreactors enables low expenses of reagents per test 
reaction run. Tolerance of microreactors to high pressure means that reac-
tion mixture can be heated to temperatures high above the boiling point of 
the solvent used. Due to the low overall heat capacity and high surface-to-
volume ratio, the designated temperature is reached instantaneously, which 
results in dramatically decreased reaction times compared to conventional 
setup. These factors give microchannel systems a lot of flexibility and allow 
quick optimization of the labeling conditions for the product being investi-
gated. However, scaling up the discovered optimal conditions to batch pro-
cedures is connected with a number of important drawbacks.
First, the total volume of [18F]fluoride and precursor solutions (hundreds of 
microliters) does not fit into the microfluidic reactor (a few tens of microli-
ters) at once, so reagents have to be pumped through the reactor portion by 
portion. For instance, reacting a test bolus of 20 μl for 60 sec by pumping it 
through a 2 m Nanotek reactor takes 2.25 min, but reacting 800 µl (total vol-
ume of [18F]fluoride and precursor loops in our setup) under the same condi-
tions would take 52.25 min. In our batch synthesis procedure, with effective 
labeling time of 10 sec, 8 min were needed to pump all reagents through the 
reactor. Therefore, in batch syntheses, the use of microfluidic setup does 
not decrease total labeling time compared to conventional setup. In order 
to cut total labeling time further, the degree of [18F]fluoride concentration 
before labeling has to be enhanced.
Second, in microfluidic labeling, the drying of [18F]fluoride and the actual 
labeling takes place in different locations, and the transfer of radioactivity 
incurs extra losses, decreasing overall isolated yield. The biggest losses are 
connected with azeotropic distillation of [18F]fluoride, but some radioactiv-
ity is also retained in the loops and tubing lines of the microfluidic system. 
In our work we observed both types of radioactivity loss, and as a result, the 
isolated yields of [18F]FEtTos and [18F]fluorobenzaldehyde obtained via auto-
mated batch protocols with azeotropic distillation were quite low: 28±11% 
and 14±6%, respectively.
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However, eliminating azeotropic distillation and adding tBuOH as co-
solvent almost doubled the isolated yields of [18F]FEtTos (to 53±9%) and 
[18F]fluorobenzaldehyde (to 37±7%). Such yields are comparable to isolated 
yields of the same compounds prepared in our laboratory via manual pro-
cedures with azeotropic distillation (30−40% for [18F]FEtTos and 40−60% for 
[18F]fluorobenzaldehyde, see Chapters 4 and 5). The observed increase in iso-
lated yields was not the consequence of improved conversion of [18F]fluoride 
to products, but of improved efficiency of 18F-radioactivity transfer through 
consecutive steps of the synthesis procedure. Switching from AD to FE pro-
tocol for [18F]fluoride preparation decreased the losses during [18F]fluoride 
radioactivity transfer from the drying step to the labeling step from 39±15% 
to 3±0% for [18F]FEtTos labeling and from 49±13% to 5±1% for [18F]fluoro-
benzaldehyde labeling. Losses during radioactivity transfer from the label-
ing step to the purification step in the same syntheses were also decreased, 
respectively, from 27±7% to 21±5% and from 39±20% to 24±4%. These re-
sults highlight the usefulness of azeotropic distillation-free schemes.
Even if automated batch microfluidic syntheses do not provide advantage in 
synthesis time or isolated yields of the product compared to manual proce-
dures, they still have an advantage in decreasing personnel exposure to ra-
dioactivity and enabling the use of higher starting amounts of radioactivity, 
as is the case for any automated procedures including those implemented 
on conventional synthesis modules. [18F]FEtTos and [18F]fluorobenzalde-
hyde obtained by automated synthesis procedures developed in this work 
were successfully used as building blocks for the preparation of candidate 
PET tracers, including 18F-labeled aminomethylchromanes described in 
Chapters 3–5 of the current thesis and 18F-labeled pyrazolo-triazolo-pyrim-
idines [28] for the imaging of adenosine receptors in the central nervous 
system.
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CONCLUS ION
We have demonstrated that both SN2 and SNAr 
18F-fluorination can be car-
ried out in mixtures of tBuOH and polar aprotic solvents inside the micro-
fluidic reactor using tetraethylammonium bicarbonate as phase transfer 
agent. Substituting the flushing-elution procedure of [18F]fluoride prepa-
ration for conventional azeotropic distillation increased the efficiency of 
[18F]fluoride use and reduced synthesis time. Our findings are corroborat-
ed by the more recent reports of successful 18F-fluorinations performed in 
water-containing solutions of tetraethylammonium bicarbonate under 
conventional conditions, and suggest that switching from water to tertiary 
alcohols may increase the yields of 18F-labeled radiopharmaceuticals 
even further. We have also successfully automated the syntheses of 4-[18F]
fluorobenzaldehyde and 2-[18F]fluoroethyl tosylate, 18F-synthons relevant 
for our research work, implementing the developed azeotropic distillation-
free approach to [18F]fluoride preparation.
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Motivation and aim of the work
Dopamine is an important neurotransmitter involved in the regulation of 
numerous functions of the brain. Alterations of central dopamine signal-
ing are thought to underlie movement disorders, cognitive disorders and 
addiction [1–7]. In the brain, dopamine binds to receptors which belong to 
the G-protein coupled receptor (GPCR) superfamily. Dopamine receptors 
belonging to D2 and D3 subtypes (D2/3) have received a lot of attention in 
neuroscience, and, of all neuroreceptors, have been most thoroughly inves-
tigated by non-invasive positron emission tomography (PET) imaging [8].
In vitro data show that GPCRs (including D2/3) exist in states of high- and low 
affinity for the agonists (including dopamine itself), depending on whether 
G-proteins are bound to them or not. Antagonists do not distinguish be-
tween these two affinity states. Because the high-affinity state is a subset of 
receptors to which G-proteins are pre-coupled, it arguably can be thought of 
as the functional subpopulation of receptors [9,10].
By virtue of selective binding to this “functional” subset of receptors, agonist 
may be superior to antagonist tracers in such applications as neurotransmit-
ter release measurement and agonist drug occupancy studies. Also, the use 
of agonist tracers may improve our understanding of the pathogenesis of 
neuropsychiatric disorders presumably caused by dysregulation of the rela-
tive abundance of the high-affinity state and possibly facilitate the diagno-
sis of these disorders.
Chapter 2 discusses the concept of the high-affinity state and potential 
advantages of agonist tracers over antagonist tracers for the imaging 
of neuroreceptors belonging to the GPCR family. It also reviews experimen-
tal paradigms aiming to demonstrate these advantages and experimental 
evidence gathered using such paradigms. Although it is doubtful whether 
D2/3 agonist tracers really image a subset of all receptors recognized by D2/3 
antagonist tracers, in one application, measurement of changes in intra-
synaptic dopamine levels, D2/3 agonist tracers are indeed superior to D2/3 an-
tagonist tracers.
A common liability of all D2/3 agonist PET tracers available for use in hu-
mans at the time of the initiation of this work was the isotope they were 
labeled with, namely carbon-11. The short half-life of carbon-11 (20.4 min) 
restricts the use of 11C-labeled tracers to institutions with on-site cyclo-
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trons. Fluorine-18-labeled tracers are much better suited for widespread 
use, because the longer half-life of fluorine-18 (109.8 min) makes it possible 
to deliver the radiopharmaceutical to numerous imaging institutions from 
a single production hub.
This work aimed to develop and evaluate fluorine-18-labeled agonist radio-
pharmaceuticals that could be used for the imaging of the functional state 
of dopamine D2/3 receptors in humans.
Design of candidate compounds
At the time that this work was initiated, the most popular scaffolds for the 
development of D2/3 agonist PET tracers were naphtoxazine, apomorphine 
and 2-aminotetraline scaffolds (see [11] and Figure 1). Naphtoxazine and 
apomorphine-derived radioligands with the 18F-label introduced into one 
of the substituents at the main amino nitrogen atom were not successful 
[12,13]. One 18F-labeled 2-aminotetraline derivative, capable of visualizing 
D2/3 receptors in the brain with a moderate signal-to-noise ratio, was re-
ported [14], but there did not appear to be a lot of room for further optimi-
zation, as similar compounds with somewhat more complex structures had 
inferior imaging characteristics [15,16]. Therefore, the decision was taken to 
develop tracers “from scratch” instead of further modifying the structures of 
existing 11C-labeled tracers. An additional benefit of this decision was that 
it provided the opportunity to patent and license the newly developed com-
pounds for the market if they turned out to be successful as PET imaging 
agents.
Aminomethylchromanes (AMCs), a class of high-affinity D2/3 agonists that 
had not been previously evaluated as radioligands, were chosen for the de-
velopment of new 18F-labeled tracers.
Chapter 3 describes the design of candidate compounds based on this scaf-
fold. A PET tracer for brain imaging should be lipophilic enough to pene-
trate the blood-brain-barrier by passive diffusion, but should also have high 
enough affinity towards its target so that its specific binding in brain tissue 
would be distinguishable from non-specific binding. The tracer should also 
be metabolically stable to be able to penetrate into the brain tissue from the 
blood before being metabolized. When the tracer is eventually metabolized, 
the label should go off the molecule in fragments sufficiently hydrophilic so 
as not to penetrate the blood-brain-barrier.
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The D2/3 agonist pharmacophore, to which AMCs also conform, consists of 
an aromatic core, hydrogen-bonding hydroxyl groups attached to it, and a 
positively charged nitrogen (Figure 1). The advantage of the AMC scaffold 
for radioligand development is that the substituent at the nitrogen atom is 
directed towards a relatively spacious ancillary binding pocket. Therefore, 
the structure of the N-substituent can be modified with considerable free-
dom in order to achieve the necessary lipophilicity and accommodate the 
radiolabel without much impact on the D2/3 affinity or agonism.
Figure 1. Comparison of the molecular structures of dopamine, aminomethyl 
chromane, aminotetraline, naphtoxazine and apomorphine ligands.
Aryl cores, basic nitrogens and H-bond donating hydroxyls are marked with color. Ligands 
are oriented in a rough representation of their putative receptor-bound conformations. The 
“upward-looking” benzyl substituent of benzyl-AMC and propyl substituent of S-(−)5-OH-DPAT 
can access the spacious ancillary binding pocket of the D2 receptor, while the “downward-look-
ing” propyl substituents of S-(−)5-OH-DPAT, (+)PHNO and (−)NPA are pointed towards a minor 
binding pocket that cannot accommodate groups greater than propyl. Adapted from Chapter 3.
Alkyl-, benzyl- and arylpiperazino-substituted AMCs were developed in this 
work (Figure 2). Structures of candidate compounds were designed to pos-
sess predicted lipophilicities (LogP7.4 = LogD) between 1 and 3, which is the 
preferred range for brain radiopharmaceuticals [17]. In the majority of can-
didate compounds, the fluorine label was introduced in fluoroalkoxy groups, 
and the lengths of the alkyl chains were adjusted to obtain the right LogD 
values. Nevertheless, the AMC moiety remained the main hydrophobic core 
in all candidate compounds. The radioactive fluorine atom was incorporated 
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far from the AMC moiety in groups likely to be cleaved from the molecule 
core by metabolic enzymes. This was done to ensure that radioactive metab-
olites formed from the candidate tracers would not be lipophilic and would 
not include the D2/3-pharmacophore, because lipophilic radiometabolites, 
especially those possessing D2/3 affinity, could interfere with the quantifica-
tion of the specific uptake of candidate tracers in the brain.
Figure 2. Structures of candidate AMCs (fluorinated and reference compounds) 
prepared in this work.
Synthesis and pharmacological characterization 
of candidate compounds
Chapters 3 and 4 describe the preparation of candidate AMCs and their 
evaluation in vitro. Chirality of AMCs plays a decisive role in their affinity 
towards D2 and D3 receptors, with (R)-enantiomers being the eutomers. An 
enantiomerically pure (R)-7-hydroxy-2-ethoxycarbonyl chromane building 
block was prepared from its racemate using a kinetic lipase resolution pro-
cedure. This building block was further modified to eventually obtain alkyl-, 
benzyl- and arylpiperazino-substituted AMCs, with and without fluorine 
atoms in their structure.
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The pharmacological properties of synthesized compounds were evaluated 
in radioligand competition assays in membrane homogenates from human 
embryonic kidney (HEK) and Chinese hamster ovary (CHO) cells expressing 
various human dopamine receptor subtypes and in functional assays such 
as adenylate cyclase inhibition and β-arrestin recruitment. Two benzyl- and 
one arylpiperazino-substituted AMC, codenamed AMC20, FBu-AMC13and 
FEt-AMC15, respectively, were recognized as good candidates for radiola-
beling (in Chapter 3, the latter two compounds are denoted as 12a and 12d, 
respectively). In membrane homogenates with D2 receptors, these com-
pounds distinguished between high- and low-affinity binding sites (D2high 
and D2low), having 10–1000-fold preference for the former over the latter. 
Their affinities towards D2high were in the subnanomolar to nanomolar 
range: from 85 pM for AMC20 to 6.7 nM for FEt-AMC15. In addition, they 
bound with high affinity to D3 receptors (from 0.6 nM for AMC20 to 12.1 nM 
for FBu-AMC13), did not bind significantly to D1 receptors and showed al-
most full agonism in functional assays at D2 receptors.
Preparing radiolabeled candidate tracers and assessing 
their lipophilicity
The radiolabeling of AMC20 is described in Chapter 4, while the radiolabel-
ing of FBu-AMC13 and FEt-AMC15 is described in Chapters 3 and 5. For the 
latter two compounds, several homologues with varying fluoroalkyl chain 
lengths were prepared in order to find out what length resulted in the high-
est signal-to-noise ratios in real brain tissue.
In the AMC20 structure, the fluorine atom was directly attached to the 
benzyl group. Because the benzyl group has an electron-rich aryl ring that 
cannot be directly labeled by nucleophilic fluorination, synthesis of this 
compound started from the preparation of 4-[18F]fluorobenzaldehyde which 
was then coupled with AMC-amine and converted to [18F]fluorobenzyl group 
by reductive amination. In FBu-AMC13 and FEt-AMC15, the fluorine atom 
was part of a fluoroalkoxy group. These compounds were obtained by fluo-
roalkylation of phenol precursors (Figure 3).
Radiolabeling procedures for the production of the first [18F]AMCs were 
selected so as to maximize ease and flexibility. Radiosynthetic procedures 
lasted for 2−2.5 hours. [18F]fluoroalkyl-AMCs were obtained in isolated ra-
diochemical yields of 3−15%, while average isolated radiochemical yield of 
[18F]AMC20 was 24%. Molar radioactivities of [18F]AMCs were in the range of 
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10−100 GBq/µmol, which was high enough to carry out in vivo PET imaging 
at tracer doses. Production of [18F]fluoroalkyl tosylates and 4-[18F]fluoroben-
zaldehyde was automated at later stages of the work (Chapter 6), further 
simplifying the production of tracers for in vitro and in vivo evaluation.
Figure 3. Radiolabeling schemes used for the preparation of [18F]AMCs.
A – reductive amination of 4-[18F]fluorobenzaldehyde with the amine precursor of AMC20; 
B – [18F]fluoroalkylation of phenol precursors for AMC13 and AMC15 homologues. For simplic-
ity, the actual aminomethyl chromane moieties and the final deprotection of their 7-OH group 
are not shown.
The experimentally determined LogD value of [18F]AMC20 was 2.33. For 
AMC13 homologues LogD varied from 1.67 ([18F]FEt-AMC13) to 2.50 
([18F]FBu-AMC13). For AMC15 homologues, LogD varied from 1.48 ([18F]FEt- 
AMC15) to 2.71 ([18F]FBu-AMC15). All LogD values fall within the range 
considered optimal for passive diffusion from the plasma into the brain 
tissue [17].
In vitro and in vivo evaluation of radiolabeled 
candidate tracers
Results of in vitro and in vivo evaluation of radiolabeled candidate trac-
ers are described in Chapters 4 and 5. All radiolabeled compounds were 
evaluated by in vitro autoradiography in rat brain slices to assess the sig-
nal-to-noise ratios of their binding to D2/3 receptors in real tissue. Specific 
binding ratios (SBRs) were calculated from radioactivity concentrations 
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in striatal (D2/3-rich) and cerebellar (D2/3-poor) regions. For [
18F]AMC20, a 
fluorobenzyl-substituted AMC with the highest measured affinity towards 
D2high (85  pM), striatal SBR reached 6.27 at a concentration of 1.7  nM 
(Chapter 4). Among [18F]fluoroalkoxy-labeled AMCs, the highest SBRs were 
shown by fluoroethoxybenzyl-substituted [18F]FEt-AMC13 and (fluoroe-
thoxy)phenylpiperazino-substituted [18F]FEt-AMC15: 3.40 at 0.9  nM and 
1.64 at 5.8 nM, respectively (Chapter 5). For all radioligands, co-incubation 
with the D2/3 antagonist raclopride or guanosine triphosphate (GTP) de-
creased SBRs by 60−80%, confirming that their striatal binding is specific to 
the high-affinity state of D2/3 receptors.
[18F]AMC20, [18F]FBu-AMC13, [18F]FEt-AMC13 and [18F]FEt-AMC15 were 
evaluated in Sprague-Dawley rats. In living rats, [18F]FEt-AMC15 showed 
very low penetration into the brain, which could be due to its relatively high 
hydrophilicity and the presence of two basic nitrogens or possibly because it 
interacted with pump proteins like P-glycoprotein (P-gp). On the contrary, 
[18F]AMC20, [18F]FBu-AMC13, and [18F]FEt-AMC13 penetrated into the brain 
in good amounts: brain uptake peaked at 1.7%, 0.9% and 0.7% injected dose, 
respectively. For [18F]FBu-AMC13, the brain region with the highest uptake 
was the brainstem, but [18F]FEt-AMC13 and [18F]AMC20 preferentially ac-
cumulated in the striatum, resulting in striatum-to-cerebellum ratios of 
about 2 for both tracers. All radioactive metabolites of [18F]FEt-AMC13 and 
[18F]AMC20 were considerably less lipophilic than their parent tracers and 
did not penetrate the blood-brain barrier. Finally, for both tracers, a 20−40% 
decrease (depending on the measurement method) of preferential striatal 
binding in response to pre-treatment with 1 mg/kg raclopride was detect-
able in PET measurements, ex vivo biodistribution and ex vivo autoradiog-
raphy (Chapters 4 and 5).
Although in vivo and ex vivo data obtained for [18F]FEt-AMC13 and 
[18F]AMC20 were consistent with specific binding of these two tracers to D2/3 
receptors in rat striatum, these radioligands had two common drawbacks. 
One was that the difference between striatal and cerebellar uptake, typically 
used as a surrogate measure of D2/3 specific binding, was not decreased by 
more than 40% by pre-treatment with raclopride. This is less than half of 
reported decreases for existing 11C-labeled agonists at the same (1 mg/kg) or 
lower raclopride doses (at least 80% decrease [18–20]). This could be a result 
of either insufficient raclopride dosage or imperfect pharmacological selec-
tivity of the tracers. Based on the available data it is impossible to choose 
between the two explanations.
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Another, more important drawback, was that the baseline signal-to-noise 
ratios of [18F]FEt-AMC13 and [18F]AMC20 were lower than what was reported 
in rats for existing 11C-labeled D2/3 agonist tracers. Striatal BPND values for 
our tracers were ~0.5 compared to 0.9 for [11C]MNPA [18], while striatum-
to-cerebellum ratios were ~2 compared to 3 or more for [11C](−)NPA and 
[11C](+)PHNO [19,20]. So, even if absolute selectivity for D2/3 receptors can 
be proven for [18F]FEt-AMC13 and [18F]AMC20, and >90% decrease of striatal 
BPND can be achieved by increasing raclopride dose, they will still be less 
suitable for the measurement of striatal D2/3 receptor availability in vivo 
than [11C]MNPA, [11C](−)NPA or [11C](+)PHNO.
Conclusion
We have designed and prepared a series of fluorinated aminomethylchro-
mane derivatives and evaluated them as potential agonist radiotracers for 
the imaging of dopamine D2/3 receptors with PET.
The best two compounds of those investigated by us, [18F]AMC20 and 
[18F]FEt-AMC13, distinguished between high- and low- affinity states of D2/3 
receptors, did not form lipophilic metabolites in vivo, penetrated well into 
the rat brain, preferentially accumulated in the striatum and were sensi-
tive to D2/3 blockade by raclopride. Although the signal-to-noise ratios of 
[18F]AMC20 and [18F]FEt-AMC13 are lower than those of existing 11C-labeled 
D2/3 agonist tracers, our results demonstrate that aminomethylchromanes 
are a viable scaffold for the development of D2/3 agonist radioligands.
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Quest for 18F-labeled dopamine D2/3 receptor agonists
As our research into 18F-labeled aminomethylchromanes was being carried 
out, other research groups were pursuing the development of 18F-labeled 
D2/3 agonists based on other scaffolds. In particular, for the apomorphine 
scaffold, the focus of 18F-labeling attempts shifted from the substituents 
at the amino nitrogen to the substituents at the oxygen atoms attached to 
the apomorphine core. This has yielded [18F]MCL-524, a 18F-labeled dopa-
mine D2/3 agonist tracer with a structure very similar to [
11C]MNPA [1]. In 
cynomolgus monkeys, mean striatal binding potential (BPND) measured for 
[18F]MCL-524 was 2.0, which is higher than the value of 1.5 measured for 
[11C]MNPA [2]. [18F]MCL-524 was also sensitive to changes in endogenous 
dopamine levels, so there is a chance that implementation of this tracer in 
clinical research will result in wider application of D2/3 imaging than is cur-
rently feasible with 11C-labeled D2/3 agonist tracers and allow more precise 
measurement of fluctuations in synaptic dopamine levels than is currently 
achievable with D2/3 antagonist tracers.
It would be beneficial, though, to have 18F-labeled agonist tracers from dif-
ferent scaffolds available to be able to distinguish between their general 
and scaffold-specific properties. Modifications of other scaffolds popular in 
D2/3 agonist tracer development to accommodate an 
18F atom have not been 
successful (see [3] for review). In naphtoxazines like (+)PHNO, the only suit-
able place for the 18F-label is the N-propyl substituent. [18F]fluoropropyl-(+)
HNO showed a homogeneous distribution in rat brain with no discernible 
specific binding despite 0.4 nM affinity towards D2high measured in vitro 
[4]. Possible reason for this is decreased basicity of the nitrogen atom re-
sulting from the negative inductive effect of fluorine, but elongation of the 
N-propyl substituent in the PHNO structure adversely affects D2high bind-
ing affinity, because this substituent points into a restricted ancillary pocket 
of the D2 receptor, which is unable to accommodate greater moieties.
Aminotetralins are more flexible than naphtoxazines regarding possible 
locations for radiolabeling. Like in aminomethylchromanes, one of the 
substituents at the nitrogen atom of the aminotetralins can access the spa-
cious ancillary binding pocket (while the second still cannot be greater than 
propyl, see Figure 1 in Chapter 7) [5,6]. Optimizing the N-substituent led 
to the development of aminotetralin derivatives with affinities towards 
D2 receptors as high as 10 pM in case of the aminotetralin ZYY-339 [7]. How-
ever, this compound was also relatively lipophilic (LogD 3.0), and apparently 
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because of that, [11C]ZYY-339 showed striatum-to-cerebellum ratios of only 
1.5 in rats [8]. Less lipophilic aminotetralins with less bulky N-substituents 
had lower D2 affinities but showed somewhat greater striatum-to-cerebel-
lum ratios: 1.8 for the 11C-labeled N,N’-dipropyl aminotetralin [11C]5-OH-
DPAT (D2 affinity of 2.5 nM, LogD of 1.4) [9] and up to 2.0 for the 
18F-fluoro-
pentyl-substituted aminotetralin [18F]5-OH-FPPAT (LogD 1.60, IC50 6.95 nM 
at rat D2/3 receptors) [10]. Recently reported [
18F]fluorohexyl-substituted 
aminotetralins [18F]5-OH-FHXPAT (logD 1.8, affinity not reported) and 
[18F]7-OH-FHXPAT also showed striatum-to-cerebellum ratios around 2 in 
rats and mice [11]. All these tracers, to sum up, are inferior to [11C](+)PHNO or 
[11C](−)NPA in their signal-to-noise ratios, but comparable to the AMC trac-
ers developed in the current work. It should be noted that all aminotetraline 
tracers were tested in their racemic form, so converting them to eutomers 
may increase signal-to-noise ratios. It’s unlikely, however, that the gain will 
be more than 2-fold: assuming only non-specific binding for the distomers, 
striatal specific binding ratios (SBRs) relative to cerebellum could increase 
from 1 to 2 (equivalent to striatum-cerebellum ratios of 3) after switching to 
pure eutomers, but not greater. Therefore, the prospects of aminotetralin-
based D2/3-agonist tracers are arguably similar to the prospects of amino-
methylchromane-based ones.
The main problem with aminomethylchromane ligands obtained in this 
work is their low signal-to-noise ratios: in living rat brain, striatal SBRs for 
these ligands did not exceed 1.5, and binding potential (BPND [12]) values did 
not exceed 0.6. Specific binding (“signal”) of the radioligands results from 
their affinity to their target, while non-specific binding (“noise”) results 
mainly from the ligands’ lipophilicity. It can be claimed, therefore, that low 
signal-to-noise ratios of aminomethylchromane ligands are a consequence 
of suboptimal combinations of their affinities and lipophilicities.
On the one hand, the affinity of [18F]AMC20 (investigated in Chapter 4) to-
wards D2high was considerably high, 0.03–0.14 nM, 85 pM on average, but 
its signal-to-noise ratio had probably been limited by its non-specific bind-
ing. The LogD value of [18F]AMC20 was 2.33, which is close to the middle of 
the 2.0−3.0 range that corresponds to the maximum brain penetration by 
passive diffusion [13]. Indeed, 1.7% of injected [18F]AMC20 dose penetrated 
into the rat brain, but apparently for the AMC scaffold such LogD values 
also result in too much non-specific binding in the brain. Optimization of 
radioligands starting from [18F]AMC20 should involve decreasing lipophilic-
ity while keeping the affinity at the same level.
318 Chapter 8
On the other hand, [18F]FEt-AMC13 (investigated in Chapter 5) had much 
lower LogD value (1.67), but approximately the same signal-to-noise 
ratio as [18F]AMC20. Apparently, the reason was its rather low D2high 
affinity (not measured directly for FEt-AMC13, average of 5.6 nM measured for 
FBu-AMC13) compared to [18F]AMC20. Brain penetration of [18F]FEt-AMC13 
was 0.7% injected dose. Therefore, if [18F]FEt-AMC13 is considered as 
a starting point for the development of new radioligands, an improvement 
in affinity is clearly more desirable than a further decrease in lipophilicity.
Figure 1. Relationship between affinities, lipophilicities and in vivo striatal 
SBRs for AMC tracers, aminotetraline tracers, (−)NPA and (+)PHNO.
Affinities for AMCs, (−)NPA and (+)PHNO are expressed as pKi at the high-affinity state of re-
combinant human D2 receptor (Long isoform). Affinities for aminotetralins are expressed as 
pIC50 at rat striatal D2/3 receptors (aggregate values without distinction by subtype, isoform or 
affinity state). Circle areas are proportional to maximum ex vivo SBRs in rats, actual SBR values 
shown beside. All data for AMC tracers and pKi values for (-)NPA and (+)PHNO were obtained 
in the current work (see Chapters 3, 4 and 5); pKi of FEt-AMC13 is assumed to be equal to pKi 
of FBu-AMC13. All the other data are taken from the literature (see [3]).
Affinity, lipophilicity and striatal SBR values obtained in rats for selected 
aminomethylchromanes, aminotetralins, [11C](−)NPA and [11C](+)PHNO are 
compared in Figure 1. Note that IC50 and Ki values are prone to experimen-
tal variation and are not directly comparable to each other [14], while the 
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relationship between LogD value and non-specific binding is not uniform, 
especially when tracers being compared are based on different scaffolds. 
Therefore, the relative placement of different tracers on affinity and lipo-
philicity scales should be taken with a grain of salt. Nevertheless, presented 
results suggest that aminomethylchromane and aminotetralin ligands with 
optimal characteristics for imaging should be located around the “target 
area” shown in Figure 1: ligands with sub-nanomolar D2high affinities and 
LogD values of 1.5−2. Creating such ligands will probably be easier using the 
aminomethylchromane scaffold. This scaffold has an oxygen atom in the 
bicyclic core, which lowers its inherent lipophilicity, and many high-affinity 
D2 agonist derivatives with a secondary nitrogen atom (not tertiary, as is 
typical, though not necessary, for aminotetralins [5]) are already described.
Mewshaw’s research into aminomethylchromanes eventually branched out 
into tricyclic derivatives [15], the best of which had 3-fold higher affinity 
to the high-affinity state of D2 receptors than (R)-2-((benzylamino)methyl)
chroman-7-ol, while also being less lipophilic (Figure 2). During the design 
of the candidate AMC tracers, we aimed for relatively lipophilic compounds 
to ensure high brain penetration, therefore these tricyclic scaffolds were 
not considered for development. However, for benzyl-substituted AMCs, 
brain penetration turned out to be a lesser problem than affinity and non-
specific binding, so shifting the focus to intrinsically more hydrophilic de-
rivatives may be reasonable. If further research into 18F-labeled D2/3 agonist 
PET tracers is to be done on Mewshaw’s compounds, evaluating the newer 
tricyclic derivatives will be worthwhile. Before labeling, however, the phar-
macological selectivity of these compounds should be investigated in more 
detail. While the D2-over-D1 dopamine receptor selectivity of Mewshaw’s 
compounds is beyond doubt (see Chapters 3 and 4), their selectivity towards 
D2-like dopamine receptors versus other monoamine receptors abundant in 
the striatum has to be conclusively confirmed. For instance, racemic AMC20 
was reported to possess 5-HT1A affinity of 71.5 nM [16]. This is a relative-
ly low value, but it suggests that D2-over-5-HT1 selectivity of AMCs might 
be lower than their D2-over–D1 selectivity. Meanwhile, serotonergic 5-HT1 
receptors are 5−6 times more abundant in rat striatum than D2/3 receptors 
(1200−3400 pmol/g vs 111−522 pmol/g, respectively [17,18]).
If selectivity for D2/3, at least within the striatum, is successfully established, 
an obvious first option would be to attach the 18F-atom to the benzyl ring of 
structure shown in Figure 2. Recently developed approaches to high-molar-
radioactivity 18F-fluorination, like nucleophilic fluorination with aryliodo-
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nium moieties as leaving groups [19] or transition metal-catalyzed fluorina-
tion [20–23], mean that even compounds with 18F-label in the electron-rich 
aromatic ring can potentially be prepared via short radiosynthetic routes 
suitable for commercial production.
Figure 2. Comparison of D2 affinities and lipophilicities of (R)-2-((benzylamino)
methyl) chroman-7-ol and its later derivatives developed by Mewshaw and co-
workers.
Inhibition constants for the high-affinity state of D2 receptors are taken from [15]. LogD val-
ues at pH 7.4 are calculated using the web application at www.chemicalize.org (Chemaxon, 
Hungary).
Value of agonist tracers for neuroreceptor PET imaging
Whether [18F]MCL-524 and hypothetical new 18F-labeled aminotetralins and 
aminomethylchromanes will be superior to D2/3 antagonist tracers in ap-
plications beyond the measurement of intrasynaptic dopamine levels, and 
whether agonist tracers for other neuroreceptors will be superior to corre-
sponding antagonist tracers in any application, is not clear at the moment. 
The development of agonist tracers for neuroreceptors was inspired by the 
hypothesis that GPCRs in the living brain are separated into high and low-
affinity subpopulations, but this hypothesis is not supported by existing 
preclinical experimental evidence.
In the clinic, the imaging of subjects in whom alterations in the relative 
abundance of the high-affinity state were hypothesized, such as patients 
with neuropsychiatric disorders or drug users, also provided results disap-
pointing for the “high-low-affinity state” theory. There was either no dif-
ference between studied groups [24–27], or the difference could be well ex-
plained by factors other than the agonist’s preference for the high affinity 
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state. For instance, a lot of alterations in D2/3 receptor availability in neu-
ropathological states were discovered with the D2/3 agonist [
11C](+)PHNO, 
but these successes can be attributed to the fact that [11C](+)PHNO is a 
D3-preferring tracer in vivo [28]. From a clinical point of view, therefore, do-
paminergic receptor imaging should benefit more from novel tracers of any 
intrinsic activity that are selective for the D2 or the D3 receptor subtype than 
from novel agonist tracers that bind to several D2-like receptor subtypes 
at once. This is especially true for the D3 subtype, given the findings with 
[11C](+)PHNO [28]. Also, D3 receptors have the highest affinity towards dopa-
mine of all dopamine receptor subtypes [29], so selective imaging of D3 may 
provide more sensitivity to changes in intrasynaptic levels of endogenous 
dopamine than selective imaging of D2 (and non-selective imaging of D2/3).
Structure-activity relationships for D2 and D3 selectivity are especially well 
researched for the arylpiperazine scaffold (see e.g. [30–32]) and D2 and 
D3-selective arylpiperazine radioligands with partial agonist activity have 
already been reported [33]. [11C]SV-III-120, a D2-selective arylpiperazine, 
showed promising results in monkeys [34]. The usefulness of this tracer 
for clinical imaging of dopamine receptors remains to be evaluated. Can-
didate D3-selective arylpiperazines and related arylimidazolidinones, both 
agonists [35–37] and antagonists [38–41], suffer from low or zero specific 
binding levels. For some of these ligands [37], but not for all [42], low spe-
cific binding could be caused by high competition with endogenous dopa-
mine. [18F]7-OH-FHXPAT, a recently reported aminotetralin tracer, showed 
results consistent with preferential binding to D3 receptors in rat and mouse 
brain [11], but its signal-to-noise ratio is moderate, while its D3-selectivity 
has yet to be confirmed using conventional in vitro methods. Therefore, 
[11C](+)PHNO remains the best currently available tool for D3 imaging.
For other neuroreceptors, the relative merits of agonist and antagonist trac-
ers have not been investigated as extensively as for dopamine receptors. 
New evidence in this regard is most likely to appear for neuroreceptors for 
which both agonist and antagonist tracers with similar receptor subtype se-
lectivity profiles are available. Such are serotonin 5-HT1A ([
11C]CUMI-101 vs 
[11C]WAY100635), serotonin 5-HT2A ([
11C]CIMBI-36 vs [11C]MDL100907) and 
kappa-opioid ([11C]GR103545 vs [11C]LY2975050) receptors. Agonist tracers 
for these three receptors have only undergone preliminary evaluations in 
humans [43–48]. Time will tell if there are any applications in which these 
agonists are superior to corresponding antagonist tracers.
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Fate of the high-affinity state hypothesis
As discussed in Chapter 2, there is a gap between ample evidence for the 
existence of high-affinity state as a separate subpopulation of receptors 
in membrane homogenates and lack of such evidence in the living brain 
(Figure 3). What can be done to bridge that gap?
Figure 3. Lack of agreement and contiguousness between assessments of the 
abundance of receptors configured in high-affinity state in different setups.
For D2/3 receptors, a certain percentage of receptors (considerably less than 100%) is known 
to exist in high-affinity state in membrane homogenates [49]. However, no high-affinity state 
can be detected at equilibrium in intact cells [50–52], while in tissues and living animals all 
receptors appear to be configured in the high-affinity state [18,53].
Reproduced from Chapter 2.
High-affinity state imaging beyond D2/3 receptors
Obviously, in-depth head-to-head comparisons of agonist and antagonist 
PET tracers for non-dopaminergic receptors are very valuable for the re-
finement of our understanding of the high-affinity state in vivo. The first 
head-to-head comparisons of 5-HT1A and 5-HT2A receptor tracers have only 
recently been published [46,54–56]. Agonist and antagonist tracers with 
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matching pharmacological selectivities (i.e. same relative affinities towards 
various receptor subtypes in vivo) are also available for κ-opioid receptors 
[57–59], but there are no reports of their head-to-head comparisons yet.
The ternary complex model of GPCR signaling was first validated on 
β-adrenergic receptors [60], and the mode of receptor-G-protein coupling 
for adrenergic receptors in general is very well investigated (see e.g. [61]). 
It would be interesting to attempt to detect the high-affinity state of these 
receptors by PET imaging. Currently, there are no agonist tracers for ad-
renergic receptors suitable for in vivo CNS imaging, but non-subtype-se-
lective tracers for α2-adrenoceptors like [
11C]yohimbine and the selective 
α2C-adrenoceptor tracer [
11C]ORM13070 are available and have been used 
for brain imaging in several animal species and humans [62–64]. Non-
subtype selective β-adrenoceptor antagonists S-1’-[18F]fluorocarazolol and 
[18F]fluoroethylcarazolol can also be used for brain imaging, though only in 
preclinical settings due to their mutagenicity [65–68]. Building in vivo dis-
placement curves using adrenoceptor antagonist tracers and unlabeled adren-
ergic drugs of varying intrinsic activity (agonists in the first place) will further 
our understanding of the fate of GPCR high-affinity state in vivo, although 
the effects of drugs used for displacement on heart and lung functioning 
is a potential concern.
“Vertical integration” of in vitro and in vivo setups
Although reviewing the data obtained by separate research groups reveals 
a discrepancy between the relative abundances of the high-affinity state 
found in membrane homogenates, intact cells and tissues (see Figure 3), few 
studies featured attempts to detect high-affinity state in the same receptor 
population using several experimental set-ups at once [50,51,69–71].
For example, more data are necessary to clarify the relationship between 
measurements of high-affinity state on disperse intact cells and in living 
tissues. Studies looking for the high-affinity state of D2/3 receptors natu-
rally expressed on intact cells have been carried out with cells from bovine 
pituitary [50] and rat pituitary adenoma [72], but never with striatal cells, 
though the latter are most often used in attempts to detect the high-affinity 
state in vivo.
New studies that would assess the relative abundance of the high-affinity 
state in the same receptor population (region of interest in the brain of a 
certain species) using membrane homogenates, dispersed intact cells, and 
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live animals, would shed more light on the reasons behind the current con-
fusion regarding the existence of the high-affinity state.
Further investigation of the role of kinetic factors 
on the outcome of pharmacological experiments
As discussed in Chapter 2, two hypotheses have been proposed to explain 
why high-affinity state cannot be detected in vivo:
(1) All receptors are constantly coupled to G-proteins in vivo and thus are all 
in the high-affinity state (see [53])
(2) Receptors readily couple to G-proteins in vivo and can become fully 
coupled (i.e. fully converted to the high-affinity state) if the agonist con-
centration is high enough. As almost all experimental paradigms used to 
detect the high-affinity state in vivo involve high concentrations of agonists 
(tracers/drugs/neurotransmitters), the apparent relative abundance of the 
high-affinity state is inflated to values close to 100%, even if it is less than 
that at baseline (see [73,74]).
The first hypothesis is conceptually simpler than the second. However, giv-
en the growing understanding that kinetics is an important factor in GPCR 
signaling [75], the second hypothesis is also worth investigating.
For instance, while many studies found D2/3 agonist and antagonist ra-
dioligands to be equally vulnerable to displacement by D2/3 agonist drugs 
[73,76,71], Seeman reported that both in vitro and in vivo, the D2/3 agonist 
[3H](+)PHNO showed higher vulnerability than the antagonist [3H]raclopride 
to displacement by the unlabeled agonist (−)NPA as long as the radioligands 
reached the receptors before (−)NPA [77]. It will be interesting to see if these 
findings can be replicated, and in particular to investigate the influence of 
the relative timing of tracer and drug administration on the outcome of 
competition experiments.
Alternatively, if agonist tracers can influence the relative abundance of the 
high-affinity state by their very presence, preparation of ultra-high-mo-
lar-radioactivity radioligands [78] may help minimize this effect. Data on 
agonist and antagonist tracer binding at “normal” and “ultra-high” molar 
radioactivities can then be analyzed by a conventional Scatchard plot to 
compare binding site densities and/or to look for non-linearities in the plot 




The high-affinity state of adrenergic receptors could be detected by studying 
the time course of agonist ligand binding to intact cells [79]. This paradigm 
could be expanded into a systematic in vitro study of the relationship be-
tween the concentration and intrinsic activity of radioligands and the kinet-
ics of their binding to receptors in membrane homogenates, intact cells or 
tissues. The degree of a ligand’s influence on the receptor-G-protein bind-
ing equilibrium is dependent on receptor occupancy, and there is a feedback 
loop between ligand binding to the receptors and G-protein recruitment to 
or decoupling from them, so both the intrinsic activity and the ligand con-
centration will influence the shape of the binding curve (Figure 4). Math-
ematical simulations and kinetic modeling not unlike that used for in vivo 
PET data analysis would be of great help there.
Figure 4. Hypothetical influence of ligand-receptor and receptor-G-protein 
binding cooperativity on ligand binding time course.
Lines show changes with time of the two parameters: receptor occupancy B by the ligand L and 
the percentage %Rhigh of receptors configured in the high-affinity state. Changes are shown 
for high (blue and solid grey lines) and low (orange and dashed grey lines) ligand concentra-
tions [L]. “High” concentration is defined as greater than the ligand’s dissociation constant Kd 
(equilibrium occupancy >50%), while “low” concentration is defined as less than 0.1 Kd (equi-
librium occupancy <10%).
Left panel: if %Rhigh is stable throughout the experiment, binding time courses for the ligand 
at any concentration should be described well by first-order saturation curves.
Middle panel: if ligand binding promotes high-affinity state formation (increase in %Rhigh), 
it should result in a more complex, multi-order saturation curve shape at high [L], but when [L] 
and B are low, %Rhigh is stable, so the binding curve should stay first-order.
Right panel: if ligand binding promotes high-affinity state disintegration (fall in %Rhigh), 
at high [L] the binding curve should have a prominent peak. The same peak can be expected 
to be much less pronounced at low [L].
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Receptor imaging beyond agonist and antagonist tracers
Imaging of GPCRs with agonist tracers was conceived as an approach to as-
sess the availability of functional receptors in the living brain in a simple 
and non-invasive manner. If the baseline degree of G-protein pre-coupling 
to receptors is not what determines the ability of receptors to function, how 
can one assess this ability?
Given that GPCR homo- and hetero-oligomerization is a factor that influ-
ences the pharmacological properties of GPCRs, including their affinity to-
wards the ligands (see Chapter 2), development of oligomer-specific tracers 
for non-invasive in vivo imaging could be a great step forward. A lot of work 
has been done on the development of ligands targeting homo- and heterodi-
mers of GPCRs (see [80] for review), but few of them were radiolabeled for 
use as radiopharmaceuticals. Nevertheless, a high-affinity bivalent PET li-
gand for serotonin 5-HT1A receptor homodimers has recently been success-
fully evaluated in rats [81].
Another path potentially providing big insights into receptor signaling 
is imaging of second messenger pathways activated by receptors instead 
of receptors themselves. A number of tracers is available for the imaging 
of the activity of phosphodiesterase enzymes and of membrane phospholip-
id turnover (see reviews [82,83]). However, attempts to directly spot visible 
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Motivatie en doel van het werk
Dopamine is een belangrijke neurotransmitter, die betrokken is bij de reg-
ulatie van talloze functies van de hersenen. Er wordt verondersteld dat 
ontregelingen van dopaminesignalering in het centrale zenuwstelsel ten 
grondslag te liggen aan bewegingsstoornissen, cognitieve stoornissen en 
verslaving. Receptoren, waaraan dopamine in de hersenen bindt, behoren 
tot de superfamilie van G-proteïnegekoppelde receptoren (GPCR). Dopami-
nereceptoren van de subtypes D2 en D3 (D2/3) hebben veel aandacht gekregen 
in neurologisch onderzoek. Van alle neuroreceptoren, zijn ze ook meest uit-
gebreid onderzocht door middel van positron emissie tomografie (PET).
Gegevens uit in vitro onderzoek tonen aan dat GPCRs (dus ook D2/3 recep-
toren) bestaan als twee subpopulaties met hoge en lage affiniteit voor de 
agonisten (verbindingen die in staat zijn om de receptoren te activeren, 
bijvoorbeeld dopamine). De affiniteit van een gegeven receptor voor de ago-
nist is afhankelijk van het feit of er ook een G-eiwit aan deze receptor is 
gebonden. Antagonisten (verbindingen die aan de receptoren wel kunnen 
binden, maar ze niet kunnen activeren) maken geen onderscheid tussen 
deze twee affiniteitstoestanden. Omdat de hoge affiniteitstoestand een ver-
zameling is van receptoren waaraan G-eiwitten zijn gekoppeld, kan de hoge 
affiniteitstoestand worden beschouwd als de functionele deelverzameling 
van de receptoren.
Voor toepassingen zoals receptorbezettingstudies van agonistische ge-
neesmiddelen en meting en beeldvorming van de afgifte neurotransmitters 
wordt verondersteld dat agonistische tracers geschikter zijn dan antagonis-
tische tracers, want ze binden op een selectieve manier aan de “functionele” 
deelverzameling van de receptoren.. Het gebruik van agonistische tracers 
kan ook onze kennis verbeteren van de pathogenese van neuropsychiatrische 
aandoeningen welke vermoedelijk veroorzaakt worden door de ontregeling 
van de relatieve abundantie van receptoren in de hoge affiniteitstoestand, 
en mogelijk de diagnose van deze aandoeningen vergemakkelijken.
Hoofdstuk 2 legt bestaande concepten van de hoge affiniteitstoestand uit 
en somt op potentiële voordelen van agonistische tracers in vergelijking 
met antagonistische tracers met betrekking tot de beeldvorming van neuro-
receptoren behorende tot de GPCR-familie. Hetzelfde hoofdstuk geeft ook 
een overzicht van experimentele paradigma’s ontwikkeld om deze voordel-
en te demonstreren en van experimenteel bewijs verzameld met behulp van 
deze paradigma’s. Hoewel het te betwijfelen valt of D2/3-agonistische tracers 
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inderdaad een deelverzameling herkennen van alle receptoren herkend door 
D2/3-antagonistische tracers, zijn in één toepassing, namelijk het detecteren 
van veranderingen in de intrasynaptische concentratie dopamine, D2/3-ago-
nistische tracers inderdaad superieur aan D2/3-antagonistische tracers.
Het algemene nadeel van alle D2/3-agonistische PET tracers die beschikbaar 
waren voor het gebruik in mensen op het moment dat het werk beschreven 
in dit proefschrift werd begonnen is dat ze allemaal gelabeld zijn met kool-
stof-11. Door de korte halfwaardetijd van koolstof-11 (20.4  min) kunnen 
11C-gelabelde tracers alleen gebruikt worden op instellingen die hun eigen 
cyclotron hebben. Tracers gelabeld met fluor-18 zijn veel beter geschikt 
voor het wijdverbreide gebruik, want de langere halfwaardetijd van fluor-18 
(109,8 min) maakt het mogelijk om de radiofarmaca uit één productiehub (in 
bezit van een cyclotron) naar talrijke “satellietcentra” (zonder cyclotron) te 
leveren voor beeldvorming.
Het werk beschreven in dit proefschrift had als doel de ontwikkeling en 
evaluatie van 18F-gelabelde agonistische radiofarmaca welke zouden kun-
nen worden gebruikt voor de beeldvorming van de functionele subpopulatie 
(d.w.z. hoge affiniteitstoestand) van D2/3 dopaminereceptoren bij de mens.
Het ontwerpen van de kandidaatverbindingen
Op het moment dat dit onderzoeksproject werd gestart, waren de meest 
populaire scaffolds voor de ontwikkeling van D2/3-agonistische PET-tracers 
naphtoxazine, apomorfine en 2-aminotetraline (zie Figuur 1). Radioligan-
den afgeleid van naphtoxazine en apomorfine met het 18F-label geïntro-
duceerd in één van de substituenten op het primaire amino-stikstofatoom 
bleken ongeschikt te zijn voor in vivo beeldvorming. Met één 18F-gelabel-
de derivaat van 2-aminotetraline wist men D2/3-receptoren in de hersenen 
van ratten te visualiseren met een matige signaal-ruisverhouding, maar er 
leek niet veel ruimte beschikbaar te zijn voor verdere optimalisatie, want 
gelijkaardige verbindingen met wat complexere structuren had nog lagere 
beeldvormingsprestaties. Daardoor was de beslissing door ons genomen om 
de nieuwe tracers vanuit een andere scaffold te ontwikkelen in plaats van 
verdere modificaties van de structuren van bestaande 11C-gelabelde tracers. 
Een bijkomend voordeel van deze beslissing was dat die de gelegenheid gaf 
om de ontwikkelde verbindingen te patenteren en op de markt te brengen in 
het geval dat ze succesvol zouden bleken als agenten voor PET-beeldvorm-
ing.
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Aminomethylchromanen (AMC), een klasse van D2/3-agonisten met hoge 
affiniteit, die vroeger niet geëvalueerd waren als radioliganden, werden 
gekozen als het startpunt voor de ontwikkeling van nieuwe 18F-gelabelde 
tracers.
Hoofdstuk 3 beschrijft het ontwerpen van kandidaatverbindingen op basis 
van de AMC scaffold. Een PET-tracer voor de beeldvorming van de hersenen 
moet lipofiel genoeg zijn om de bloed-hersenbarrière door passieve diffusie 
te kunnen doordringen, maar moet ook niet te lipofiel zijn zodat de speci-
fieke binding in het hersenweefsel onderscheiden kan worden van de niet-
specifieke binding. Natuurlijk moet de tracer voldoende affiniteit voor de 
doelreceptoren hebben om meetbare specifieke binding te laten zien. Nog 
één eis is dat de tracer het metabolisme goed genoeg moet weerstaan om 
naar het hersenweefsel vanuit het bloed te kunnen diffunderen voordat die 
gemetaboliseerd wordt. Wanneer de metabolisering uiteindelijk toch zou 
gebeuren, moet het radioactieve label van het tracermolecuul gaan in frag-
menten die hydrofiel zijn en de bloed-hersenbarrière niet kunnen doordrin-
gen.
De structuur van de D2/3-agonistische farmacofoor, waaraan AMCs ook 
voldoen, bestaat uit een aromatische kern, waterstofbrugvormende hy-
droxylgroepen daaraan gekoppeld, en een positief geladen stikstofatoom 
(Figuur 1). Een eigenschap van de AMC-scaffold die handig is bij de ontwik-
keling van radioliganden is dat de substituent op het primaire amino-stikstof-
atoom is gericht naar een betrekkelijk ruim onderdeel van de bindingsholte 
van de dopaminereceptor. Daarom kan de structuur van de N-substituent 
met veel vrijheid worden gemodificeerd om de noodzakelijke lipofiliciteit te 
bereiken en de radioactieve label te introduceren zonder veel effect op de 
D2/3-affiniteit of agonisme.
In dit werk waren AMCs ontwikkeld met alkyl-, benzyl- en arylpiperazino-
substituenten (Figuur 2). Structuren van kandidaatverbindingen waren ont-
worpen om voorspelde lipofiliteitswaarden (LogP7.4 = LogD) tussen 1 en 3 te 
hebben, wat het voorkeursbereik is bij de radiofarmaca voor hersenbeeld-
vorming. Bij meeste kandidaat-verbindingen werd het fluor-label geïn-
troduceerd in fluoroalkoxy groepen, terwijl de lengten van de alkylketens 
werden aangepast om de juiste LogD waarden te verkrijgen. De AMC-kern 
bleef echter de belangrijkste hydrofobe kern in alle kandidaat-verbindin-
gen. Het radioactieve fluoratoom werd bewust geïntroduceerd op afstand 
van de AMC-kern, in groepen die relatief gemakkelijk gesplitst konden wor-
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den van het molecuul door de werking van metabolische enzymen. Dit werd 
gedaan om te verzekeren dat radioactieve metabolieten gevormd uit kan-
didaat-tracers niet lipofiel zouden zijn en de D2/3-farmacofoor niet zouden 
bevatten, want lipofiele radiometabolieten, met name die met D2/3 affiniteit, 
kunnen interfereren met de kwantificering van de specifieke opname van 
kandidaat-tracers in de hersenen.
Figuur 1. Vergelijking van de moleculaire structuren van dopamine en dopami-
nerge liganden afgeleid van de structuren van aminomethylchromaan (links 
beneden), aminotetraline (midden boven) naphtoxazine (midden beneden) en 
apomorfine (rechts).
Aromatische kernen, basische stikstofatomen en waterstofbugdonerende hydroxylgroepen zijn 
in kleur weergegeven. Liganden zijn georiënteerd in een ruwe representatie van de vermoede-
lijke receptorgebonden conformaties. De “opwaarts gerichte” benzyl substituent van benzyl-
AMC en de propyl substituent van S-(−)5-OH-DPAT hebben toegang tot het ruime onderdeel 
van de bindingsholte van de D2-receptor, terwijl de “neerwaarts gerichte” propyl substituenten 
van S-(−)5-OH-DPAT, (+)PHNO en (−)NPA wijzen in de richting van een en gedeelte van de 
bindingsholte waar er slechts genoeg ruimte is voor groepen niet groter dan propyl. Aangepast 
van Hoofdstuk 3.
Synthese en farmacologische karakterisering 
van kandidaat-verbindingen
Hoofdstukken 3 en 4 beschrijven de bereiding van kandidaat-verbindin-
gen afgeleid van de AMC scaffold en hun evaluatie in vitro. Chiraliteit van 
de AMCs speelt een beslissende rol in hun affiniteit voor D2 en D3-recep-
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toren, en (R)-enantiomeren zijn de eutomeren. De enantiomerisch zuivere 
(R)-7-hydroxy-2-ethoxycarbonylchromaan bouwsteen werd bereid uit het 
racemische vorm van dezelfde stof door het kinetische resolutiemethode 
met gebruik van lipase-enzyme. Deze bouwsteen werd verder gemodificeerd 
om uiteindelijk alkyl-, benzyl- en arylpiperazinyl-gesubstitueerde AMCs te 
verkrijgen, met en zonder fluoratomen in hun structuur.
Figuur 2. Structuren van gefluorideerde kandidaat-AMCs en referentieverbindin-
gen bereid in dit werk.
De farmacologische eigenschappen van de gesynthetiseerde verbindin-
gen werden geëvalueerd in competitie-assays met radioliganden in 
membraanhomogenaten van humane embryonale nierencellen (HEK) en 
Chinese hamster-eierstokcellen (CHO) cellen, die verschillende subtypen 
van humane dopaminereceptoren tot expressie brachten. Ook werden met 
gesynthetiseerde verbindingen functionele testen uitgevoerd zoals remming 
van adenylaatcyclase en rekrutering van β-arrestine. Twee benzyl- en één 
arylpiperazinyl-gesubstitueerde AMCs, genoemd, in respective volgorde, 
AMC20, FBu-AMC13 en FEt-AMC15, werden beschouwd als goede kandi-
daten voor de radiolabeling (in Hoofdstuk 3 zijn de laatste twee verbindin-
gen aangeduid als 12a en respectievelijk 12d). In membraanhomogenaten 
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maakten deze verbindingen goed onderscheid tussen hoge en lage affiniteit-
stoestanden van D2-receptoren (D2high en D2low), zodat de affiniteit voor de 
hoge affiniteittoestand 10 tot 1000 maal groter was dan voor de lage affinit-
eitstoestand. Affiniteiten van de verbindingen voor D2high lagen in het sub-
nanomolaire of nanomolaire bereik: van 85 pM voor AMC20 tot 6.7 nM voor 
FEt-AMC15. Bovendien bonden ze met hoge affiniteit aan D3-receptoren 
(gemeten affiniteitswaarden van 0.6 nM voor AMC20 tot 12.1 nM voor FBu-
AMC13), lieten geen significante binding aan D1 receptoren zien en toonden 
bijna volledig agonisme in functionele testen op D2 receptoren.
Synthese van radioactief gelabelde kandidaat-tracers 
en beoordeling van hun lipofiliteit
De radiolabeling van AMC20 wordt beschreven in Hoofdstuk 4, terwijl de 
radiolabeling van FBu-AMC13 en FEt-AMC15 wordt beschreven in Hoofd-
stukken 3 en 5. Voor die laatste twee verbindingen, een aantal homologen 
met variërende fluoralkylketenlengtes werd bereid om na te gaan welke ke-
tenlengte een ligand met de hoogste signaal-ruisverhouding in het werkeli-
jke hersenweefsel zou opleveren.
In de structuur van AMC20 is het radioactieve fluoratoom direct aan de 
benzylgroep gehecht. Omdat de benzylgroep een elektronrijke arylgroep 
is die niet rechtstreeks door nucleofiele fluoridering gelabeld kan worden, 
werd deze verbinding bereid uitgaande van 4-[18F]fluorbenzaldehyde, welke 
vervolgens tot een [18F]fluorbenzyl groep werd omgezet via een reductieve 
amineringsreactie met AMC-amine. Bij FBu-AMC13 en FEt-AMC15 maakt 
het fluoratoom deel uit van een fluoroalkoxy groep. Deze verbindingen 
werden bereid door fluoroalkylering van fenol-precursoren (Figuur 3).
Bij het ontwerpen van de radiolabelingsproceduren voor het verkrijgen van 
de eerste [18F]AMCs wilden we bovenal gemak en flexibiliteit te bereiken. 
Radiosyntheses duurden 2–2.5 uur. [18F]fluoralkyl-AMC’s werden verkregen 
in radiochemische opbrengsten van 3−15% (gecorrigeerd voor radioactief 
verval), terwijl de gemiddelde radiochemische opbrengst van [18F]AMC20 
24% was. Molaire radioactiviteit van [18F]AMCs was in de range van 10 tot 
100 GBq/µmol, wat hoog genoeg is om in vivo PET-beeldvorming uit te vo-
eren met gebruikelijke geïnjecteerde doseringen. In de latere stadia van dit 
werk werd de bereiding van [18F]fluoralkyltosylaten en 4-[18F]fluorbenzalde-
hyde geautomatiseerd (Hoofdstuk 6), wat de de productie van tracers voor 
in vitro en in vivo onderzoek verder vereenvoudigde.
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Figuur 3. Radiosynthetische schema’s gebruikt voor de bereiding van 
[18F]AMC’s.
A – reductieve aminering van 4-[18F]fluorbenzaldehyde met de amineprecursor van AMC20; 
B – 18F-fluoroalkylering van fenolprecursoren om de homologen van AMC13 en AMC15 te ver-
krijgen. Eenvoudigheidshalve worden de aminomethylchromaangroepen en de uiteindelijke 
ontscherming van de 7-OH-groep niet getoond.
De experimenteel bepaalde LogD-waarde van [18F]AMC20 was 2.33. 
Voor de homologen van AMC13 varieerden de LogD-waarden van 1.67 
([18F]FEt-AMC13) tot 2.50 ([18F]FBu-AMC13). Voor AMC15 homologen, la-
gen de LogD-waarden in het traject van 1.48 ([18F]FEt-AMC15) tot 2.71 
([18F]FBu-AMC15). Alle LogD-waarden vallen binnen het bereik dat als op-
timaal wordt beschouwd voor passieve diffusie vanuit het bloedplasma naar 
het hersenweefsel.
In vitro en in vivo evaluatie van radioactief gelabelde 
kandidaat-tracers
Resultaten van de in vitro en in vivo evaluatie van radioactief gelabelde 
kandidaat-tracers zijn beschreven in Hoofdstukken 4 en 5. Alle radioac-
tief gelabelde verbindingen werden geëvalueerd door middel van in vitro 
autoradiografie in plakjes rattehersenen om de signaal-ruisverhouding van 
hun binding aan D2/3 receptoren in het hersenweefsel te beoordelen. Speci-
fieke bindingverhoudingswaarden (specific binding ratios, SBRs) werden 
berekend op basis van concentraties radioactiviteit gemeten in de gebie-
den van het striatum (rijk aan D2/3-receptoren) en het cerebellum (kleine 
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hersenen, arm aan D2/3-receptoren). Voor [
18F]AMC20, een fluorobenzyl-ge-
substitueerd AMC met de hoogste gemeten affiniteit voor D2high (85 pM), 
bereikte de striatale SBR de waarde van 6.27 bij de ligandsconcentratie van 
1.7 nM (Hoofdstuk 4). Onder AMC’s met een [18F]fluoroalkoxygroep war-
en de hoogste SBR-waarden getoond door de fluoroethoxybenzyl-gesub-
stitueerde [18F]FEt-AMC13 en de (fluorethoxy)-phenylpiperazinyl-gesub-
stitueerde [18F]FEt-AMC15: SBR 3.40 bij 0.9 nM en respectievelijk SBR 1.64 
bij 5.8 nM (Hoofdstuk 5). Co-incubatie met de D2/3-antagonist raclopride of 
met guanosinetrifosfaat (GTP), die de ontkoppeling van G-eiwitten van de 
receptoren stimuleert, heeft voor alle radioliganden in een 60−80% daling 
van SBR-waarden geresulteerd, hetgeen een bewijs is dat de opname van 
de AMCs in het striatum door hun specifieke binding aan de hoge affiniteit-
stoestand van D2/3 receptoren is veroorzaakt.
[18F]AMC20, [18F]FBu-AMC13, [18F]FEt-AMC13 en [18F]FEt-AMC15 waren 
verder geëvalueerd in Sprague-Dawley ratten. [18F]FEt-AMC15 liet zeer 
lage opname in de hersenen van levende ratten zien, hetgeen mogelijk 
veroorzaakt was door de relatief hoge hydrofiliciteit van deze tracer (het 
molecuul heeft ook twee basische stikstofatomen), door een interactie van 
de tracer met pompeiwitten zoals P-glycoproteïne (P-gp) of misschien door 
beide redenen. [18F]AMC20, [18F]FBu-AMC13 en [18F]FEt-AMC13 drongen 
daarentegen in ruim voldoende mate de hersenen binnen: piekopname in de 
hersenen was 1,7%, 0,9% en 0,7% geïnjecteerde dosis, respectievelijk voor 
de drie genoemde tracers. De opname van [18F]FBu-AMC13 was het hoogste 
in de hersenstam, maar [18F]FEt-AMC13 en [18F]AMC20 werden voornameli-
jk opgenomen in het striatum, resulterend in striatum-tot-cerebellum ver-
houdingen van ongeveer 2 voor beide tracers. Alle radioactieve metabolieten 
van [18F]FEt-AMC13 en [18F]AMC20 waren aanzienlijk minder lipofiel dan 
hun moederstoffen en drongen de bloed-hersenbarrière niet door. Tot slot, 
voorbehandeling van ratten met 1 mg/kg raclopride resulteerde in 20−40% 
daling (afhankelijk van de meetmethode) in D2/3-specifieke striatale opname 
van beide tracers, wat te detecteren was met PET-beeldvorming, ex vivo bio-
distributie en ex vivo autoradiografie (Hoofdstukken 4 en 5).
Hoewel de verkregen in vivo en ex vivo gegevens voor [18F]FEt-AMC13 en 
[18F]AMC20 in overeenstemming zijn met specifieke binding van deze twee 
tracers aan D2/3-receptoren in de striata van ratten, hadden deze radioligan-
den twee algemene nadelen. Het eerste was dat het verschil tussen de stria-
tale en cerebellaire opname, meestal gebruikt als een surrogaatmeting voor 
D2/3-specifieke binding, met niet meer dan 40% verlaagd werd door voorbe-
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handeling met raclopride. Dit is minder dan de helft van de dalingswaarden 
gemeld in de literatuur voor de bestaande 11C-gelabelde agonisten na voor-
behandeling met dezelfde (1  mg/kg) of lagere doseringen raclopride (ten 
minste 80% daling). Dit kan het gevolg zijn geweest van onvoldoende do-
sering raclopride of van onvolkomen farmacologische selectiviteit van onze 
tracers. Op basis van de beschikbare gegevens is het niet mogelijk om tussen 
die twee mogelijke oorzaken te onderscheiden.
Een ander belangrijker nadeel is dat de signaal-ruisverhoudingswaarden 
van [18F]FEt-AMC13 en [18F]AMC20 in controleratten lager waren dan de 
waarden gemeld voor bestaande 11C-gelabelde D2/3 agonistische tracers. 
Onze tracers toonden striatale BPND-waarden van circa 0.5, vergeleken met 
0.9 gemeld voor [11C]MNPA; striatum-tot-cerebellum verhoudingswaarden 
van onze tracers waren ongeveer 2, terwijl voor [11C](–)NPA en [11C](+)PHNO 
zijn verhoudingswaarden van 3 of meer gemeld. Daarom, zelfs als voor 
[18F]FEt-AMC13 en [18F]AMC20 een hoge selectiviteit voor D2/3-receptoren 
kon worden bewezen en >90% afname van de striatale BPND-waarden kon 
worden bereikt door verhoging van de geïnjecteerde dosis raclopride, zouden 
deze twee tracers toch minder geschikt zijn voor het beeldvormen van stria-
tale D2/3-receptoren in vivo dan [
11C]MNPA, [11C](−)NPA en [11C](+)PHNO.
Conclusie
Wij hebben een reeks gefluorideerde derivaten van aminomethylchromaan 
ontworpen en bereid en deze derivaten geëvalueerd als potentiële agonis-
tische radioliganden voor de beeldvorming van dopamine D2/3-receptoren 
door middel van positronemissietomografie.
De twee beste verbindingen uit de door ons onderzochte reeks, [18F]AMC20 
en [18F]FEt-AMC13, konden onderscheid maken tussen hoge en lage affinit-
eitstoestanden van D2/3-receptoren, vormden geen lipofiele metabolieten in 
vivo, drongen goed tot de hersenen door, werden voornamelijk opgenomen 
in het striatum van levende ratten en waren gevoelig voor D2/3-blokkade 
veroorzaakt door injectie van raclopride. Alhoewel de signaal-ruisver-
houdingen van [18F]AMC20 en [18F]FEt-AMC13 lager zijn dan die van besta-
ande 11C-gelabelde D2/3-agonistische tracers, bewijzen onze resultaten dat 
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